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Point-of-care creatinine tests to assess kidney function for
outpatients requiring contrast-enhanced CT imaging:
systematic reviews and economic evaluation
Mark Corbett ,1* Ana Duarte ,2 Alexis Llewellyn ,1 James Altunkaya ,2
Melissa Harden ,1 Martine Harris ,3 Simon Walker ,2 Stephen Palmer ,2
Sofia Dias 1 and Marta Soares 2
1Centre for Reviews and Dissemination (CRD), University of York, York, UK
2Centre for Health Economics (CHE), University of York, York, UK
3Mid Yorkshire Hospitals NHS Trust, Pinderfields Hospital, Wakefield, UK
*Corresponding author mark.corbett@york.ac.uk
Background: Patients with low estimated glomerular filtration rates may be at higher risk of post-
contrast acute kidney injury following contrast-enhanced computed tomography imaging. Point-of-care
devices allow rapid measurement of estimated glomerular filtration rates for patients referred without
a recent estimated glomerular filtration rate result.
Objectives: To assess the clinical effectiveness and cost-effectiveness of point-of-care creatinine tests
for outpatients without a recent estimated glomerular filtration rate measurement who need contrast-
enhanced computed tomography imaging.
Methods: Three systematic reviews of test accuracy, implementation and clinical outcomes, and economic
analyses were carried out. Bibliographic databases were searched from inception to November 2018.
Studies comparing the accuracy of point-of-care creatinine tests with laboratory reference tests to assess
kidney function in adults in a non-emergency setting and studies reporting implementation and clinical
outcomes were included. Risk of bias of diagnostic accuracy studies was assessed using a modified version
of the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. Probabilities of individuals
having their estimated glomerular filtration rates correctly classified were estimated within a Bayesian
framework and pooled using a fixed-effects model. A de novo probabilistic decision tree cohort model
was developed to characterise the decision problem from an NHS and a Personal Social Services
perspective. A range of alternative point-of-care testing approaches were considered. Scenario analyses
were conducted.
Results: Fifty-four studies were included in the clinical reviews. Twelve studies reported diagnostic
accuracy for estimated glomerular filtration rates; half were rated as being at low risk of bias, but there
were applicability concerns for most. i-STAT (Abbott Point of Care, Inc., Princeton, NJ, USA) and ABL
(Radiometer Ltd, Crawley, UK) devices had higher probabilities of correctly classifying individuals in the
same estimated glomerular filtration rate categories as the reference laboratory test than StatSensor®
devices (Nova Biomedical, Runcorn, UK). There was limited evidence for epoc® (Siemens Healthineers
AG, Erlangen, Germany) and Piccolo Xpress® (Abaxis, Inc., Union City, CA, USA) devices and no studies
of DRI-CHEM NX 500 (Fujifilm Corporation, Tokyo, Japan). The review of implementation and clinical
outcomes included six studies showing practice variation in the management decisions when a point-of-
care device indicated an abnormal estimated glomerular filtration rate. The review of cost-effectiveness
evidence identified no relevant studies. The de novo decision model that was developed included a total
DOI: 10.3310/hta24390 Health Technology Assessment 2020 Vol. 24 No. 39
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
v
of 14 strategies. Owing to limited data, the model included only i-STAT, ABL800 FLEX and StatSensor.
In the base-case analysis, the cost-effective strategy appeared to be a three-step testing sequence
involving initially screening all individuals for risk factors, point-of-care testing for those individuals
with at least one risk factor, and including a final confirmatory laboratory test for individuals with a
point-of-care-positive test result. Within this testing approach, the specific point-of-care device with
the highest net benefit was i-STAT, although differences in net benefit with StatSensor were very small.
Limitations: There was insufficient evidence for patients with estimated glomerular filtration rates
< 30 ml/minute/1.73 m2, and on the full potential health impact of delayed or rescheduled computed
tomography scans or the use of alternative imaging modalities.
Conclusions: A three-step testing sequence combining a risk factor questionnaire with a point-of-care
test and confirmatory laboratory testing appears to be a cost-effective use of NHS resources compared
with current practice. The risk of contrast causing acute kidney injury to patients with an estimated
glomerular filtration rate of < 30 ml/minute/1.73 m2 is uncertain. Cost-effectiveness of point-of-care
testing appears largely driven by the potential of point-of-care tests to minimise delays within the
current computed tomography pathway.
Future work: Studies evaluating the impact of risk-stratifying questionnaires on workflow outcomes in
computed tomography patients without recent estimated glomerular filtration rate results are needed.
Study registration: This study is registered as PROSPERO CRD42018115818.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 39. See the NIHR Journals Library website for further project information.
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full report with each piece of confidential data removed and replaced by the statement
‘confidential information (or data) removed’ is available on the NICE website: www.nice.
org.uk.
The present monograph presents as full a version of the report as is possible while
retaining readability, but some sections, sentences, tables and figures have been removed.
Readers should bear in mind that the discussion, conclusions and implications for practice
and research are based on all the data considered in the original full NICE report.
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Plain English summary
Before computed tomography scans are done, a contrast agent is usually needed to improve thevisibility of internal body structures. After receiving a contrast agent (through a vein), some
patients’ kidneys may be affected, especially if their kidneys already do not work well. A blood test
can identify these patients before a computed tomography scan, to reduce the risk of kidney harm.
The blood test measures creatinine, which is a marker of how well the kidneys work.
Before a contrast-enhanced computed tomography scan, some patients have a recent creatinine result
from an earlier blood test. Blood tests are normally done in a central laboratory, and usually take
at least 1 hour. Other patients do not have a recent creatinine result, so their computed tomography
scan may be delayed or rearranged. Sometimes, to avoid risking kidney harm, patients may have
scans without contrast. ‘Point-of-care’ (handheld, tabletop or portable) devices can quickly measure
creatinine (usually in patients with risk factors), often from a finger-prick blood sample. Many point-of-
care devices are available but they may not be as exact as laboratory tests, so their benefit is unclear.
This study reviewed all available evidence on the benefits and harms of point-of-care creatinine tests
before computed tomography scans and assessed whether or not they are a cost-effective use of
NHS resources. The study found that some devices [i.e. i-STAT (Abbott Point of Care, Inc., Princeton,
NJ, USA) and ABL (Radiometer Ltd, Crawley, UK)] were more accurate than others [i.e. StatSensor®
(Nova Biomedical, Runcorn, UK)]. There was insufficient evidence for other devices. The study found
that, for outpatients, doing a point-of-care test in patients who are at a higher risk of kidney harm
(according to a questionnaire) and then confirming this with a laboratory test appeared to be a
cost-effective use of NHS resources. The study found that the risk of kidney harm as a result of
contrast agents appears very low. The main benefit of point-of-care testing may be to reduce
needless delays or rearranged computed tomography scan appointments.
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Scientific summary
Background
Intravenously administered contrast agents are thought to occasionally cause acute kidney injury,
particularly in patients with existing kidney disease. There is debate about whether or not low-osmolar
and iso-osmolar contrast agents pose any meaningful risk of acute kidney injury. Some guidelines
recommend that patients with abnormal estimated glomerular filtration rates (derived from serum
creatinine measurements) may need prophylactic intravenous hydration to reduce the risk of post-contrast
acute kidney injury or that alternative imaging strategies may be used without the use of a contrast agent.
The risk of post-contrast acute kidney injury can be assessed in most hospital patients awaiting a computed
tomography scan or procedure. All inpatients should have a recent estimated glomerular filtration rate
measurement available as part of other hospital tests, as should many outpatients. However, some
outpatients present at their computed tomography scan appointment without a recent estimated glomerular
filtration rate measurement. Although a blood sample could be processed by the hospital laboratory, results
typically require at least 1 hour to be available. Consequently, rather than being subject to an uncertain
risk of post-contrast acute kidney injury, the patient’s computed tomography scan appointment may be
rescheduled or performed without a contrast agent. Point-of-care devices allow rapid blood sampling and
measurement of estimated glomerular filtration rate, enabling post-contrast acute kidney injury risk to be
assessed and, if the risk is low, the computed tomography scan appointment to go ahead as planned.
Objectives
To evaluate the clinical effectiveness and cost-effectiveness of point-of-care creatinine tests to
estimate kidney function for people who need contrast-enhanced computed tomography imaging in a
non-emergency setting and who do not have a recent serum creatinine measurement.
Methods
Assessment of clinical effectiveness
Two systematic reviews were conducted to evaluate the test accuracy of point-of-care creatinine tests
and to assess their implementation outcomes and clinical impact. Numerous bibliographic sources,
including MEDLINE and EMBASE, were searched from inception to November 2018 for published and
unpublished literature. Pragmatic reviews of the risk of acute kidney injury from contrast agents and
on prophylactic interventions for post-contrast acute kidney injury were also undertaken.
For test accuracy outcomes, observational studies that compared the results of point-of-care creatinine
tests with laboratory-based tests to assess kidney function in a non-emergency setting were included.
Studies reporting sufficient data to allow the calculation of diagnostic accuracy estimates (expressed as or
allowing calculation of sensitivity and specificity), correlation or measurement bias were included. For
clinical and implementation outcomes, any studies of point-of-care creatinine tests to assess kidney function
in adults before computed tomography imaging in a non-emergency outpatient setting were included.
Eligible point-of-care devices included StatSensor® devices (Nova Biomedical, Runcorn, UK), i-STAT
(Abbott Point of Care, Inc., Princeton, NJ, USA), ABL800 FLEX (Radiometer Ltd, Crawley, UK), ABL90
FLEX (Radiometer Ltd), epoc® (Siemens Healthineers AG, Erlangen, Germany), Piccolo Xpress® (Abaxis,
Inc., Union City, CA, USA) and DRI-CHEM NX 500 (Fujifilm Corporation, Tokyo, Japan).
DOI: 10.3310/hta24390 Health Technology Assessment 2020 Vol. 24 No. 39
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
xxiii
Two researchers independently screened titles and abstracts and full texts. Data extraction and
quality assessment were performed by at least one researcher and checked by a second. The quality
of diagnostic accuracy studies was assessed using a modified version of the Quality Assessment of
Diagnostic Accuracy Studies 2 (QUADAS-2) tool. Where sufficient data were available, probabilities
of individuals being correctly classified by the point-of-care device according to estimated glomerular
filtration rate laboratory reference test measurement categories were estimated within a Bayesian
framework using Markov chain Monte Carlo methods. Data were pooled using a fixed-effects model.
Results were reported as posterior medians with 95% credible intervals and plotted as density strips.
Economic assessment
A review of full economic evaluations was conducted. Two researchers independently screened the
titles and abstracts of all reports identified by the bibliographic searches and all full-text papers
subsequently obtained. The main findings were narratively summarised.
A de novo decision model was developed to evaluate the cost-effectiveness of point-of-care testing to
assess kidney function, for people who need contrast-enhanced computed tomography imaging in a
non-emergency outpatient setting and who present without a recent estimated glomerular filtration
rate measurement. The model provides a quantitative framework to link the diagnostic accuracy of
point-of-care creatinine tests to short-term costs and consequences (e.g. the impact on cancelled or
delayed appointments, use of contrast media with and without intravenous hydration and associated
risks such as post-contrast acute kidney injury) and final health outcomes expressed in terms of
quality-adjusted life-years. Costs were estimated from the perspective of the NHS and Personal
Social Services.
A decision tree cohort approach was used to estimate the costs and health outcomes of alternative
testing and treatment strategies, based on:
l an individual’s true estimated glomerular filtration rate status
l how these individuals are classified by different testing strategies
l clinical decisions aimed at reducing post-contrast acute kidney injury risk
l the subsequent risk and consequences of post-contrast acute kidney injury.
Fourteen strategies were evaluated, grouped into six general types:
1. laboratory testing only
2. risk factor screening combined with point-of-care testing
3. risk factor screening combined with laboratory testing
4. risk factor screening combined with point-of-care testing and laboratory testing
5. point-of-care testing only
6. point-of-care testing combined with laboratory testing.
Only those point-of-care devices that reported diagnostic accuracy data using estimated glomerular
filtration rate thresholds were included (i.e. i-STAT Alinity, ABL800 FLEX and StatSensor).
Results
Diagnostic accuracy
Fifty-four studies were included. The systematic review of test accuracy included 12 studies that
reported data for estimated glomerular filtration rates, seven that reported diagnostic accuracy data
only for creatinine, and 50 studies that presented data on correlation and/or measurement bias
between a point-of-care device and a laboratory reference test.
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Only studies of i-STAT, StatSensor and ABL reported data on diagnostic accuracy. Few studies were
available on the epoc and Piccolo Xpress devices, which reported data only on measurement bias or
correlation. There were no studies of DRI-CHEM NX 500.
Half of the diagnostic accuracy studies of estimated glomerular filtration rates were considered to be
at low risk of bias, although there were some concerns about the applicability of results to the
outpatient computed tomography setting in all but two studies.
Results of the estimated glomerular filtration rate data synthesis showed that i-STAT and ABL800/827
devices are more accurate than StatSensor devices at correctly detecting individuals with an estimated
glomerular filtration rate of < 30 ml/minute/1.73 m2 (i.e. better sensitivity). i-STAT and ABL devices
also have higher probabilities than StatSensor devices of correctly classifying individuals in the same
estimated glomerular filtration rate categories as the reference laboratory test. Additional analyses
carried out using adjusted StatSensor data and including only studies that used the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation confirmed these findings.
Of the studies reporting data on creatinine/estimated glomerular filtration rate measurement bias,
results from the StatSensor studies demonstrated wide variation in the size and direction of
measurement bias. Although potentially important measurement bias was also identified in some
studies of i-STAT and ABL devices, in most of these studies the concordance of results was generally
better than in most of the StatSensor studies. Owing to limited data, conclusions cannot be drawn
about measurement biases for the epoc and Piccolo Xpress devices.
Implementation and clinical outcomes
This review included six studies. The results illustrated variation in practice both in terms of the
proportions of patients who do not have a recent estimated glomerular filtration rate result and the
management decisions taken when a point-of-care device indicates an abnormal estimated glomerular
filtration rate. Evidence from large studies of inpatients suggests no association between contrast and
the risk of acute kidney injury in patients with an estimated glomerular filtration rate of ≥ 45 ml/minute/
1.73 m2, although uncertainty exists about whether or not contrast is associated with a small risk in
patients with an estimated glomerular filtration rate of < 45 ml/minute/1.73 m2. There was no evidence
to suggest that intravenous hydration is more effective than oral hydration for preventing post-contrast
acute kidney injury or the need for renal replacement therapy or reducing mortality.
Economic assessment
No previously published studies met the inclusion criteria for the cost-effectiveness review. One
unpublished economic study was provided in academic confidence. (Confidential information has
been removed.)
The base-case cost-effectiveness results showed that the strategy with highest net benefit (i.e.
appearing to be cost-effective) was a three-step testing sequence that involves initially screening all
individuals for risk factors using a questionnaire, then testing those with at least one risk factor with
a point-of-care device and using a confirmatory laboratory test for those individuals who screen and
test positive with point-of-care testing. Within this testing approach, the point-of-care device with the
highest net benefit was i-STAT. However, the differences in the net benefit between the i-STAT and
StatSensor devices were found to be extremely small.
Differences in the cost and diagnostic specificity of the individual testing strategies appeared more
important drivers than diagnostic sensitivity. The reduction in post-contrast acute kidney injury risk
and associated consequences were not major drivers in the model because of the low risk of post-
contrast acute kidney injury estimated for this population, the lack of evidence of an increased risk of
post-contrast acute kidney injury associated with the use of contrast media and the lack of evidence on
the impact of intravenous hydration in reducing the risk of post-contrast acute kidney injury.
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The base-case findings on the optimal type of testing strategy appeared robust to a number of
alternative assumptions explored using scenario analysis. The key exception to this was when an
additional ‘no-testing and manage all with contrast-enhanced computed tomography strategy’ was
included. This strategy was not assessed in the base-case analysis as it was not considered clinically
appropriate given current clinical guidelines that advocate testing or risk stratification prior to
contrast-enhanced computed tomography scans. The model was also sensitive to the assumption
that cancelled or delayed computed tomography would result in the loss of the imaging slot.
Discussion
The systematic reviews used transparent, reproducible and robust methods, and sought to identify
all relevant published and unpublished studies. Key review processes were performed in duplicate,
which minimised the possibility of reviewer errors and biases. Previously unpublished data from two
important studies of diagnostic accuracy based on estimated glomerular filtration rate thresholds were
obtained. Studies reporting measurement bias and clinical or workflow outcomes were included. Study
quality was evaluated in studies reporting estimated glomerular filtration rate diagnostic accuracy data
using a modified version of the QUADAS-2 tool. Appropriate synthesis methods were used to evaluate
the accuracy of the devices and provide the inputs needed for the economic evaluation in the form
of probabilities. Uncertainty was accounted for, although it was not possible to fully account for
between-study differences in results.
Most of the 54 studies that were eligible for inclusion in the systematic review reported only
measurement bias or correlation outcomes and so were of limited relevance to the economic modelling
part of the assessment. Correlation results data are limited because results that might appear impressive
can sometimes hide imperfect agreement between methods.
Some studies were limited by small sample sizes and most studies had few patients with estimated
glomerular filtration rates below < 30 ml/minute/1.73 m2. Although this is reflective of outpatient
populations, it limits the data available for analyses based on the more clinically relevant estimated
glomerular filtration rate threshold of < 30 ml/minute/1.73 m2. Few studies directly compared different
point-of-care creatinine devices, and estimated glomerular filtration rate diagnostic accuracy data were not
available for the ABL90 FLEX PLUS, DRI-CHEM NX 500, epoc and Piccolo Xpress point-of-care devices.
There were few studies that reported data on the impact of point-of-care devices in computed
tomography scanning departments on the use (or rates of non-use) of contrast agents for diagnostic
procedures nor were there many data on the use of prophylactic treatments or workflow outcomes,
such as cancelled appointments. No data were available on clinical outcomes such as need for renal
replacement therapy or hospital admissions. The impact of point-of-care testing on these important
outcomes is therefore uncertain.
The de novo decision model is the first formal evaluation of the potential clinical benefits, risks and
costs of incorporating point-of-care testing to assess kidney function in people who need contrast-
enhanced computed tomography imaging in a non-emergency outpatient setting and who present
without a recent estimated glomerular filtration rate measurement. The findings suggest that the use
of point-of-care devices may reduce costs to the health system arising from unnecessary delays in
computed tomography scanning appointments for the majority of individuals. Any savings also need to
be considered against the potential risks arising from misclassification. Although the use of point-of-
care devices results in a marginal reduction in outcomes compared with a strategy of obtaining a
laboratory test measurement for all individuals, the loss in outcomes appears more than offset by the
estimated cost savings.
SCIENTIFIC SUMMARY
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A potential limitation of the study’s findings is the assumption made in the base-case analysis that all
individuals will eventually undergo contrast-enhanced computed tomography. This simplification was
considered necessary given the limited data available, the heterogeneity in the overall population,
including underlying reasons for imaging, and challenges in linking these parameters to individualised
clinical decision-making and associated outcomes. The model was also sensitive to assumptions on the
proportion of cancelled and rescheduled computed tomography scans. However, an extensive series of
scenario analyses were undertaken to explore the potential impact of alternative assumptions on both
these parameters.
The finding that a ‘no-testing and use of intravenous contrast for all’ strategy had the highest net
benefit suggests that additional testing costs of either a laboratory reference test or a point-of-care
test result may not provide sufficient improvements in patient outcomes to warrant routine testing.
Such a strategy is, however, unlikely to be considered clinically acceptable. These findings also need to
be considered alongside the limitations of the model assumptions and the uncertainties that remain
regarding the effect of contrast media on the risk of post-contrast acute kidney injury, and the benefits
of prophylactic management to reduce the risk of post-contrast acute kidney injury.
Conclusions
A three-step testing sequence that involves combining a risk factor questionnaire, point-of-care testing
and confirmatory laboratory testing could potentially reduce unnecessary delays or rescheduling of
computed tomography scans. This testing approach appears more cost-effective than the current
approach that involves obtaining a recent laboratory-based measurement prior to administering
contrast media. However, the contribution of intravenous contrast media to the development of acute
kidney injury, particularly in patients with an estimated glomerular filtration rate of < 30 ml/minute/
1.73 m2, and the benefits and risks of intravenous hydration prophylaxis in this population remain
uncertain. Although uncertainties remain, the study’s findings suggest that these risks appear very low
and that delaying contrast-enhanced computed tomography scans appears unnecessary for the vast
majority of patients.
Studies evaluating the impact of risk stratifying questionnaires on workflow outcomes in computed
tomography scanning patients attending without recent estimated glomerular filtration rate results are
needed. Further research on the risk of contrast and benefits and harms of intravenous hydration in
patients with an estimated glomerular filtration rate of < 30 ml/minute/1.73 m2 may also be warranted.
Study registration
This study is registered as PROSPERO CRD42018115818.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 39.
See the NIHR Journals Library website for further project information.
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Chapter 1 Background
Description of the health problem
The use of computed tomography (CT) imaging has transformed the way the body can be visualised
to detect disease and inform treatment decisions across a range of diseases. This is illustrated by
the increase in the number of CT scans performed in hospitals in England, from just over 1 million in
1996–7 to almost 5 million in 2012–13.1 In clinical situations in which the use of contrast is deemed
beneficial before CT imaging is performed, an iodine-based (iodinated) contrast agent is normally
given to patients to enhance image quality and diagnostic performance. Different types of agent
are available, with the dose varying depending on the type of scan or procedure required. However,
intravenously administered contrast agents are thought to occasionally cause kidney damage or acute
kidney injury (AKI), particularly in patients with existing kidney disease. Historically, high-osmolar
contrast agents were used for radiological examinations, but these agents were considered to pose
a significant risk of contrast-induced AKI and other adverse events. The term contrast-induced AKI
(CI-AKI) or contrast-induced nephropathy (CIN) describes an AKI occurring within a few days of
receiving a contrast agent that cannot be attributed to other causes. However, the development of safer
contrast media (low-osmolar agents and iso-osmolar agents) and their widespread adoption in clinical
practice means that it is now difficult to ascribe contrast as the cause of an AKI. Much of the research
literature on the risks of CI-AKI is limited, being based on single-group cohorts, but the inclusion of
adequate control populations in more recent studies has generated results that question the risk of
AKI from contrast agents. This had led to the current debate about whether or not low-osmolar and
iso-osmolar contrast agents pose any meaningful risk of AKI.2–5 In the light of this uncertainty, the term
post-contrast AKI (PC-AKI) is now increasingly used to describe such events. Definitions of AKI vary,
but often include absolute increases in baseline levels of serum creatinine (SCr) ≥ 0.5 mg/dl or relative
increases of 25–50%.6
Although many possible clinical risk factors for PC-AKI have been suggested and studied, most risk
factors relate to chronic kidney disease (CKI) or AKI more broadly, rather than specifically to PC-AKI.
Renal dysfunction appears to be the most important risk factor for PC-AKI. A creatinine blood test
is used to identify patients at risk; elevated creatinine levels indicate likely kidney dysfunction. In
clinical practice, creatinine blood test results are often used to calculate eGFRs (estimated glomerular
filtration rates). eGFRs are considered a better measure of kidney function than creatinine alone;
eGFR is calculated using details on age, sex, race and creatinine level. Several different methods exist
to calculate eGFR in adults, with the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
equation7 and the MDRD (Modification of Diet in Renal Disease) equation8 frequently used in the NHS.
eGFR results are used to evaluate patient risk of PC-AKI before a contrast agent is administered so
that any risk from contrast agents can be minimised or removed. Patients with abnormal eGFR results
may need prophylactic intravenous hydration (IVH) to reduce the risk of AKI or alternative imaging
strategies may be used that do not require the use of a contrast agent.
The risk of PC-AKI can be quickly assessed in most hospital patients awaiting a CT scan or procedure.
All inpatients should have a recent eGFR or creatinine measurement available as part of other hospital
tests, as should many outpatients. However, some outpatients do not have a recent result available
when their CT appointment is due. Although a blood sample could be taken and sent to the hospital
laboratory, results typically become available only more than 1 hour after the blood is taken. Moreover,
some radiology services offer extended-day and 7-day services, which may not be in line with laboratory
provision. Kidney function will therefore be unknown in these patients at the time of their appointment,
so their risk of PC-AKI will be more difficult to evaluate. Consequently, rather than patients being
subject to an uncertain risk of PC-AKI, their CT appointment may be rescheduled or performed without
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a contrast agent. The former can result in patient stress and a lost appointment slot for the radiology
department, whereas the latter will result in less accurate CT images. Sometimes contrast may be
administered in patients thought to be at a low risk of AKI based on other clinical information. Point-
of-care (POC) measurement devices allow rapid blood sampling and measurement of eGFRs, enabling
PC-AKI risk to be assessed and, if the risk is low, the CT appointment to go ahead as planned.
Current service provision and care pathway
A 2015 review of the quality of available clinical practice guidance documents on different aspects
of PC-AKI, and of their recommendations, found variation in how PC-AKI was defined, how patients
at risk should be identified, and found limited consensus on the use of interventions for preventing
PC-AKI.9 In light of the significant number of recent and ongoing studies in these areas of research,
it is important that any clinical guidance is kept up to date.
Guidelines published in 2018 on the use of contrast media include the European Society of Urogenital
Radiology (ESUR) guidelines on PC-AKI,10 The Royal Australian and New Zealand College of Radiologists
(RANZCR) Iodinated Contrast Media Guideline11 and the ACR (American College of Radiology) Manual on
Contrast Media.6 The ESUR guidelines recommend measurement of eGFR before administration of an
intravascular iodinated contrast agent in either all patients or patients who have a history of renal
disease (i.e. patients with an eGFR of < 60 ml/minute/1.73 m2), kidney surgery, proteinuria, hypertension,
hyperuricaemia or diabetes mellitus. Two guidelines recommend using the CKD-EPI equation to
calculate eGFR.10,11
Broadly, there is a consensus across all three guidelines about how to identify patients who may be at
risk of PC-AKI, with agreement that there is very little evidence that iodinated contrast material is an
independent risk factor for AKI in patients with an eGFR ≥ 30 ml/minute/1.73 m2. An eGFR threshold
of < 30 ml/minute/1.73 m2 is therefore often used to identify patients at risk of PC-AKI. Nevertheless,
the RANZCR guideline notes that intravascular iodinated contrast agents should be given to any
patient regardless of renal function status if the perceived diagnostic benefit to the patient, in the
opinion of the radiologist and the referrer, justifies this administration.11 Similarly, the ACR guideline
advises that any threshold put into practice must be weighed on an individual patient level with the
benefits of administering contrast material.6
In patients identified as being at a higher risk of developing PC-AKI, pre- and post-procedural 0.9%
intravenous saline is recommended in the RANZCR guidelines as the first-line preventative strategy
to mitigate the risk.11 The ESUR guidelines recommend that in high-risk patients (with an eGFR
< 30 ml/minute/1.73 m2 or known/suspected acute renal failure) clinicians should:
l consider an alternative imaging method not using iodine-based contrast media
l use intravenous saline (3–4 hours before and 4–6 hours after contrast) or sodium bicarbonate
(1 hour before contrast agent administration)
l individualise preventative hydration in patients with severe congestive heart failure or patients with
end-stage renal failure (i.e. patient with an eGFR < 15 ml/minute/1.73 m2).
The ESUR guidelines also recommend measurement of eGFRs 48 hours after contrast agent administration,
patient monitoring for at least 30 days and eGFR measurement at regular intervals if, at 48 hours, PC-AKI
is diagnosed.
In terms of clinical practice adopted across NHS radiology departments, two surveys conducted in
2015 identified inconsistent or poor compliance with guidance, with the wide variation in practice
being thought to reflect inconsistencies in published guidance.12,13 One of the surveys reported that
most (of the responding) NHS CT departments required renal function to be assessed via a blood test
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for all patients, although in some departments only patients at high risk of PC-AKI were assessed.12
It is thought that risk-stratifying questionnaires may be a more efficient way to identify patients at
high risk of PC-AKI,14 with blood test results needed only for high-risk patients, although conclusive
evidence on this approach is still needed. One of the NHS surveys asked about the eGFR or creatinine
threshold levels at which contrast agents were contraindicated. Although the most frequently used
threshold was an eGFR of < 30 ml/minute/1.73 m2 (used in 45% of NHS trusts), overall there was
notable variation, with 19 different thresholds identified, each leading to different prophylactic
treatment strategies.12
Variation across the NHS also exists in the way creatinine is measured in laboratories.15 The Jaffe
(alkaline picrate) method is a colorimetric assay that can be affected by interfering substances
(such as ketones and bilirubin) and so is prone to overestimate creatinine. Alternatively, enzymatic
laboratory methods can be used, which are more accurate (because they are less prone to interference),
but are also more expensive. In order to reduce error and maximise the comparability of creatinine
measurements between laboratories, methods should be calibrated against isotope dilution mass
spectrometry (IDMS). Similarly, there is variation in the way eGFR is calculated across the NHS.15
Although the CKD-EPI equation is recommended in recent guidelines, the MDRD equation is also
commonly used, even though it is more prone to underestimate eGFR in some patients.16
Regardless of which particular group of patients has their renal function assessed, previous blood
test results are not always available prior to CT appointments, which can result in cancellations and
re-bookings. The use of POC devices presents a possible solution to this problem by providing eGFR
measurements in time frames short enough to avoid cancellation of CT appointments. POC testing
could be done on all patients with missing results or just on those patients identified as being at high
risk of PC-AKI using a questionnaire. Alternatively, some radiology departments avoid this problem by
adopting a ‘no blood test result – no booking’ policy, whereas others mitigate it by making efforts to
chase up missing blood results.12
Description of the technologies under assessment
Several POC devices are being assessed, based on their ability to output results as eGFRs: StatSensor®
(Nova Biomedical, Runcorn, UK), i-STAT Alinity (Abbott Point of Care, Inc., Princeton, NJ, USA), ABL90
FLEX PLUS and ABL800 FLEX (Radiometer Ltd, Crawley, UK), epoc® (Siemens Healthineers AG,
Erlangen, Germany) and Piccolo Xpress® (Abaxis, Inc., Union City, CA, USA) and DRI-CHEM NX 500
(Fujifilm Corporation, Tokyo, Japan).
Point-of-care creatinine devices are either handheld, portable or tabletop and require only very small
blood samples (usually obtained via finger prick). Some devices use test cartridges and others test
strips. Levels of creatinine are measured using enzymatic methods either as one of several analytes or
as a single measurement. Although POC devices provide results quickly, their results may not be as
accurate as those derived from laboratory reference test analyses.
Currently, only around 10% of NHS CT departments use POC devices to get a blood test result for
patients attending without a recent result.12 For POC devices to be adopted more widely in outpatient
settings, assurances will be needed about their accuracy in providing reliable estimates of eGFR at the
POC, when compared with estimates derived from laboratory reference test analyses. Another area of
concern lies in whether or not POC devices can store and transmit results to hospital databases to
ensure patient records are as up to date and complete as possible.
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Chapter 2 Aims and objectives
Overall aims and objectives of assessment
The purpose of this assessment was to assess the clinical effectiveness and cost-effectiveness of POC
creatinine tests to assess kidney function, for people who need contrast-enhanced CT imaging in a
non-emergency situation and who do not have a recent SCr measurement. To achieve this, the
following objectives were proposed.
Clinical effectiveness
l To perform a systematic review of studies that compare the results of POC creatinine tests with
laboratory-based tests to assess kidney function in a non-emergency setting.
l To perform a systematic review of the clinical impacts and implementation of POC creatinine
tests to assess kidney function before CT imaging. This will include assessment of the associated
mortality and morbidity, patient-centred outcomes, adverse events, acceptability to clinicians and
patients, and compliance.
Cost-effectiveness
l To perform a systematic review of published cost-effectiveness studies of the use of POC creatinine
tests in a secondary care setting to assess kidney function before contrast-enhanced imaging.
l To develop a decision model to estimate the cost-effectiveness of the use of POC creatinine tests to
assess kidney function before contrast-enhanced imaging. The relevant population is people who
need contrast-enhanced imaging in a non-emergency situation and who do not have a recent
SCr measurement.
l The objective of the decision model will link the diagnostic accuracy of POC creatinine tests to
short-term costs and consequences (e.g. the impact on cancelled or delayed appointments, use and
volume of contrast media and associated risks, such as PC-AKI). Short-term risks of PC-AKI will be
linked to potential longer-term costs and consequences (e.g. CKD, end-stage renal disease and
death) using the best-available evidence. Depending on the robustness of the evidence, additional
exploratory analyses using assumptions and expert opinion may be also undertaken.
l The feasibility of extending the decision model to include other clinical outcomes that could be
affected by any changes in the imaging decision based on the POC tests will also be assessed. These
outcomes could include (i) any anxiety associated with having a delayed or cancelled CT scan and
(ii) morbidity and mortality implications of performing unenhanced scans, or using lower doses of
contrast agent. However, given that these outcomes will differ depending on the specific population
and the underlying reason for imaging, it is envisaged that any extension of this nature will need to be
constrained to a specific population/reason for the scan. The practicalities and value of developing a
specific ‘exemplar’ application (with potentially limited generalisability) will be considered versus
using a simpler and more generic approach (e.g. using threshold analysis to determine the magnitude
of any impact necessary to result in a different decision based on conventional cost-effectiveness
decision rules).
l The cost-effectiveness of the alternative POC tests will be expressed in terms of incremental cost
per quality-adjusted life-year (QALY) and/or net health (or monetary) benefits.
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Chapter 3 Assessment of clinical effectiveness
Literature searches
Comprehensive searches of the literature were conducted to identify studies relating to POC devices
for measuring creatinine levels in the blood.
The search strategy was developed in MEDLINE (via Ovid) by an information specialist with input
from the review team. The strategy comprised a set of terms for POC tests combined with terms
for either creatinine or eGFR. Text word searches in the title and abstracts of records and relevant
subject headings were included in the strategy. No date or language limits were applied and the
searches were not restricted by study design. The MEDLINE strategy was adapted for use in all other
resources searched.
The searches were carried out in November 2018. The following databases were searched: MEDLINE
(including Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily
and Ovid MEDLINE), Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database
of Systematic Reviews (CDSR), Cumulative Index to Nursing and Allied Health Literature (CINAHL)
Plus, Database of Abstracts of Reviews of Effects (DARE), EMBASE, Health Management Information
Consortium (HMIC), Health Technology Assessment (HTA) Database, PubMed and the Science
Citation Index.
In addition, the following resources were searched for ongoing, unpublished or grey literature:
ClinicalTrials.gov, Conference Proceedings Citation Index: Science, EU Clinical Trials Register, Open
Access Theses and Dissertations, ProQuest Dissertations & Theses Global™ (ProQuest, Ann Arbor,
MI, USA), PROSPERO, the World Health Organization (WHO)’s International Clinical Trials Registry
Platform portal and manufacturers’ websites. References submitted by the manufacturers to the
National Institute for Health and Care Excellence (NICE) were also checked. The websites of
manufacturers of POC creatinine devices were checked and the reference lists of relevant
reviews and included studies were scanned.
Search results were imported into EndNote x8 [Clarivate Analytics (formerly Thomson Reuters),
Philadelphia, PA, USA] and deduplicated. Full search strategies can be found in Appendix 1.
Separate searches were also made to identify evidence to inform estimation of the risk of an AKI
following a contrast-enhanced CT scan (see Pragmatic reviews of further evidence to inform the
economic model).
Selection criteria
Two reviewers independently screened all titles and abstracts. Full papers of any titles and abstracts
deemed potentially eligible were obtained where possible, and the relevance of each study assessed
independently by two reviewers according to the criteria below. Any disagreements were resolved
by consensus. Conference abstracts were included provided that they reported sufficient data to
assess eligibility.
The following eligibility criteria were used to identify relevant studies.
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Participants
To maximise the number of data on test accuracy, the eligible population for test accuracy studies
was any adult patient group receiving POC creatinine testing compared with laboratory testing in a
non-emergency/intensive care setting.
For studies reporting clinical or implementation outcomes, only studies of adult patients receiving POC
tests before CT imaging in a non-emergency, outpatient setting were included.
Interventions
For test accuracy studies, details of the POC devices eligible for the review are presented in Table 1.
This list is broader than those reported in the NICE scope and in the study protocol, which were
restricted to devices that reported eGFRs. This was done to maximise the available evidence base
because early on during the screening process it became evident that many studies were of devices
that did not calculate eGFR (i.e. creatinine was measured), with eGFR being calculated manually by
the study investigators. These studies were included where it was thought (following clinical and
TABLE 1 Point-of-care devices eligible for inclusion in the systematic review
Manufacturer
and devices
Device
format
Parameters
measured
Sample
volume
Analysis
time eGFR equation used
Nova Biomedical
StatSensor
Handheld Creatinine only 1.2 µl 30 seconds MDRD, CKD-EPI, Cockcroft–Gault,
Schwartz and Counahan–Barratt
Related models: StatSensor-i, StatSensor Xpress-i
All models allow offset adjustment of results to correct for measurement bias; StatSensor and StatSensor-i also allow
slope adjustment
Abbott Point of
Care
i-STAT Alinity
Handheld Multiple parameters 65 µl 2 minutes MDRD and CKD-EPI
Related models: i-STAT1, many studies simply state ‘i-STAT’
Radiometer Ltd
ABL90 FLEX PLUS
Portable 19 parameters 65 µl 35 seconds CKD-EPI, MDRD and Schwartz
ABL800 FLEX Tabletop 18 parameters 125–250 µl 1 minute CKD-EPI and MDRD
Related models: ABL827 and ABL837
All models allow offset and slope adjustment of results to correct for measurement bias
Siemens
Healthineers
AG epoc
Handheld 11 parameters on
one test card
92 µl < 1 minute CKD-EPI, MDRD and Schwartz
Abaxis, Inc.
Piccolo Xpress
Tabletop Multiple parameters 100 µl < 14 minutes MDRD
Fujifilm
Corporation
DRI-CHEM NX
500
Tabletop Multiple parameters 10 µl 5 minutes Expected
Note
For studies reporting clinical or implementation outcomes any POC creatinine device used in a radiology or imaging
department setting was eligible.
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technical advice) that the model in question was sufficiently similar to the most recent version of the
device (all the most recent models have the facility to present eGFR results). New versions of a device
may sometimes incorporate software improvements (to allow eGFR outputs), a different interface or
improved functionality, rather than changes in the way creatinine is analysed. For example, the recently
released i-STAT Alinity was ‘built on the proven technology of the i-STAT System’,17 and hence studies
were included that used an ‘i-STAT’ device.
All the eligible devices measure whole-blood creatinine using an enzymatic method. The devices are
either handheld, tabletop or portable and need very small volumes of blood. Creatinine levels may be
analysed either as one component of a panel of parameters or as a single measurement via a test card
or specific cartridge.
Reference standard
l Non-urgent (results available after 1 hour) laboratory-based SCr measurement:
¢ Jaffe method
¢ enzymatic method.
l Urgent (results available within an hour) laboratory-based SCr measurement:
¢ Jaffe method
¢ enzymatic method.
l No testing, clinical judgement alone.
Outcomes
The eligible intermediate outcome measures were:
l diagnostic accuracy of POC creatinine devices compared with laboratory-based creatinine devices
l correlation between POC creatinine devices and laboratory-based creatinine devices
l test failure rates
l number of delayed or cancelled and rescheduled scans
l volume of intravenous contrast material used
l number of unenhanced scans
l number of hospital admissions
l hospital length of stay.
All relevant outcome definitions and cut-off points were extracted.
In addition, the following clinical outcomes were eligible:
l AKI (either PC-AKI or CI-AKI)
l fall in baseline eGFR or rise of baseline creatinine
l temporary renal replacement therapy
l new-onset CKD (stage 3 or worse)
l end-stage renal disease with the need for permanent renal replacement therapy
l health-related quality of life (HRQoL)
l mortality.
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Eligible outcomes related to the implementation of the interventions of interest and related practical
issues included:
l acceptability of POC devices (to clinicians and patients)
l patient satisfaction
l training requirements
l uptake and compliance.
Study designs
Diagnostic accuracy and correlation studies
Studies in which the POC test and laboratory reference test were performed independently on the
same patients were eligible.
Clinical effectiveness/implementation
Any experimental or observational study that compared POC tests with laboratory testing and that
reported relevant clinical outcomes as listed in Outcomes were eligible. Studies with a single-group
design were also eligible. Relevant publications reporting issues that were related to the implementation
of, or practical advice relating to, POC creatinine test technologies (experimental or observational
studies or reviews) were also included.
Case reports and studies focusing only on technical aspects of POC creatinine test technologies
(such as technical descriptions of the testing process or specifications of machinery) were excluded.
Data extraction
Data on study characteristics and results were extracted by one reviewer using a standardised data
extraction form and independently checked by a second reviewer (MC and AL). Discrepancies were
resolved by discussion, with involvement of a third reviewer (SD) where necessary. Data from relevant
studies with multiple publications were extracted and reported as a single study, quoting the most recent
or most complete publication. Given the large number of included studies, the checking of reference lists
of included studies, to identify further studies, was not systematically undertaken.Where appropriate,
study authors and manufacturers were contacted to seek more detailed or missing diagnostic or clinical
data. If data on mean measurement bias were reported without 95% limits of agreement [or confidence
intervals (CIs)] these were estimated if a standard deviation and sample size was reported using the
Bland and Altman formula.18
The type of diagnostic accuracy data and synthesis required for this assessment are different from
the typical diagnostic accuracy study in which a device might be tested for its ability to detect a
dichotomous (yes/no) risk of PC-AKI. As the definition of PC-AKI risk has changed over time, sensitivity
and specificity data at a given threshold are not relevant as both the laboratory reference test and
POC device thresholds for defining risk have changed. Therefore, reported sensitivity and specificity
will refer to different diagnoses of risk. In addition, this assessment aimed to describe the accuracy of
the POC devices in correctly classifying individuals according to their PC-AKI risk categories determined
by different levels of eGFR as given in Table 2. These thresholds were chosen because they reflect
both the thresholds used in guidelines – which have varied over time – and the thresholds used in
defining CKD.19,20
Therefore, the probability that individuals are correctly classified into the four risk categories in Table 2
was estimated and the probabilities that they are incorrectly classified into one of the other categories
were estimated.
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Therefore, data were primarily extracted on the number of individuals in each of the cells in a four-by-four
table, defined by the categories in Table 2. A data extraction template is presented in Appendix 2, Table 38.
Where data were reported as a combination of these categories (e.g. number of individuals with an eGFR
of < 60 ml/minute/1.73 m2), these were also extracted.
Critical appraisal
The quality of the diagnostic accuracy studies was assessed using the QUADAS-2 (quality assessment
of diagnostic accuracy studies 2) tool, modified to incorporate review-specific issues. QUADAS-2
evaluates both risk of bias and concerns about study applicability to the review question. The Cochrane
risk-of-bias tool was used to evaluate randomised controlled trials (RCTs) identified in the pragmatic
reviews. The quality of other studies included in the review was not assessed formally, as these studies
did not directly inform the quantitative synthesis or parameters informing the economic analyses.
Quality assessments were performed by one reviewer (AL) and independently checked by a second
reviewer (MC). Disagreements were resolved through consensus and, where necessary, by consulting
a third reviewer (SD).
Methods of data synthesis
Synthesis of diagnostic accuracy data
For each device, estimates of the probabilities that individuals are classified by the POC device as having
an eGFR in one of the four categories in Table 2 given their true eGFR is in one of those categories were
required. These probabilities relate to the sensitivity and specificity of each device, which were used
to populate the economic model in Diagnostic accuracy of point-of-care creatinine tests. Individuals are
categorised as being at risk of PC-AKI if their eGFR is < 30 ml/minute/1.73 m2 (i.e. category 1 in Table 2).
Therefore, the probability that each POC device correctly classifies individuals in this category will
reflect their sensitivity to detecting individuals at risk. To calculate the specificity of each POC device
it is necessary to know the underlying distribution of patients across the different eGFR categories
(see Diagnostic accuracy of point-of-care creatinine tests for details).
Separate syntheses were carried out for POC devices for which two or more studies reported data
on individuals classified into the different categories by laboratory reference test and POC device.
Devices with sufficient data were StatSensor (including StatSensor, StatSensor-i and StatSensor
Xpress-i), i-STAT (including i-STAT and i-STAT1) and ABL (including ABL827 and ABL800 FLEX);
hence, three separate analyses were carried out, pooling the data on three devices (i.e. StatSensor,
i-STAT and ABL), assuming that the different specifications of each device does not differ in their
diagnostic characteristics.
TABLE 2 Estimated glomerular filtration rate categories
considered in the analysis
Category eGFR (ml/minute/1.73 m2)
1 0–29
2 30–44
3 45–59
4 ≥ 60
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For each study i reporting data on all cells of Table 38 in Appendix 2 the number of individuals classified
by a POC device as belonging to eGFR category k = 1, . . . ., 4, given true eGFR category (as determined
by the laboratory reference test) j = 1, . . . ., 4, rijk were assumed to follow a multinomial distribution,
which is a generalisation of the binomial distribution to more than two categories:
(rijk1, rijk2, rijk3, rijk4, )∼Multinomial

(p j1, p j2, p j3, p j4,), nij,

, (1)
with nij defining the number of individuals with true eGFR in category j in study i, and pjk defining the
probabilities of being classified by a POC device in eGFR category k, when the true category is j
(j, k = 1, . . . ., 4), which were assumed common to all studies.
The model was estimated in a Bayesian framework using Markov chain Monte Carlo in OpenBUGS
(version 3.2.3; OpenBUGS Foundation, Imperial College London, London, UK),21,22 in which the
probabilities were given a non-informative Dirichlet prior distribution:
(p j1, p j2, p j3, p j4)∼Dirichlet(1, 1, 1, 1). (2)
The Dirichlet distribution is an extension of the beta distribution to multiple dimensions and ensures
that the estimated probabilities always add to one.21,23 Setting all the parameters equal to one, as in
Equation 2, assigns equal density a priori to any vector of probabilities that sums to one.
Studies reporting only on collapsed categories were assumed to provide information on a function of the
probabilities pjk. This function varied depending on which categories were collapsed, with relationships
determined using partitioning properties of conditional probabilities. Estimation of the probability that an
individual in an included study (as opposed to the underlying population of interest for this assessment –
see Diagnostic accuracy of point-of-care creatinine tests) has true eGFR in category j, T[j] was also required.
For details see Appendix 3, Model for the probability that an individual has a true estimated glomerular filtration
rate in each category.
As the posterior distributions of the probabilities are bounded at zero and one, they are expected to
be highly skewed. Therefore, results are reported as posterior medians with 95% credible intervals
(CrIs) and plotted as density strips. In Diagnostic accuracy of point-of-care creatinine tests, the mean
probability estimates, calculated from 1000 simulated values from the posterior distribution obtained
by thinning the 30,000 posterior values generated in each analysis of the evidence synthesis, were used
to derive specificity and sensitivity. Density strips are horizontal rectangles that can represent an entire
probability distribution in one dimension: the rectangle is darkest at the point of highest probability
density, then shaded with darkness proportional to the density, gradually fading to white at points of
zero density.24 The width of the rectangle itself has no meaning, and is used only to distinguish between
distributions arising from different analyses. Standard lines representing point and interval estimates
tend to give the impression that the data equally support all points in the interval, whereas density
strips give a better description of the uncertainty in a probability distribution, particularly for non-
symmetric distributions.
Each model was run until convergence was satisfactory and then the results were based on a further
sample of iterations from two separate chains. Convergence was assessed by inspecting history and
Brooks–Gelman–Rubin plots.25,26
Data from different studies were pooled under the assumption that they estimate common probabilities,
given a true eGFR category (i.e. using a fixed-effects model). Extension to a model allowing for between-
study heterogeneity in probabilities was considered, but as a result of the small number of studies reporting
data on all categories and the small number of individuals in some categories (including several zeros),
this was not deemed feasible. The OpenBUGS code and data used are given in Appendix 4.
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Clinical effectiveness results
Quantity and quality of research available
Figure 1 presents the study selection process in a Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) flow diagram. The literature searches identified a total of 3350 unique
records. After title and abstract screening, 171 references were retrieved and 54 unique studies were
included in the review. Of these, 12 studies reported diagnostic accuracy data (expressed as, or
allowing calculation of, sensitivity and specificity) for eGFRs,27–38 seven reported diagnostic accuracy
data for only SCr,39–45 and 50 studies presented data on correlation and/or measurement bias between
a POC device and a laboratory reference test.14,27,28,30–76 Six studies reported data on workflow or
clinical outcomes.29,59,62,77–79
All studies that reported data on diagnostic accuracy of either eGFR or SCr also reported correlation/
measurement bias results, except one.29 Three of the studies that reported data on workflow or clinical
outcomes also reported data on diagnostic accuracy or correlation/bias.29,59,62
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(n = 567)
Total unique records
(n = 3350)
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(n = 3350)
Records excluded
(n = 3179)
Full-text articles assessed
for eligibility
(n = 171)
Full-text articles excluded,
with reasons
(n = 117)
Studies included in qualitative
synthesis
(n = 54)
• eGFR diagnostic accuracy, n = 12
• SCr diagnostic accuracy, n = 7
• Correlation and bias, n = 50
• Flow and clinical outcomes, n = 6
Studies included in
quantitative synthesis
(meta-analysis)
(n = 10)
• Not eligible population, n = 26
• Not eligible intervention, n = 38
• No eligible outcome, n = 28
• No eligible design, n = 11
• Conference abstracts linked to
    main publication, n = 8
• Ongoing, no results, n = 2
• Irretrievable, n = 4
FIGURE 1 Study identification process: PRISMA flow diagram.
DOI: 10.3310/hta24390 Health Technology Assessment 2020 Vol. 24 No. 39
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
13
Risk-of-bias assessment
Table 3 summarises the results of the QUADAS-2 assessment, split by POC device. Full results,
including all signalling questions, are reported in Appendix 5.
Six studies were rated as being at low risk across all risk-of-bias domains, including two studies of
ABL800,31,37 three studies of i-STAT33,37,38 and three studies of StatSensor.28,30,37 Among the six studies27,29,34–36
with at least one domain rated as being at unclear or high risk of bias, three used correction factors after
comparing initial POC results with laboratory reference test results from the same samples, including two
studies of i-STAT34,35 and one StatSensor study.36 Correction factors can be entered into StatSensor devices
to correct for measurement bias (see Table 1). However, in these studies the correction was applied to
align POC test results with the reference standard results using the same samples. Therefore, adjusted
analyses reported in these studies may overestimate the accuracy of the POC devices. None of the ABL
studies reported using its offset correction functionalities. Four studies27,34–36 (including three conference
abstracts27,34,35) reported insufficient information to assess bias related to patient selection. Other risk-
of-bias issues included the use of different MDRD equations between the index test and the reference
TABLE 3 Risk-of-bias and applicability assessments of eGFR diagnostic accuracy studies
Study (author and
year of publication)
Assessment
Risk of bias Concerns about applicability
Patient
selection
POC and
laboratory
reference
tests
Flow and
timing Population Thresholds
Test
POC
Laboratory
reference
Radiometer studies
Botz et al., 201327 ? + + ? + + +
Korpi-Steiner et al., 200931 + + + + – – +
Snaith et al., 201837 + + + + + + +
i-STAT studies
aBotz et al., 201327 ? + + ? + + +
Korpi-Steiner et al., 200931 + – + + – – +
Nichols et al., 200733 + + + + – + +
aObrador et al., 201234 ? – + – – – +
aShephard et al., 200835 ? – ? ? – – +
Snaith et al., 201837 + + + + + + +
Snaith et al., 201938 + + + + + + +
StatSensor studies
Dorward et al., 201828 + + + – – + +
Houben et al., 201729 + ? + – + + +
Inoue et al., 201730 + + + + – – +
Korpi-Steiner et al., 200931 + – + + – – +
Krige, 201732 + – + – + + +
Shephard et al., 201036 ? – + – – + +
Snaith et al., 201837 + + + + + + +
+, Low risk of bias or level of applicability concerns; ?, unclear risk/concerns; –, high risk/concerns.
a Conference abstract.
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standard,31 and the use of a Jaffe method for the laboratory reference test (vs. an enzymatic method for
the POC test).32
Only two studies had low applicability concerns across all domains, including one study of ABL800, i-STAT
and StatSensor,37 and one study of i-STAT.38 The most common applicability concern was the use of eGFR
threshold. Three studies of i-STAT,31,33,35 three of StatSensor28,31,36 and one ABL800 study31 used an eGFR
cut-off point of 60 ml/minute/1.73 m2 or above (see Background). Several studies included disease-specific
populations, including two StatSensor studies28,36 and two i-STAT studies;29,34 therefore, their applicability
to a broader population of outpatients referred to CTwithout a recent eGFR may be limited. One study
used a non-standard CKD staging34 and one study30 used a country-specific Japanese equation to calculate
eGFR, which limits their applicability to the review question.
Overall, two studies were rated as being at low risk of bias and had low applicability concerns across all
domains assessed, including one that evaluated ABL800, i-STAT and StatSensor,37 and one of i-STAT only.38
Some studies are presented in several lines as they compare multiple devices (e.g. the 2018 publication
by Snaith et al.37).
Studies reporting bias or correlation outcomes
Fifty studies reported bias or correlation outcomes.14,27,28,30–76 Eighteen studies were available only as
conference abstracts (Table 4). Where reported, sample sizes ranged from 10 to 3087 patients. Four
studies were set in the UK37,38,43,53 and 11 studies were reported as being conducted in a radiology or
CT setting14,27,30,31,38,40,41,46,59,62,74
Studies of StatSensor devices
Twenty-six studies reported measurement bias or correlation results for a StatSensor POC device14,28,30–32,
36,37,39–46,53,62,67,69–76 Eight studies were available only as a conference abstract.40,43,45,53,70–72,74 A large majority
of studies were of the StatSensor or StatSensor-i model, with six studies being of the StatSensor Xpress
(or Xpress-I) model.28,39,42,44,53,76 Sample sizes ranged from 15 to 1467 patients. Most studies reported
measurement bias results based on levels of creatinine, with only three studies reporting results based
on eGFR.30,62,70 Among the studies that either explicitly reported mean measurement bias results or for
which an indication of mean bias could be derived from Bland–Altman plots, there appeared to be no clear
trend in terms of the direction of bias, with nearly as many studies reporting positive bias (in StatSensor
creatinine measurements) as reporting negative bias. Only two studies reported results following offset
correction to adjust for bias.39,41
Enzymatic laboratory reference methods are far more specific for measuring creatinine than Jaffe
laboratory methods. The latter methods are prone to overestimate creatinine (especially at low
concentrations) as picric acid reacts with other metabolites or drugs. Results from studies that use
enzymatic laboratory methods are therefore preferable to those using Jaffe methods. Of the
10 studies28,30,31,36,37,53,62,70,73,76 that used an enzymatic laboratory reference, five reported a positive
measurement bias in creatinine levels when using StatSensor28,30,37,53,70 and five reported a negative
bias.31,36,62,73,76 However, some bias results were reported only as percentage changes. The results of
those enzymatic reference standard studies that reported mean biases in mg/dl or µmol/l (including the
often wide limits of agreement) indicated that many StatSensor creatinine measurements are likely to be
inaccurate enough to have a clinically significant impact on subsequent eGFR calculations. This impact
was evident in studies that reported bias results based on eGFRs; for example, Morita et al.62 reported a
mean eGFR bias of 11 ml/minute/1.73 m2 (95% limits of agreement –22.4 to 44.4 ml/minute/1.73 m2).
Even studies that did not report significant mean bias reported the presence of important bias in
measures of variance around the mean; for example, in the study by Snaith et al.37 the mean bias was
very small at 3.56 µmol/l (0.04 mg/dl), but the 95% limits of agreement were −27.7 µmol/l (–0.31 mg/dl)
to 34.8 µmol/l (0.39 mg/dl). Several studies did not report a measure-of-bias variance. Five studies
indicated that bias tended to increase at higher creatinine concentrations.39,42,67,72,73
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TABLE 4 Studies reporting measurement bias or correlation outcomes
Study (author
and year of
publication) Population (N) and country POC device(s) Laboratory reference Results (for creatinine unless stated) and notes
Aumatell et al.,
201046
24 undergoing CT scans
Australia
StatSensor VITROS® (version 5; Ortho Clinical
Diagnostics, Raritan, NJ, USA)
r2 values for three different StatSensor devices were
0.9886, 0.9866 and 0.9935 (mean 0.990)
The B–A plot indicated underestimation of creatinine
using StatSensor (a small negative bias), but no further
bias results were reported
Azzouz et al.,
201414
1467 outpatients with renal dysfunction
before MRI or CT
Denmark
StatSensor NR This study evaluated a structured questionnaire and
reported an r2= 0.9 when comparing laboratory
reference with StatSensor
Bahar et al.,
201647
244 oncology outpatients split into
three cohorts corresponding to three
different periods
USA
i-STAT Jaffe (Beckman Coulter DxC 800,
Beckman Coulter, Inc., Pasadena,
CA, USA)
l Cohort 1: n = 39, mean bias = –0.48 mg/dl
l Cohort 2: n = 85, mean bias = –0.08 mg/dl
l Cohort 3: n = 120, mean bias = 0.17 mg/dl
Baier et al., 200348 15 organ donors
USA
i-STAT NR r2= 0.95
aBender et al.,
201249
54 patients prescribed carboplatin
chemotherapy and zoledronic acid; and
56% of patients were female
USA
i-STAT Enzymatic (VITROS 5600, Ortho
Clinical Diagnostics)
The study was designed to determine if whole
blood and SCr measurements were interchangeable
when calculating dosages for carboplatin and
zoledronic acid
For the CG eGFR results i-STAT had an average
negative bias of –19.25mg/dl, whereas the MDRD
eGFR and CKD-EPI eGFR results had positive biases
of 115.2mg/dl and 28.0mg/dl, respectively
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Study (author
and year of
publication) Population (N) and country POC device(s) Laboratory reference Results (for creatinine unless stated) and notes
aBetman et al.
201550
Not reported
USA
i-STAT and epoc Olympus platform (no other
details)
Patient serum samples with known creatinine levels
were pooled to create three standards: normal,
high and very high range creatinine. Serial dilutions
of hydroxycarbamide were added to aliquots of
each standard
i-STAT: a typical dose of hydroxycarbamide could
result in a creatinine level with a positive bias of
6.15 mg/dl. i-STAT SCr measurements showed a
dose–response relationship, with the concentration
of hydroxycarbamide, but epoc did not
aBobilewicz,
200851
70 potential organ donors,
post-extensive surgery
Poland
ABL 800 Enzymatic (Cobas INTEGRA® 800,
Roche Holding AG, Basel,
Switzerland)
r2= 0.997
aBotz et al., 201327 2042 patients at risk of renal disease prior
to radiological examinations; and 43% of
patients were female
USA
ABL827 and
i-STAT1 (sample
type NR)
Enzymatic, (Cobas C-501, Roche
Holding AG)
Mean bias for i-STATwas + 0.03mg/dl (SD 0.13mg/dl,
95% LoA estimated by EAG as –0.22 to 0.28)
Mean bias for ABL827 was –0.06mg/dl (SD 0.13mg/dl,
95% LoA estimated by the EAG as –0.31 to 0.19mg/dl)
Cao et al., 201752 10 patients
USA
epoc VITROS 5600 (Ortho Clinical
Diagnostics)
r2= 0.9313
Mean bias: −0.025 mg/dl (−3.4%)
aCory et al., 201853 15 pregnant women and non-pregnant
control patients
UK
StatSensor Xpress Enzymatic (type NR) r2= 0.95
r2= 0.96 (pregnant population subgroup, n= 11)
The median difference with the reference test was
12 µmol/l
Dimeski et al.,
201354
40 laboratory staff and renal outpatients
Australia
i-STAT Jaffe (Beckman Coulter DxC 800) Results presented by method of blood sampling:
l r2= 0.996 for lithium heparin
l r2= 0.995 for blood gas syringe
B–A plots indicated small mean positive biases with
i-STAT of between 3 and 8 µmol/l
continued
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TABLE 4 Studies reporting measurement bias or correlation outcomes (continued )
Study (author
and year of
publication) Population (N) and country POC device(s) Laboratory reference Results (for creatinine unless stated) and notes
bDohnal et al.,
200855
NRc
Czech Republic
Piccolo Xpress VITROS 950 and Konelab 60
(Thermo Fisher Scientific,
Waltham, MA, USA)
Statistically significant bias (8%; p < 0.05)
dDorward et al.,
201828
187 HIV-positive patients from a POC
RCT; median age 31 years; 62% female;
and mean creatinine concentration of
69.0 µmol/l
South Africa
StatSensor Xpress-I
(capillary)
Enzymatic (Dimension® EXL™ 200
IDMS, Siemens AG, Munich,
Germany)
Mean POC bias was 10.4 µmol/l (95% LoA –17.6 to
38.3 µmol/l); r2 = 0.58
Gault et al., 200156 149 randomly selected samples, with a
mean creatinine concentration of
220 µmol/l
Canada
i-STAT Jaffe (Beckman Coulter Synchron
CX7, Beckman Coulter, Inc.,
Pasadena, CA, USA)
r2= 0.99; mean bias 10.9%; mean difference
20.1 µmol/l (SD 30.3 µmol/l); 95% LoA estimated by
the EAG as –39.3 to 79.5 µmol/l
aGeorgievskaya
et al., 201157
33 oncology patients
Country NR
i-STAT Enzymatic (Dimension Vista®
System, Siemens AG, Munich,
Germany)
r2= 0.926; mean bias –0.02 mg/dl
Griffin et al.,
201839
Two studies of field workers:
l Derivation cohort, n= 104; all male;
mean age, 29 years; baseline eGFR,
117 ml/minute/1.73 m2
l Validation cohort, n= 105; all male;
mean age, 30 years; baseline eGFR,
111 ml/minute/1.73 m2
Guatemala
StatSensor Xpress Jaffe Creatinine overestimated before adjustment:
l Derivation cohort unadjusted results mean
bias = 0.20 mg/dl (95% CI 0.17 to 0.24 mg/dl)
l Adjusted results mean bias = –0.04 mg/dl (95% CI
–0.01 to –0.07 mg/dl)
l B–A plot indicated that differences were greater
at higher creatinine levels
Confidential
information has
been removed
Confidential information has
been removed
Confidential
information has
been removed
Confidential information has
been removed
Confidential information has been removed
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Study (author
and year of
publication) Population (N) and country POC device(s) Laboratory reference Results (for creatinine unless stated) and notes
Haneder et al.,
201241
401 referred for CT scan at two centres;
mean age was 62 years (SD 14 years); and
63% male
Germany
StatSensor (two
devices: A and B)
Jaffe (Dimension RXL, Siemens AG;
Olympus AU2700, Beckman
Coulter, Inc.)
Centre 1:
l Device A: r2 = 0.93
l Device B: r2= 0.92
Centre 2:
l Device A: r2 = 0.85
l Device B: r2= 0.82
Creatinine was underestimated by StatSensor
before adjustment
Centre 1 (n = 201):
l Device A: % bias before offset adjustment, –16%
l Device B: % bias before offset adjustment, –15%
l Device A: % bias after offset adjustment, 0.4%
l Device B: % bias after offset adjustment, 0.0%
Inoue et al.,
201730
123 (with unadjusted results), scheduled
for CT; mean eGFR 75.3 ml/minute/
1.73 m2 (SD 21.4 ml/minute/1.73 m2);
mean creatinine 0.8 mg/dl (SD 0.29 mg/dl)
Japan
StatSensor-i
(capillary)
Enzymatic (BioMajesty™ BM2250,
Jeol Ltd, Tokyo, Japan)
r2 for eGFR= 0.80; r2 for creatinine = 0.88. Mean
bias not reported
B–A plots indicated a positive bias (overestimation)
with StatSensor for creatinine and a negative bias
for eGFR
aJanetto et al.,
200658
85 heparinised samples
USA
ABL800 FLEX Jaffe (Olympus AU5431, Beckman
Coulter, Inc.)
r2= 0.996; mean bias –0.22 mg/dl
continued
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TABLE 4 Studies reporting measurement bias or correlation outcomes (continued )
Study (author
and year of
publication) Population (N) and country POC device(s) Laboratory reference Results (for creatinine unless stated) and notes
Korpi-Steiner
et al., 200931
266 excess samples taken before CT
procedures; mean age 68 years; and
39% female
USA
ABL800 FLEX,
i-STAT
StatSensor
(with slope and
intercept offset
option)
Heparinised venous
samples
Enzymatic, (Cobas INTEGRA 400,
Roche Holding AG)
Mean bias:
l StatSensor: –0.23 mg/dl (SD 0.18 mg/dl, 95% LoA
estimated by the EAG as –0.58 to 0.12 mg/dl)
¢ r2= 0.61 (assumed to be without offset option)e
l i-STAT: 0.13 mg/dl (SD 0.08 mg/dl, 95% LoA
estimated by the EAG as –0.03 to 0.29 mg/dl)
¢ r2 = 0.93
l ABL800: –0.05 mg/dl (SD 0.09 mg/dl, 95% LoA
estimated by the EAG as –0.23 to 0.13 mg/dl)
¢ r2 = 0.89
Kosack et al.,
201542
60 patients and laboratory workers
The Netherlands
StatSensor Xpress VITROS 5,1FS (Ortho Clinical
Diagnostics)
r2= 0.97
l Normal SCr levels (< 115 µmol/l): 0.69
l Low SCr levels (115 to 270 µmol/l): 0.90
l High SCr levels (270 to 600 µmol/l): 0.83
B–A plot showed a tendency for StatSensor
to underestimate high creatinine values
(i.e. > 600 µmol/l)
fKrige, 201732 103 mixed-ancestry South Africans; mean
age 52 years; and 69% female
South Africa
StatSensor
(capillary)
Jaffe (AU5800 Clinical Chemistry
Analyzer, Beckman Coulter, Inc.)
Mean bias not reported, but the B–A plot of
creatinine showed a negative bias
Lee-Lewandrowski
et al., 201259
3087 referred for contrast-enhanced scan
(CT or MRI) without a recent eGFR
USA
i-STAT Jaffe (Cobas C501, Roche
Holding AG)
r2= 0.99 for creatinine
B–A plot: i-STAT values were slightly lower for SCr
values > 2mg/dl, whereas a t-test showed no
difference for values < 2 mg/dl
f,gLehtonen, 201360 n= 63 samples
Finland
i-STAT Modular EVO Mean bias: 8.8% (NS)
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Study (author
and year of
publication) Population (N) and country POC device(s) Laboratory reference Results (for creatinine unless stated) and notes
aMahlow et al.,
201661
540 samples; oncology outpatients
presenting for chemotherapy infusion
USA
i-STAT Enzymatic (COBAS 8000, Roche
Holding AG)
Small but consistent positive bias: i-STAT SCr values
were on average higher than the laboratory analyser
by 0.11 mg/dl (SD 0.04 mg/dl, 95% LoA estimated by
EAG as 0.03 to 0.19 mg/dl)
r2= 0.926
eGFR was underestimated by 4–12% depending on
gender and absolute creatinine value
aMcGough et al.,
201843
33 dialysis patients
UK
StatSensor Jaffe (Cobas 8000, Roche
Holding AG)
Mean bias was –0.15 mg/dl (–3.4%)
Minnings et al.,
201544
100 patients from a health centre or
hospital setting; 70% female; and median
SCr concentration of 0.72 mg/dl
Nicaragua
StatSensor Xpress Jaffe (Roche Cobas INTEGRA 400,
Roche Holding AG)
Median bias was 0.32 mg/dl
Morita et al.,
201162
113 patients scheduled for CT or MRI
without a recent eGFR measurement
Japan
StatSensor Enzymatic (7700 Clinical Analyzer,
Hitachi High-Technologies
America, Inc., Tokyo, Japan)
For creatinine: mean bias =−0.10 mg/dl (95% LoA
−0.43 to 0.22 mg/dl); r2 = 0.74.
For eGFR: mean bias= 11ml/minute/1.73m2
(95% LOA –22.4 to 44.4ml/minute/1.73m2); r2= 0.74
Murata et al.,
201863,80
60 residual samples
USA
Piccolo Xpress VITROS 5600 (Ortho Clinical
Diagnostics)
r2= 0.93
B–A plot indicted a negative bias
dNaugler et al.,
201464
Discarded samples
Canada
i-STAT Enzymatic (Cobas 6000, Roche
Holding AG)
eGFR: mean bias of −2.18 ml/minute/1.73 m2
B–A plot indicated better agreement for lower
eGFR values than for higher values (i.e. > 60ml/
minute/1.73 m2)
Nichols et al.,
200733
50 chemotherapy patients
USA
i-STAT (venous) Enzymatic (Roche Holding AG)
and Jaffe
Positive bias for i-STAT compared with Jaffe (mean
difference 14.1 µmol/l, 95% CI 11.5 to 16.8 µmol/l;
r2= 0.997) and with enzymatic (mean difference
19.4 µmol/l, 95% CI 16.8 to 22.1 µmol/l; r2 = 0.998)
continued
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TABLE 4 Studies reporting measurement bias or correlation outcomes (continued )
Study (author
and year of
publication) Population (N) and country POC device(s) Laboratory reference Results (for creatinine unless stated) and notes
aObrador et al.,
201234
257 diabetic patients; mean age, 57 years;
62% women; and mean creatinine
concentration of 0.8 mg/dl (SD 0.4 mg/dl)
Mexico
i-STAT (capillary) NR (Olympus AU5400 High
Volume Chemistry Immuno
Analyzer, Olympus Corporation
of the Americas, Center Valley,
PA, USA)
r2= 0.93 (capillary)
r2= 0.90 (venous)
Park et al., 200965 60 samples (20 low, 20 medium and
20 high levels of SCr)
The Republic of Korea (published in
Korean)
Piccolo Xpress TBA 200-FR (Toshiba Co.,
Tokyo, Japan)
r2= 0.9978; mean bias –0.2 mg/dl (SD 0.2 mg/dl, 95%
LoA estimated by the EAG as –0.59 to 0.19 mg/dl)
aRensburg et al.,
201445
Number NR
South Africa
StatSensor Jaffe (ADVIA®, Siemens
Healthineers)
r2= 0.987
aSchnabl et al.,
200866
40 samples, a broad range of
concentrations of SCr
Piccolo Xpress NR (ARCHITECT c8000, Abbott,
Abbott Park, IL, USA)
Average positive bias for SCr: 14%: ‘good correlation’
(r2=NR, but ≥ 0.88)
Schnabl et al.,
201067
191 patients, which included 97 pre-
dialysis and 57 post-dialysis patients
Canada
StatSensor Jaffe (ARCHITECT c8000) r2= 0.9328 overall; r2= 08312 for pre-dialysis
patients; r2 = 0.9347 for post-dialysis patients
Few bias data were reported: a negative bias was
seen at high creatinine concentrations, especially in
pre-dialysis patients in which the bias was –30%
aShephard et al.,
200835
101 venous blood samples
Australia
i-STAT (venous) Enzymatic (NR) The i-STAT displayed a positive bias relative to the
IDMS-aligned laboratory method (mean % bias of
5.6% overall, 10.4% for samples < 150 µmol/l and 4.5%
for samples > 150 µmol/l). This bias was eliminated by
applying a correction formula and IDMS alignment
Shephard et al.,
201036
100; 63 renal/dialysis patients attending
clinic, 37 healthy patients; and 52% female
Australia
StatSensor
(capillary)
Enzymatic (Creatinine Plus assay,
Roche Holding AG)
Better concordance in patients with higher SCr
levels for both StatSensor devices pre and post
calibration. There was greater bias for both
StatSensor devices pre calibration, that is,
before-and-after correction of a mean positive bias of
5.6% and alignment to the IDMS reference method
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Study (author
and year of
publication) Population (N) and country POC device(s) Laboratory reference Results (for creatinine unless stated) and notes
Recalibration
time point r2
Mean bias (µmol/l)
(95% CI)
Pre recalibration
Low levels of SCr (i.e. < 150 µmol/l)
StatSensor 1 0.83 –7.3 (–11.0 to –3.6)
StatSensor 2 0.84 –6.7 (–10.3 to –3.1)
All
StatSensor 1 0.97 –47.3 (–63.6 to –31.1)
StatSensor 2 0.97 –46.5 (–63.6 to –29.3)
Post recalibration
Low levels of SCr (i.e. < 150 µmol/l)
StatSensor 1 0.83 4.2 (–0.2 to 8.7)
StatSensor 2 0.84 5.0 (0.8 to 9.3)
All
StatSensor 1 0.97 –4.3 (–14.5 to 5.9)
StatSensor 2 0.97 –5.5 (–16.4 to 5.3)
Skurup et al.,
200868
104 samples
Denmark
ABL837 Enzymatic (Cobas INTEGRA, Roche
Holding AG)
r2= 0.999
B–A plot indicated a very small positive bias that
appeared to decrease as levels of creatinine
increased
continued
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TABLE 4 Studies reporting measurement bias or correlation outcomes (continued )
Study (author
and year of
publication) Population (N) and country POC device(s) Laboratory reference Results (for creatinine unless stated) and notes
Snaith et al.,
201837
300 phlebotomy outpatients attending for
routine blood tests; mean age 60 years;
47% female; and mean creatinine
concentration of 92 µmol/l
UK
ABL800 FLEX,
StatSensor
(capillary) and
i-STAT (venous)
Enzymatic (Cobas 8000, Roche
Holding AG)
ABL800 FLEX had the strongest agreement with
laboratory-measured SCr concentrations (r2= 0.991;
mean bias=−0.86 µmol/l, 95% LoA −9.6 to
7.9 µmol/l) followed by i-STAT (r2= 0.985; mean
bias = 3.88 µmol/l, 95% LoA −8.8 to 16.6 µmol/l)
and StatSensor (r2 = 0.891; mean bias = 3.56 µmol/l,
95% LoA −27.7 to 34.8 µmol/l)
Snaith et al.,
201938
300 adult outpatients attending for a
contrast-enhanced CT scan, mean age
65 years, 48% female
UK
i-STAT (venous) Enzymatic (Cobas 8000, Roche
Holding AG)
Mean bias –0.21 (units not reported), 95% LoA
–13.94 to 13.51; r2= 0.948
Srihong et al.,
201269
40 random blood samples from the central
laboratory
Thailand
StatSensor Jaffe (Beckman Coulter DxC 800) r2= 0.984
aStojkovic et al.,
201770
56 participants; 48% female; and mean
age around 53 years
Serbia
StatSensor Enzymatic (Cobas, Roche Holding
AG)
B–A plot showed a mean eGFR bias of –2± 10 ml/
minute/1.73 m2
CKD-EPI equation used for eGFR
aStraseski et al.,
200971
50 inpatients; and median creatinine
concentration of 1.30 mg/dl
USA
StatSensor
(‘EZ CHEM’)
Enzymatic (Roche Holding AG,
Hitachi Modular)
Mean bias reported only for subgroups. 0.69 mg/dl
for the 14 samples (10 patients) with discordant
results (differed by > 0.5 mg/dl between the two
methods). A control group (n = 10) that was age,
gender and race matched to the patients with
discordant results had a mean bias of 0.14 mg/dl
aStraseski et al.,
201072
150 inpatients
USA
StatSensor
(‘EZ CHEM’)
Enzymatic (Roche Holding AG,
Hitachi Modular) and IDMS
r2= 0.791 when compared with IDMS method
Higher discordance in patients with elevated creatinine
values (> 2.0mg/dl). Compared with the enzymatic
method, 34 (23%) samples differed by > 0.5mg/dl.
Of these samples, 23 (68%) had enzymatic creatinine
results > 2.0mg/dl. Correlation with enzymatic method
was not reported
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Study (author
and year of
publication) Population (N) and country POC device(s) Laboratory reference Results (for creatinine unless stated) and notes
Straseski et al.,
201173
119 intensive care and oncology
inpatients; 45% female; and mean age
59 years
USA
StatSensor Enzymatic (Roche Holding AG,
Hitachi Modular) and IDMS
When compared with the enzymatic method there
was increased discordance for results at higher
creatinine concentrations
r2= 0.88
B–A plot suggested a negative bias. 22 patients had
creatinine concentration results that differed by
≥ 0.50 mg/dl. 19 of the 22 patients had eGFR values
< 30ml/minute/1.73 m2
aTreves and
Boehre, 201174
NR; radiology setting
France
StatSensor LX20 (Beckman-Coulter) and
RXL (Siemens)
r2= 0.908
Too et al., 201575 52 ‘leftover’ blood samples
Singapore
StatSensor NR Positive bias of 11.3% (95% LoA –24.3% to 47.0%)
van Lint et al.,
201576
138 kidney transplant outpatients
The Netherlands
StatSensor Xpress-i Enzymatic (Modular P800, Roche
Holding AG)
Mean bias = –12.38 µmol/l (95% LoA –58.8 to
34.1 µmol/l)
B–A, Bland–Altman; CG, Cockcroft–Gault; EAG, External Assessment Group; HIV, human immunodeficiency virus; LoA, limits of agreement; MRI, magnetic resonance imaging;
PhD, Doctor of Philosophy; NR, not reported; NS, not significant; SD, standard deviation.
a Conference abstract.
b Reported in Czech.
c Not reported in English nor extractable using Google (Google Inc., Mountain View, CA, USA) translate.
d Letter to the editor.
e eGFR concordance for StatSensor values was calculated with and without application of an offset of 0.28 mg/dl (25 µmol/l) of creatinine, which was the offset that maximised
overall concordance between StatSensor whole-blood and plasma eGFR values for the sample data set.
f PhD thesis.
g Reported in Finnish.
Notes
r = correlation coefficient between POC device and laboratory reference, for bias results values < 0 indicate a negative bias and values > 0 indicate a positive bias.
Results in mg/dl can be converted to µmol/l by multiplying by 88.4.
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Most of the studies that reported data on how well StatSensor results correlate with laboratory results
(r2) found high levels of correlation. However, these data have limited relevance to this assessment
because good correlation of results does not necessarily mean there is good agreement between the
two methods of measurement.
Studies of i-STAT devices
Eighteen studies reported measurement bias or correlation results for an i-STAT POC device.27,31,33–35,37,38,47–50,
54,56,57,59–61,64 Seven were available only as conference abstracts.27,34,35,49,50,57,61 Sample sizes ranged from 15 to
3087 patients. Most studies reported bias results based on levels of creatinine; two studies reported results
based on eGFRs.61,64 Most studies reported using enzymatic laboratory methods; two studies used Jaffe
methods.54,56 One study focused on bias following the addition of serial dilutions of hydroxycarbamide.50
Eight studies indicated that there were positive biases in creatinine values derived from i-STAT devices
when compared with laboratory results,31,33,35,56,60,61,64 whereas two studies showed a negative bias.38,47 In four
other studies the bias was very small, being close to zero.27,37,54,57 Many of the biases appeared large enough
to have a clinically significant impact on subsequent eGFR calculations. The two studies61,64 that examined
the effect on eGFR reported a underestimation by 4–12%,61 depending on gender and absolute creatinine
value, and a mean bias of –2.2 ml/minute/1.73 m2.64 Limits of agreement (where available) were mostly
narrow, indicating that the biases were quite consistent and predictable.
Studies of ABL series devices
Six studies reported measurement bias or correlation results relating to an ABL device,27,31,37,51,58,68
although three studies were available only as conference abstracts.27,51,58 Four studies were of the
ABL800 device,31,37,51,58 one was of the ABL82727 and one was of the ABL837.68 Sample sizes ranged from
7051 to 2042.27 All studies used an enzymatic laboratory reference method except one.58 All bias data
related to levels of creatinine. Very small negative mean biases from ABL devices were reported in two
studies,27,31 with both estimates having narrow 95% limits of agreement. One study reported a mean
bias that was close to zero37 but with 95% limits of agreement that were notably broader than the two
aforementioned studies.27,31 One study58 reported a substantial negative bias (i.e. of –0.22 mg/dl) without
an accompanying measure of variance.
Studies of Piccolo Xpress devices
Four studies reported measurement bias or correlation data for the Piccolo Xpress device.55,63,65,66 One
study was reported in Czech,55 so only minimal data could be extracted, and one study was available
only as a conference abstract.66 It was unclear whether enzymatic or Jaffe laboratory reference methods
were used in all four studies.55,63,65,66 All the studies were small (n ≤ 60), although this information could
not be extracted for the study published in Czech.55 Two studies reported bias data only as percentages,
with both studies reporting positive biases (of 8%55 and 14%66), one study did not report an numerical
estimate of bias (but did present a Bland–Altman plot),63 and one study65 reported a negative bias of –
0.2 mg/dl (95% limits of agreement estimated as –0.25 to –0.15 mg/dl).
Studies of epoc devices
One study reported measurement bias and correlation data for an epoc device.52 This study found that
epoc device measurements resulted in a small negative mean bias (i.e. of − 0.025 mg/dl). The other
epoc study – available only as a conference abstract – investigated whether or not hydroxycarbamide
caused interference in creatinine measurements using i-STAT and epoc devices, and whether or not the
interference resulted in bias.50 No interference was found for the epoc device.
Studies that compared different types of device
Three of the studies listed in Table 4 directly compared different types of POC device.27,31,37 The Snaith
et al.37 and Korpi-Steiner et al.31 studies both compared StatSensor, i-STAT and ABL800 FLEX devices.
Both studies found that the ABL800 FLEX had the strongest agreement with laboratory-measured SCr,
followed by i-STAT and then StatSensor. The study available only as a conference abstract compared an
ABL827 device with an i-STAT, concluding that creatinine results from both devices correlated well with
laboratory-measured SCr.27
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Summary
Overall, results from the StatSensor studies illustrate wide variation in the size and direction of
measurement bias that can be encountered when using this device. It may be relevant for users to be
aware of the availability of the offset functionality to correct for any bias observed with an individual
StatSensor device. Only two StatSensor studies reported using an offset adjustment for measurement
bias. This raises the possibility that issues such as lack of awareness or difficulties in implementing the
adjustment function to align the POC test to local laboratory methods could be relevant in clinical
practice. The tendency for measurement bias to increase at higher creatinine levels (as seen in some
studies) is also a concern, as this has important implications for the care decisions made about sicker
patients. Although potentially important measurement bias was identified in some studies of i-STAT
and ABL devices, in most of these studies the concordance of results was generally better than was
found in most of the StatSensor studies. Few studies were available on the epoc and Piccolo Xpress
devices; the limited data and reporting in these studies, coupled with their small sample sizes, made it
difficult to draw conclusions about creatinine measurement biases.
Although the concordance and measurement bias results reported in these studies suggest that there
may be important limitations to using POC devices to measure creatinine, it is more important to
consider the impact of any measurement bias on results categorised according to clinically important
thresholds that may be used for clinical decision-making. Studies that report such data are presented in
Studies reporting diagnostic accuracy results using estimated glomerular filtration rate thresholds.
Studies reporting diagnostic accuracy results based on creatinine thresholds
Seven studies reported diagnostic accuracy data relating to creatinine thresholds (Table 5), with four
being reported as published papers39,41,42,44 and three as conference abstracts.40,43,45 Where reported,
sample sizes ranged from 33 to 401 patients. Population details were limited with one study (appearing
to be) set in the UK43 and one reported as being of patients due to receive CT scans.41 All the studies
were of StatSensor POC devices. Six studies used a Jaffe method39–41,43–45 for the laboratory reference
standard and in one study this was unclear.42
The creatinine thresholds used in the studies (to calculate sensitivity and specificity) ranged from 1.1 mg/dl
to 1.5 mg/dl (i.e. 97 µmol/l to 133 µmol/l). As eGFR (rather than creatinine alone) is used to estimate
kidney function in clinical practice, diagnostic accuracy results based on creatinine thresholds are not as
clinically relevant or useful than those based on eGFR thresholds. Moreover, all these (creatinine) studies
are of the StatSensor POC device, which allows users to implement offset adjustment of biased results.
Two of the seven studies explicitly reported results that incorporated an offset adjustment.39,41 The other
five studies did not report using offset adjustment.40,42–45 Notwithstanding these limitations, most studies
reported unadjusted sensitivities that were higher than specificities, indicating that StatSensor tended to
overestimate creatinine levels compared with laboratory Jaffe results. The exceptions were the study by
Haneder et al.,41 which reported much lower (unadjusted) sensitivities than specificities in the two devices
tested, and the small UK study which reported both a sensitivity and specificity of 100%.43 Although most
studies indicated overestimation of creatinine by StatSensor, the Haneder et al. study41 illustrated that
some StatSensor devices may underestimate creatinine. This variation in over- or underestimation was
also seen across the studies that reported results for creatinine level bias (see Studies reporting bias or
correlation outcomes).
The results of the Griffin et al.39 and Haneder et al. studies41 indicate that, even after offset adjustment
of creatinine results, StatSensor can produce false-negative (FN) and false-positive (FP) results. This has
the potential to result in unnecessary prophylactic treatment or scans without contrast (i.e. FP) or to
unnecessarily expose high-risk patients to contrast (i.e. FN). The laboratory reference standards used in
these studies also limits their value, as the adjustments may themselves be inaccurate, being based on
Jaffe methods rather than more accurate enzymatic methods.
DOI: 10.3310/hta24390 Health Technology Assessment 2020 Vol. 24 No. 39
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
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TABLE 5 Studies reporting diagnostic accuracy outcomes using creatinine thresholds
Study (author
and year of
publication) Population (N) and country POC device(s) Laboratory reference Results and notes
Griffin et al., 201839 Two studies of field workers:
1. Derivation cohort: n=104; all male;
mean age 29 years; and baseline eGFR of
117ml/minute/1.73m2
2. Validation cohort: n= 105; all male;
mean age 30 years; and baseline eGFR
111ml/minute/1.73 m2
Guatemala
StatSensor Xpress Jaffe Adjusted results with unadjusted
results in brackets:
1. For derivation cohort –
¢ 1.1 mg/dl cut-off point:
sensitivity = 70% (90%) and
specificity = 90% (69%)
¢ 1.3 mg/dl cut-off point:
sensitivity = 73% (91%) and
specificity = 99% (85%)
Confidential
information has
been removed
Confidential information has been removed Confidential
information has
been removed
Confidential information has
been removed
Confidential information has
been removed
Haneder et al.,
201241
401 patients referred for a CT scan at two centres;
mean age was 62 years (SD 14 years); and 63% male
Germany
StatSensor (two
devices: A and B)
Jaffe (Dimension RXL, Siemens AG;
Olympus AU2700, Beckman
Coulter, Inc.)
Centre 1 at a cut-off point of 1.2 mg/dl:
l Sensitivity = 35% (A) and 42% (B)
l Specificity = 99% (A) and 99% (B)
Following offset adjustment the
corresponding results were:
l Sensitivity = 81% (A) and 71% (B)
l Specificity = 98% (A) and 94% (B)
Centre 2: NR
Kosack et al., 201542 60 patients and laboratory workers
The Netherlands
StatSensor Xpress VITROS 5,1FS (Ortho Clinical
Diagnostics)
At a cut-off point of ≥ 115 µmol/l
(1.3 mg/dl):
l TP: 38
l FP: 2
l TN: 20
l FN: 0
That is a sensitivity of 100% and a
specificity of 91%
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Study (author
and year of
publication) Population (N) and country POC device(s) Laboratory reference Results and notes
aMcGough et al.,
201843
33 dialysis patients
UK
StatSensor Jaffe (Cobas 8000, Roche
Holding AG)
At a cut-off point of 1.5 mg/dl both
sensitivity and specificity were 100%
Minnings et al.,
201544
100 patients from a health centre or hospital setting;
70% female; and a median SCr concentration of
0.72 mg/dl
Nicaragua
StatSensor Xpress Jaffe (Roche Cobas INTEGRA 400,
Roche Holding AG)
At a cut-off point of 1.1 mg/dl:
l Sensitivity = 92%
l Specificity = 67%
At a cut-off point of 1.2 mg/dl:
l Sensitivity = 100%
l Specificity = 79%
At a cut-off point of 1.3 mg/dl:
l Sensitivity = 100%
l Specificity = 84%
At a cut-off point of 1.4 mg/dl:
l Sensitivity = 100%
l Specificity = 86%
At a cut-off point of 1.5 mg/dl:
l Sensitivity = 100%
l Specificity = 89%
aRensburg et al.,
201445
Number NR
South Africa
StatSensor Jaffe (ADVIA®, Siemens
Healthineers)
At a cut-off point of 130 µmol/l
(1.5 mg/dl):
l Negative predictive value: 100%
l Positive predictive value: 80%
FN, false negative; FP, false positive; NR, not reported; TN, true negative; TP, true positive.
a Conference abstract.
Note
Results in mg/dl can be converted to µmol/l by multiplying by 88.4.
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Studies reporting diagnostic accuracy results using estimated glomerular filtration
rate thresholds
Table 6 summarises the characteristics of the 12 studies that reported diagnostic accuracy data of
eGFR measurements with POC creatinine test devices.
All included studies were observational. The sample size ranged from 50 to 2042 participants. Two
studies included outpatients referred for a contrast-enhanced CT scan.30,38 Two studies included patients
undergoing a radiological examination, but did not specify what proportion were outpatients.27,31 Four
studies included disease-specific populations, including people with CKD,36 cancer,33 diabetes mellitus34
or infected with human immunodeficiency virus (HIV).28 One study focused on women referred for
contrast-enhanced spectral mammography.29 Other studies included phlebotomy outpatients37 and
mixed-ancestry South African patients.32
Three studies were conducted in the USA.27,31,33 Two studies each were conducted in the UK,37,38
Australia35,36 and South Africa.28,32 A single study was conducted in the following countries: the
Netherlands,29 Japan30 and Mexico.34 Three studies were reported only as a conference abstract.27,34,35
Seven studies evaluated i-STAT27,31,33–35,37,38 and seven studies evaluated a StatSensor device.28–32,36,37
Three studies included Radiometer Ltd’s POC device, including ABL80031,37 and ABL827.27 Two studies
evaluated three POC devices (ABL, i-STAT and StatSensor)31,37 and one study evaluated two devices
(ABL and i-STAT).27 There were no studies of other eligible POC tests, such as ABL90 FLEX PLUS,
DRI-CHEM NX 500, epoc and Piccolo Xpress.
All sample types used with StatSensor were capillary,28–30,32,36,37 except in one study (which used a
venous sample).31 Conversely, most i-STAT devices used venous samples31,33,35,37,38 except in one study
(which used a capillary sample).34 Another i-STAT study did not specify the sample type used.27 None
of the studies compared the accuracy of a single device using two different sample types.
Three StatSensor30,31,36 and two i-STAT studies34,35 reported using an offset correction to estimate
concordance between the POC test and laboratory reference test derived from the study sample.
Adjusted and unadjusted results were reported in all three StatSensor studies, but only adjusted
results were presented by the two i-STAT studies.
The laboratory reference method was Jaffe in two studies32,33 and not reported in one study.34 All other
studies used an enzymatic method. Equations used to calculate eGFR varied across the studies, and
only three studies used CKD-EPI.34,37,38
Individual study results, including contingency tables, are presented in Table 6. Eight studies reported
sufficient data to calculate accuracy at an eGFR threshold of 30 ml/minute/1.73 m2.27,29,30,32,33,36–38 Four
studies only reported results using higher eGFR thresholds: two studies used an eGFR cut-off point of
60 ml/minute/1.73 m2;31,35 one study used an eGFR threshold of 90 ml/minute/1.73 m2 (although some
limited data on an eGFR threshold of 60 ml/minute/1.73 m2 were extractable);28 and one study only
reported eGFR results according to a non-standard CKD classification (stages 0–4).34 Two studies were
conference abstracts and did not provide sufficient data to be included in the synthesis.34,35 Both
studies evaluated i-STAT and reported accuracy results following an offset correction.
Shephard et al.35 compared the accuracy of i-STAT against an enzymatic method using 101 venous
blood samples. After correction of a mean positive bias of 5.6% and alignment to the IDMS reference
method, i-STAT had 96% sensitivity and 96% specificity for an eGFR threshold of 60 ml/minute/1.73 m2
compared with the laboratory reference test.
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TABLE 6 Studies reporting eGFR diagnostic accuracy data
Study (author
and year of
publication)
Population (N) and
country
POC device(s)
(sample type)
Laboratory
reference eGFR equation Results and notes
aBotz et al., 201327 2042 patients at
risk of renal disease
prior to radiological
examinations; 43% of
patients were female
USA
ABL827 and
i-STAT1 (sample
type NR)
Enzymatic, (Cobas
C-501, Roche
Holding AG)
MDRD Contingency table: ABL827 and i-STAT accuracy at eGFR 30 and 60ml/minute/1.73m2 cut-off points
Source: publication
Device, number of tests (n)
ABL827 i-STAT
eGFR < 30ml/
minute/1.73m2
≥ 30ml/
minute/1.73m2
eGFR < 30ml/
minute/1.73m2
eGFR ≥ 30ml/
minute/1.73m2
Laboratory
eGFR < 30ml/minute/1.73m2 26 3 12 2
eGFR ≥ 30ml/minute/1.73m2 NR NR NR NR
eGFR < 60ml/
minute/1.73m2
eGFR ≥ 60ml/
minute/1.73m2
eGFR < 60ml/
minute/1.73m2
eGFR ≥ 60ml/
minute/1.73m2
eGFR < 60ml/minute/1.73m2 520 183 NR NR
eGFR ≥ 60ml/minute/1.73m2 24 2517 NR NR
Notes
Sensitivity and specificity for i-STAT at < 60 and ≥ 60ml/minute/1.73m2 were both 93%.
n= 3244 for ABL827 and n= 2042 for i-STAT (for patients with same-day measurements).
bDorward et al.,
201828
187 HIV-positive
patients from a POC
RCT; median age
31 years; 62% female;
and a mean creatinine
concentration of
69.0 µmol/l
South Africa
StatSensor Xpress-I
(capillary)
Enzymatic
(Dimension®
EXL 200 IDMS,
Siemens AG)
Modified
MDRD (without race)
At an eGFR < 90ml/minute/1.73m2 threshold, sensitivity was 87.1% (95% CI 76.2% to 94.3%), specificity was
52% (95% CI 42.9% to 61.0%). One patient had a laboratory-measured eGFR of < 60ml/minute/1.73m2; this
was correctly identified by StatSensor
At a creatinine threshold of > 106 µmol/l (1.2mg/dl), sensitivity was 100% and specificity 95.1%
(95% CI 90.9% to 97.7%)
continued
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TABLE 6 Studies reporting eGFR diagnostic accuracy data (continued )
Study (author
and year of
publication)
Population (N) and
country
POC device(s)
(sample type)
Laboratory
reference eGFR equation Results and notes
Houben et al.,
201729
351 women due for
contrast-enhanced
spectral
mammography
The Netherlands
StatSensor CREAT
(capillary)
Enzymatic (Cobas
8000, Roche)
MDRD Contingency table: StatSensor accuracy at eGFR 30 and 60ml/minute/1.73m2 cut-off points
Source: publication
Device, number of tests (n)
StatSensor
eGFR < 30ml/
minute/1.73m2
eGFR 30–44ml/
minute/1.73m2
eGFR 45–59ml/
minute/1.73m2
eGFR ≥ 60ml/
minute/1.73m2
Laboratory
eGFR < 30ml/minute/
1.73m2
0 0 0 0
eGFR 30–44ml/minute/
1.73m2
0 0 1 2
eGFR ≥ 60ml/minute/
1.73m2
0 0 348
Notes
Seven patients had an eGFR < 60ml/minute/1.73m2, necessitating additional preparation prior to contrast
delivery. The POC device failed to categorise six of these seven patients (86%), leading to unwanted
contrast administration. Two patients (including one of the three patients with an eGFR of 45ml/minute/
1.73m2) subsequently developed CIN after 2–5 days, which was normalised after 30 days.
Inoue et al., 201730 123 patients (with
unadjusted results),
scheduled for CT;
mean eGFR 75.3ml/
minute/1.73m2
(SD 21.4ml/minute/
1.73m2); mean
creatinine 0.8mg/dl
(SD 0.29mg/dl)
Japan
StatSensor-i
(capillary)
Enzymatic
(BioMajesty™
BM2250, Jeol Ltd)
Modified
MDRD (Japanese
CKD patients)
Contingency table: StatSensor accuracy at eGFR < 30, 30–44 and ≥ 45ml/minute/1.73m2 cut-off points
(unadjusted results)
Source: publication table and plots
Device, number of tests (n)
eGFR < 30ml/
minute/1.73m2
eGFR 30–44ml/
minute/1.73m2
eGFR ≥ 45ml/
minute/1.73m2
Laboratory
eGFR < 30ml/minute/1.73m2 4 0 0
eGFR 30–44ml/minute/1.73m2 1 7 0
eGFR ≥ 45ml/minute/1.73m2 1 11 99
Adjustment was performed by applying offset correction on the basis of the slope and intercept of
internal sample
Plots presented after correction suggested that eGFR laboratory measurements were unexpectedly
affected by this adjustment; therefore, only unadjusted results were extracted
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Study (author
and year of
publication)
Population (N) and
country
POC device(s)
(sample type)
Laboratory
reference eGFR equation Results and notes
Korpi-Steiner et al.,
200931
266 excess samples
taken before CT
procedures; mean
age 68 years; and
39% female
USA
ABL800 FLEX,
i-STAT,
StatSensor (with
slope and intercept
offset option)
Heparinised
venous samples
Enzymatic, (Cobas
INTEGRA 400,
Roche Holding AG)
INTEGRA 400 and
ABL800 used adjusted
MDRD (IDMS
traceable). i-STAT and
StatSensor used
conventional MDRD
Contingency table: ABL800 and i-STAT accuracy at eGFR 60ml/minute/1.73m2 cut-off points
Source: publication
Device, number of tests (n)
ABL800 i-STAT
eGFR < 60ml/
minute/1.73m2
eGFR ≥ 60ml/
minute/1.73m2
eGFR < 60ml/
minute/1.73m2
eGFR ≥ 60ml/
minute/1.73m2
Laboratory
eGFR < 60ml/minute/1.73m2 55 13 66 2
eGFR ≥ 60ml/minute/1.73m2 6 192 32 166
Contingency table: StatSensor accuracy at eGFR 60ml/minute/1.73m2 cut-off points, with and without
correction offset
Source: publication
Device, number of tests (n)
StatSensor StatSensor offset
eGFR < 60ml/
minute/1.73m2
eGFR ≥ 60ml/
minute/1.73m2
eGFR < 60ml/
minute/1.73m2
eGFR ≥ 60ml/
minute/1.73m2
Laboratory
eGFR < 60ml/minute/1.73m2 11 57 40 28
eGFR ≥ 60ml/minute/1.73m2 0 198 24 174
An offset of 0.28mg/dl was applied that maximised overall concordance between the POC test and the
laboratory reference in this data set
continued
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TABLE 6 Studies reporting eGFR diagnostic accuracy data (continued )
Study (author
and year of
publication)
Population (N) and
country
POC device(s)
(sample type)
Laboratory
reference eGFR equation Results and notes
cKrige, 201732 103 mixed-ancestry
South Africans; mean
age 52 years; and
69% female
South Africa
StatSensor
(capillary)
Jaffe (AU5800
Clinical Chemistry
Analyzer, Beckman
Coulter, Inc.)
MDRD (SI units) Contingency table: StatSensor-i accuracy at eGFR < 30, 30–44, 45–59 and ≥ 60ml/minute/1.73m2
cut-off points
Source: individual patient data
in thesis
Device, number of tests (n)
eGFR < 30ml/
minute/1.73m2
eGFR 30–44ml/
minute/1.73m2
eGFR 45–59ml/
minute/1.73m2
eGFR ≥ 60ml/
minute/1.73m2
Laboratory
eGFR < 30ml/minute/
1.73m2
1 0 0 0
eGFR 30–44ml/minute/
1.73m2
0 0 0 0
eGFR 45–59ml/minute/
1.73m2
0 0 1 1
eGFR ≥ 60ml/minute/
1.73m2
0 0 0 100
Notes
The three low eGFR values were:
• POC, 22ml/minute/1.73m2; laboratory, 1ml/minute/1.73m2
• POC, 48ml/minute/1.73m2; laboratory, 49ml/minute/1.73m2
• POC, > 90ml/minute/1.73m2; laboratory, 56ml/minute/1.73m2
Nichols et al.,
200733
50 chemotherapy
patients
USA
i-STAT (venous) Enzymatic (Roche
Holding AG) and
Jaffe
Cockcroft–Gault and
MDRD
Diagnostic accuracy of i-STAT against two laboratory reference methods and two eGFR equations at an
eGFR < 60 ml/minute/1.73m2 cut-off point
Source: publication Sensitivity (%) Specificity (%)
MDRD Jaffe 100 87.2
CG Jaffe 100 59.2
MDRD enzymatic 100 85
CG enzymatic 100 72.5
CG, Cockcroft–Gault.
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Study (author
and year of
publication)
Population (N) and
country
POC device(s)
(sample type)
Laboratory
reference eGFR equation Results and notes
aObrador et al.,
201234
257 diabetic patients;
mean age, 57 years;
62% women; and
mean creatinine
concentration
of 0.8mg/dl
(SD 0.4mg/dl)
Mexico
i-STAT (capillary) NR (Olympus
AU5400 High
Volume Chemistry
Immuno Analyzer,
Olympus
Corporation of the
Americas)
CKD-EPI Contingency table: i-STAT accuracy by CKD stage (stages 0–4)
Source: table in abstract
Device, number (n)
IDMS SCr – laboratory reference
CKD stage
0 1 2 3 4
i-STAT SCr
CKD stage
0 154 0 0 0 0
1 0 53 5 0 0
2 0 4 13 3 0
3 1 0 3 15 2
4 0 0 0 0 4
Total 155 57 21 18 6
Simple linear regression was used to estimate a correction factor to align i-STAT SCr to IDMS-SCr.
Following this correction, no patient was incorrectly classified as not having CKD by i-STAT (capillary
sample) (100% sensitivity). One patient was incorrectly classified as having CKD (99.4% specificity)
aShephard et al.,
200835
101 venous blood
samples
Australia
i-STAT (venous) Enzymatic
(IDMS aligned)
(device NR)
NR The i-STAT had a positive measurement bias relative to the IDMS-aligned laboratory method (mean bias
of 5.6% overall, 10.4% for samples < 150 mmol/l and 4.5% for samples > 150 mmol/l). This bias was
corrected and an IDMS alignment performed using a correction formula based on the regression equation
between the i-STAT and laboratory methods:
l x (corrected i-STAT-measured creatinine)= 0.97y (IDMS laboratory-measured creatinine) – 6.5
Following correction, sensitivity and specificity were both 96% for an eGFR cut-off point of
60ml/minute/1.73m2
continued
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TABLE 6 Studies reporting eGFR diagnostic accuracy data (continued )
Study (author
and year of
publication)
Population (N) and
country
POC device(s)
(sample type)
Laboratory
reference eGFR equation Results and notes
Shephard et al.,
201036
100; 63 renal/dialysis
patients attending
clinic and 37 healthy
patients; and 52%
female
Australia
StatSensor
(capillary)
Enzymatic
(Creatinine Plus
assay, Roche
Holding AG)
MDRD Diagnostic accuracy of two StatSensor devices at an eGFR 60ml/minute/1.73m2 cut-off point before and
after recalibration
Source: publication Sensitivity (%) Specificity (%)
Pre-laboratory recalibration
StatSensor 1 86.8 100
StatSensor 2 82.4 100
Post-laboratory recalibration
StatSensor 1 96.2 78.7
StatSensor 2 92.2 78.7
After correction of a mean positive bias of 5.6% and alignment to the IDMS reference method
Contingency table: StatSensor accuracy at an eGFR 60ml/minute/1.73m2 cut-off point before and after
recalibration
Source: publication in
paper
Device, number of tests (n)
StatSensor 1
Pre recalibration Post recalibration*
Laboratory
eGFR < 60ml/
minute/1.73m2
eGFR ≥ 60ml/
minute/1.73m2
eGFR < 60ml/
minute/1.73m2
eGFR ≥ 60ml/
minute/1.73m2
eGFR < 60ml/
minute/1.73m2
46 7 51 2
eGFR ≥ 60ml/
minute/1.73m2
0 46 10 37
After correction of a mean positive bias of 5.6% and alignment to the IDMS reference method
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TABLE 6 Studies reporting eGFR diagnostic accuracy data (continued )
Study (author
and year of
publication)
Population (N) and
country
POC device(s)
(sample type)
Laboratory
reference eGFR equation Results and notes
Snaith et al., 201837 300 phlebotomy
outpatients attending
for routine blood
tests; mean age
60 years; 47% female;
and mean creatinine
concentration of
92 µmol/l
UK
ABL800 FLEX,
StatSensor
(capillary) and
i-STAT (venous)
Enzymatic (Cobas
8000, Roche
Holding AG)
CKD-EPI (and MDRD
for comparison)
After correction of a mean positive bias of 5.6% and alignment to IDMS reference method
No further accuracy results were reported for StatSensor 2
Contingency table: i-STAT accuracy at eGFR < 30, 30–44, 45–59 and ≥ 60ml/minute/1.73m2 cut-off points
Source: correspondence
with author
Device, number of tests (n)
i-STAT
eGFR < 30ml/
minute/1.73m2
eGFR 30–44ml/
minute/1.73m2
eGFR 45–59ml/
minute/1.73m2
eGFR ≥ 60ml/
minute/1.73m2
Laboratory
eGFR < 30ml/minute/
1.73m2
12 0 0 0
eGFR 30–44ml/
minute/1.73m2
3 25 0 0
eGFR 45–59ml/
minute/1.73m2
0 5 29 1
eGFR ≥ 60ml/minute/
1.73m2
0 1 14 210
Contingency table: ABL800 accuracy at eGFR < 30, 30–44, 45–59 and ≥ 60ml/minute/1.73m2 cut-off points
Source: correspondence
with author
Device, number of tests (n)
ABL800
eGFR < 30ml/
minute/1.73m2
eGFR 30–44ml/
minute/1.73m2
eGFR 45–59ml/
minute/1.73m2
eGFR ≥ 60ml/
minute/1.73m2
Laboratory
eGFR < 30ml/
minute/1.73m2
12 0 0 0
eGFR 30–44ml/
minute/1.73m2
0 24 4 0
eGFR 45–59ml/
minute/1.73m2
0 2 31 2
eGFR ≥ 60ml/
minute/1.73m2
0 0 1 224
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Study (author
and year of
publication)
Population (N) and
country
POC device(s)
(sample type)
Laboratory
reference eGFR equation Results and notes
Contingency table: StatSensor accuracy at eGFR < 30, 30–44, 45–59 and ≥ 60ml/minute/1.73m2 cut-off points
Source: correspondence with
author
Device, number of tests (n)
StatSensor
eGFR < 30ml/
minute/1.73m2
eGFR 30–44ml/
minute/1.73m2
eGFR 45–59ml/
minute/1.73m2
eGFR ≥ 60ml/
minute/1.73m2
Laboratory
eGFR < 30ml/minute/1.73m2 8 4 0 0
eGFR 30–44ml/minute/1.73m2 3 17 8 0
eGFR 45–59ml/minute/1.73m2 0 10 17 8
eGFR ≥60ml/minute/1.73m2 0 1 33 191
Test failures occurred four times with StatSensor and once with ABL800 FLEX (none for i-STAT). All
5-second tests were successful
Snaith et al., 201938 300 adult outpatients
attending for a
contrast-enhanced
CT scan, mean age
65 years, 48% female
UK
i-STAT (venous) Enzymatic (Cobas
8000, Roche
Holding AG)
CKD-EPI Contingency table: i-STAT accuracy at eGFR < 30, 30–44, 45–59 and ≥ 60ml/minute/1.73m2 cut-off points
Source: correspondence with
author
Device, number of tests (n)
i-STAT
eGFR < 30ml/
minute/1.73m2
30–44 eGFR
30–44ml/
minute/1.73m2
eGFR
45–59ml/
minute/1.73m2
eGFR ≥ 60ml/
minute/1.73m2
Laboratory
eGFR < 30ml/minute/1.73m2 0 0 0 0
30–44 eGFR 30–44ml/
minute/1.73m2
1 9 4 0
eGFR 45–59ml/minute/1.73m2 0 2 35 7
eGFR ≥ 60ml/minute/1.73m2 0 1 7 234
Six POC test failures were recorded
B–A, Bland–Altman; HIV, human immunodeficiency virus; NR, not reported; PhD, Doctor of Philosophy.
a Conference abstract.
b Letter to the editor.
c PhD thesis.
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Obrador et al.34 evaluated the accuracy of i-STAT in 257 diabetic patients. Concordance with the
laboratory reference test was evaluated according to a CKD classification ranging from 0 to 4, with
0 indicating no CKD. No further details were provided on the CKD classification; therefore, it is not
clear how these results compare to the standard Kidney Disease Improving Global Outcomes (KDIGO)
classification, as presented in Table 2. The study used a simple linear regression to estimate a correction
factor to align i-STAT SCr to IDMS SCr. After this correction, the Obrador et al.3 study found that all
patients with CKD (stages 1–4) were correctly classified by the POC test (100% sensitivity) and all but
one were correctly classified as CKD free (99.4% specificity).
Available data for quantitative synthesis
Studies of StatSensor devices
Data from the seven studies28–32,36,37 included in the analysis for StatSensor devices are given in
Appendix 2 (see Table 42). One study28 provided limited data on only one individual with an eGFR
of < 60 ml/minute/1.73 m2 who was correctly classified by StatSensor Xpress-i, but no other data
on individuals in other eGFR categories. For StatSensor-I, one study30 reported data on collapsed
categories of eGFR and another reported data on all eGFR categories.32 The StatSensor device was
compared in four studies,29,31,36,37 one of which37 reported data on all eGFR categories in Table 2.
Two studies31,36 of StatSensor devices included a user-specified adjustment (see Table 1) to correct
for systematic measurement bias. A third study30 reported data using an alternative adjustment that
cannot be applied directly to the device. A possible scenario for use of this device in clinical practice
is to identify whether or not there is a systematic bias in device performance and then incorporate an
adjustment into the device, to correct subsequent samples. To assess the performance of StatSensor
under this scenario, an additional ‘adjusted data’ analysis was carried out, in which the reported
adjusted data from Korpi-Steiner et al.31 and Shephard et al.36 were used. However, Inoue et al.30 was
removed, as bias was identified but the correction was not one that could be implemented in practice.
Studies of i-STAT devices
Data from the five studies27,31,33,37,38 included in the analysis for i-STAT devices are given in Appendix 2
(see Table 40). All studies presented results for the i-STAT device, except for Botz et al.,27 which
provided limited data on individuals with an eGFR of < 30 ml/minute/1.73 m2 and their classification
using i-STAT1. Two studies37,38 reported data on all eGFR categories, although Snaith et al.38 did not
observe any individuals with an eGFR of < 30 ml/minute/1.73 m2.
Studies of ABL series devices
Data from the three studies27,31,37 included in the analysis for ABL (Radiometer Ltd) devices are given
in Appendix 2 (see Table 41). Two types of device were compared: ABL800 FLEX31,37 and ABL827.27
Only one study provided data on all eGFR categories.37
Studies calculating estimated glomerular filtration rate using Chronic Kidney
Disease Epidemiology Collaboration
All studies used the MDRD equation to calculate eGFR except for two, which used CKD-EPI.37,38
The first of these studies included StatSensor, i-STAT and ABL800 FLEX devices37 and the second
study included only the i-STAT device.38 In addition, these two studies37,38 were the only ones rated
as being at low risk of bias and with applicability concerns (see Table 3). An additional analysis using
only the data in these two studies was carried out to check for any differences in classification
accuracy. Although only one study included a StatSensor or ABL device, in order to properly quantify
the uncertainty in the probabilities, the model described in Synthesis of diagnostic accuracy data
(see Equations 1 and 2) was still used.
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Results: assessment of diagnostic accuracy
Convergence was achieved for all synthesis models at (or before) 5000 iterations. A further 30,000
iterations on two chains were run; therefore, all results are based on 60,000 post-convergence iterations.
Probability of belonging to each category
The probabilities that an individual belongs to each eGFR category in Table 2 were calculated from
the number of individuals in each category reported by all included studies (i.e. regardless of the device
being evaluated, one study reporting results on two sets of patients27). The probabilities reported in each
study are given in Table 7 (raw data in Tables 39–41). The pooled probabilities of belonging to each of the
four categories of interest, T[j], j = 1,2,3,4, used in the main synthesis model are given in Table 8.
Most studies included a few individuals in category 1 (i.e. an eGFR of < 30 ml/minute/1.73 m2) and
more individuals in higher eGFR categories. However, Shephard et al.36 included a majority of renal
patients and, therefore, individuals had a higher probability of being in category 1, than those in other
included studies (33% compared with 0–4%). Excluding Shephard et al.36 reduced the pooled probability
of patients being in category 1, T[1], slightly but hardly impacted the other probabilities (Table 8). A
sensitivity analysis was conducted to assess how this affected the estimation of the main probabilities
of interest (see Sensitivity analysis for true probability calculations).
TABLE 7 Reported probabilities of belonging to the laboratory eGFR categories in each study
Laboratory eGFR category
(ml/minute/1.73 m2)
Study (author and year of publication), probability
Snaith et al., 201837 Snaith et al., 201938 Krige 201732
< 30 0.040 0.000 0.010
30–44 0.093 0.047 0.000
45–59 0.117 0.147 0.019
≥ 60 0.750 0.807 0.971
Inoue et al., 201730 Houben et al., 201729
< 30 0.033 0.000
30–44 0.065 0.009
≥ 45 0.902 0.991
Shephard et al., 201036
Botz et al., 2013
(ABL)27
< 30 0.330 0.009
30–59 0.200 0.208
≥ 60 0.470 0.783
Botz et al., 2013
(i-STAT)27
< 30 0.007
≥ 30 0.993
Korpi-Steiner et al.,
200931
Dorward et al.,
201828
Nichols et al.,
200733
< 60 0.256 0.005 0.184
≥ 60 0.744 0.995 0.816
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Probability of classification by point-of-care device, given a laboratory-defined
category
The pooled probabilities of being classified by a POC device in category k, given the laboratory
classification j, pjk = p[j,k], with j,k = 1,2,3,4, are given in Table 9 and plotted as density strips in Figure 2.
TABLE 8 Estimated probabilities of belonging to each eGFR category
Probability
Estimated probability
All data Shephard et al., 201036 removed
Median 95% CrI Median 95% CrI
T[1] 0.014 0.011 to 0.017 0.009 0.007 to 0.012
T[2] 0.051 0.039 to 0.064 0.051 0.039 to 0.064
T[3] 0.143 0.127 to 0.159 0.143 0.127 to 0.159
T[4] 0.792 0.780 to 0.803 0.797 0.785 to 0.808
Notes
T[j] is the probability of belonging to eGFR category j.
Categories are described in Table 2.
TABLE 9 Pooled probabilities for the three types of device
Probability
Device, pooled probabilitity
StatSensor i-STAT ABL
Median 95% CrI Median 95% CrI Median 95% CrI
p[1,1] 0.74 0.61 to 0.85 0.85 0.69 to 0.94 0.87 0.75 to 0.95
p[1,2] 0.18 0.08 to 0.30 0.04 0.00 to 0.18 0.03 0.00 to 0.14
p[1,3] 0.03 0.00 to 0.12 0.04 0.00 to 0.18 0.03 0.00 to 0.14
p[1,4] 0.04 0.01 to 0.11 0.04 0.00 to 0.16 0.04 0.00 to 0.15
p[2,1] 0.09 0.03 to 0.19 0.10 0.04 to 0.21 0.02 0.00 to 0.11
p[2,2] 0.57 0.42 to 0.71 0.77 0.64 to 0.87 0.78 0.61 to 0.90
p[2,3] 0.22 0.12 to 0.36 0.10 0.04 to 0.21 0.15 0.05 to 0.29
p[2,4] 0.10 0.03 to 0.24 0.01 0.00 to 0.06 0.03 0.00 to 0.15
p[3,1] 0.01 0.00 to 0.03 0.01 0.00 to 0.05 0.02 0.00 to 0.08
p[3,2] 0.14 0.09 to 0.20 0.10 0.04 to 0.17 0.06 0.01 to 0.16
p[3,3] 0.25 0.16 to 0.34 0.81 0.72 to 0.88 0.74 0.62 to 0.85
p[3,4] 0.60 0.51 to 0.69 0.08 0.04 to 0.13 0.17 0.09 to 0.26
p[4,1] 0.00 0.00 to 0.01 0.00 0.00 to 0.01 0.00 0.00 to 0.01
p[4,2] 0.00 0.00 to 0.01 0.01 0.00 to 0.02 0.00 0.00 to 0.01
p[4,3] 0.06 0.04 to 0.08 0.08 0.06 to 0.10 0.01 0.00 to 0.01
p[4,4] 0.94 0.91 to 0.95 0.91 0.89 to 0.93 0.99 0.98 to 0.99
Notes
p[i,j] is the probability of being classified in category j by the POC device when the laboratory category is i.
Categories are described in Table 2.
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FIGURE 2 Density strips for classification probabilities for each device with vertical lines defining the median and
95% CrI. (a) StatSensor; (b) i-Stat; and (c) ABL. p[j,k], probabilities of being classified in category k, given a laboratory
classification j. Categories are described in Table 2.
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The i-STAT and ABL devices have higher median probabilities of correct classification in each of the three
lowest categories (i.e. p[1,1], p[2,2], p[3,3]) than the StatSensor, with StatSensor appearing particularly poor
at correctly classifying individuals in category 3 (i.e. individuals with an eGFR of 45–59 ml/minute/1.73 m2).
However, there is considerable uncertainty in these probabilities for all devices.
The median probabilities of being correctly classified as being at risk of PC-AKI (i.e. defined as an eGFR of
< 30 ml/minute/1.73 m2, sensitivity) using i-STAT or ABL devices are similar (85% and 87%, respectively),
whereas for StatSensor devices this median probability is lower (74%). The median probability of being
incorrectly classified as being at risk of PC-AKI by the POC device for individuals with an eGFR of
30–44ml/minute/1.73 m2 ranges from 2% for ABL devices to 9–10% for StatSensor and i-STAT devices;
however, there is some uncertainty around these values. The probabilities of being incorrectly classified as
at risk reduce considerably for individuals with an eGFR ≥ 45 ml/minute/1.73 m2.
Additional analyses
Two (non-prespecified) additional analyses were conducted: one using adjusted data for StatSensor
devices and a second using data only from studies using the CKD-EPI equation to calculate eGFR
(see Available data for quantitative synthesis).
StatSensor-adjusted data analysis
Adjusted data reported by Korpi-Steiner et al.31 and Shephard et al.36 are given in Table 42 (in Appendix 2).
The pooled probabilities for StatSensor obtained using these adjusted data and removing Inoue et al.30
data are given in Table 10. Figure 3 presents density strips for the probabilities obtained for StatSensor
in the main analysis (dark blue, wide), and using the adjusted data (light blue, narrow).
TABLE 10 Pooled probabilities for the StatSensor device under a measurement bias adjustment scenario
Probability
Pooled probability
Median 95% CrI
p[1,1] 0.84 0.73 to 0.93
p[1,2] 0.11 0.04 to 0.22
p[1,3] 0.02 0.00 to 0.08
p[1,4] 0.01 0.00 to 0.08
p[2,1] 0.11 0.04 to 0.22
p[2,2] 0.51 0.35 to 0.67
p[2,3] 0.28 0.15 to 0.44
p[2,4] 0.09 0.02 to 0.22
p[3,1] 0.01 0.00 to 0.04
p[3,2] 0.12 0.06 to 0.20
p[3,3] 0.49 0.37 to 0.60
p[3,4] 0.38 0.28 to 0.49
p[4,1] 0.00 0.00 to 0.01
p[4,2] 0.00 0.00 to 0.01
p[4,3] 0.12 0.09 to 0.14
p[4,4] 0.88 0.85 to 0.90
Notes
p[i,j] is the probability of being classified in category j by the POC device when the laboratory category is i.
Categories are described in Table 2.
Adjusted data for Korpi-Steiner et al.31 and Shephard et al.36 were used and data from Inoue et al.30 were removed.
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There is good overlap of the 95% CrIs for classifications of individuals with true eGFRs in the first two
categories, although the adjusted analysis gives a higher probability that individuals are correctly
classified as being at risk of PC-AKI (sensitivity) (p[1,1] median is 84%, in Table 10, compared with 74%
in the unadjusted analysis, in Table 9).
However, there is conflict between results from the adjusted data analysis and the main analysis for
categories 3 and 4, particularly for estimated probabilities p[3,3], p[3,4], p[4,3] and p[4,4]. The main
analysis suggests a lower probability of correctly classifying individuals in category 3, but a higher
probability of correctly classifying individuals in category 4, than in the adjusted data analysis. In
addition, the main analysis suggests that individuals in category 3 have a lower probability of being
classified as belonging to this category than to category 4, whereas this is not the case in the
adjusted analysis.
Including only studies using Chronic Kidney Disease Epidemiology Collaboration equation
The pooled probabilities of being classified by POC device in category k, given a laboratory
classification in category j, pjk = p[j,k], with j,k = 1,2,3,4, for StatSensor and ABL800 FLEX estimated
from data from the only study that used the CKD-EPI equation,37 and for i-STAT using data from the
two studies37,38 that used the CKD-EPI equation, are presented in Table 11.
TABLE 11 Chronic Kidney Disease Epidemiology Collaboration equation data only: pooled probabilities for the three
types of devices
Probability
Device, pooled probabilitity
StatSensor i-STAT ABL800 FLEX
Median 95% CrI Median 95% CrI Median 95% CrI
p[1,1] 0.56 0.32 to 0.79 0.83 0.60 to 0.96 0.83 0.60 to 0.96
p[1,2] 0.31 0.12 to 0.55 0.05 0.00 to 0.22 0.05 0.00 to 0.22
p[1,3] 0.05 0.00 to 0.22 0.05 0.00 to 0.22 0.04 0.00 to 0.22
p[1,4] 0.05 0.00 to 0.22 0.05 0.00 to 0.22 0.05 0.00 to 0.22
p[2,1] 0.12 0.04 to 0.26 0.10 0.04 to 0.21 0.02 0.00 to 0.11
p[2,2] 0.56 0.39 to 0.73 0.76 0.63 to 0.87 0.79 0.63 to 0.90
p[2,3] 0.28 0.14 to 0.45 0.10 0.04 to 0.21 0.15 0.05 to 0.30
p[2,4] 0.02 0.00 to 0.11 0.02 0.00 to 0.08 0.02 0.00 to 0.11
p[3,1] 0.02 0.00 to 0.09 0.01 0.00 to 0.04 0.02 0.00 to 0.09
p[3,2] 0.28 0.15 to 0.43 0.09 0.04 to 0.17 0.07 0.02 to 0.18
p[3,3] 0.46 0.31 to 0.62 0.79 0.69 to 0.86 0.83 0.69 to 0.92
p[3,4] 0.23 0.11 to 0.37 0.11 0.05 to 0.18 0.07 0.02 to 0.18
p[4,1] 0.00 0.00 to 0.02 0.00 0.00 to 0.01 0.00 0.00 to 0.02
p[4,2] 0.01 0.00 to 0.02 0.01 0.00 to 0.02 0.00 0.00 to 0.02
p[4,3] 0.15 0.11 to 0.20 0.05 0.03 to 0.07 0.01 0.00 to 0.02
p[4,4] 0.84 0.79 to 0.88 0.95 0.92 to 0.96 0.98 0.96 to 1.00
Notes
p[i,j] is the probability of being classified in category j by the POC device when the laboratory category is i.
Categories are described in Table 2.
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StatSensor results
Figure 3 presents density strips for the probabilities obtained for StatSensor using only the CKD-EPI
data (orange, narrow). These results broadly agree with the adjusted data analysis (light blue, narrow),
although uncertainty in the probabilities for an eGFR < 30 ml/minute/1.73 m2 is larger in the CKD-EPI
analysis as only one study37 is used with only a few individuals in this category.
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FIGURE 3 StatSensor: density strips for classification probabilities for the main analysis (dark blue, wide), the adjusted
data analysis (light blue, narrow) and the analysis including only CKD-EPI data (orange, narrow). Vertical lines define the
medians and 95% CrIs. p[j,k] is the probability of being classified by the POC device in eGFR category k, given laboratory
classification in category j. Categories are described in Table 2.
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i-STAT results
Figure 4 presents density strips for the probabilities obtained for i-STAT in the main analysis (dark blue,
wide) and the analysis using only the CKD-EPI data37,38 (orange, narrow). There is good overlap of all
density strips, with the main analysis producing slightly more precise results.
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FIGURE 4 i-STAT: density strips for classification probabilities for the main analysis (dark blue, wide) and the sensitivity
analysis including only CKD-EPI data (orange, narrow). Vertical lines define the medians and 95% CrIs. p[j,k] is the
probability of being classified by the POC device in eGFR category k, given laboratory classification in category j.
Categories are described in Table 2.
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ABL results
Figure 5 presents density strips for the probabilities obtained for ABL devices in the main analysis
(dark blue, wide) and the analysis using only the CKD-EPI data37 (orange, narrow). There is good
overlap of all density strips, with the main analysis producing slightly more precise results, particularly
for the probabilities of being correctly classified as at risk of PC-AKI (eGFR < 30 ml/minute/1.73 m2).
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FIGURE 5 ABL800 FLEX: density strips for classification probabilities for the main analysis (dark blue, wide) and the sensitivity
analysis including only data from Snaith et al.78 (orange, narrow). Vertical lines define the medians and 95% CrIs. p[j,k] is
the probability of being classified by the POC device in eGFR category k, given laboratory classification in category j.
Categories are described in Table 2.
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Sensitivity analysis for true probability calculations
To assess the impact of using different values of T[j] (see Table 8) in the model for the probabilities of
interest, pjk, a sensitivity analysis was conducted for each device with Shephard et al.36 removed from
the calculation of the T[j] (but retained in the StatSensor synthesis of pj). The resulting probabilities are
reported in Table 12 and are very similar to those reported in the main analysis (see Table 9).
Summary
Data on the classification of individuals according to their PC-AKI risk by POC devices compared with
a laboratory reference test were pooled to estimate the probabilities that individuals are correctly or
incorrectly classified into one of the four eGFR categories used to determine PC-AKI risk. Results
suggest that i-STAT and ABL devices are better than StatSensor devices at correctly categorising
individuals, particularly for the lower eGFR categories: StatSensor was less accurate at correctly
classifying patients with true eGFRs < 30 ml/minute/1.73 m2 (i.e. lower sensitivity).
The StatSensor device can incorporate an adjustment to better align results with those of the
reference laboratory test. An additional analysis using adjusted data improved this device’s
classification of individuals with low eGFRs, although there were still larger probabilities of
misclassification at higher eGFR values than for the other devices.
Analyses that included studies that only measured eGFR with the CKD-EPI equation showed that the
results were consistent and robust for i-STAT and ABL, whereas results for StatSensor showed some
TABLE 12 Sensitivity analysis: pooled probabilities for the three types of device
Probability
Device, pooled probability
StatSensor i-STAT ABL
Median 95% CrI Median 95% CrI Median 95% CrI
p[1,1] 0.74 0.61 to 0.85 0.84 0.69 to 0.94 0.87 0.75 to 0.95
p[1,2] 0.18 0.08 to 0.30 0.04 0.00 to 0.18 0.03 0.00 to 0.14
p[1,3] 0.03 0.00 to 0.13 0.04 0.00 to 0.18 0.03 0.00 to 0.14
p[1,4] 0.03 0.00 to 0.11 0.04 0.00 to 0.17 0.04 0.00 to 0.15
p[2,1] 0.09 0.03 to 0.19 0.10 0.04 to 0.21 0.02 0.00 to 0.11
p[2,2] 0.57 0.41 to 0.71 0.77 0.64 to 0.87 0.78 0.61 to 0.90
p[2,3] 0.22 0.12 to 0.36 0.10 0.04 to 0.21 0.15 0.05 to 0.30
p[2,4] 0.10 0.03 to 0.24 0.01 0.00 to 0.06 0.03 0.00 to 0.15
p[3,1] 0.01 0.00 to 0.03 0.01 0.00 to 0.04 0.02 0.00 to 0.08
p[3,2] 0.14 0.09 to 0.20 0.10 0.05 to 0.17 0.06 0.02 to 0.16
p[3,3] 0.25 0.16 to 0.34 0.81 0.72 to 0.88 0.74 0.62 to 0.84
p[3,4] 0.60 0.51 to 0.69 0.08 0.04 to 0.13 0.16 0.09 to 0.26
p[4,1] 0.00 0.00 to 0.01 0.00 0.00 to 0.01 0.00 0.00 to 0.01
p[4,2] 0.00 0.00 to 0.01 0.01 0.00 to 0.02 0.00 0.00 to 0.01
p[4,3] 0.06 0.04 to 0.08 0.08 0.06 to 0.10 0.01 0.00 to 0.01
p[4,4] 0.94 0.91 to 0.95 0.91 0.89 to 0.93 0.99 0.98 to 0.99
Notes
p[i,j] is the probability of being classified in category j by the POC device when the laboratory category is i.
Categories are described in Table 2.
Data from Shephard et al.36 are excluded from the calculation of probability of being in each true category.
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differences. Overall, results suggest that i-STAT and ABL devices show better agreement with the
reference laboratory test in the classification of individuals’ eGFR, particularly for the lower categories,
which are of greatest clinical importance.
Studies reporting clinical, workflow or implementation outcomes
Six studies reported clinical, workflow or implementation outcomes relating to POC devices
(Table 13).29,59,62,77–79 One study was available only as a conference abstract.79 Patient sample sizes
ranged from 113 to 3087 and one study was a survey of staff at 68 NHS trust sites.78 Any POC device
was eligible to be included in this section of the review: three studies used StatSensor,29,62,79 one used
an i-STAT device59 and one used a Reflotron® Plus (Roche Holding AG, Basel, Switzerland) POC device
(and a screening questionnaire).77
In Lee-Lewandrowski et al.’s59 US study, an average of 5.3% of patients presented for a CT or magnetic
resonance imaging (MRI) requiring a contrast agent, but without a recent creatinine or eGFR result.
A 1-month audit of these patients (n = 384) found that the i-STAT POC device identified 74% of
patients as having normal results (defined as an eGFR ≥ 60 ml/minute/1.73 m2), with the CT/MRI study
proceeding as planned. Of the patients with an abnormal eGFR (i.e. an eGFR of < 60 ml/minute/1.73 m2),
TABLE 13 Studies reporting clinical, workflow or implementation outcomes
Study (author
and year of
publication)
Population (N) and
country Device(s) eGFR equation Results and notes
Houben et al.,
201729
351 women due for
contrast-enhanced
spectral mammography
The Netherlands
POC device(s) MDRD Seven patients had an eGFR
< 60ml/minute/1.73m2,
necessitating additional
preparation prior to contrast
delivery. The POC device
failed to categorise six of
these seven patients (86%),
leading to unwanted
contrast administration.
Two patients (including one
of the three patients with
an eGFR of 45ml/minute/
1.73m2) subsequently
developed CIN after
2–5 days, which was
normalised after 30 days
Ledermann et al.,
201077
796 of 1766 patients
scheduled for contrast-
enhanced CT with at
least 1 ESUR risk factor
for renal insufficiency;
55% female; and mean
age 61 years
Switzerland
Reflotron plus
and screening
questionnaire
MDRD (Levey
modified)
The diagnostic procedure
was adapted in 132 patients
(16.6%): 85 (10.7%) had a
contrast dose reduction,
40 (5.0%) had CTwithout
contrast, three (0.38%) had
MRI scanning and four
(0.5%) had scintigraphy
Lee-Lewandrowski
et al., 201259
3087 patients were
referred for contrast-
enhanced scan (CT or
MRI) without a recent
eGFR
USA
i-STAT MDRD 1-month audit: 285 (74%)
of 384 patients referred
for CT/MRI had a normal
eGFR and could undergo a
scan with contrast. Of the
99 patients (26%) with an
abnormal eGFR (< 60ml/
minute/1.73 m2), 73 (74%)
received a scan with
contrast and 26 (26.3%)
without contrast
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TABLE 13 Studies reporting clinical, workflow or implementation outcomes (continued )
Study (author
and year of
publication)
Population (N) and
country Device(s) eGFR equation Results and notes
Morita et al.,
201162
113 patients scheduled
for CT or MRI without
a recent eGFR
measurement
Japan
StatSensor Modified Japanese
Society of
Nephrology–
Chronic Kidney
Disease Initiatives
Seven patients with an
eGFR of 30–50ml/minute/
1.73 m2 underwent i.v.
hydration
No symptoms of PC-AKI
were observed [the median
follow-up period from the
examination day was 94 days
(range 2–248 days)]
Test failures in 10 patients
(8.8%), of which six were
due to ‘flow errors’,
although measurements
were successfully made
at the second attempt
Snaith et al.,
201678
Survey of NHS trusts
sites; and 68 out of 174
responded (39%)
UK
NA NA 26 sites had considered
using POC technology.
Six sites indicated POC
tests would be carried out
if a result was unavailable.
POC was in regular use at
a further two sites and was
currently being evaluated
at another six. The
remaining 12 sites had
rejected POC technology as
an adjunct, mostly for cost
reasons. Other reasons for
rejected POC technology
included a lack of support
from pathology, reliability
and accuracy of the
equipment and
incompatibility with
pathology measures. Three
sites also raised concerns
that the immediacy of a
POC result could lead to
a reduction in imaging
capacity (e.g. lost slot)
aStahr et al.,
201079
360 patients in a
PET/CT unit
Denmark
StatSensor NR Before-and-after
(introduction of StatSensor)
comparison of scans
performed with and
without i.v. contrast:
l Before (March 2009):
92 of 114 patients had
i.v. contrast (81%)
l After (March 2010): 215
of 246 patients had i.v.
contrast (87%)
17 StatSensor
measurements were
performed in March 2010
i.v., intravenous; MRI, magnetic resonance imaging; NA, not applicable; NR, not reported; PET, positron emission
tomography.
a Conference abstract.
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74% of scans were performed with contrast and 26% without contrast. The authors commented
that the decision to use contrast agents in patients with abnormal eGFRs considered the type of
study being performed (vascular vs. non-vascular) and an assessment of the overall risk/benefit of
administering or not administering a contrast agent. Houben et al.29 also used an eGFR threshold
of < 60 ml/minute/1.73 m2 for identifying abnormal results, with StatSensor failing to identify six of
the seven patients with abnormal results as measured in the laboratory reference test. This resulted in
unwanted contrast agent administration. Two patients subsequently developed PC-AKI after 2–5 days,
which was normalised after 30 days.
Ledermann et al.77 studied 1766 patients referred for contrast-enhanced CT at a private Swiss radiology
facility. Only 3.5% of patients had external SCr values on their referral forms (as was requested).
A Reflotron POC device was used on patients who had risk factors for PC-AKI (identified using a
questionnaire). No fixed eGFR threshold on which to base decisions was adopted; although 116 the
796 patients with a risk factor had a POC-measured eGFR of < 60 ml/minute/1.73 m2, the diagnostic
procedure was modified in 132 patients. The most frequently adopted changes in the management
of these 132 patients was a reduction in contrast agent volume (in 64% of patients) and CT scanning
performed without a contrast agent (30%). Morita et al.62 studied the effect of using a StatSensor
device on 113 Japanese patients awaiting CT or MRI examinations who did not have a recent eGFR.62
Twenty-one patients had an eGFR of < 60 ml/minute/1.73 m2. The seven patients who had an eGFR of
30–50 ml/minute/1.73 m2 underwent IVH with 500 ml of saline.
Snaith et al.78 considered implementation issues in a survey that examined adherence of UK hospitals
to guidance on the use of gadolinium-based contrast agents in MRI; the risk of nephrogenic systemic
fibrosis is elevated in patients with impaired renal function. Six out of 68 sites indicated that POC
creatinine testing would be carried out where recent blood test results were unavailable. Twelve sites
had rejected using a POC device as an adjunct, mostly for cost reasons.
Stahr et al.’s79 study reported the proportion of scans involving intravenous contrast agent before and
after the introduction of a StatSensor device. However, the results are limited by the study design
used, the small sample size and the details reported (it was available only as a conference abstract).
Together, the results of these studies illustrate variation in practice both in terms of the proportions
of patients who do not have a recent eGFR result and in the management decisions taken when a POC
device indicates an ‘abnormal’ eGFR. However, many of these studies were undertaken several years
ago, so the value of their results is somewhat limited because the eGFR thresholds for defining an
abnormal result have decreased over time.
Pragmatic reviews of further evidence to inform the economic model
Evidence of the risk of acute kidney injury from contrast agents
Patients who need contrast-based imaging sometimes have other risk factors for AKI that make it
difficult to ascribe a causative role to contrast agents. Determining the true incidence of CI-AKI from
the published literature can be difficult as many studies do not include a control group of patients not
receiving contrast agents. Such studies will probably also include kidney injuries unrelated to contrast
agents. Another important issue when considering the risk of kidney injury following administration of
contrast agents is the outcomes being evaluated. AKI is typically defined as a specific change (relative
or absolute) in SCr levels, which makes it a surrogate outcome. The clinical significance of surrogate
events can be questionable as they sometimes resolve spontaneously without the patient being aware
of their existence. Wherever possible, the identification of the risk of real clinical outcomes – such
as mortality or the need for dialysis – is more important and useful to patients, clinicians and
researchers alike.
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These issues seem particularly important in patients with high SCr levels. In a retrospective study81 of
32,161 patients who had not received iodinated contrast material, researchers analysed SCr levels over 5
consecutive days. The study found that, during the 5-day period, more than two-fifths of patients showed a
change in level (up or down) of at least 0.4 mg/dl, with higher initial creatinine values being associated with
a higher frequency of a given absolute change.81 These results are important given that some commonly
used definitions of AKI cover absolute increases in SCr of ≥ 0.3 to 0.5 mg/dl.6 Similarly, a retrospective
study in a more relevant population (11,588 patients undergoing CT investigations either with or
without contrast agents) found that the incidence of AKI increased with increasing baseline creatinine
concentration in both contrast and no-contrast groups, concluding that much of the creatinine elevation
was attributable to background fluctuation, underlying disease or treatment.82 Finally, a prospective study
of 716 CT or MRI outpatients found that eGFR values varied independently of whether or not patients
received a contrast agent.When comparing pre-imaging values with those 3 days after, 45% of CT patients
had a change > ± 10ml/minute/1.73 m2 in the contrast group (n = 237), compared with 59% in the smaller
control group (n = 97).83
It is anticipated that a large number of studies would report on the risk of kidney injury after contrast agent
administration; therefore, initially it was sought to identify any recent reviews on the subject. A search of
MEDLINE was undertaken for reviews reporting data on the risk of AKI in CT patients. The search was run
to identify papers published from 2012 to present; the start year was chosen pragmatically to keep the
review manageable and to restrict it to the more up-to-date evidence (literature search strategy details are
presented in Appendix 1). From the 291 titles and abstracts retrieved, five potentially relevant reviews were
identified. However, the results from three reviews had limited applicability to the outpatient population
considered in this assessment, as they were of kidney transplant patients,84 critically ill patients,85 and a
mixture of emergency, ICU and inpatients.86 In the two remaining reviews, the quality of included studies
was limited because the studies lacked non-contrast agent control groups.87,88
Therefore, we focused on the most recent of the five reviews identified (i.e. Aycock et al.86), which was
also the largest study in terms of patient numbers and the broadest in terms of populations. The study
reported that, compared with non-contrast CT, intravenous contrast-enhanced CT was not significantly
associated with AKI [odds ratio (OR) 0.94, 95% CI 0.83 to 1.07], need for renal replacement therapy
(OR 0.83, 95% CI 0.59 to 1.16) or all-cause mortality (OR 1.0, 95% CI 0.73 to 1.36). Although all the
studies in the Aycock et al.86 review had control groups, many studies were small and most did not
attempt to match groups on factors associated with outcomes. Therefore, the largest studies were
identified with matched control groups included in this review: retrospective studies by McDonald
et al. (n = 21,346)89 and Davenport et al. (n = 20,242).90 The McDonald et al.89 study looked at AKI,
mortality and the need for renal replacement therapy, reporting similar results to the pooled results
reported in the Aycock et al.86 review (described above). The Davenport et al.90 study reported results
by subgroups based on SCr thresholds, concluding that iodinated contrast material is a nephrotoxic risk
factor for AKI, but not in patients with a stable SCr levels < 1.5 mg/dl.
In outpatient clinical practice it is eGFR, not creatinine alone, that is used to estimate kidney function
(and make decisions on whether or not to use contrast agents), so studies that quantify the risk of AKI
in populations subgrouped by baseline eGFR thresholds are more relevant to this assessment. Citation
searching using Google Scholar (Google Inc., Mountain View, CA, USA), together with reference lists
searches, identified large propensity score-matched studies by the same research groups that reported
results risk stratified by eGFR thresholds.91,92 The characteristics and results of these two studies are
presented in Table 14.
Propensity score-matching attempts to account for the selection bias inherent in non-randomised
studies by accounting for patient characteristics that are associated with the development of AKI
and other clinical outcomes, and which can affect decisions on whether or not to use a contrast agent.
Matched propensity score analyses matches patients based on risk factors, which predict both whether
or not a contrast-enhanced scan is given and the outcome, by calculating a propensity score that
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reflects the likelihood that a patient is offered a contrast-enhanced scan, if the risk factors are present.
The choice of covariates used to calculate the propensity score is crucial: all covariates believed
to be related to both the decision to use contrast agent and the outcome should be measured and
included. Propensity score analyses can only adjust for known and measured covariates, as opposed
to randomised studies, in which both known and unknown confounders tend to be balanced across
groups, thus the possibility of residual confounding cannot be completely ruled out. Inclusion of
covariates that are related to contrast assignment but not outcome may reduce efficiency of the
method, although this is not a serious limitation in large data sets.93 In addition, the choice of matching
method can affect the amount of residual bias.94
TABLE 14 Comparison of two large propensity score-matched studies of AKI risk stratified by eGFR thresholds in
populations undergoing CT examinations
Study details
Study (author and year of publication)
McDonald et al., 201492 Davenport et al., 201391
Population Around 90% inpatients, 10% outpatients All inpatients
Sample size 12,508 (CT examinations between
2000 and 2010)
17,652 (CT examinations between
2000 and 2010)
eGFR method MDRD Not reported
AKI definition Increase of ≥ 0.5 mg/dl SCr, 24–72 hours
after CT
Increase of ≥ 0.3 mg/dl of SCr or a SCr
increase 1.5-fold above baseline within
48 hours (AKIN criteria)
Propensity score-matching
methods
Generated separately for each eGFR
subgroup using logistic regression derived
from 13 clinical variables. Nearest-neighbour
one-to-one matching (with calliper) without
replacement
Generated for the whole group using
logistic regression derived from
13 clinical variables
eGFR thresholds and
results: number of AKIs
eGFR:
l ≥ 90 ml/minute/1.73 m2: 10/821 contrast
vs. 11/821 no contrast
l 60–89ml/minute/1.73 m2: 40/1935
contrast vs. 39/1935 no contrast
l 30–59ml/minute/1.73 m2: 161/2755
contrast vs. 170/2755 no contrast
l < 30 ml/minute/1.73 m2: 102/743 contrast
vs. 105/743 no contrast
eGFR:
l ≥ 60ml/minute/1.73 m2: 379/6971
contrast vs. 384/6996 no contrast
l 45–59ml/minute/1.73 m2: 134/1273
contrast vs. 130/1207 no contrast
l 30–44ml/minute/1.73 m2: 90/538
contrast vs. 78/551 no contrast
l < 30ml/minute/1.73 m2: 16/44
contrast vs. 14/72 no contrast
AKI incidencea eGFR:
l ≥ 90 ml/minute/1.73 m2: OR 0.91
(95% CI 0.38 to 2.15)
l 60–89ml/minute/1.73 m2: OR 1.03
(95% CI 0.66 to 1.60)
l 30–59ml/minute/1.73 m2: OR 0.94
(95% CI 0.76 to 1.18)
l < 30 ml/minute/1.73 m2: OR 0.97
(95% CI 0.72 to 1.30)
eGFR:
l ≥ 60ml/minute/1.73 m2: OR 1.00
(95% CI 0.86 to 1.12)
l 45–59ml/minute/1.73 m2: OR 1.06
(95% CI 0.82 to 1.38)
l 30–44ml/minute/1.73 m2: OR 1.40
(95% CI 1.00 to 1.97)
l < 30ml/minute/1.73 m2: OR 2.96
(95% CI 1.22 to 7.17)
The OR was adjusted for two covariates:
1. ‘CT performed when patient in the
intensive care unit’
2. ‘Type 1 diabetes mellitus’ (also
included in propensity
score calculation)
AKIN, Acute Kidney Injury Network.
a Results as ORs by eGFR threshold.
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Although the eGFR thresholds to define subgroups mostly differ, the studies’ results are concordant
for the risk of AKI in patients with an eGFR ≥ 45 ml/minute/1.73 m2, with contrast agent not being
associated with increased risk. The results differ most notably for the eGFR < 30 ml/minute/1.73 m2
subgroups, with the McDonald et al.92 study reporting no increased risk and the Davenport et al.91
study reporting a statistically significant increase in risk in patients receiving contrast agent (see
Table 14). Although the Davenport et al. study91 has the largest overall sample size, it has far fewer
patients in the eGFR < 30 ml/minute/1.73 m2 subgroup (i.e. 116 vs. 1486), which is reflected in its very
wide CIs for the estimated ORs.
Another factor that may have contributed to the eGFR < 30 ml/minute/1.73 m2 subgroup results being
different is the difference in AKI definitions. Davenport et al.91 used a lower absolute SCr increase
of 0.3 mg/dl, compared with the 0.5 mg/dl increase used by McDonald et al.92 Given the (previously
discussed) natural fluctuation in SCr levels, the use of a lower threshold is likely to detect more AKI
events in patients with higher baseline SCrs. These events may be less likely to be clinically significant
(in terms of their impact on real clinical outcomes) than AKIs defined using larger increases in SCr. This
‘noise’ of excess events may hamper interpretation of the Davenport et al.91 study results, given the very
small denominators in the eGFR < 30 ml/minute/1.73 m2 subgroups. The difference in propensity score
adjustment methods and matching may also contribute to the differences in results. McDonald et al.92
derived the propensity scores separately for each eGFR subgroup, which will better account for the
different clinical characteristics expected in patients with a lower eGFR score and lead to better
matching. In contrast, Davenport et al.91 derived propensity scores for the whole cohort, with mixed
eGFR scores, which may explain why differences between two covariates (whether or not CTwas
performed in the intensive care unit and whether or not the patient had type 1 diabetes mellitus)
remained statistically significant after matching.
The Davenport et al.91 study required that patients have both a baseline and an index pre-CT creatinine
measurement – around 16,000 patients were excluded as a result of unstable kidney function.
McDonald et al.92 did not require a baseline creatinine measurement, although the study excluded
patients with pre-existing dialysis requirements and patients with acute renal failure in the preceding
14 days. These different criteria may explain the differing numbers across the two studies of patients
with an eGFR < 30 ml/minute/1.73 m2. The small numbers mean that the Davenport et al.91 study eGFR
< 30 ml/minute/1.73 m2 results may be prone to chance effects. This can be investigated by calculating
the fragility index of the eGFR < 30 ml/minute/1.73 m2 subgroup result. The fragility index is the
minimum number of patients whose status would have to change from a non-event to an event in
order to turn a statistically significant result to a non-significant result: the smaller the fragility index,
the more ‘fragile’ the result.95 The fragility index is calculated using a Fisher’s exact test, although other
methods, such as a chi-squared test, are often used in studies. The p-value from a Fisher’s exact test
can be discrepant from a chi-squared test, especially for small studies. In cases in which a Fisher’s
exact test produces a non-significant p-value (i.e. without converting a patient from a non-event to an
event), the fragility index is reported as zero, indicating a lack of robustness of the result. For the
Davenport et al.91 study, for an eGFR < 30 ml/minute/1.73 m2 result based on the published summary
patient data, the fragility index is zero (i.e. the result is not statistically significant using Fisher’s exact
test). However, as mentioned previously, following propensity matching the Davenport et al.91 study
OR was adjusted, and the fragility index for the statistically significant OR of 2.96 cannot be calculated
from the data available.
If it was assumed that the Davenport et al.91 study eGFR < 30 ml/minute/1.73 m2 subgroup result was
robust, then the ‘number need to harm’ is six, that is, for every six inpatients with an eGFR < 30 ml/
minute/1.73 m2 who receive contrast, one inpatient will have an AKI caused by the contrast agent.
However, it should be remembered that this result is for a surrogate outcome – it is unclear to what
extent increases of 0.3 mg/dl in the SCr level of patients with a baseline eGFR < 30 ml/minute/1.73 m2
translate into real clinical outcomes, such as mortality or the need for dialysis. The McDonald et al.92
study identified in the in the Aycock et al.86 systematic review reported data on real clinical outcomes –
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the results suggested that there was no association between the use of contrast agents and need for
dialysis, or death, for all eGFR subgroup analyses (eGFR subgroups were based on stages of chronic
renal failure).89 Although the number of clinical events in this study were quite small, particularly for
the dialysis outcome. Moreover, if there is a risk of CI-AKI associated with an eGFR < 30 ml/minute/
1.73 m2, it is likely to be lower in the outpatient population of interest in this assessment, given that
inpatients are more likely to have other AKI risk factors (including acute illness and exposure to
nephrotoxic treatments). Nevertheless, uncertainty about the level of risk remains, primarily because of
the unmeasured clinical characteristics, which could not contribute to the propensity scores – most notably
the level of prophylactic measures (e.g. IVH) used in the contrast groups and the prevalence of potentially
nephrotoxic medication use at time of scanning.
The citation and reference searching identified three further publications of interest on the risk of
AKI from contrast agents.96–98 The first was a review of propensity score-matching studies on AKI
after contrast,96 which lists several studies by McDonald et al.92 and Davenport et al.91 research groups.
This review96 also cited a large study (n = 17,934) by a different research group that reported results
by baseline eGFR subgroups.97 The study setting was an emergency department – different from
the inpatients studied by McDonald et al.92 and Davenport et al.91 – with comparisons made between
contrast-enhanced CT, unenhanced CT and no-CT groups. The results were similar to those reported
by McDonald et al.,92 with rates of AKI being similar among all groups, including the eGFR 15–30 ml/
minute/1.73 m2 subgroups.
The review of propensity score-matching studies96 also cited a further study by McDonald et al.98 that
reported the effect of contrast agents on dialysis and mortality, reported by baseline eGFR subgroups.
The study was of 5758 inpatients, emergency patients and outpatients who had a CT scan either with or
without contrast agents. Contrast agents were not associated with higher rates of dialysis or mortality
for any subgroup comparisons, including the CKD stages 4–5 subgroup (i.e. patients with an eGFR
< 30 ml/minute/1.73 m2), although the last results are limited by the small number of patients in the
contrast group (90, falling to 76 after propensity score matching).
Summary
Although debate about the risk of AKI from contrast agents is ongoing,2–4 evidence from large propensity
score-matching studies of inpatients is consistent in suggesting that there is no association between the
use of contrast agents and the risk of AKI in patients with an eGFR ≥ 45 ml/minute/1.73 m2. In patients
with an eGFR < 45 ml/minute/1.73 m2, there is some uncertainty about whether or not contrast agents
are associated with a small risk, although the most robust evidence available suggests that there is no
association in inpatients. If a risk does exist, it would be expected to be lower in outpatients than
in inpatients.
Evidence on prophylactic interventions for post-contrast acute kidney injury
Pragmatic searches of MEDLINE and recent guidelines were conducted to identify evidence on the
clinical effectiveness and safety of standard prophylaxis intravenous saline hydration for preventing
PC-AKI in high-risk patients. Recent systematic reviews (from 2012 onwards) of RCTs comparing
IVH with oral hydration, placebo or no treatment for preventing PC-AKI in patients with chronic
renal failure (defined as an eGFR < 60 ml per min/1.73 m2) undergoing radiological procedures
requiring low-osmolality contrast media were included. Risk of bias was assessed using the Cochrane
risk-of-bias tool.99
Review of reviews
Three recent systematic reviews with meta-analysis were identified.100–102 Characteristics and results of
the reviews are summarised in Table 15.
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TABLE 15 Summary of recent systematic reviews on PC-AKI prophylaxis
Review details
Study (author and year of publication)
Ahmed et al., 2018102 Agarwal et al., 2015101 Hiremath et al., 2013100
Number of studies;
number of participants
197; 42,273 5; 447 6; 513
Search date Up to April 2017 Up to April 2015 Up to November 2011
Population Patients with an eGFR
< 60 ml/minute/1.73 m2 or
a SCr level of > 1.3 mg/dl
(114 mmol/l): 50.2%
Coronary angiography: 72.5%a
CT imaging: 8%a
Peripheral angiography±
angioplasty and stenting: 1.5%a
CKD (63.7%) (definition NR)
non-emergency cardiac
catheterisation: one study/
11.9% of participants
Coronary angiography
and/or angioplasty: three
studies/53.9% of participants
Various radiological
procedures: one study/34.2%
of participants
Cardiac catheterisation:
two studies/17.3% of
participants
Coronary angiography
and/or angioplasty:
three studies/52.8%
Various radiological
procedures: one study/29.8%
Interventions: number
of studies; number of
participants
44 types including:
l i.v. hydration: 41; 5136
l NAC: 68; 6095
l control: 88; 9120
l NaHCO3: 32; 3393
l statins: 14; 3040
l oral hydration: 5; 254
l placebo: 70; 7044
l allopurinol: 4; 204
l PGE1: 4; 304
l oxygen: 2; 436
i.v. hydration (simple saline) or
oral hydration
i.v. hydration (simple saline)
or oral hydration
Contrast media type: %
studies
Low osmolar: 55.5%
Iso-osmolar: 22%
Hyper-osmolar: 1.5%
Other/NS: 21%
Low osmolar: 100% Low osmolar: four
studies/77.8%
NR: two studies/22.2%
Synthesis method Network meta-analysis
946 pair-wise comparisons,
including 81 direct
comparisons
Pairwise meta-analysis Pairwise meta-analysis
Outcomes CI-AKI: ≥ 25% relative
increase or ≥ 0.5 mg/dl
increase from baseline
creatinine 1–5 days post
contrast exposure
CIN (multiple definitions)
> 44.2 µmol/l (> 0.5 mg/dl)
absolute increase or > 25%
relative increase in SCr level,
within 48–72 hours of
contrast exposure
CIN (multiple definitions)
> 44.2 µmol/l (0.5 mg/dl)
absolute increase or
> 26.4 mmol/l (0.3 mg/dl), or
> 25% relative increase in
SCr level, within 48–72 hours
of contrast exposure
Main findings Top ranked interventions were:
l allopurinol, PGE1, oxygen
and i.v. hydration vs. oral
hydration: OR 0.83
(95% CI 0.35 to 1.95)b
l i.v. hydration vs. placebo: OR
0.91 (95% CI 0.60 to 1.34)b
l i.v. hydration vs. control: OR
0.71 (95% CI 0.52 to 0.99)b
l oral hydration vs. placebo: OR
1.09 (95% CI 0.41 to 2.75)c
l oral hydration vs. control:
OR 0.86 (95% CI 0.86 to
2.13)c
PC-AKI incidence:
l i.v. hydration: 7.7%
l oral hydration: 8.2%
RR of 0.97 (95% CI 0.36 to
2.94; I2= 48%)
Subgroup of three studies
with CKD patients: RR 1.73
(95% CI 0.69 to 4.33)
PC-AKI incidence:
l i.v. hydration 8.1%
l oral hydration 9.6%
OR 1.19 (95% CI 0.46 to
3.10; I2 = 57%)
continued
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All three reviews100–102 included RCTs evaluating prophylactic treatments to prevent PC-AKI in patients
undergoing contrast-enhanced procedures. Two meta-analyses evaluated the relative efficacy of
intravenous and oral hydration in head-to-head comparisons and one network meta-analysis evaluated
44 different prophylactic interventions. Most of the evidence focused on patients undergoing cardiac
procedures. Overall, all three reviews found no significant difference between intravenous and oral
hydration to prevent PC-AKI. None of the reviews reported data on mortality, dialysis outcomes or
complications of IVH.
Ahmed et al.102 conducted a large systematic review and network meta-analysis comparing the efficacy
of 44 therapies for the prevention of PC-AKI in patients undergoing a contrast-enhanced procedure.
The review included 197 RCTs (including 42,273 participants). Nearly three-quarters of the patients
included underwent coronary angiography and 8% underwent a CT procedure. Half of included patients
had reduced kidney function, which was defined as either an eGFR < 60 ml/minute/1.73 m2 or a SCr
level of > 1.3 mg/dl (114 mmol/l). The number of patients with an eGFR < 45 ml/minute/1.73 m2 was not
reported. The most common interventions were N-acetylcysteine (68 studies, 6095 participants), IVH
(41 studies, 5136 participants), NaHCO3 (sodium bicarbonate) (32 studies, 3393 participants) and statins
(14 studies, 3040 participants). Oral hydration was also evaluated (five studies; 254 participants). The
most common comparators were placebo (70 studies, 7044 participants) and control/no treatment
(88 studies, 9120 participants). Over half of the studies (55.5%) reported using low-osmolar contrast
agents. Most studies were in cardiac patients; coronary angiography was the contrast-dependent
procedure in 72.5% of studies. The primary outcome of the review was PC-AKI (referred to as CI-AKI
in the review), defined as ≥ 25% relative increase or ≥ 0.5 mg/dl increase from baseline creatinine level
1–5 days post contrast agent exposure. Overall, the review found that the best-ranked interventions
were allopurinol, prostaglandin E1 and oxygen, although these results are based on a few trials with a
small number of participants. There was no significant difference in the ORs of PC-AKI between IVH or
oral hydration compared with placebo (IVH vs. placebo: OR 0.91, 95% CI 0.60 to 1.34 in all studies;
OR 0.97, 95% CI 0.52 to 1.9 in studies with low eGFRs/high baseline renal profile; oral hydration vs.
placebo: OR 1.09, 95% CI 0.41 to 2.75), and there was no significant difference between intravenous
and oral hydration (OR 0.83, 95% CI 0.35 to 1.95). Compared with control/no treatment, there was a
statistically significant difference favouring IVH (OR 0.71, 95% CI 0.52 to 0.99), but not oral hydration
(OR 1.09, 95% CI 0.41 to 2.75). Overall heterogeneity was 0.55 (95% CrI 0.41 to 0.69, using a vague
prior distribution) and 0.50 (95% CrI 0.37 to 0.64, using an informative prior distribution), which is
moderate to large on the log-OR scale. Although Ahmed et al.102 state that consistency was assessed
using an inconsistency plot, reported results are insufficient to conclude whether or not it was present.
TABLE 15 Summary of recent systematic reviews on PC-AKI prophylaxis (continued )
Review details
Study (author and year of publication)
Ahmed et al., 2018102 Agarwal et al., 2015101 Hiremath et al., 2013100
Conclusions Some options (particularly
allopurinol, PGE1 and oxygen)
deserve to be tested in larger
RCTs
Oral hydration is at least as
effective as i.v. hydration with
saline to prevent PC-AKI
Oral hydration may be as
effective as i.v. hydration for
the prevention of PC-AKI
i.v., intravenous; NAC, N-acetylcysteine; NaHCO3, sodium bicarbonate; NR, not reported; NS, not significant;
PGE1, prostaglandin E1; RR, risk ratio.
a Percentage of comparative analyses unless otherwise specified.
b An OR < 1 favours i.v. hydration.
c An OR < 1 favours oral hydration.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Agarwal et al.101 reported on a meta-analysis of five RCTs (447 participants) comparing oral and IVH for
the prevention of CIN (thereafter PC-AKI) in patients receiving low-osmolar contrast agents. All five
RCTs were also included in Ahmed et al.102 Two-thirds of included participants had CKD (not defined),
and all except one study only included patients undergoing cardiac procedures. There was no significant
difference in the incidence of PC-AKI between IVH (7.7%) and oral hydration (8.2%) [risk ratio (RR) 0.97,
95% CI 0.36 to 2.94; I2 = 48%]. A subgroup analysis of CKD patients (not defined) found no statistically
significant difference between treatment arms (RR 1.73, 95% CI 0.69 to 4.33; I2 = 0%). The review
concluded that oral hydration is at least as effective as IVH to prevent PC-AKI.
Hiremath et al.100 included six RCTs (513 participants) that compared the relative efficacy of oral
hydration and IVH. Four of these trials were also included in Agarwal et al.,101 and all were included in
Ahmed et al.102 All except one study (i.e. Dussol et al.103) focused exclusively on patients undergoing
cardiac procedures. There was no significant difference in the incidence of PC-AKI between IVH (8.1%)
and oral hydration (9.6%) (OR 1.19, 95% CI 0.46 to 3.10; I2 = 57%).
Randomised controlled trial evidence
As most of the review evidence focused on patients undergoing cardiac procedures, the applicability of
the review findings may be limited for the population of outpatients scheduled for contrast-enhanced
CT scanning without a recent eGFR measurement who may be at a higher risk of PC-AKI. Therefore,
references of studies included in the reviews were checked for RCTs comparing oral hydration or IVH
versus no treatment for preventing post-contrast AKI in outpatients with chronic renal failure (i.e. an
eGFR < 60 ml/minute/1.73 m2) undergoing non-cardiac radiological procedures requiring non-ionic,
low-osmolality contrast agents.
Two trials met this study’s inclusion criteria: A MAastricht Contrast-Induced Nephropathy Guideline
(AMACING)104,105 and Dussol et al.103 The characteristics and results of both trials are reported in Table 16.
Risk-of-bias assessment is summarised in Table 48 (in Appendix 5). AMACING104 was designed as an
non-inferiority trial and was therefore not sufficiently powered to detect a significant difference between
treatments. Dussol et al.103 was significantly smaller (with approximately one-quarter of the participants
being assigned to IVH or to the control) and did not report allocation concealment methods; therefore,
a risk of bias cannot be excluded.103 Both trials could not blind study participants and study personnel,
although this is unlikely to significantly affect the assessment of PC-AKI.
The AMACING104 study was a single-centre, randomised, parallel-group, open-label, Phase 3, non-
inferiority trial of no prophylaxis compared with guideline-recommended prophylaxis in preventing what
the authors termed CIN (thereafter PC-AKI). In addition, the trial was to explore the effect on long-term
post-contrast agent exposure adverse outcomes. A total of 660 adults with an eGFR between 30 and
59 ml/minute/1.73 m2 undergoing an elective procedure requiring an iodinated contrast agent were
randomised to standard intravenous prophylactic hydration or no prophylaxis. PC-AKI was measured
at 2–6 days post contrast agent exposure. The trial found no significant difference in the incidence of
PC-AKI between intravenous prophylaxis (2.7%) and no treatment (2.6%) at follow-up (RR 1.04, 95% CI
0.39 to 2.73). No haemodialysis or related deaths occurred within 35 days. Eighteen (5.5%) patients
in the intravenous prophylaxis group experienced IVH treatment-related adverse events. At 1 year
following contrast agent exposure, there was no significant difference in the proportion of patients
requiring dialysis between intravenous prophylaxis and the control group (0.6% incidence in both
groups; RR 1.01, 95% CI 0.14 to 7.14), and no difference in mortality [IVH 9.8% vs. control 10.8%;
hazard ratio (HR) 1.12, 95% CI 0.70 to 1.80].
The study by Dussol et al.103 was a single-centre, randomised, parallel-group, open-label trial comparing
the efficacy of oral saline hydration with that of intravenous saline hydration, with or without theophylline
or furosemide, for preventing PC-AKI. Patients undergoing radiological procedures with a non-ionic, low-
osmolality contrast agent with an eGFR ranging between 15 and 60ml/minute/1.73 m2 were randomised
to one of four groups: oral hydration, standard IVH, IVH with theophylline and IVH with furosemide.
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TABLE 16 Characteristics and results of RCTs of PC-AKI prophylaxis
Study (trial
acronym/
author and
year of
publication)
Characteristics
ResultsDesign Selection criteria
Population
characteristics Interventions
Mean volume of
contrast agent (SD)a PC-AKI definition
AMACING104,105 Randomised,
parallel-group,
open-label, non-
inferiority trial
The Netherlands
N= 660
l Included: adults
with an eGFR
30–59ml/minute/
1.73 m2; and
undergoing an
elective
procedure
requiring
iodinated
contrast agents
l Excluded: adults
with an eGFR
< 30 ml/minute/
1.73 m2; and
undergoing RRT
l Age: 72 years
(SD 9 years)
l Male: 62%
l Inpatient: 8.7%
l Baseline eGFR:
¢ i.v. hydration:
47.3 ml/minute/
1.73 m2
(SD 7.95 ml/
minute/1.73 m2)
¢ Control: 47.59 ml/
minute/1.73 m2
(SD 8.01 ml/minute/
1.73 m2)
l Diabetes mellitus: 32%
l CVD: 75%
i.v. hydration
0.9% NaClb
or no i.v.
hydration
l i.v. hydration:
92 ml (SD 41 ml)
l Control: 89 ml
(SD 41ml)
Increase in SCr
levels by > 25% or
44 µmol/l within
2–6 days post
contrast agent
PC-AKI incidence
(2–6 days’ follow-up):
l i.v. hydration: 8/296
(2.7%)
l Control: 8/307 (2.6%)
l RR 1.04, 95% CI 0.39
to 2.73c
Treatment-related AEs
(35 days’ follow-up):
no haemodialysis or
treatment-related deaths
l i.v. hydration:
18/328 (5.5%),
including 13 leading
to premature
discontinuation, forced
diuresis or extended
hospitalisation; one
case of hyponatraemia;
and four cases
of arrhythmia
during hydration
l Control: NA
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TABLE 16 Characteristics and results of RCTs of PC-AKI prophylaxis (continued )
Study (trial
acronym/
author and
year of
publication)
Characteristics
ResultsDesign Selection criteria
Population
characteristics Interventions
Mean volume of
contrast agent (SD)a PC-AKI definition
Dussol et al.,
2006103
Randomised,
parallel-group,
four-arm, open-
label trial
France
N= 330
l Included: patients
with chronic renal
failure (i.e. a
creatinine
clearance
rate of 15–60ml/
minute/1.73 m2);
and patients
undergoing scans
with a non-ionic,
low-osmolality
contrast agent
l Excluded: patients
aged < 18 years;
patients with a
LVEF < 30%; and
patients with
uncontrolled
hypertension
l Age: 64 years
(SD 11 years)
l Male: 84%
l Inpatient: 0
l Baseline eGFR:
¢ i.v. hydration: 38 ml/
minute/1.73 m2
(SD 13 ml/minute/
1.73 m2)
¢ Control: 33 ml/
minute/1.73 m2
(SD 11 ml/minute/
1.73 m2)
l Diabetes: 29%
l Heart failure: 19%
i.v. hydration
0.9% NaCl
or oral
hydration
l i.v. hydration:
115 ml (SD 57ml)
l Oral hydration:
120 (SD 40 ml)
Increase in SCr
levels ≥ 0.5 mg/dl
(44 µmol/l) above
baseline at 48
hours post
contrast agent
PC-AKI incidence
(48 hours of follow-up):
l i.v. hydration:
5/76 (6.6%)
l Oral hydration:
4/77 (5.2%)
l RR 1.27 (95% CI
0.35–4.54)c
No significant
differences in between-
arm differences at
24 hours’ follow-up
(results NR in study)
Dialysis, fluid overload,
significant increase in BP
(48 hours’ follow-up):
none in either trial arm
Other adverse events
(48 hours’ follow-up):
l Oral hydration:
vomiting (n= 1). No
other AEs reported
Further results for
theophylline and
furosemide arms were
reported
AE, adverse event; BP, blood pressure; CVD, cardiovascular disease; HR, hazard ratio; i.v., intravenous; LVEF, left ventricular ejection fraction; NA, not available; NaCl, sodium chloride;
NR, not reported; RRT, renal replacement therapy; SD, standard deviation.
a 300 mg of iodine per ml of contrast agent.
b Standard prophylaxis: 3–4ml/kg per hour for 4 hours before and 4 hours after contrast agent administration; calculated on a modified ITT basis, including 603 (91%) of 660
patients with a follow-up measurement.
c Calculated.
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The proportion of patients with an eGFR < 30 ml/minute/1.73 m2 was not reported. The study found
no significant difference in the incidence of PC-AKI between intravenous prophylaxis (6.6%) and oral
hydration (5.2%) (RR 1.27, 95% CI 0.35 to 4.54) at 48 hours post contrast agent exposure. There were
no significant adverse events in either study arm.
Overall, both trials found that oral hydration was not inferior to IVH for preventing AKI in patients
with an eGFR < 60 ml/minute/1.73 m2. There was mixed evidence on the safety of IVH: one trial
(AMACING104) suggested that IVH was associated with treatment-related complications, and another
found no adverse events.103
Non-randomised evidence
Owing to the lack of RCT-based evidence in patients with an eGFR < 30 ml/minute/1.73 m2, further
pragmatic MEDLINE searches were conducted to identify relevant non-randomised evidence. One
retrospective cohort study was found.106
Nijssen et al.106 included patients referred for an elective procedure who received intravascular iodinated
contrast material administration with an eGFR < 30ml/minute/1.73 m2 and who were excluded from
the AMACING trial.104 Outcomes included CIN (as referred to in the trial, thereafter PC-AKI) (2–6 days’
follow-up), dialysis and mortality within 35 days post contrast agent exposure, and complications of
prophylactic IVH. The characteristic and results of Nijssen et al.106 are reported in Table 43.
Of the 155 patients with an eGFR < 30 ml/minute/1.73 m2 who received contrast material, 119 (76.8%)
received 0.9% intravenous sodium chloride (i.e. standard IVH), 12 (7.8%) received 1.4% NaHCO3
hydration and 24 (15.5%) received no prophylaxis. Reasons for deviation from standard prophylaxis are
reported in Table 43. Data on 2- to 6-day SCr measurements were available for only 59 (50%) of the
standard prophylaxis patients. Data on other clinical outcomes were available for 99–100% of standard
prophylaxis patients. The incidence of clinical outcomes were reported separately for patients with an
eGFR < 30 ml/minute/1.73 m2 receiving standard prophylaxis, NaHCO3 hydration and no prophylaxis.
PC-AKI occurred in 8 out of 59 (13.6%) patients with standard prophylaxis, in 1 out of 12 (8.3%)
NaHCO3-hydrated patients, and in 1 out of 18 (5.6%) no-prophylaxis patients. Dialysis within 35 days
of contrast agent exposure occurred in 1 out of 118 (0.85%) standard prophylaxis patients, in 1 out of
12 (8.3%) NaHCO3-hydrated patients and in none of the 23 patients receiving no prophylaxis. Death
within 35 days of post-contrast agent exposure occurred in 11 out of 119 (9.2%) of standard
prophylaxis patients. There were no deaths in patients receiving NaHCO3 or no prophylaxis.
Results of patients with an eGFR < 30 ml/minute/1.73 m2 who received standard prophylaxis were
analysed against the IVH arm of the AMACING trial104 in unadjusted or unmatched comparisons.
Compared with the AMACING trial104 active-arm participants, the incidence of PC-AKI was significantly
higher in patients with an eGFR < 30 ml/minute/1.73 m2 (13.6% vs. 2.7%; p = 0.0019). Death within
35 days of contrast agent exposure was also higher in the cohort arm (9.2% vs. 0.0%; p < 0.0001).
There was no difference in the incidence of complications of prophylactic IVH (5.9% vs. 5.5%;
p = 0.8529) and 35-day dialysis (0.9% vs. 0.0%; p = 0.2646) between the two trial groups.
Results from Nijssen et al.106 may not be reliable as a result of the lack of randomisation, the lack of
matching and adjusted comparison, and the significant rate of missing PC-AKI data in higher-risk
patients undergoing standard hydration.
Summary of prophylaxis evidence
This study found three recent systematic reviews and meta-analyses evaluating prophylactic treatments
to prevent PC-AKI in patients undergoing contrast-enhanced procedures. The reviews were consistent in
showing no evidence of a difference in effectiveness between intravenous and oral hydration to prevent
PC-AKI. However, relevant pooled estimates from meta-analyses had wide CIs and there was evidence
of heterogeneity; therefore, the true effect (or lack of effect) of IVH compared with oral hydration to
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prevent PC-AKI remains uncertain. None of the reviews reported on mortality, dialysis or complications
from IVH. Most evidence from systematic reviews focused on patients undergoing cardiac procedures,
and incidence of PC-AKI was significantly higher than that reported in outpatient populations scheduled
for contrast-enhanced CT scanning without a recent eGFR measurement; therefore, the applicability of
much of the evidence to this study’s population of interest is uncertain.
The evidence in patients at higher risk of PC-AKI who are referred for a non-emergency scan
with contrast media is more limited. Two RCTs of non-cardiac outpatients with CKD (i.e. an eGFR
< 60 ml/minute/1.73 m2) were identified, and both found no evidence that intravenous prophylaxis
reduced the incidence of post-contrast agent AKI compared with no IVH. This is consistent with the
broader evidence from the systematic reviews that were identified, which primarily included cardiac
patients. This study found only limited non-RCT evidence for patients with an eGFR < 30 ml/minute/
1.73 m2. There was mixed evidence on the safety of IVH in non-cardiac outpatients with CKD (eGFR
< 60 ml/minute/1.73 m2): one trial suggested that IVH was associated with treatment-related
complications and another found no adverse events.
Overall, there is no evidence to suggest that IVH is more effective than oral hydration or placebo in
preventing PC-AKI, renal replacement therapy (RRT) or reducing mortality. Evidence on complications
of IVH is inconclusive. The certainty of the evidence on the efficacy of IVH is limited by the lack of
precision in intermediate outcome estimates, lack of hard clinical outcomes and broader issues
surrounding the existence of PC-AKI in patients with CKD.
Evidence of practice variation in renal function assessment
Two quite recent studies that have evaluated how renal function assessment practice varies in the UK
were identified by reference list searching and citation searching. A survey undertaken in 2015 by
Cope et al.13 assessed compliance with UK 2013 guidelines107,108 for the prevention, recognition and
management of CI-AKI. All UK acute NHS providers with a clinical radiology audit lead registered with
the Royal College of Radiologists (RCR) were invited to complete a questionnaire. In order to demonstrate
guidance compliance in daily practice, audit data on 40 consecutive stable outpatients who had undergone
CTwith intravenous iodine-based contrast agents were also requested from each NHS provider.
Eighty-nine of the 172 (52%) health service providers responded to the questionnaire and 91 out of
212 (43%) hospitals provided audit data. In general, the paper by Cope et al.13 noted wide variation in
clinical practice and poor compliance with guidelines. Although kidney function test results within
3 months of the scan were available for 86% of outpatients, eGFR results (as recommended in the
guidelines) were available for only 66%. Responsibility for checking baseline kidney function was taken
by the radiology department in 49% of departments; in 51%, the responsibility was either devolved to
the referring clinician or was not clearly defined. Only 30% of radiology departments had a policy for
management of patients who developed PC-AKI or had locally agreed arrangements in place for the
care of patients when repeat blood tests demonstrate PC-AKI. The requirement for intravenous volume
expansion for high-risk patients prior to the scan was met by 64% of departments.
Audit data were available for 3590 fit outpatients. Analyses were reported for a subgroup of 513 patients
with a baseline eGFR < 60ml/minute/1.73 m2; 288 (56%) had pre- and post-contrast kidney function tests
– no change was seen in the median SCr level 2 days post contrast. The incidence of clinically significant
(requiring treatment or resulting in death) PC-AKI was zero in 3590 outpatients.
Harris et al.12 also undertook a UK survey in 2015, requesting data from CT managers in 174 NHS
trusts to identify screening practices prior to outpatient contrast-enhanced CT. The response rate
(47%) was similar to that reported in Cope et al.’s13 survey. The RCR guideline109 was most frequently
used, although 20% of responders did not cite the use of a specific guideline. Most responding sites
(75/82, 92%) required renal function to be assessed via a blood test; most sites did this for all patients,
although 20% of sites assessed only ‘high-risk’ patients. Variation in how blood tests were organised
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was found, with most radiology departments sharing the responsibility with the referring clinician.
Most radiology departments removed or minimised the risk of patients attending radiology without
a recent kidney function result by checking blood results either before booking appointments (56%)
or when appointments were made (16%), with blood tests booked if needed. Just over one-quarter
of radiology departments (28%) indicated that results are reviewed on the day of the scan (or the
night before).
Variation was also evident in the eGFR or SCr thresholds at which contrast was deemed to be
contraindicated; 19 different threshold levels were identified, each leading to different prophylactic
strategies. The most frequently used threshold was an eGFR of < 30 ml/minute/1.73 m2, which was
used in 35 of the 77 (45%) NHS trusts. Blood test results were not checked by 7 out of 82 (9%) sites –
sites indicated that it was the referrer’s responsibility. For patients attending without a recent blood
result, 45% send the patient away to have a blood test and scan either on the same day (if possible)
or on a different day, and 11% of sites use POC devices to get a quick blood test result. Most of
the remaining sites said that they would seek advice from a consultant radiologist. Data on practice
variation in obtaining follow-up (post-contrast) blood tests were also reported. The authors concluded
that the wide variation in practice is a reflection of inconsistencies in published guidance and that an
evidence-based consensus on risk thresholds was needed.
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Chapter 4 Assessment of existing
economic evidence on point-of-care testing
This chapter provides an overview of existing cost-effectiveness evidence on the use of POCcreatinine tests in an outpatient non-emergency secondary care setting to assess kidney function
before contrast-enhanced CT imaging. The relevant population includes adult patients who do not have
a recent eGFR measurement. Eligible studies were systematically identified and the main findings
narratively summarised and tabulated for comparison. Other sources of evidence, with more qualitative
consideration of the potential implications of introducing POC testing in the context of the current
decision problem, were also reviewed. These sources of evidence included:
1. one existing Medtech innovation briefing (MIB) on POC devices for creatinine testing
2. a report produced by the King’s Technology Evaluation Centre (KiTEC; King’s College London,
London, UK) to support the External Assessment Group (EAG)’s report.
The findings from the reviews helped inform the development of a new decision-analytic model
reported in Chapter 5, Independent economic assessment.
Methodology of the cost-effectiveness review
Searches
The literature search reported in Chapter 3, Assessment of clinical effectiveness, Searches, was also used
to identify studies reporting on the cost-effectiveness of POC creatinine testing in an outpatient
non-emergency setting before contrast-enhanced CT imaging.
Selection process
A broad range of studies were considered in the review, including economic evaluations conducted
alongside trials, modelling studies and analyses of administrative databases. Only full economic
evaluations that compared two or more options and considered both costs and consequences
(i.e. cost-minimisation, cost-effectiveness, cost–utility and cost–benefit analyses) were included in
the review. The inclusion criteria also defined the relevant population as non-emergency outpatients
scheduled to receive intravenous contrast-enhanced CT imaging.
The selection of relevant studies was performed in two stages:
1. Titles and abstracts identified by the search strategy were examined and screened for possible inclusion.
2. Full texts of the potentially relevant studies were obtained and screened for inclusion.
Two researchers (AD and JA) independently screened the titles and abstracts of all reports identified
by the bibliographic searches and full-text papers were subsequently obtained for assessment and
screened by at least two researchers. Any disagreement was resolved by consensus.
Confidential information
This report contains reference to confidential information provided as part of the NICE appraisal
process. This information has been removed from the report and the results, discussions and conclusions
of the report do not include the confidential information. These sections are clearly marked in the report.
Results
A total of 3628 records were identified by the initial search of economic databases. Three studies were
identified as potentially relevant from their titles and/or abstracts. The full-text articles of these records
were assessed for eligibility; however, none was found to meet the inclusion criteria. Figure 6 presents a
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flow diagram of the selection process. Table 49 in Appendix 6 lists excluded studies alongside reasons
for exclusion.
Although no published studies were identified from the systematic review, one unpublished economic
study was identified, which was considered potentially relevant (Professor Beverley Snaith, Mid
Yorkshire Hospitals NHS Trust, 2019, personal communication). Following discussion with the lead
author, a draft version of the manuscript was provided. This draft was provided by the lead author in
academic in confidence.
Review of Shinkins et al.
Overview
(Confidential information has been removed.)
Relevance of findings
(Confidential information has been removed.)
Overview of other sources of evidence
Although no other studies were identified that met the review inclusion criteria, several additional
sources of evidence were identified that provided a more qualitative consideration of the potential
implications of introducing POC testing in an outpatient non-emergency secondary care setting to
assess kidney function before contrast-enhanced CT imaging. These additional sources of evidence are
briefly summarised below.
Resourcing implications identified in the Medtech innovation briefing
The MIB (specifically MIB13615) identifies POC testing technologies as an alternative to laboratory-
based testing in those patients who present for contrast CT scanning without a recent eGFR
measurement. In the absence of a recent creatinine measurement, these patients may otherwise have
their imaging cancelled or rescheduled – given national guidelines for a recent eGFR to be available
before imaging.108,110 If the scan is not cancelled, the authors of MIB suggest that the patient would
either undergo non-contrast-enhanced scanning or continue with contrast scanning as planned, thus
putting the patient at risk of kidney injury.
Potentially relevant
articles identified and
screened for retrieval
(n = 3628)
Total full papers
screened
(n = 3)
Total full papers
accepted
(n = 0)
Papers rejected at the
title stage
(n = 3625)
Full papers excluded
(n = 3)
FIGURE 6 Assessment of cost-effectiveness: summary of study selection and exclusion.
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FIGURE 7 Confidential information has been removed. (continued)
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The authors therefore identify a key benefit of POC devices to be reducing the incidence of cancelled
CT scans as a result of the expectation of a reduced patient waiting time for eGFR measurements for
those patients who present without a recent eGFR measurement. MIB specialist commentators note
the administrative cost of cancelling or rescheduling scans, and the impact of cancellations on overall
scanning capacity. The other benefit is more accurately identifying the subset of patients without a
recent eGFR measurement who should not proceed with a contrast CT scan because of their elevated
risk of kidney disease (i.e. those patients with an eGFR < 30 ml/minute/1.73 m2). These patients are most
likely to suffer adverse effects of contrast-induced kidney injury and, thus, should not generally proceed
to contrast CT scanning unless appropriate prophylaxis is provided, their contrast dose is reviewed or
they are in urgent need of diagnostic information provided only by contrast-enhanced imaging.
The MIB authors note that POC devices are expected to deliver eGFR results from a whole-blood
sample in ≤ 9 minutes, compared with laboratory testing, which can take between 60 minutes and
24 hours. The specialist clinical group that was consulted note that this reduction in waiting time would
reduce the need for additional appointments, delayed appointments and increase patient throughput.
The MIB authors note that POC devices would be most useful in assessing kidney function in the
subgroup of the overall patient population at highest risk of kidney disease, including those patients
with diabetes mellitus, people taking metformin and older people.
The MIB authors note that POC testing would increase upfront costs compared with standard
laboratory-based testing. The unit cost of a laboratory test for blood/serum/plasma creatinine was
£1.29 at 2015/16 prices (i.e. reference cost DAPS04111). The MIB authors note that the unit cost per
FIGURE 7 Confidential information has been removed.
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POC test for the devices that they consider vary between £0.17 and £4.75. The authors also note the
significant upfront capital costs of POC devices. On a practical front, the authors note the potential
requirement for staff training and compliance and quality assurance policies, as well as an increase in
storage space for POC consumables; however, the MIB authors also note that all of these requirements
would be unlikely to be a significant change. The MIB authors also note that additional resources may
be required for participation in external quality assurance schemes, with specialist commentators
also suggesting potential costs for the integration of recording POC results with the existing hospital
reporting system. The specialist group of clinical advisors held divergent opinions on whether or not
POC testing would replace central laboratory testing or supplement it.
The MIB authors note some economic benefits of early diagnosis of CKD through the use of POC
testing as opposed to waiting for GP testing; however, the authors note that these savings would be
minimal. The authors also cite a US-based study112 that showed a reduction in waiting times for eGFR
results from an average of 1 hour 54 minutes to 5 minutes following the introduction of radiology
POC testing. This US study also suggested that the volume of contrast material used was also reduced
for 26.4% of patients (33/125 patients). Although not directly reported in the MIB, this study suggests
that rapid testing will enable radiology departments to reduce costs by reducing the number of
full-time-equivalent administrative positions needed for checking laboratory results prior to testing.
In addition, the rapid testing will also reduce technician overtime as a result of the reduced need to
accommodate delayed examination times due to waiting for laboratory results.
Implications for the care pathway identified in the King’s Technology Evaluation
Centre’s report
As part of the report produced by KiTEC to support the EAG’s report,113 clinical experts were also
interviewed regarding their views on the implications of introducing POC creatinine testing within the
current CT imaging pathway. The KiTEC report noted that all the clinical experts that were interviewed
expressed concerns regarding the use of these devices in their departments. The report highlighted two
main reasons for these concerns. First, the clinical experts highlighted that referring clinicians would rely
even more on the radiology department to check patients’ eGFR. As a result of this behavioural change,
the clinical experts thought that this would result in an increase in the number of patients referred for
a CT appointment without a recent eGFR measurement. Second, the clinicians noted that this would
increase the responsibility and resourcing required by the radiology department not only to action upon
a low eGFR but also to explain to the attending patient that their result was abnormal and may require
further investigations and changes in management.
Discussion of existing cost-effectiveness evidence and relevance to current
decision problem
(Confidential information has been removed.)
To address the issues and uncertainties identified in the review and, in particular, to inform the
cost-effectiveness of POC creatinine testing for the specific decision population under consideration,
a new independent decision model was developed.
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Chapter 5 Independent economic assessment
Overview
Chapter 4 identified several issues and uncertainties arising from previously published studies. A number
of important limitations were also identified in relation to the current decision problem, specifically:
1. Only one cost–consequence analysis was identified and no studies have formally assessed the
cost-effectiveness of POC testing in the decision context considered in this appraisal.
2. The lack of any study that has attempted to formally compare different POC testing devices.
3. The absence of any study that has attempted to quantify the benefits and risks associated with
incorporating POC testing within the current CT imaging pathway.
For these reasons, it has been necessary to develop a de novo decision model.
Contribution of the model
The purpose of the decision model is to assess the cost-effectiveness of POC testing to assess kidney
function in people who need contrast-enhanced CT imaging in a non-emergency situation and who do not
have a recent eGFR measurement. The model provides a quantitative framework to link the diagnostic
accuracy of POC creatinine tests to short-term costs and consequences (e.g. the impact on cancelled or
delayed appointments, use of contrast media with and without IVH and associated risks such as PC-AKI)
and final health outcomes (e.g. end-stage renal disease and death) expressed in terms of QALYs. This
linkage is necessary in order to provide decision makers with an indication of the health gain achieved by
POC tests, relative to their additional cost, in units that permit comparison with other uses of health
service resources.
The purpose of the POC and existing laboratory-based tests (urgent and non-urgent) is to inform subsequent
scanning decisions, specifically the use of contrast material, prophylactic hydration or the use of alternative
imaging modalities. The model characterises the impact of the alternative tests (POC vs. laboratory based)
based on the person’s estimated eGFR and the subsequent decisions according to specific eGFR thresholds.
These decisions will affect the use of contrast, prophylaxis and alternative imaging modalities. For example,
the volume of contrast will depend on whether or not a decision is made to proceed with CT imaging using
contrast material or to proceed with an unenhanced CT scan or even to an alternative imaging modality.
These decisions, and the subsequent use of contrast material and prophylactic hydration, also need to be
linked to any possible impact on the risks of PC-AKI and to final health outcomes, including morbidity
and mortality.
The use of POC testing within the current CT pathway has implications to the health system that
relate to the following main components:
l System level and resourcing: the use of POC testing may reduce system inefficiencies related to ensuring
that a recent laboratory-based eGFR measure is available prior to the CT appointment. Although
significant efforts are often made to ensure that a recent eGFR measure is available prior to the
scheduled CT appointment, a proportion of individuals may present on the day of the scan without a
recent eGFR measurement. As a result, these individuals may be sent for blood tests in the hospital
laboratory, which means that the planned CT scan appointment may need to be delayed or rescheduled.
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l Diagnostic (in)accuracy: POC tests (used with or without additional risk questionnaires) inevitably
introduce some level of misclassification compared with laboratory testing, in that some of the
individuals may be misclassified as having a high risk of PC-AKI (i.e. FP) and others, who are truly
high risk, may be misclassified as low risk (i.e. FN). As a consequence of misclassification, these
individuals may not receive the appropriate clinical management strategies, leading to potential
morbidity and even mortality implications.
l Risk of PC-AKI: equally, POC devices may help to identify individuals at high risk of PC-AKI,
particularly those patients presenting at their appointment without a recent eGFR measurement
and for whom a decision to proceed to contrast-enhanced CT scanning is made based on clinical
judgement alone. By providing a timely eGFR measurement, more individuals at a higher risk of
PC-AKI may be identified, allowing more appropriate management strategies to be followed. That is,
preventative strategies can be put in place, including the use of oral hydration or IVH or identifying
individuals for whom the use of contrast media can be avoided, without significantly compromising
accuracy by performing an unenhanced CT scan or changing diagnostic modality.
The modelling proposed in this study is designed to address these three components and to be able
to determine the overall value of POC testing inferred from each of the possible risks and benefits.
The following sections outline the decision problem and the structure of the model. In addition, the
sections also provide an overview of the key assumptions and data sources used to populate the model.
Model structure
Overview
The model evaluates the cost and health outcomes of a cohort of outpatients presenting for a
non-emergency contrast-enhanced CT scan without a recent eGFR measurement. The model is
populated using the results from the quantitative synthesis of the diagnostic accuracy of POC testing
as described in Chapter 3, Results: assessment of diagnostic accuracy. Other relevant parameters were
informed by a series of additional reviews described throughout this section. These parameters are
used to provide a link between the diagnostic accuracy of a given testing strategy, the impact on
subsequent treatment decisions and the ultimate effect on health outcomes and costs.
Costs are presented from the perspective of the NHS and Personal Social Services (PSS) and are
reported in Great British pounds at a 2018 price base. Outcomes are expressed in terms of QALYs.
Outcomes beyond the first year are discounted at a rate of 3.5% per annum.
The model uses a decision tree cohort approach to estimate, based on best available data, the costs
and health outcomes of the relevant testing and treatment strategies. The model structure captures:
1. individuals’ true eGFR status (with the cohort dichotomised based on a cut-off point of
30 ml/minute/1.73 m2)
2. how these individuals are subsequently classified by different testing strategies (with classification
dichotomised on the same eGFR cut-off point of 30 ml/minute/1.73 m2 and probabilities conditional
on true eGFR status)
3. any actions taken to mediate PC-AKI risk in patients identified (correctly or incorrectly) as below
the eGFR cut-off point
4. the subsequent risk of PC-AKI (conditional on eGFR status and any actions taken to mediate
PC-AKI risk)
5. the risk of renal replacement therapy (conditional on whether or not a patient experienced PC-AKI).
Costs and QALYs are linked to the use of screening tests, mediating actions taken and the use of RRT.
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A simplified model schematic is shown in Figure 8. Patients are defined as true positives (TPs), FPs, true
negatives (TNs) and FNs according to their overall classification across each testing strategy and not
in relation to individual tests in the sequence. Testing approaches may combine up to three testing
elements to identify patients. The elements of testing considered were:
1. screening on the basis of a risk factor questionnaire
2. testing with a POC device
3. testing with a laboratory test (urgent or non-urgent).
Patients identified as negative by the testing approach will receive no alternative management and
undergo contrast-enhanced CT. Patients identified as positive will receive mediating action, which in
the base case is assumed to be the use of IVH prior to undergoing contrast-enhanced CT. Following
their scan, patients may experience a PC-AKI and may subsequently undergo RRT.
Chance
Decision
Terminal
RRT
No PC-AKI
No RRT
TN No action 
Patients correctly classified as eGFR 
≥ 30  ml/minute/1.73 m2
RRT
PC-AKI
No RRTScreening and/or
testing
True eGFR ≥ 30 ml/
minute/1.73 m2
RRT
No PC-AKI
No RRT
FP Action 
Patients missclassified as eGFR 
< 30 ml/minute/1.73 m2
RRT
PC-AKI
No RRT
RRT
No PC-AKI
No RRT
FN No action
Patients missclassified as eGFR 
≥ 30  ml/minute/1.73 m2
RRT
PC-AKI
Screening and/or
testing No RRT
True eGFR < 30 ml/
minute/1.73 m2 RRT
No PC-AKI
No RRT
TP Action 
Patients correctly classified as eGFR 
< 30 ml/minute/1.73 m2
RRT
PC-AKI
No RRT
Node
FIGURE 8 Decision tree general schematics.
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A key assumption in the base-case analysis is that all individuals will eventually proceed to contrast-
enhanced CT. Hence, the only difference between the alternative testing strategies that were evaluated
concerns the costs and potential health impact of delayed or rescheduled CT, whether or not any
mediating action is taken to reduce the risk of PC-AKI (i.e. use of IVH) and the consequences of PC-AKI.
The base-case analysis does not attempt to include other clinical outcomes that could be affected by
changes to the imaging decision itself. These outcomes could include anxiety associated with delayed
or cancelled scanning, and morbidity and mortality implications of performing unenhanced scanning
or using an alternative imaging modality. This simplification was considered necessary given the
limited data available and the challenges of characterising the heterogeneity in the overall population
and the underlying reason for imaging and linking this to individualised clinical decision-making and
associated outcomes.
The challenges of linking different decisions regarding the use of contrast media in imaging to patient
outcomes were also highlighted in KiTEC’s report.113 Clinical experts interviewed in the KiTEC report
stated that it is difficult to quantify the impact of decisions regarding the use of contrast media on
patient outcomes as the benefits of using intravenous contrast vary depending on the underlying
population and scanning indication. The use of intravenous contrast was considered by the clinical
experts to be well-established practice, but none was aware of any landmark study that could be
used to quantify the benefits compared with alternative imaging decisions.
Although the base-case analysis imposes boundaries around the specific clinical outcomes assessed
because of practical considerations and data gaps, a series of additional scenario analyses were
undertaken to explore the robustness of the base-case analysis to alternative assumptions concerning
the potential impact of alternative imaging decisions on costs and outcomes. These scenarios considered
the potential costs as well as any anxiety effects associated with delayed CT scan or a use of an
alternative imaging modality. The full set of scenarios are discussed in more detail in later sections.
The model evaluates the cost-effectiveness of 14 alternative testing strategies to identify and manage
patients with an eGFR < 30 ml/minute/1.73 m2. The likelihood of an individual being classified as positive
(i.e. with an eGFR < 30 ml/minute/1.73 m2) or negative (i.e. with an eGFR ≥ 30 ml/minute/1.73 m2) is
estimated for each strategy based on an individual’s true eGFR status and the diagnostic accuracy
(sensitivities and specificities) of the different elements of testing that constitute the overall testing
strategy.Where a strategy involves multiple tests, an individual will progress from one test to the next
if the first test classifies them as positive, which in the case of risk factor screening will involve them
being classified as at risk or, in the case of a POC device, of having an eGFR < 30 ml/minute/1.73 m2.
An individual will be identified as positive (either TP or FP) if the final test in the strategy classifies
them as having an eGFR < 30 ml/minute/1.73 m2.
The risk of PC-AKI is conditioned on an individual’s true eGFR value, with higher risk assumed in patients
with an eGFR < 30ml/minute/1.73m2. This risk is assumed to be modifiable by providing either prophylactic
measures prior to the provision of contrast agent or changing the imaging modality. Individuals who test
negative are managed with their planned contrast-enhanced CT scan, whereas those individuals who
test positive are managed to reduce their risk of PC-AKI. The model assumes that the risk of PC-AKI is
modifiable only for patients who have a true eGFR measure < 30ml/minute/1.73 m2. Therefore, individuals
who are misclassified as positive (i.e. FP) will incur the costs of the actions taken to reduce their perceived
PC-AKI risk, but do not derive any health benefit in terms of a reduction in PC-AKI risk and subsequent
clinical events. Individuals who are misclassified as negative (i.e. FN) will not incur the cost of these
mediating actions, but will fail to realise the health benefits of receiving an action that would reduce their
risk of PC-AKI. In the base case, the mediating action is assumed to be IVH prior to a full-contrast CT scan.
In a scenario analysis, individuals were considered to receive a range of possible mediating actions, with a
proportion of patients receiving IVH prior to a full-contrast CT scan, a proportion receiving an unenhanced
CT scan and a proportion receiving a MRI scan.
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Based on evidence from a series of reviews, all individuals are assumed to be at risk of requiring
temporary RRT within 6 months of imaging and this risk is assumed to be conditional solely on
experiencing a PC-AKI. Based on this evidence, it is also assumed that PC-AKI has no impact on
mortality, and that there are no differences between strategies in terms of patients’ costs and HRQoL
after 6 months post imaging.
The model considers the costs of testing patients according to the combination of testing components in
each strategy. In the base case, undertaking a laboratory test was assumed to always cause a delay and
cancellation of the initial CT scan, with consequent loss of the imaging time slot and associated costs.
Scenario analyses explored the robustness of the results to alternative assumptions, including that a
proportion of the laboratory tests would be urgent and would not result in a delay unless a positive test
result was obtained requiring mediating action. Risk factor screening and POC testing would cause the
delay and cancellation of the initial CT scan only if they are the final testing component in that strategy
and the final result was positive resulting in mediating action being taken. For individuals who undergo
mediating actions (i.e. IVH in the base case), the cost of the action taken and any associated adverse
events were captured. PC-AKI events are assumed to impose no costs, although PC-AKI events do alter
the risk of a patient requiring RRT, which was costed.
Outcomes of patients are captured in QALYs over their remaining lifetime. All patients in the model are
assumed to have the same life expectancy and HRQoL as the age- and sex-adjusted general population,
with HRQoL decrements applied to those patients who require RRT for a duration of 3 months. No further
HRQoL impacts are assumed in the base-case analysis. A scenario analysis considered a HRQoL decrement
as a result of anxiety caused by any delay of the CT scan or use of an alternative imaging modality.
Further details of the main structural and input assumptions and the sources of evidence considered
for each are discussed in detail in later sections of the report.
Strategies
The strategies included in the model represent the potential pathways that are either part of current
clinical practice or represent ways in which POC testing could be integrated into clinical practice.
These can be grouped into six types of strategy, according to the testing approach followed:
1. laboratory testing only
2. risk factor screening combined with POC testing
3. risk factor screening combined with laboratory testing
4. risk factor screening combined with POC testing and laboratory testing
5. POC testing only
6. POC testing combined with laboratory testing.
A strategy of ‘no testing and manage all with contrast-enhanced CT’ was not included in the base-case
analysis. Although this represents a potentially feasible strategy, it was not deemed to be clinically
appropriate given the consistent recommendations reported across clinical guidelines recommending
the use of some form of screening or testing to identify individuals at risk of PC-AKI. However, for
completeness and to aid the overall interpretation of the results, this strategy was included in a
separate scenario. Similarly, a strategy of risk factor screening alone was initially considered but then
excluded, as this strategy was not deemed to be clinically feasible as a result of the high rate of FPs
that would require IVH and the limited capacity to provide this.
Laboratory testing consists of performing a blood test on all individuals presenting without a recent
eGFR measurement prior to imaging. Although the NICE scope distinguished between urgent and
non-urgent laboratory tests, no evidence was subsequently identified concerning differences in test
performance or unit costs. However, access to urgent laboratory testing has important implications for
the timing of clinical decisions and the impact on scanning decisions (i.e. whether or not the scan can
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be rescheduled within the same day or requires the scan to be rebooked for a separate day). Inevitably,
there exists significant heterogeneity across NHS sites in terms of provision and access to urgent
laboratory testing. In the base-case analysis, it was assumed that laboratory testing would require the
CT scan to be rescheduled on a separate day (i.e. only non-urgent testing). A series of scenarios were
also undertaken that assumed that a proportion of patients (i.e. 25%, 50%, 75% and 100%) would
receive urgent laboratory testing, allowing their CT scan to be rescheduled for the same day and hence
avoiding the full opportunity cost of a lost CT scan appointment.
Individuals who test negative with laboratory testing are assumed to be managed with the planned
contrast-enhanced CT scan. Those individuals who test positive receive mediating action to reduce
their PC-AKI risk, with management consisting of IVH followed by contrast-enhanced CT in the
base-case analysis.
Figure 9 provides a schematic of the model structure for the laboratory testing strategy.
Risk factor screening combined with POC testing consists of screening individuals with a risk factor
questionnaire followed by a POC test for individuals identified with at least one risk factor (risk factor
positive). Individuals who screen risk factor negative or test negative with the POC test are assumed
to proceed with the planned contrast-enhanced CT scan. Individuals who screen positive and have an
eGFR measurement of < 30 ml/minute/1.73 m2 with the POC device receive IVH to reduce their
PC-AKI risk.
Figure 10 provides a schematic of the model structure for the risk factor screening combined with POC
testing strategy.
Risk factor screening combined with laboratory testing consists of screening individuals with a risk
factor questionnaire followed by a laboratory test for those individuals who screen positive for at
least one risk factor. Individuals who have no risk factors, and those who test negative on the laboratory
test, receive contrast-enhanced CT scanning. Individuals who screen and test positive receive additional
management to reduce their risk of PC-AKI.
No PC-AKI
#
True eGFR ≥ 30 ml/
minute/1.73 m2 Laboratory test Full contrast-enhanced CT scan
# Specificity
PC-AKI
p2
No PC-AKI
#True eGFR < 30 ml/
minute/1.73 m2 Laboratory test
Full contrast-enhanced
CT scan + IVH
p1 Sensitivity
PC-AKI
p3
TP
TN
FIGURE 9 Model structure: laboratory testing. p1, probability of an eGFR < 30 ml/minute/1.73 m2; p2, probability of AKI
conditional on an eGFR ≥ 30ml/minute/1.73 m2 and contrast-enhanced CT scan; and p3, probability of AKI conditional on
an eGFR < 30ml/minute/1.73 m2 and contrast-enhanced CT scan with prophylactic IVH.
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FIGURE 10 Model structure: risk factor screening combined with POC testing. p1, probability of an eGFR < 30ml/minute/1.73 m2; p2, probability of AKI conditional on an eGFR
≥ 30ml/minute/1.73 m2 and contrast-enhanced CT scan; p3, probability of AKI conditional on an eGFR ≥ 30ml/minute/1.73 m2 and contrast-enhanced CT scan with prophylactic IVH;
p4, probability of AKI conditional on an eGFR < 30 ml/minute/1.73 m2 and contrast-enhanced CT scan; and p5, probability of AKI conditional on an eGFR < 30ml/minute/1.73 m2 and
contrast-enhanced CT scan with prophylactic IVH. RF, risk factor.
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Figure 11 provides a schematic of the model structure for the risk factor screening combined with
laboratory testing strategy.
Risk factor screening combined with POC and laboratory testing comprises a three-step testing
sequence that involves screening all individuals for risk factors, testing with POC devices those with
at least one risk factor, and providing individuals who screen and test positive (with POC devices) with
a confirmatory laboratory test. All individuals that have a negative result at any point in the testing
sequence are managed with a contrast-enhanced CT scan. Individuals who test positive at all three
steps of the testing sequence receive management to reduce their risk of PC-AKI.
Figure 12 provides a schematic of the model structure for the risk factor screening combined with POC
and laboratory testing strategy.
Point-of-care testing consists of testing all individuals with a POC device, with those individuals testing
negative managed with a contrast-enhanced CT scan and those individuals testing positive receiving
mediating action to reduce their risk of PC-AKI.
Figure 13 provides a schematic of the model structure for the POC testing strategy.
No PC-AKI
#
Negative to RF screening  
Full contrast-enhanced
CT scan
RF questionnaire specificity
True eGFR ≥ 30 ml/
minute/1.73 m2
# PC-AKI
p2
No PC-AKI
#
Positive to RF screening Laboratory test
Full contrast-enhanced
CT scan
# Specificity
PC-AKI
p2
No PC-AKI
#
Negative to RF screening  
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CT scan
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p1
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Positive to RF screening Laboratory test
Full contrast-enhanced
CT scan + IVH
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PC-AKI
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FIGURE 11 Model structure: risk factor screening combined with laboratory testing. p1, probability of an eGFR
< 30 ml/minute/1.73 m2; p2, probability of AKI conditional on an eGFR ≥ 30ml/minute/1.73 m2 and contrast-enhanced
CT scan; p3, probability of AKI conditional on an eGFR < 30ml/minute/1.73 m2 and contrast-enhanced CT scan; and
p4, probability of AKI conditional on an eGFR < 30ml/minute/1.73 m2 and contrast-enhanced CT scan with prophylactic
IVH. RF, risk factor.
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FIGURE 12 Model structure: risk factor screening combined with POC and laboratory testing. p1, probability of an eGFR < 30ml/minute/1.73 m2; p2, probability of AKI conditional
on an eGFR ≥ 30 ml/minute/1.73 m2 and contrast-enhanced CT scan; p3, probability of AKI conditional on an eGFR < 30ml/minute/1.73 m2 and contrast-enhanced CT scan; and
p4, probability of AKI conditional on an eGFR < 30 ml/minute/1.73 m2 and contrast-enhanced CT scan with prophylactic IVH. RF, risk factor.
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The last strategy type combines POC testing with laboratory testing. Individuals who test positive on
the POC test receive a confirmatory laboratory test. Those testing negative on either test receive a
contrast-enhanced CT scan, and those testing positive on both sequences receive mediating action to
reduce their risk of PC-AKI.
Figure 14 provides a schematic of the model structure for the POC testing combined with laboratory
testing strategy.
For each type of strategy that includes POC testing, the model considers separate strategies for each
of the POC devices. The POC devices considered in the cost-effectiveness analysis are restricted to
those that reported diagnostic accuracy data using eGFR thresholds reported in the quantitative
synthesis (see Chapter 3, Results: assessment of diagnostic accuracy). The three devices considered in the
model are i-STAT Alinity, ABL800 FLEX and StatSensor. In line with the clinical effectiveness review,
the different models of i-STAT, ABL 800 series and StatSensor are assumed to be equivalent in terms
of diagnostic accuracy data within brand, whereas the costs are derived for the models that are
commercially available in the UK, according to the manufacturer.
Although different types of laboratory-based SCr tests are used in clinical practice to derive eGFR
values, it is assumed that these values are all equivalent in terms of diagnostic accuracy and costs.
The laboratory test is assumed to have perfect diagnostic accuracy (i.e. 100% sensitivity and specificity)
and, therefore, laboratory-measured eGFR is assumed equivalent to a ‘true’ eGFR value.
No PC-AKI
#
Negative POC test
Full contrast-enhanced
CT scan
POC specificity
PC-AKITrue eGFR ≥ 30 ml/
minute/1.73 m2 p2
#
No PC-AKI
#
Positive POC test
Full contrast-enhanced
CT scan + IVH
#
PC-AKI
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No PC-AKI
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Negative POC test
Full contrast-enhanced
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p4True eGFR < 30 ml/
minute/1.73 m2
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No PC-AKI
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CT scan + IVH
POC sensitivity
PC-AKI
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FIGURE 13 Model structure: POC testing. p1, probability of an eGFR < 30ml/minute/1.73 m2; p2, probability of AKI
conditional on an eGFR ≥ 30ml/minute/1.73 m2 and contrast-enhanced CT scan; p3, probability of AKI conditional on an
eGFR ≥ 30ml/minute/1.73 m2 and contrast-enhanced CT scan with prophylactic IVH; p4, probability of AKI conditional on
an eGFR < 30ml/minute/1.73 m2 and contrast-enhanced CT scan; and p5, probability of AKI conditional on an eGFR
< 30 ml/minute/1.73 m2 and contrast-enhanced CT scan with prophylactic IVH.
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Clinical guidelines recommend that only individuals considered at high risk of PC-AKI have their eGFR
measured prior to undergoing contrast-enhanced CT.6,10–12 However, these guidelines do not recommend
the use of any particular screening tool, and there is a lack of consistency across this literature regarding
the specific criteria that would allow the identification of high-risk individuals. Therefore, screening in the
model was assumed to be conducted with a generic risk factor questionnaire.
Laboratory testing requires time for the test to be processed, which means that some individuals
may not be able to undergo CT on the same day. In the base case it was assumed that all individuals
undergoing a laboratory test would have their CT scan cancelled. However, a scenario analysis allowed
for a proportion of patients to receive a rapid laboratory test, and those patients who test negative are
assumed not to have their CT scan cancelled.
Risk factor screening and POC testing are assumed to be conducted within the original CT scan time slot
and, therefore, do not introduce any further delays (and associated costs). However, if individuals are
identified as requiring alternative management to mitigate the PC-AKI risk, it may also be unfeasible to
conduct this within the same day for which their original CT scan was planned. The base case assumes
that all patients who require a laboratory test or test positive at the last step of the testing sequence
will incur the costs of delay. The proportions requiring delay are varied in scenario analyses.
No PC-AKI
#
Negative POC test
Full contrast-enhanced
CT scan
POC specificityTrue eGFR ≥ 30 ml/
minute/1.73 m2 PC-AKI
# p2
No PC-AKI
#
Positive POC test Laboratory test
Full contrast-enhanced
CT scan
# Specificity
PC-AKI
p2
No PC-AKI
#
Negative POC test
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minute/1.73 m2
p1
No PC-AKI
#
Positive POC test Laboratory test
Full contrast-enhanced
CT scan + IVH
POC sensitivity Sensitivity
PC-AKI
p4
TN
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FIGURE 14 Model structure: POC testing combined with laboratory testing. p1, probability of an eGFR < 30 ml/minute/
1.73m2; p2, probability of AKI conditional on an eGFR ≥ 30ml/minute/1.73m2 and contrast-enhanced CT scan; p3, probability
of AKI conditional on an eGFR < 30ml/minute/1.73m2 and contrast-enhanced CT scan; and p4, probability of AKI conditional
on an eGFR < 30ml/minute/1.73m2 and contrast-enhanced CT scan with prophylactic IVH.
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The model considers three alternative management options for patients who are identified as having
an eGFR < 30 ml/minute/1.73 m2 by any of the testing approaches described above. These
management approaches are:
1. IVH followed by contrast-enhanced CT scan
2. unenhanced CT scan
3. unenhanced MRI scan.
It is assumed that all approaches are equivalent in terms of diagnostic accuracy of the imaging modality,
but differ in terms of cost and effect on the risk of PC-AKI. As previously stated, all patients in the base-
case analysis identified as being at high risk of PC-AKI are assumed to be managed with prophylactic IVH
and proceed with a full-contrast dose CT scan. It is assumed that adverse events from IVH are associated
only with costs and not with any HRQoL loss. Separate scenarios are presented assuming alternative
management approaches.
Table 17 summarises the 14 strategies evaluated in the base-case cost-effectiveness analysis.
TABLE 17 Strategies evaluated in the base-case analysis
Strategy
number
Testing
ManagementLabel Description
1 Lab Test all with a laboratory test Test negative:a
contrast-enhanced
CT scan
Test positive:b
IVH + contrast-
enhanced CT scan
2 RF + i-STAT Screen with RF questionnaire. Patients who screen positive
are tested with i-STAT
3 RF +ABL800 FLEX Screen with RF questionnaire. Patients who screen positive
are tested with ABL800 Flex
4 RF + StatSensor Screen with RF questionnaire. Patients who screen positive
are tested with StatSensor
5 RF + Lab Screen with RF questionnaire. Patients who screen positive
are also tested with a laboratory test
6 RF + i-STAT + Lab Screen with RF questionnaire. Patients who screen positive
are tested with i-STAT. Patients who test positive with POC
testing are also tested with a laboratory test
7 RF +ABL800
FLEX + Lab
Screen with RF questionnaire. Patients who screen positive
are tested with ABL800 Flex. Patients who test positive
with POC testing are tested with a laboratory test
8 RF + StatSensor + Lab Screen with RF questionnaire. Patients who screen positive
are tested with StatSensor. Patients who test positive with
POC testing are tested with a laboratory test
9 i-STAT Test with i-STAT. Patients who test positive with POC
testing are tested with a laboratory test
10 ABL800 FLEX Test with ABL800 Flex. Patients who test positive with
POC testing are tested with a laboratory test
11 StatSensor Test with StatSensor. Patients who test positive with POC
testing are tested with a laboratory test
12 i-STAT + Lab Test with i-STAT. Patients who test positive with POC
testing are tested with a laboratory test
13 ABL800 FLEX+ Lab Test with ABL800 Flex. Patients who test positive with
POC testing are tested with a laboratory test
14 StatSensor + Lab Test with StatSensor. Patients who test positive with POC
testing are tested with a laboratory test
RF, risk factor questionnaire.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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Model input parameters
Population characteristics
The cost-effectiveness of the alternative strategies will be dependent on the characteristics of the
patient population being considered, including the distribution of eGFR and the number of patients
who are likely to present without a recent eGFR measurement. The population considered here is
non-emergency adult outpatients presenting for intravenous contrast-enhanced CT scanning without
an available eGFR measurement at the radiology department.
Distribution of estimated glomerular filtration rate
No published studies were identified in non-emergency adult outpatients presenting for intravenous
contrast-enhanced CT scanning without an available eGFR measurement that presented sufficient
information to determine the underlying distribution of eGFR. Therefore, additional evidence was sought
from the clinical adviser to the EAG (Martine Harris; Dr Martine Harris, Mid Yorkshire Hospitals NHS
Trust, 2019, personal communication). Dr Harris provided 1 month’s routine outpatient audit data across
three sites from the Mid Yorkshire Hospitals NHS Trust. Data were grouped by bins of eGFR width of
10 ml/minute/1.73 m2 (with an eGFR < 30 ml/minute/1.73 m2 and > 90 ml/minute/1.73 m2 treated as
individuals bins) and were available for 816 outpatients, of whom 104 attended radiology without a
recent eGFR measure.
Table 54 (see Appendix 8) presents the distribution in the overall sample of 816 outpatients and in the
subgroup of patients who attended radiology without a recent eGFR measure. Only one patient in the
overall sample (i.e. ‘all outpatients’) had an eGFR < 30 ml/minute/1.73 m2 (0.12%), whereas no patients
in the subgroup who attended without a prior eGFR had a measure < 30 ml/minute/1.73 m2. The
overall sample and the subgroup without a prior eGFR measurement appear to be broadly comparable,
with similar proportions falling into each eGFR bin.
The data provided by Dr Harris (personal communication) were further disaggregated by the reason
for referral for CT (suspected cancer, urgent and routine referrals). Table 55 (see Appendix 8) presents
the eGFR distribution by reason for referral in the overall sample and in the subgroup of patients who
attended radiology without a recent eGFR measure. The reasons for referral appear to differ between
the overall sample and the subgroup without a prior eGFR measurement, with the majority of those
patients without a prior eGFR measurement being referred routinely (74%), whereas only one-third of
the overall sample were referred routinely. Given the additional stratification and, therefore, smaller
numbers, the percentages within each eGFR bin appear more variable across reason for referral within
the subgroup without prior eGFR measurement. In the overall sample, the percentages across the
eGFR bins for each reason for referral appear broadly comparable.
Evidence at less disaggregated eGFR levels (i.e. bands of < 30, 30–60 and ≥ 60 ml/minute/1.73 m2) was
also available from two published studies38,114 and a separate report by KiTEC,113 which was commissioned
to support this appraisal. The KiTEC report113 provided evidence on the eGFR distribution from a 2-week
audit of outpatient radiology patients at Guy’s and St Thomas’ NHS Foundation Trust (GSTT; London, UK).
Table 18 summarises the evidence from these studies compared with the data provided by Dr Harris
(personal communication). Both of the Harris populations (i.e. all outpatients and the subgroup without
a prior eGFR measurement) appear broadly similar to the populations from the two published studies,
although the population in Moos et al.114 appears slightly less severe, with a higher percentage of
patients with eGFR scores > 60 ml/minute/1.73 m2. The audit of outpatient radiology patients at GSTT
reports a more severe population, with 15.86% of patients reported to have an eGFR < 30 ml/minute/
1.73 m2. The reason for this marked difference was not clear based on the evidence provided in the
KiTEC report;113 however, it highlights that the underlying eGFR distribution may vary considerably
across different NHS sites.
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Given the granularity with regard to the narrower eGFR bins of the Harris data (personal communication)
and comparability with the two published studies,38,114 the Harris data were used to inform the distribution
of eGFR of patients in the base-case analysis. In addition, given the similarity in overall eGFR distribution
in the overall sample and the subgroup without a prior eGFR measurement, the eGFR distribution in the
larger overall sample is used in the base-case analysis. Separate scenario analyses were undertaken using
the eGFR distribution from the subgroup with missing eGFRs at presentation and the alternative eGFR
distribution provided in the KiTEC report113 from GSTT.
Parametric distributions were fitted to estimate the probability a patient falls into four eGFR
categories. These categories represent the eGFR bands reported in the clinical effectiveness review
and synthesis (i.e. < 30, 30–45, 45–60 and ≥ 60 ml/minute/1.73 m2). Fitting distributions to the full set
of data points resulted in a poor visual fit at the lower levels of eGFRs; therefore, the distribution was
fitted only up to an eGFR of 60 ml/minute/1.73 m2, with the probability of being above or below 60 ml/
minute/1.73 m2 estimated separately. The log-normal distribution was considered to provide the best
visual fit. The resulting probabilities are shown in Table 19. For the overall sample, the fitted log-normal
distribution predicted a probability of 0.62% of a patient having an eGFR < 30 ml/minute/1.73 m2.
Number of patients without a recent estimated glomerular filtration
rate measurement
The number of patients who present for a contrast-enhanced CT scan without a recent eGFR
measurement will determine the size of the population to which POC testing may be offered in the
NHS. Based on surveys of NHS services12,13 and discussions with clinical advisers, the behaviour of
practices regarding the absence of eGFR measurements is likely to be heterogeneous.
TABLE 18 Estimated glomerular filtration rate distribution from different studies
eGFR category
(ml/minute/1.73 m2)
Study (first author and year), % of patients
Harris,a 2019
Moos et al.,
2014114
Snaith et al.,
201938
KiTEC,
2019113All outpatients
Patients without a prior
eGFR measurement
< 30 0.12% 0.00% 0.32% 0.00% 15.86%
30–60 22.18% 22.12% 9.84% 19.33% 25.17%
> 60 77.70% 77.88% 89.84% 80.67% 58.97%
Total 816 104 925 300 580
a Personal communication.
TABLE 19 Fitted distribution of eGFR values
eGFR category (ml/minute/1.73 m2)
Probability of eGFR in category
All patients (n= 816) Patients with missing eGFR (n= 104)
< 30 0.62% 0.27%
30–45 6.28% 5.1%
45–60 15.45% 16.44%
> 60 77.67% 78.18%
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The type of practice behaviour most commonly seen in the NHS can be characterised as follows:
1. CT scans are not allowed to be booked until a recent eGFR measurement can be reported in the referral
request; this implies that no individuals arrive for a CT scan without a recent eGFR measurement.
2. CT scans are allowed to be booked without a record of a recent eGFR measurement, but efforts are
made by the radiology department to obtain a recent measurement prior to the scan appointment
(i.e. by checking electronic records, requesting a blood test from the referrer or directly instigating a
laboratory test).
3. CT scans are allowed to be booked without a record of a recent eGFR measurement, but no further
checks are implemented by the radiology department prior to the CT scan appointment.
The first type of practice behaviour means that individuals will not present without a recent eGFR
measurement and, hence, implies no role for POC creatinine testing; therefore, this type of practice
behaviour is not explicitly considered in the model.
Practices that allow booking of a contrast-enhanced CT scan without a confirmed recent eGFR
measure differ in terms of the processes and protocols followed regarding how eGFR measurements
missing at the time of booking are obtained prior to the scan appointment. Thus, practice behaviour
will determine the proportion of patients without a recent eGFR at the point of CT scan. This also has
implications for patient throughput and the costs of POC tests. It may also affect the underlying eGFR
distribution of patients without a recent eGFR measure.
A formal assessment of the cost-effectiveness of different types of practice behaviour was considered
beyond the scope of this appraisal. Instead, a series of assumptions were made concerning the proportion
of patients likely to attend without a recent eGFR measurement. Scenario analysis was undertaken to
explore the impact of using alternative assumptions and throughput estimates.
Table 20 summarises the evidence identified that reported on the proportion of patients in an
outpatient setting presenting with and without recent eGFR values at the different stages at which
eGFR measurements are checked.
TABLE 20 Availability of eGFR measurements over time
Availability of eGFR
measurements
Study (first author and year)
Cope et al.,
201713
Snaith et al.,
201938
Harris,a
2019 – all
outpatients
data
KiTEC, 2019113
Clinical
experts
GSTT data
Audit 2015 January 2019
% eGFR measurements
available (n/N) at
referral/vettingb
NR 54.0
(162/300)
43.9
(358/816)
NR 53.5
(77/144)
47.7
(580/1215)
% eGFR measurements
that were provided
after booking by
referrer or from other
records
NR NR 43.4
(354/816)
NR 26.4
(38/144)
NR
% eGFR measurements
missing (n/N) with test
instigated by the
radiology department
NR 12.3
(37/300)
12.7
(104/816)
NR NR NR
% eGFR measurements
missing (n/N) at CT scan
34
(1220/3584)
1.33
(4/300)
1.1
(9/816)
Small but
non-zero
16.7
(24/144)
NR
NR, not reported.
a Personal communication.
b Stage at which the justification for the scan is checked.
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The report by Cope et al.13 provides the largest source of UK evidence. However, the results from this
audit are aggregated for all responding practices and, thus, the heterogeneity of practice behaviour
cannot be characterised. Therefore, the percentage of patients with missing eGFR values (34%) will
include all types of practice behaviour.
Another source of data on outpatients was the sample of 1-month CT attendance data retrospectively
collected for the three radiology sites of the Mid Yorkshire Hospitals NHS Trust (Dr Martine Harris,
personal communication) [also used by Shinkins and colleagues (Dr Bethany Shinkins, University of
Leeds, 2019, personal communication)], which was also used to inform the eGFR distribution in the
model. These data may be more reflective of what would be observed in a practice similar to practice
type 2, in which patients are actively chased for an eGFR measurement up until the scan. When POC
testing is not available, the radiology department would try to obtain a laboratory result up until the
day of the scan, and 1.1% of patients would still present on the day without a valid eGFR measurement.
However, if POC creatinine testing was an option, it was assumed that the radiology department would
be unlikely to directly instigate any laboratory tests and the proportion of patients presenting to the CT
scan without an eGFR measurement would be closer to 12.7%. The results from Snaith et al.38 appear
broadly consistent with this.
The KiTEC report presents results from three sources of data:
1. interviews with clinical experts
2. an internal audit data conducted at GSTT
3. a raw data extraction of patients records for outpatients referred for a CT scan at GSTT over
2 weeks in January 2019.
The clinical experts provided only qualitative data that cannot be used in the model. According to the
audit data, a fairly high proportion of patients will present to a CT scan without a recent eGFR
measurement (i.e. 16.7%). The GSTT raw data included information only on patients at the point of
referral, so the proportion of patients with missing eGFR values at the point of scan is unknown. The
only data available are the proportion of patients with a valid eGFR measure at the point of referral
(47.7%), which is lower than in Snaith et al.38 (54.0%), but higher than in the Mid Yorkshire Hospitals
NHS Trust data (43.4%).
Of the sources identified, the estimates from Cope et al.13 were considered to be the most
representative of the ‘average’ practice behaviour in a UK setting. Therefore, the base-case analysis
assumes that 34% of patients have missing eGFR values at the point of CT scan. Scenario analyses
were also undertaken to explore the impact of heterogeneity and implications for the throughput
assumptions informing the costs of POC testing.
Subgroups
The NICE scope identified two subgroups: (1) people with known existing kidney disease and (2) people at
different levels of risk of PC-AKI. In the absence of diagnostic accuracy data specific to these separate
subgroups or data reporting the underlying eGFR distributions, a formal assessment of cost-effectiveness
in these subgroups was not possible. Although the alternative testing strategies included in the model
consider the use of POC testing in different subgroups (i.e. POC testing in all individuals or restricted to
only those individuals identified at high risk of PC-AKI), diagnostic accuracy is assumed to be the same for
each device regardless of where POC testing is used within the overall patient pathway.
Diagnostic accuracy
Diagnostic accuracy of point-of-care creatinine tests
The model is parameterised using the diagnostic accuracy data from the quantitative synthesis presented
in Chapter 3, Results: assessment of diagnostic accuracy. The diagnostic accuracy of the POC devices in
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Chapter 3, Results: assessment of diagnostic accuracy, are presented in terms of the probability a patient is
classified in a given eGFR category (i.e. < 30, 30–44, 45–59 and ≥ 60ml/minute/1.73 m2) by a POC device
conditional on their true eGFR category. However, the economic model considers only a single cut-off
point of an eGFR of < 30ml/minute/1.73 m2 for informing alternative management decisions. In addition,
evidence reported in later sections suggests sufficient similarity in risks of PC-AKI and effects of mediating
actions on PC-AKI across the range of eGFR in individuals with an eGFR ≥ 30ml/minute/1.73 m2.115 Hence,
the model structure was further simplified by dichotomising the overall population into those with an
eGFR < 30 ml/minute/1.73 m2 and those with an eGFR ≥ 30ml/minute/1.73 m2. The true eGFR value is
assumed to correspond to the laboratory measurement regardless of the method used, although there are
variations in diagnostic accuracy across the different laboratory methods. This is a necessary simplifying
assumption.
Dichotomising the population based on a single eGFR threshold (i.e. an eGFR < 30 and an eGFR
≥ 30 ml/minute/1.73 m2) means that the sensitivity and specificity of the POC devices for this threshold
need to be derived from the probabilities reported for each eGFR category (i.e. < 30, 30–44, 45–59 and
≥ 60 ml/minute/1.73 m2) in Chapter 3, Results: assessment of diagnostic accuracy. The sensitivity of the
tests can be taken directly from the results of the quantitative synthesis as the probability that an
individual with an eGFR < 30 ml/minute/1.73 m2 is correctly categorised as eGFR < 30 ml/minute/
1.73 m2 (p[1,1]). However, by simplifying the model and combining the patients with a true eGFR of
> 30 ml/minute/1.73 m2 into one group, it was necessary to combine information on the distribution
of population eGFR with the probability of being classified as an eGFR < 30 ml/minute/1.73 m2 for a
given true eGFR category (p[i,1] for i [2,3,4]) to estimate the specificity of the POC devices.
The specificity is estimated as the weighted average of the probabilities of being classified as eGFR
< 30 ml/minute/1.73 m2 for the eGFR categories (30–44, 45–59 and > 60 ml/minute/1.73 m2) with
the weights based on the proportions of patients falling into the eGFR categories. Specificity was
estimated using the following equation for each device:
∑
4
i = 2
(1− p½i,1) × Weighti, (3)
in which p[i,1] is the probability that a patient with true eGFR category i is classified as an eGFR
< 30 ml/minute/1.73 m2 and Weighti represents the proportion of the patient population with an eGFR
> 30 ml/minute/1.73 m2 who fall into true eGFR category i.
Given that specificity is based on not only the diagnostic accuracy evidence from Chapter 3, Results:
assessment of diagnostic accuracy, but also the distribution of population eGFR, it should be noted that
when this distribution is altered the specificity of the device will also change.
The base-case analysis estimates are informed by the main analysis reported from the quantitative
synthesis. Additional scenario analyses were undertaken using results based on the sensitivity analysis
reported in Chapter 3, Results: assessment of diagnostic accuracy, and included:
l a StatSensor-adjusted data analysis
l an analysis with studies using the CKD-EPI equation to calculate eGFR.
Table 21 reports POC creatinine diagnostic accuracy estimates applied in the base-case and the scenario
analyses. Mean p[i,j] estimates were calculated from 1000 simulated values from the posterior distribution
obtained by thinning the 30,000 posterior values generated in each analysis of the evidence synthesis, and
used to derive specificity and sensitivity. Means were preferred to medians to ensure that the expected
costs and health outcomes predicted by the model reflect the average patient. The model sampled from
the p[i,j]-simulated values to derive specificity and sensitivity in the probabilistic sensitivity analysis.
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Diagnostic accuracy of risk screening questionnaires
Clinical guidelines recommend risk factor screening for patients without prior eGFR measurements
presenting for contrast-enhanced CT scans to avoid unnecessary blood testing.6,10,11,62 However,
these guidelines do not recommend the use of any particular screening tool, and there is a lack
of consistency across this literature regarding the specific criteria to identify high-risk patients.12
Furthermore, survey data of UK radiology departments suggest that different guidelines are followed
in clinical practice, resulting in heterogeneity of clinical practice behaviour to prevent PC-AKI.
Another issue relates to the evidence context in which the guidelines and risk factor questionnaires
were developed. The eGFR cut-off point at which PC-AKI risk is considered to increase to clinically
relevant values has altered over time, and patients are now considered to be at high risk of PC-AKI
only at eGFR values < 30 ml/minute/1.73 m2. Therefore, it is unclear if existing screening tools would
accurately identify patients at risk of PC-AKI under the currently used diagnostic criterion, especially in
patient populations in which the average eGFR is expected to be high, as is the case for non-emergency
CT scan outpatients.
Studies identified through reference list searching and citation searching, conducted as part of the
pragmatic reviews described in Pragmatic reviews of further evidence to inform the economic model, were
examined to identify diagnostic accuracy evidence for risk factor questionnaires. Four studies14,75,114,116
that examined the diagnostic accuracy of risk factor screening questionnaires in an outpatient setting
were identified as potentially relevant. In addition, unpublished risk factor screening diagnostic
accuracy data were obtained from the 2019 Snaith et al.38 study (Professor Beverley Snaith, personal
communication).
Table 56 (in Appendix 8) summarises the risk factors included in each of the questionnaires. The studies
examined 12 different questionnaires used to identify individuals at increased risk of PC-AKI. None of
the questionnaires included exactly the same risk factors, but all questionnaires considered previous
renal disease and diabetes mellitus as risk factors.
Three of the studies14,38,75 compared the diagnostic accuracy of risk factor screening questionnaires
against POC devices, whereas three had a laboratory test as a reference test.38,114,116 Only three
studies14,38,75 included exclusively outpatients and all included patients presenting for a contrast-
enhanced CT scan. Data for the relevant eGFR cut-off point (i.e. eGFR < 30 ml/minute/1.73 m2) were
reported for three of the studies.14,38,75
Diagnostic accuracy estimates at different eGFR thresholds are reported, alongside study characteristics,
for studies using laboratory and POC test as a reference test in Table 57 (in Appendix 8) and Table 22,
respectively.
TABLE 21 Point-of-care creatinine diagnostic accuracy estimates in the model
Analysis
Device
Diagnostic accuracy
evidence synthesis
i-STAT ABL800 FLEX StatSensor
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
Base case 84.1% 98.9% 86.1% 99.2% 73.9% 99.1% Base-case (main)
analysis
Scenario 84.1% 98.9% 86.1% 99.2% 84.1% 99.0% StatSensor-adjusted
data analysis
81.7% 98.9% 81.4% 99.1% 56.4% 98.4% Analysis with the
CKD-EPI equation
studies only
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TABLE 22 Diagnostic accuracy of risk factor screening: reference POC test
Questionnaire (first
author and year)
Reference
test
eGFR
equation Population
eGFR category (ml/minute/1.73 m2)
< 30 < 45 < 60
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
Azzouz et al., 201414 StatSensor CKD-EPI Outpatients scheduled for a CT scan with and
without contrast and MRI
88.2% 45.2% 85.4% 47.1% – –
Too et al., 201575
Original StatSensor CKD-EPI Outpatients without recent measurement
scheduled for contrast-enhanced CT scan
100.0% 65.2% 92.9% 65.3% 65.9% 65.8%
Modified – – 85.7% 86.0% 43.2% 86.3%
Snaith et al., 201938
Originala i-STAT CKD-EPI Outpatients attending for a contrast-enhanced
CT scan
100.0% 47.8% 69.2% 48.4% 62.7% 50.2%
Modifieda 100.0% 67.6% 38.5% 67.6% 35.6% 68.0%
RANZCR RF 0.0% 82.9% 23.1% 83.3% 25.4% 85.1%
RF, risk factors.
a The definition of acute illness differed across these two questionnaires. The modified version of the questionnaire considered patients as acutely ill only if they indicated acute
admission, diarrhoea and vomiting or recent commencement of antibiotics. Alternatively, the original questionnaire considered any acute illness.
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1
Although diagnostic accuracy data comparing risk factor questionnaires to a gold standard reference
test would have been preferable to inform the model, no studies reported these data for the diagnostic
cut-off point of interest (i.e. eGFR < 30 ml/minute/1.73 m2). However, the data reported for the eGFR
< 45 and < 60 ml/minute/1.73 m2 cut-off points in the studies against a laboratory reference suggest
that the sensitivity of the questionnaires is high; sensitivity becomes 100% for the majority of most
questionnaires as there is a move from a higher to a lower eGFR cut-off point. The only questionnaires
that do not have a sensitivity of 100% at an eGFR < 45 ml/minute/1.73 m2 are those applied in the
Snaith et al. study38 (Professor Beverley Snaith, personal communication).
The diagnostic accuracy data from studies comparing risk factor questionnaires to POC devices also
suggest that high sensitivity tends to be 100% at the lower eGFR cut-off point (i.e. < 30 ml/minute/
1.73 m2). The questionnaire based on The RANZCR guidelines11 is the exception with a sensitivity of
0%, but it is also worth noting that only one patient in Snaith et al.38 had an eGFR < 30 ml/minute/
1.73 m2 and, thus, results are very uncertain. Specificity at an eGFR < 30 ml/minute/1.73 m2 varies
between 45.2% and 82.9%. The questionnaire with the lowest overall diagnostic accuracy was that
examined by the Azzouz et al. study.14
In the base-case analysis, the diagnostic accuracy estimates for risk factor screening data were derived
from the study by Too et al.75 This study reported a sensitivity of 100%, which is consistent with the
data reported for the studies that used laboratory test as a reference (albeit at higher diagnostic
cut-off points). As uncertainty about the diagnostic performance of screening tools remains, a scenario
analysis was conducted with data from the Azzouz et al. questionnaire.14
Table 23 summarises the risk factor screening diagnostic accuracy estimates applied in the model. Beta
distributions were fitted to the sensitivity and specificity data to generate random distributions of
these parameters in the probabilistic sensitivity analysis.
Risks of post-contrast acute kidney injury
Clinical guidelines have highlighted that individuals with an eGFR < 30 ml/minute/1.73 m2 are
potentially at an increased risk of PC-AKI following contrast-enhanced CT and that actions should be
taken to mitigate that risk, such as considering an alternative imaging method not using iodine-based
contrast media or by providing IVH prophylaxis prior to undertaking contrast-enhanced CT.6,10,11
Whether or not there is an elevated risk in those individuals with an eGFR between 30 and 45 ml/
minute/1.73 m2 undergoing contrast-enhanced CT remains unclear.6,11
For the purposes of modelling the impact of identifying patients with low eGFRs, it is important to
establish the risk of PC-AKI conditional on eGFR and any actions taken to mitigate the risk (e.g.
providing IVH). This section considers the evidence for the risk of PC-AKI conditional on eGFRs in
individuals receiving contrast-enhanced CT, the effect of IVH on that risk and the effect of removing
intravenous contrast on that risk.
Risk of post-contrast acute kidney injury conditional on estimated glomerular
filtration rate
Most evidence on the risk of PC-AKI following contrast-enhanced CT comes from inpatient settings in
which patients’ creatinine levels are routinely monitored following a scan. However, these patients are
TABLE 23 Risk factor screening diagnostic accuracy estimates in the model
Analysis Sensitivity Specificity Source (authors and year)
Base case 100.0% 65.2% Too et al., 201575
Scenario 88.2% 45.2% Azzouz et al., 201414
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not considered representative of the outpatient population considered in this appraisal as these
patients are likely to have greater comorbidities and associated risk factors for PCI-AKI. Therefore,
further evidence was sought to estimate the risk of PC-AKI conditional on eGFR in a non-emergency
outpatient setting.
Eight studies containing PC-AKI evidence in outpatients were identified through reference list searching
and citation searching conducted as part of the pragmatic reviews described in Chapter 3, Pragmatic
reviews of further evidence to inform the economic model. Three of the eight studies identified104,115,117
had a high percentage of patients with complete follow-up data for all patients, rather than only for
patients considered at risk at baseline. Park et al.115 was considered the most relevant study to identify
baseline risk in the population because it contained data from 8 years of follow-up, including patients
across eGFR subgroups considered, and used contemporary PC-AKI definitions of an absolute increase
in levels of SCr of 0.5 ml/minute or 25% from baseline levels. The study by Park et al.115 also reported
data on the consequences of PC-AKI in terms of mortality and need for RRT, which are discussed in
later sections.
Park et al.115 examined the risk of PC-AKI in 1666 patients with an eGFR < 60 ml/minute/1.73 m2
undergoing contrast-enhanced CT after receiving prophylactic IVH and presented the PC-AKI rate for
different eGFR categories (i.e. < 30, 30–44 and 45–60 ml/minute/1.73 m2). These rates are presented
in Table 24. Patients with an eGFR < 30 ml/minute/1.73 m2 had a PC-AKI rate of 10.80%, and this
decreased to 2.39% in patients with an eGFR between 45 and 60 ml/minute/1.73 m2.
Several other outpatient studies were identified that presented the risks of PC-AKI conditional on an
eGFR in patients with an eGFR < 60 ml/minute/1.73 m2. The results from these other studies are
presented in Table 58 (in Appendix 8). The results from these studies are broadly comparable with
those from Park et al.,115 with the PC-AKI rate in the 30–60 ml/minute/1.73 m2 eGFR group and ranging
from 1.3% to 2.6% and from 10.8% to 12.07% in the < 30 ml/minute/1.73 m2 eGFR group.
Given the size of the patient population and its comparability with the other identified outpatient
studies, the estimates from Park et al.115 were used to inform the model. Given the similarity in AKI risk
in the eGFR 30–44 ml/minute/1.73 m2 and the eGFR 45–60 ml/minute/1.73 m2 groups, these eGFR
categories were pooled, resulting in separate PC-AKI risks applied in the model for an eGFR < 30 and
≥ 30 ml/minute/1.73 m2.
As all patients in the Park et al.115 study received IVH, additional evidence was also sought to inform the
PC-AKI rate in individuals who would be incorrectly misclassified and, hence, would not receive IVH.
Effect of prophylactic intravenous hydration on post-contrast acute kidney injury risk
To account for the effect of prophylactic IVH on the risk of PC-AKI following contrast-enhanced CT
imaging, evidence from meta-analyses and other randomised and non-randomised studies was examined.
TABLE 24 Post-contrast acute kidney injury events in patients undergoing contrast-enhanced CT angiography: Park et al.115
eGFR (ml/minute/1.73 m2) Number of patients Number of PC-AKI events PC-AKI rate
< 30 250 27 10.80%
30–44 579 14 2.42%
45–60 837 20 2.39%
All patients 1666 61 3.66%
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Full details of study sources considered are provided in Chapter 3, Evidence on prophylactic interventions for
post-contrast acute kidney injury.
Three meta-analyses100–102 examined the effectiveness of contrast-associated AKI prevention methods,
the largest and most recent of which was used to parameterise the model.102 The study by Ahmed
et al.102 considered the impact of prophylactic IVH in patients with an eGFR < 60 ml/minute/1.73 m2
and found for the comparison against placebo an OR of 0.97 (95% CI 0.52 to 1.9). However, data
from the AMACING study104 indicated that there was no effect of IVH on PC-AKI in patients with an
eGFR between 30 and 60 ml/minute/1.73 m2. Therefore, for the base case, it was assumed that the
prophylactic IVH OR of 0.97 (95% CI 0.52 to 1.9) would be applied to patients with an eGFR < 30 ml/
minute/1.73 m2, but that there would be no effect on risk in patients with an eGFR ≥ 30 ml/minute/
1.73 m2. A scenario analysis was undertaken using the lower bound of the OR (i.e. 0.52), implying a
greater protective effect of IVH compared with the base-case analysis.
Effect of contrast on post-contrast acute kidney injury risk
A review of propensity-matched evidence, identified from the recent Aycock et al.86 meta-analysis, was
conducted to identify studies providing evidence on the effect of contrast agents on PC-AKI stratified
by eGFR. Three studies91,92,97 provided evidence on contrast-enhanced CT against unenhanced scans by
eGFR category. Table 25 summarises the evidence from these three studies, two of which are reported
in detail in Chapter 3, Evidence of the risk of acute kidney injury from contrast agents.
Hinson et al.97 was a large propensity-matched study identified through citation searching of the
Aycock et al.86 study. The study by Hinson et al.97 was excluded from the clinical effectiveness review
of evidence of PC-AKI because it was set in an emergency department. However, given the conflicting
findings reported by Davenport et al.90 and McDonald et al.,89 the additional evidence reported by
Hinson et al.97 was considered relevant and the results from all three studies were pooled to inform the
model inputs.
A fixed-effects meta-analysis of these three studies suggested no effect of contrast agents on PC-AKI
risk (OR 0.98, 95% CI 0.88 to 1.08). Hence, it was assumed in the base case that there was no effect of
contrast agents on the risk of PC-AKI.
Risks of post-contrast acute kidney injury conditional on estimated glomerular
filtration rate, prophylactic intravenous hydration and use of contrast agents
For the cost-effectiveness model, the risk of PC-AKI, conditional on eGFR and with and without the
use of prophylactic IVH and/or contrast agents was required.
The evidence on PC-AKI conditional on eGFR from the Park et al.115 study was combined with evidence
on the impact of IVH from Ahmed et al.102 to estimate the probability of a PC-AKI in patients with an
eGFR < 30 ml/minute/1.73 m2 and ≥ 30 ml/minute/1.73 m2 who did not receive IVH (with the values
TABLE 25 Effect of contrast on PC-AKI risk
Study (author and year of
publication) Outcome of interest Type OR (95% CI)
Hinson et al., 201797 AKI and an eGFR 15–29ml/
minute/1.73 m2
0.3 mg/dl or 50% above
baseline
0.96 (0.86 to 1.08)
Davenport et al., 201390 AKI and an eGFR < 30 ml/
minute/1.73 m2
0.3 mg/dl or 50% above
baseline
2.96 (1.22 to 7.17)
McDonald et al., 201489 AKI and an eGFR < 30 ml/
minute/1.73 m2
0.5 mg/dl above baseline 0.97 (0.72 to 1.30)
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for those receiving prophylactic IVH taken directly from Park et al.115). It was assumed that patients
with an eGFR ≥ 60 ml/minute/1.73 m2 had the same risk as those in the eGFR 30–60 ml/minute/
1.73 m2 group. Based on the meta-analysis reported in Effect of contrast on post-contrast acute kidney
injury risk, it was assumed that there was no impact of contrast agents on the risk of PC-AKI in the
base-case analysis.
Table 26 summarises the PC-AKI risks used in the cost-effectiveness model.
The parameters in Table 26 were set up probabilistically in the model by fitting beta distributions
to the probabilities of PC-AKI with IVH (for both an eGFR ≥ 30 ml/minute/1.73 m2 and an eGFR
< 30 ml/minute/1.73 m2) from Park et al.115 and a log-normal distribution to the OR of PC-AKI for
IVH versus placebo from Ahmed et al.102
Acute kidney injury consequences and overall mortality
A separate review of published models focusing on the management and consequences of AKI was
conducted to further inform the model structure, parameter inputs and assumptions. Further details of
the review are reported in Appendix 9.
Based on the review’s findings, the main consequences of PC-AKI include potential mortality risks and
the need for RRT. The literature reviewed to inform the risks of PC-AKI in the model was examined for
evidence on mortality and risk of RRT conditional on PC-AKI. Park et al.115 was considered the most
relevant to characterise the consequences of PC-AKI in outpatients presenting for CT scan, as the
publication reports risks of mortality and initiation of RRT over time by PC-AKI status.
Park et al.115 present Kaplan–Meier curves by PC-AKI status (PC-AKI vs. no PC-AKI) for time from
CT scan until event for (1) death and (2) initiation of RRT (renal survival). Two analyses are presented
for each outcome: before and after propensity score matching. The study by Park et al.115 also reports
HRs comparing PC-AKI with no PC-AKI for the full study sample and subgroups by eGFR category
(i.e. < 30 vs. ≥ 30 ml/minute/1.73 m2) and timing of events (within 6 months vs. after 6 months of
contrast-enhanced CT scan), which are reported in Table 59 (in Appendix 8).
The published Kaplan–Meier curves suggest no difference in terms of mortality for patients who had
PC-AKI compared with those who did not, as the curves are largely overlapping for the two groups
of patients. This is further supported by the mortality HRs comparing PC-AKI with no PC-AKI, which
are consistently non-statistically significant across all analyses; therefore, mortality in the model is
assumed to be the same for all patients regardless of PC-AKI status. Mortality was incorporated in
the model by applying the costs and QALYs to the PC-AKI pay-offs in the model to the proportion of
patients alive at 6 months in Park et al.115 (i.e. 94.5%). This proportion is assumed to be the same for
patients with and without PC-AKI. As baseline mortality risks were not reported by eGFR category,
mortality was also assumed to be independent of eGFR levels.
TABLE 26 Risks of PC-AKI used in the cost-effectiveness model
eGFR (ml/minute/1.73 m2)
Risk of PC-AKI
Contrast-enhanced CT scan
Unenhanced CT scanWith IVH Without IVH
< 30 10.80% 11.1% 11.1%
≥ 30 2.40% 2.40% 2.40%
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A significant effect of PC-AKI was identified on the probability of RRT initiation. Statistically significant
HRs for RRT initiation for the full follow-up period and when events occurring only within 6 months of
a CT scan are considered (see Table 59 in Appendix 8). The effect of PC-AKI on the probability of RRT
initiation does not appear to be statistically significant in the analysis excluding patients with events
after the first 6 months, suggesting that any impact of PC-AKI on the rates of RRT initiation occurs
within 6 months of contrast-enhanced CT scanning.
The baseline probability of RRT initiation in the model (i.e. 0.014) is derived from the probability of
not having started RRT at 6 months, which is derived from the Kaplan–Meier figure reported for the
group who did not experience PC-AKI. The HR for the within-6-months subgroup (i.e. 8.61) is applied
to the baseline risk of RRT initiation to estimate the probability of RRT initiation for individuals who
experience a PC-AKI event (i.e. 0.111). The HR for RRT initiation for PC-AKI compared with no PC-AKI
was set up probabilistically in the model by fitting a log-normal distribution to the data reported in
Park et al.115
Mortality and health-related quality of life
Quality-adjusted life-years were estimated based on estimated mortality and HRQoL. QALYs were
discounted at an annual rate of 3.5%. Mortality over 6 months was estimated from a study of post-CT
scan patients,115 with mortality post 6 months based on the general population (age and sex adjusted).
HRQoL was based on the general population (age and sex adjusted) with utility decrements applied for
adverse outcomes, namely undergoing RRT or anxiety resulting from delayed scans. In the base case,
RRT is considered the only source of disutility. A scenario analysis also considers the disutility
associated with anxiety from delayed scans.
The proportion of patients expected to be alive 6 months post CT scan was derived from Park et al.115
(i.e. 94.5%) and was estimated as a weighted average of the proportion of patients alive in this study
at 6 months post contrast-enhanced CT scan by PC-AKI status (PC-AKI and no PC-AKI). A beta
distribution was fitted to the proportion of patients alive at 6 months to derive probabilistic estimates
for this parameter. UK life tables were sourced from the Office for National Statistics118 for mortality
post 6 months.
Age- and sex-specific general population HRQoL was derived using the equation proposed by Ara and
Brazier,119 and applied to the proportion of patients expected to be alive each year (from start age in
the model until 100 years old).
Renal replacement therapy was assumed to consist of haemodialysis, based on the study by Kim
et al.117 reporting an earlier data cut-off value of Park et al.115 The disutility associated with RRT was
sourced from a meta-analysis and a metaregression of utilities in CKD patients120 that was identified
on the reference list of one of the studies (i.e. Hall et al.121) examined in the context of the AKI models
systematic review. The estimate of –0.11 represents the disutility from dialysis. A gamma distribution
was fitted to the utility estimate in the model to generate random draws of the parameter for the
probabilistic sensitivity analysis. The disutility is applied for 3 months in the model based on NICE’s
Clinical Guideline 169.108,110 Disutility from anxiety was calculated by assuming that patients would
incur the disutility from a EuroQol-5 Dimensions, three-level version (EQ-5D-3L), questionnaire score
change from level 1 to level 3 (i.e. –0.236) in the depression/anxiety domain for 2 weeks. The 2-week
duration of anxiety was assumed to be the maximum time that patients would have to wait before
they could have a CT scan after cancellation of the originally planned scan.
Table 27 details the disutility estimates applied in the model alongside the respective sources
and assumptions.
The model does not consider the impact from the delay of the planned CT scan on patient outcomes as
a result of any change in their underlying condition during the waiting period. Given the heterogeneity
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in reasons for referral for a CT scan in the relevant population, and the lack of data sources to
characterise the potential impact of delay on HRQoL and disease progression across a wide range of
conditions, it was considered unfeasible to include this element in the model. No disutility from PC-AKI
was considered, as clinical opinion suggests that the majority of PC-AKI events are asymptomatic.
The potential disutility from adverse events associated with IVH was also not included in the model.
The AMACING trial, which compared the cost-effectiveness of IVH to prevent PC-AKI in patients with
an eGFR between 30 and 60 ml/minute/1.73 m2 with no IVH, found a small difference in excess
hospitalisation days due to adverse events from IVH between treatment arms (i.e. 0.06 days).104
Therefore, it was considered that any adverse events from IVH would have a short duration and have
a very limited impact on HRQoL.
Resource use and costs
Point-of-care device costs
Six manufacturers of a total of seven devices (one manufacturer producing two of the devices)
provided evidence on the device costs. These costs included the capital costs per device, consumables
per test, quality control consumable costs and annual maintenance costs. The cost of training was not
included in the test cost estimates because of a lack of data to inform these parameters. Resource use
estimates provided included the time to conduct a test, the time to conduct a quality control procedure
and the frequency of quality control procedures required. Information was also provided on the
expected lifespan of each device.
Table 28 below details the capital cost per device. For the three devices considered in Chapter 5, the
price per device ranged from £4995 to £37,495. The higher capital cost of the Radiometer Ltd ABL800
TABLE 27 Utility estimates applied in the model
Adverse
outcomes Utility value (95% CI) Source Assumptions
RRT –0.11 (–0.15 to –0.08) Wyld et al., 2012120 3 months’ duration
Anxiety –0.236 (NA) EQ-5D-3L score decrement change from
level 1 to 3 on the depression/anxiety domain122
2 weeks’ duration
NA, not available.
TABLE 28 Capital cost per device
Device (manufacturer; device) Capital cost (per device) VAT status
Devices included in the model
Abbott; i-STAT Alinity £6500 Excluding
Nova Biomedical; StatSensor £4995 Uncertain
Radiometer Ltd; ABL800 FLEX £37,495 Excluding
Other devices
Abaxis, Inc.; Piccolo Xpress £11,000 Excluding
Fujifilm Corporation; DRI-CHEM NX 500 £8500 Excluding
Radiometer Ltd; ABL90 FLEX PLUS £14,995 Excluding
Siemens Healthineers AG; epoc £6240 Excluding
VAT, value-added tax.
DOI: 10.3310/hta24390 Health Technology Assessment 2020 Vol. 24 No. 39
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
97
FLEX reflects that this device is a benchtop unit that allows the user to measure a full panel of up to
18 STAT parameters on the same blood sample. This contrasts with the handheld, single-use design
provided by i-STAT Alinity and StatSensor devices.
In terms of the lifespan of the devices, only two manufacturers provided a lifespan estimate. Radiometer
Ltd stated that the maximum lifespan of devices would be 7–10 years, whereas Fujifilm Corporation
considered the maximum lifespan of its device as 6 years. Other manufacturers noted that it is difficult
to assess lifespan of devices, as it will be conditional on the way the devices are used.
Capital costs were annuitised in the model over the expected lifetime of the devices. Given the
difficulties in obtaining robust lifetime estimates across the devices, the model assumed a common
lifetime estimate of 7 years for all of the devices considered, to estimate the expected annual capital
cost of the device.
Table 60 (in Appendix 8) details the consumables cost per test for each device, as well as the expected
time taken for the test to report results. For the three devices considered in the model (see Table 28),
the cost of consumables per test ranged from £2.88 to £4.75, and the time the devices took to report
results varied from 30 seconds to 2 minutes.
Table 61 (in Appendix 8) details the costs of a quality control check required for each device (including,
where necessary, multiple levels), as well as the frequency of quality control checks recommended by
the manufacturer. The cost per quality control is presented in two ways: the first way includes the total
cost of quality control materials for a complete quality control test (this is based on the splitting of
quality control materials from larger vials as required); and the second way also includes the cost of
any test-based consumables required for the quality control procedure (see Table 60 in Appendix 8).
For the three POC devices included in the cost-effectiveness model (see Table 28), the cost per quality
control check excluding test-based consumables ranged from £0.20 to £5.01 and when test-based
consumables were also included from £4.15 to £6.80. For two of the POC devices considered, quality
control needs to be conducted each day, whereas for the other test it must be conducted every week
or every 25 tests, whichever is more frequent.
Table 62 (in Appendix 8) details the annual maintenance costs for each device. The cost for the devices
considered in the model ranges from £850 per annum to £4685 per annum.
To estimate the cost per POC test it is necessary to combine this information on costs with expected
throughput. Throughput affects the amount of capital cost, the annual maintenance cost and the
quality control cost attributed per test conducted (with test consumable costs not being affected
by throughput).
Estimates of throughput were based on the data provided by Dr Harris (Dr Martine Harris, personal
communication) based on 1 month’s routine outpatient audit data across three sites from the Mid
Yorkshire Hospitals NHS Trust. Over a 1-month period, 816 individuals were scanned across three
separate sites (272 per site per month). Combining this estimate with the percentage of patients
who are assumed to present at their scan appointment without a recent eGFR measurement (34%
in the base-case analysis), results in an estimated monthly throughput of 92.6 patients (i.e. 1111 per
annum) for the POC devices. If a risk factor questionnaire is used to screen individuals prior to a
POC test, fewer individuals will undergo a POC test, resulting in lower throughput and higher costs
per POC test. In such cases, throughput for the POC device will be conditional on the accuracy of the
risk factor screening and the distribution of eGFRs in the population. In the base case, risk factor
screening prior to a POC test results in a POC throughput of 32.6 patients per month. Alternative
throughput assumptions were considered in separate scenario analyses.
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Table 63 (in Appendix 8) presents the total device cost per POC test based on the expected monthly
throughput of 92.6 patients undergoing a POC test assumed in the base-case analysis. For the three
devices included in the model, the total device cost per test ranged from £6.71 to £14.07. It should
be noted that these costs do not include any consumables for collecting or transferring blood to
the POC device, nor are any additional costs included for storage of consumables (e.g. additional
refrigerator capacity).
Point-of-care testing will also involve the use of staff time to conduct the tests, including taking blood
samples, using the device and conducting quality control checks. Details of the staff time required for
each device for pretesting, time to use the device and for quality controls are provided in Table 64
(in Appendix 8).
It was assumed that an additional 3 minutes of staff time would be required for pretesting (i.e.
collecting blood), which is assumed to be taken after the patient is cannulated in preparation for the
administration of contrast. The time for using the device was based on manufacturers’ estimates of
the time it takes the device to report results, with the assumption that the staff member would not
conduct any other activities while the device was analysing the sample. For quality control testing,
it was assumed that preparation of quality control material would take 1.5 minutes for each device
(based on one manufacturer’s reported time) and that conducting the quality control test would take
the same time as the device takes to analyse a sample. Where the quality control checking was
automatic (two devices), no staff costs were assumed.
Table 64 (in Appendix 8) also reports the estimated total staff cost per test conducted and per quality
control procedure conducted (all assumed to be conducted by a band 3 clinical support worker). The
staff cost for each test for the three devices considered ranged from £1.66 to £2.14 and the staff cost
for conducting the quality control check ranged from £0.00 to £1.46. As with the device-related quality
control costs, quality control staff costs need to be attributed per test conducted based on expected
throughput. The final column in Table 64 shows the estimated total staff cost per test conducted
(including the allocated quality control staff cost). For the three devices considered in the model, this
estimated total staff cost ranged from £1.66 to £2.14 based on a monthly throughput of 92.6 patients
(1111 per annum). It should be noted that no staff time has been considered for training.
Other costs
Testing costs
The previous section considered costs associated with the POC devices, including staff costs for
conducting tests and quality control costs. Other costs considered in the model in the testing stage
include risk factor screening, laboratory testing and a phlebotomist’s time. Risk factor screening was
assumed to take 2 minutes and 40 seconds by a clinical support worker,77 whereas taking a blood
sample was assumed to take (confidential information has been removed) of a phlebotomist’s time
(Dr Bethany Shinkins, personal communication). These costs were combined with published national
unit costs to estimate the cost per test.123 The cost of laboratory testing was taken from the National
Schedule of Reference Costs – Year 2017–18 – NHS Trust and NHS Foundation Trusts.124
Table 29 details the unit costs for each of these costs and the cost per POC test (inclusive of capital,
consumable, quality control and staff costs) based on the base-case throughput assumptions of 92.6
patients receiving a POC test without risk factor screening and 32.6 patients with risk factor screening.
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Table 30 reports the testing costs for each stage of all of the strategies, as well as the total identification
costs if a patient undergoes all of the screening and test steps for that strategy. Risk factor screening
costs £1.11, whereas POC test costs vary from £8.52 to £15.73 when used without risk factor screening
and from £11.96 to £36.36 when used with risk factor screening. A laboratory test costs £3.31.
For POC test costs, there is an additional £2.50 cost for setting up the cannula if the contrast-
enhanced CT scan is cancelled because of a positive POC test result. This was based on the assumption
that 6 minutes of a clinical support worker’s time is needed to set up the cannula for the admission of
intravenous contrast agents for the CT scan, which is done prior to the taking of blood for the POC
test (which was assumed to take an additional 3 minutes of the clinical support worker’s time). This
cost is captured in the contrast-enhanced CT Healthcare Resource Group (HRG) and so is already
reflected in the cost applied if the patient goes on to receive a contrast-enhanced CT scan (described
in Management and imaging costs). However, if the CT scan is cancelled, the cost of an unenhanced CT
scan HRG is used to reflect the cost of a cancelled test, which would not include the cost of the initial
TABLE 29 Unit costs of the identification stage of the model
Cost
category Resource use Units Source Unit cost Source/assumptions Cost
RF
screening
Clinical support
worker
2.67 minutes Ledermann
et al., 201077
£25.00/hour Curtis and Burns,123
2017
Assumed the
equivalent to a
hospital nurse
(band 3)
£1.11
Laboratory
test
Laboratory worker One test – £1.11/test National Schedule of
Reference Costs –
Year 2017–18 –
NHS Trust and NHS
Foundation Trusts124
Reference cost
DAPS04,111 directly
accessed clinical
biochemistry
Phlebotomist Confidential
information
has been
removed
Dr Bethany
Shinkins,
personal
communication
Confidential
information
has been
removed
Confidential
information has
been removed
Total cost of a laboratory test £3.31
POC tests i-STAT – without RF
screening
One test See Point-of-
care device costs
£8.85/test See Point-of-care
device costs
£8.85
ABL800 FLEX –
without RF screening
One test £15.73/test £15.73
StatSensor – without
RF screening
One test £8.52/test £8.52
i-STAT – with RF
screening
One test £11.96/test £11.96
ABL800 FLEX –
with RF screening
One test £36.36/test £36.36
StatSensor – with RF
screening
One test £14.25/test £14.25
RF, risk factor.
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cannulisation. Therefore, the additional cost of 6 minutes of a clinical support worker’s time is added.
For laboratory testing, whether or not cannulisation is done subsequently to a POC test, it is assumed
that an additional 6 minutes of a phlebotomist’s time is required, and the cost of £3.31 for the
phlebotomist (£2.20) and laboratory work (£1.11) is always applied.
Management and imaging costs
In addition to the identification costs, there are also the costs associated with patient management and
the imaging conducted. Management costs include cancellation and rebooking of appointments, follow-up
appointments with nephrologists for those patients categorised as having an eGFR < 30 ml/minute/
1.73 m2, IVH for patients before undergoing full-contrast CT scans and costs associated with adverse
events from IVH. Imaging considered includes contrast-enhanced CT, unenhanced CT and MRI.
Table 31 summarises the costs used for patient management and imaging. Costs were estimated based on
resource use estimates and assumptions and combined with national reference costs.123,124 If a scan is
cancelled, the cost of an unenhanced CT scan (£87.92) is applied to reflect the cost of the cancelled scan.
It is assumed that it takes (confidential information has been removed) of a staff member’s time to rebook
a CT scan and/or book IVH, costing (confidential information has been removed) (Dr Bethany Shinkins,
personal communication). If a patient is identified as having an eGFR < 30ml/minute/1.73 m2, it is assumed
that they will have a follow-up appointment with a nephrologist to discuss their CKD, costing £186.49.
Patients who require IVH are assumed to be admitted as a day case at a cost of £340.89. IVH is also
associated with adverse events including hospitalisation, specialist inpatient consultation and in-hospital
diagnostics. The probability of these adverse events occurring was taken from Nijssen et al.104 and the
costs of each from NHS reference costs, resulting in an expected cost of adverse events per patient
TABLE 30 Testing costs for each strategy
Strategy
Costs
Risk factor
screening
POC
testa
Laboratory
test
Total testing (excluding additional
phlebotomist cost for a positive POC test)
1. Lab – – £3.31 £3.31
2. RF+ i-STAT £1.11 £11.96 – £13.07
3. RF+ABL800 FLEX £1.11 £36.36 – £37.47
4. RF+ StatSensor £1.11 £14.25 – £15.36
5. RF+ Lab £1.11 – £3.31 £4.42
6. RF+ i-STAT + Lab £1.11 £11.96 £3.31 £16.38
7. RF+ABL800 FLEX + Lab £1.11 £36.36 £3.31 £40.78
8. RF+ StatSensor + Lab £1.11 £14.25 £3.31 £18.67
9. i-STAT – £8.85 – £8.85
10. ABL800 FLEX – £15.74 – £15.74
11. StatSensor – £8.52 – £8.52
12. i-STAT + Lab – £8.85 £3.31 £12.16
13. ABL800 FLEX + Lab – £15.74 £3.31 £19.05
14. StatSensor + Lab – £8.52 £3.31 £11.83
Lab, laboratory; RF, risk factor.
a An additional cost for blood collection (i.e. 6 minutes of a clinical support worker’s time; £2.50 per test) for a POC
test was assumed whenever the patient did not proceed to contrast-enhanced CT scanning.
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TABLE 31 Unit costs related to the management and imaging of patients
Cost
category Resource use Units Source Unit cost Source/assumptions Cost
Imaging CT scan – contrast
enhanced
One scan – £111.65 per scan NHS Reference Costs 2017/18;124 activity-weighted
average of HRG currency codes RD21A, RD24Z,
RD25Z for outpatients and direct access
undergoing CT scanning with contrast
£111.65
CT scan –
unenhanced
One scan – £87.92 per scan NHS Reference Costs 2017/18;124 activity-weighted
average of HRG currency codes RD20A, RD23Z,
RD25Z for outpatients and direct access
undergoing CT scanning without contrast
£87.92
MRI One scan – £151.98 per scan NHS Reference Costs 2017/18;124 activity-weighted
average of HRG currency code RD04Z for
outpatients and direct access undergoing MRI
without contrast
£170.53
Cancellations Rebooking CT scan
and/or hydration
Confidential
information has
been removed
Dr Bethany
Shinkins, personal
communication
Confidential information
has been removed
Confidential information has been removed Confidential
information has
been removed
Cancellation One scan Assumption £87.92/scan Same as an unenhanced CT scan £87.92
Follow-up Nephrologist One visit Assumption £186.49 NHS Reference Costs 2017/18;124 all outpatient,
consultant led, Nephrology
£186.49
i.v. hydration Admission 1 day – £340.89 per day NHS Reference Costs 2017/18;124 weighted average
of HRG KC05K-N, fluid or electrolyte disorders,
without interventions
£340.89
AEs from i.v.
hydration
Hospitalisation 0.06 Nijssen et al.,
2017104
£431.00 per night NHS Reference Costs 2017/18;124 elective inpatient
excess bed-days (across all codes)
Specialist inpatient
consultation
0.04 Nijssen et al.,
2017104
£143.44 per visit NHS Reference Costs 2017/18;124 average across
HRGs of outpatient consultant-led appointments
In-hospital
diagnostics
0.02 Nijssen et al.,
2017104
£58.36 per test NHS Reference Costs 2017/18;124 activity-weighted
average of HRG currency code AA33C. Total HRG
activity excluding excess bed-days
Total cost of AEs from i.v. hydration per patient £32.76
AE, adverse events; i.v., intravenous.
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undergoing IVH of £32.76. To reflect the variation in the number of areas being scanned and whether
the scans were costed as outpatients or direct access, weighted averages of HRG codes were used to
estimate the cost of each type of scan (i.e. unenhanced CT, contrast-enhanced CT and MRI), with the
weight reflecting the total number of each type of HRG in the NHS. The costs of imaging were £87.92
for an unenhanced CT scan, £111.65 for a contrast-enhanced CT scan and £151.98 for a MRI scan.
Costs associated with outcomes
The model considers the occurrence of PC-AKI and RRT. Clinical opinion suggests that the majority of
PC-AKI events in the study population are asymptomatic and, therefore, unlikely to require the use of
health-care resources. Hence, only the costs associated with RRT are included in the model.
The cost of RRT is applied to patients who underwent RRT in the model. Table 65 (in Appendix 8)
summarises the costs of RRT. As highlighted in Mortality and health-related quality of life, RRT was
assumed to consist of haemodialysis and have a duration of 3 months. The number of haemodialysis
sessions per week was sourced from NICE’s clinical guideline number 169,108,110 and unit costs taken
from NHS reference costs.124 The total cost of RRT applied in the model was £9758.
Analytic methods
Overview
The decision-analytic model is evaluated deterministically and probabilistically for the base-case analysis
using 1000 Monte Carlo simulations to reflect the joint uncertainty across all of the inputs according to
the probability distributions assigned to each input. The parameters set up probabilistically in the model
are POC devices diagnostic accuracy data; risk factor questionnaire diagnostic accuracy data; risks of
PC-AKI; the HR for the initiation of RRT; the proportion of patients alive at 6 month post contrast; and
disutility from RRT.
Following conventional decision rules for cost-effectiveness, the mean costs and QALYs for the
various strategies are presented and cost-effectiveness compared by estimating the incremental
cost-effectiveness ratios (ICERs), as appropriate.
A limitation of conventional ICER decision rules is that the interpretation of negative and positive
ICERs is ambiguous without reference to the cost-effectiveness plane. In contrast to conventional ICER
decision rules, the net benefit approach provides an unambiguous decision rule. Net benefits can be
expressed on the effect scale [i.e. net health benefits (NHBs)] or the cost scale [i.e. net monetary benefits
(NMBs)] and are estimated by rearranging the elements of the conventional ICER equation, where:
NHB =QALYs −
Costs
Cost-effectiveness threshold
. (4)
NMB =QALYs × cost-effectiveness threshold – cost. (5)
In contrast to conventional ICER decision rules, the net benefit approach provides an unambiguous
decision rule. For a given cost-effectiveness threshold, the strategy with the highest net benefit is the
same strategy that would be considered cost-effective when comparing ICERs against the threshold.
A further advantage of using the net benefit framework in the current appraisal is that it may provide
a more useful way to summarise results when there are very small differences in QALYs between
strategies. In this situation ICERs can be highly sensitive to very small changes in the denominator
(i.e. QALY differences).
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Uncertainty regarding the appropriate source of data, the appropriate assumptions or model structure
and other scenarios are explored using a series of deterministic scenario analysis, as described further
in Scenario analyses.
Base-case analysis
The parameters and main assumptions used within the base-case economic model, and their
characteristics, are summarised in Table 66 (in Appendix 8).
Scenario analyses
To investigate the impact of several key parameter and structural assumptions, a series of deterministic
scenario analyses were undertaken. These scenarios are summarised in Table 32.
TABLE 32 Summary of scenario analyses
Number Scenario name Element of uncertainty Description
1 StatsSensor-adjusted
analysis
Diagnostic accuracy –
additional analyses
Data for StatSensor based on adjusted data analysis
(see Additional analyses)
2 CKD-EPI equation
studies
Diagnostic accuracy –
additional analyses
Quantitative synthesis based only on studies
calculating eGFR using CKD-EPI equation (see
Additional analyses)
3 Alternative risk factor
questionnaire
Diagnostic accuracy –
quantitative synthesis
Diagnostic accuracy of risk factor screening
questionnaires informed by data on an alternative
questionnaire (from the Azzouz et al. study14)
4 eGFR distribution –
Harris subgroup
eGFR distribution Distribution of eGFRs based on the subgroup of
individuals without a prior eGFR measurement at
referral (the Mid Yorkshire Hospitals NHS Trust)
5 eGFR distribution –
GSTT audit
eGFR distribution Distribution of eGFRs based on a raw data extraction
of patient records for outpatients referred to a CT
scan at the GSTT over 2 weeks in January 2019
6.1 Throughput Throughput estimates Throughput estimates adjusted for alternative
assumptions concerning the proportion of individuals
attending a scan appointment without a recent eGFR
measurement
12.7% (compared with 34% in base-case analysis)
based on data from the Mid Yorkshire Hospitals
NHS Trust
6.2 Throughput Throughput estimates Throughput estimates 50% lower than base case
6.3 Throughput Throughput estimates Throughput estimates 50% higher than base case
7.1 Proportion of cancelled
CT scans (0%)
Opportunity cost of
delayed/rescheduled
CT scan
0% of CT scans are cancelled as a result of requiring
a laboratory test (i.e. all laboratory testing assumed
to be urgent)
7.2 Proportion of cancelled
CT scans (25%)
Opportunity cost of
delayed/rescheduled
CT scan
25% of CT scans are cancelled as a result of
requiring a laboratory test (i.e. 75% of laboratory
testing assumed to be urgent and 25% non-urgent)
7.3 Proportion of cancelled
CT scans (50%)
Opportunity cost of
delayed/rescheduled
CT scan
50% of CT scans are cancelled as a result of
requiring a laboratory test (i.e. 50% of laboratory
testing assumed to be urgent and 50% non-urgent)
7.4 Proportion of cancelled
CT scans (75%)
Opportunity cost of
delayed/rescheduled
CT scan
75% of CT scans are cancelled as a result of
requiring a laboratory test (i.e. 25% of laboratory
testing assumed to be urgent and 75% non-urgent)
8 Anxiety from delay HRQoL impact of scan
delay
Disutility from anxiety is included for patients who
have their CT scan delayed
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Model validation
The model was developed by one researcher (AD) and the programming was checked by a second
researcher (MS). A separate version of the model was independently programmed by a third
researcher (SW), who successfully replicated the base-case results.
Results of the independent economic assessment
Base case
Deterministic and probabilistic results expressed in NMB and NHB at a cost-effectiveness threshold of
£20,000 per QALY are presented in Tables 33 and 34, respectively. Strategy ranking from the highest
(1) to the lowest (14) average net benefit is presented in both tables. Incremental net benefit was
calculated for each strategy compared with laboratory testing (‘Lab’). Results for the upper bound of
the cost-effectiveness threshold recommended by NICE, that is, £30,000 per additional QALY, are not
presented, with the exception of probabilities, which are presented for the range of cost-effectiveness
thresholds. Results were consistent across the range of cost-effectiveness thresholds considered, and
for both deterministic and probabilistic analyses.
The strategy with highest incremental net benefit is strategy 6, that is, ‘RF + i-STAT + Lab’, with an
incremental NMB of £87.42 (Table 33) compared with ‘Lab’. Strategy 6 is also the strategy with the
highest probability of being the most cost-effective (Table 34; 79.3% for cost-effectiveness thresholds
of £20,000 and £30,000 per additional QALY). The strategy ‘RF + i-STAT + Lab’ is also the least costly
of all strategies under comparison, with expected total costs of £275.84, but generates fewer QALYs
than the majority of other strategies.
TABLE 32 Summary of scenario analyses (continued )
Number Scenario name Element of uncertainty Description
9 Effect of i.v. hydration
(PC-AKI risk)
Effect of i.v. hydration
on PC-AKI risk (an
eGFR < 30ml/minute/
1.73 m)
The effect of i.v. hydration in reducing the risk of
PC-AKI was increased using the lower bound of
the treatment effect reported by Ahmed et al.102
(OR 0.52 vs. 0.97 applied in the base-case analysis)
10.1 Management approach
for test positives
Management approach
assumed for patients
who test positive to
POC/laboratory tests
50% receive i.v. hydration followed by a contrast-
enhanced CT scan
50% receive unenhanced CT scan
10.2 Management approach
for test positives
Management approach
assumed for patients
who test positive to
POC/laboratory tests
One-third receive i.v. hydration followed by a
contrast-enhanced CT scan
One-third receive an unenhanced CT scan
One-third receive a MRI
11.1 No testing – i.v.
contrast media for all
Exclusion of no-testing
strategy in the base
case
All patients assumed to be given i.v. contrast with no
additional testing
11.2 No testing – i.v.
contrast media for all
Exclusion of no-testing
strategy in the base
case and more
optimistic assumption
concerning the effect
of i.v. hydration is
reducing PC-AKI risk
(an eGFR < 30 ml/
minute/1.73 m)
Combination of scenarios 9 and 11.1
i.v., intravenous.
DOI: 10.3310/hta24390 Health Technology Assessment 2020 Vol. 24 No. 39
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
105
TABLE 33 Base-case deterministic cost-effectiveness results: net benefit
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH+ contrast-enhanced
CT scan
£363.26 9.991371010 9.97321 £199,464.16 0.00000 £0.00 14
2 RF + i-STAT £278.02 9.991371002 9.97747 £199,549.40 0.00426 £85.25 4
3 RF +ABL800 FLEX £285.87 9.991371003 9.97708 £199,541.55 0.00387 £77.39 9
4 RF + StatSensor £277.84 9.991370997 9.97748 £199,549.58 0.00427 £85.42 3
5 RF + Lab £304.06 9.991371010 9.97617 £199,523.36 0.00296 £59.20 13
6 RF + i-STAT + Lab £275.84 9.991371002 9.97758 £199,551.58 0.00437 £87.42 1
7 RF +ABL800
FLEX+ Lab
£284.39 9.991371003 9.97715 £199,543.03 0.00394 £78.87 8
8 RF + StatSensor + Lab £276.15 9.991370997 9.97756 £199,551.27 0.00436 £87.11 2
9 i-STAT £286.35 9.991371002 9.97705 £199,541.07 0.00385 £76.91 10
10 ABL800 FLEX £290.99 9.991371003 9.97682 £199,536.43 0.00361 £72.28 12
11 StatSensor £283.96 9.991370997 9.97717 £199,543.46 0.00396 £79.30 7
12 i-STAT+ Lab £280.08 9.991371002 9.97737 £199,547.34 0.00416 £83.18 6
13 ABL800 FLEX + Lab £286.70 9.991371003 9.97704 £199,540.72 0.00383 £76.56 11
14 StatSensor + Lab £279.09 9.991370997 9.97742 £199,548.33 0.00421 £84.17 5
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 34 Base-case probabilistic cost-effectiveness results: net benefit
Identification Management
Total At £20,000 per QALY
NB
rank
Probability cost-effective
at
Costs QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
£20,000
per QALY
£30,000
per QALY
1 Lab l Test negativea – contrast-
enhanced CT scan
l Test positiveb –
IVH + contrast-enhanced
CT scan
£367.12 9.993255191 9.97490 £199,497.99 0.00000 £0.00 14 0.0% 0.0%
2 RF + i-STAT £281.87 9.993255167 9.97916 £199,583.23 0.00426 £85.24 4 0.0% 0.0%
3 RF +ABL800 FLEX £289.72 9.993255171 9.97877 £199,575.39 0.00387 £77.40 9 0.0% 0.0%
4 RF + StatSensor £281.70 9.993255154 9.97917 £199,583.40 0.00427 £85.42 3 0.0% 0.0%
5 RF + Lab £307.94 9.993255191 9.97786 £199,557.17 0.00296 £59.18 13 0.0% 0.0%
6 RF + i-STAT + Lab £279.70 9.993255167 9.97927 £199,585.40 0.00437 £87.42 1 79.3% 79.3%
7 RF +ABL800
FLEX+ Lab
£288.24 9.993255171 9.97884 £199,576.87 0.00394 £78.88 8 0.0% 0.0%
8 RF + StatSensor + Lab £280.01 9.993255154 9.97925 £199,585.09 0.00436 £87.10 2 20.7% 20.7%
9 i-STAT £290.20 9.993255167 9.97875 £199,574.90 0.00385 £76.91 10 0.0% 0.0%
10 ABL800 FLEX £294.83 9.993255171 9.97851 £199,570.27 0.00361 £72.28 12 0.0% 0.0%
11 StatSensor £287.82 9.993255154 9.97886 £199,577.29 0.00396 £79.30 7 0.0% 0.0%
12 i-STAT+ Lab £283.93 9.993255167 9.97906 £199,581.17 0.00416 £83.19 6 0.0% 0.0%
13 ABL800 FLEX + Lab £290.55 9.993255171 9.97873 £199,574.55 0.00383 £76.57 11 0.0% 0.0%
14 StatSensor + Lab £282.95 9.993255154 9.97911 £199,582.15 0.00421 £84.17 5 0.1% 0.1%
INHB, incremental net health benefit; INMB, incremental net monetary benefit; lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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Table 77 (in Appendix 10) shows the results of the fully incremental ICER analysis. The ICER of strategy 5,
RF + Lab, compared with strategy 6, ‘RF + i-STAT + Lab’, is £3.61M per additional QALY and, therefore,
suggests that strategy 6 is the most cost-effective strategy at conventional cost-effectiveness threshold
ranges. As highlighted in Analytical methods, Overview, the fully incremental ICERs appear particularly
sensitive to the small effect differences between strategies, limiting their interpretability. Given the small
effect differences, and challenges of interpreting the ICER results, fully incremental ICER results are
presented only for the base case, with all other results expressed in terms of net benefits.
In general, strategies that combine risk factor screening with POC and laboratory testing result in
higher net benefit than other types of strategies involving a POC testing component, as the strategies
that combine risk factor screening with POC and laboratory testing have a high positive predictive
value (PPV) (Table 35) at a lower average total cost (Table 36). Strategies combining risk factor
screening with POC testing and laboratory testing all have a PPV of 1, meaning that all patients
identified as positive are TPs. This avoids unnecessary management of FPs with IVH, which imposes
costs associated with cancelling and rebooking CT scans (for those patients identified as being TN
at only the laboratory testing stage), delivery of IVH, treatment of IVH adverse events and patient
follow-up. The appropriate management of patients with a true eGFR > 30 ml/minute/1.73 m2 appears
to be a key driver of cost-effectiveness, with the appropriate management of patients with a true
eGFR < 30 ml/minute/1.73 m2 being less important given their low prevalence. The next highest
ranking strategies are those that combine risk factor screening with POC testing but which do not
use confirmatory laboratory testing. These strategies have lower overall specificity and result in more
FPs than risk factor screening combined with POC and confirmatory laboratory testing, with increased
costs from unnecessary management of patients misclassified as positive (cancelling and rebooking
CT scans, delivery of IVH, treatment of IVH adverse events and patient follow-up).
TABLE 35 Base case: overall diagnostic accuracy by strategy and probability of PC-AKI and RRT
Identification Management
Diagnostic accuracy Probability of
FPa FNa
Test
positivea PPV PC-AKI RRT
1 Lab l Test negativea –
contrast-enhanced
CT scan
l Test positivea –
IVH+ contrast-
enhanced CT scan
0.0000 0.0000 0.0062 1.000 0.024529 0.0158936
2 RF+ i-STAT 0.0039 0.0010 0.0091 0.569 0.024532 0.0158939
3 RF +ABL800 FLEX 0.0027 0.0009 0.0080 0.664 0.024532 0.0158938
4 RF + StatSensor 0.0031 0.0016 0.0076 0.599 0.024534 0.0158941
5 RF + Lab 0.0000 0.0000 0.0062 1.000 0.024529 0.0158936
6 RF + i-STAT + Lab 0.0000 0.0010 0.0052 1.000 0.024532 0.0158939
7 RF +ABL800
FLEX + Lab
0.0000 0.0009 0.0053 1.000 0.024532 0.0158938
8 RF + StatSensor + Lab 0.0000 0.0016 0.0046 1.000 0.024534 0.0158941
9 i-STAT 0.0113 0.0010 0.0165 0.315 0.024532 0.0158939
10 ABL800 FLEX 0.0077 0.0009 0.0130 0.407 0.024532 0.0158938
11 StatSensor 0.0088 0.0016 0.0133 0.342 0.024534 0.0158941
12 i-STAT + Lab 0.0000 0.0010 0.0052 1.000 0.024532 0.0158939
13 ABL800 FLEX+ Lab 0.0000 0.0009 0.0053 1.000 0.024532 0.0158938
14 StatSensor + Lab 0.0000 0.0016 0.0046 1.000 0.024534 0.0158941
Lab, laboratory; RF, risk factor.
a According to the last test in the testing sequence.
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TABLE 36 Base-case cost-effectiveness deterministic results: disaggregated costs
Identification Management
Probability of Costs
Total
costs
Incurring
a delay
Unnecessary
IVH Testing
Cancellation and
rebooking
Follow-
up
IVH
and
AEs CT scan
Post
contrast
1 Lab Test negativea – contrast-
enhanced CT scan
Test positivea – IVH + contrast-
enhanced CT scanb
1.0000 0.0000 £3.31 £89.75 £1.15 £2.30 £111.65 £155.09 £363.26
2 RF + i-STAT 0.0091 0.0039 £5.34 £0.82 £1.70 £3.41 £111.65 £155.10 £278.02
3 RF +ABL800 FLEX 0.0080 0.0027 £13.92 £0.72 £1.49 £2.99 £111.65 £155.10 £285.87
4 RF + StatSensor 0.0076 0.0031 £6.14 £0.68 £1.42 £2.84 £111.65 £155.10 £277.84
5 RF + Lab 0.3519 0.0000 £2.28 £31.58 £1.15 £2.30 £111.65 £155.09 £304.06
6 RF + i-STAT + Lab 0.0091 0.0000 £5.37 £0.82 £0.97 £1.94 £111.65 £155.10 £275.84
7 RF +ABL800
FLEX+ Lab
0.0080 0.0000 £13.95 £0.72 £0.99 £1.98 £111.65 £155.10 £284.39
8 RF + StatSensor + Lab 0.0076 0.0000 £6.17 £0.68 £0.85 £1.70 £111.65 £155.10 £276.15
9 i-STAT 0.0165 0.0113 £8.89 £1.48 £3.07 £6.16 £111.65 £155.10 £286.35
10 ABL800 FLEX 0.0130 0.0077 £15.77 £1.17 £2.43 £4.87 £111.65 £155.10 £290.99
11 StatSensor 0.0133 0.0088 £8.55 £1.20 £2.49 £4.98 £111.65 £155.10 £283.96
12 i-STAT+ Lab 0.0165 0.0000 £8.94 £1.48 £0.97 £1.94 £111.65 £155.10 £280.08
13 ABL800 FLEX + Lab 0.0130 0.0000 £15.81 £1.17 £0.99 £1.98 £111.65 £155.10 £286.70
14 StatSensor + Lab 0.0046 0.0000 £8.59 £1.20 £0.85 £1.70 £111.65 £155.10 £279.09
Lab, laboratory; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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Strategies with POC testing and laboratory testing have a lower average net benefit than risk factor
screening combined with POC testing strategies, despite not misclassifying patients as FPs (with
associated costs of management), because of the higher costs of testing arising when all patients
receive POC testing.
The strategies where POC testing is used in isolation are the lowest ranking among strategies involving
POC testing, because they misclassify more patients as FPs than any other strategies and all patients
incur the cost of POC testing.
Although the highest ranking strategy at £20,000 per additional QALY is strategy 6, ‘RF + i-STAT + Lab’,
it is worth noting that the corresponding strategy with StatSensor, strategy 8, has only a marginally
smaller average incremental net benefit (i.e. £87.11 compared with £87.42 for strategy 6). i-STAT and
StatSensor are both handheld devices with similar diagnostic accuracy, with StatSensor having a slightly
higher specificity (99.1% vs. 98.9%) and lower sensitivity (81.7% vs. 84.1%). The cost per test appears
higher for StatSensor (£14.25) than for i-STAT (£11.96) when these tests are preceded by risk factor
screening, but similar when POC testing is the first step of the testing sequence (£8.52 and £8.85 for
StatSensor and i-STAT, respectively), because of the impact of different throughput assumptions. In all
other types of strategies involving POC testing (i.e. risk factor screening combined with POC testing,
POC testing with laboratory testing and POC testing only), the strategies with StatSensor have a higher
net benefit than corresponding ones with i-STAT. This highlights the importance of specificity in the
model given the high costs associated with FPs.
Strategies including testing with ABL800 FLEX (i.e. strategies 3, 7, 10 and 13) have a consistently
lower net benefit than corresponding strategies with i-STAT and StatSensor, as a result of the higher
costs of testing with this device. The ABL800 FLEX is a benchtop device with much higher capital
costs than the handheld devices (see Resource use and costs, Point-of-care device costs). The cost per
ABL800 FLEX test is, therefore, considerably higher than that of i-STAT and StatSensor, especially
at lower patient throughputs (e.g. when strategies including risk factor screening determine that
fewer patients receive POC tests). Although ABL800 FLEX is the best-performing device in terms of
diagnostic accuracy, any net benefit gains from avoided misclassification are offset by the higher cost
of the device.
The strategies that yield the higher QALY gains, that is, strategies 1, ‘Lab’, and 5, ‘RF + Lab’, are those
that avoid misclassification of patients resulting in no FPs or FNs. These are also the strategies with
the lowest average net benefit because the small QALY benefits from the appropriate management of
patients are offset by the highest costs of cancellation and rebooking (especially for strategy 1) and of
managing patients who test positive.
The base-case cost-effectiveness results appear to be largely driven by the balance between the costs
of testing and the costs associated with mismanagement of FPs. The reduction of PC-AKI risk, and thus
the probability of RRT (see Table 35), do not appear to be major drivers in the model. Owing to the
low prevalence of patients who have a true eGFR < 30 ml/minute/1.73 m2, the low risk of PC-AKI in
the model population and lack of evidence of impact of IVH in reducing this risk, the expected risk
of PC-AKI is similar across strategies. Consequently, the QALY gains (see Table 33) and the costs
resulting from RRT (see Table 36) are also similar across all strategies. The QALY gains of appropriately
managing patients who have a true eGFR < 30 ml/minute/1.73 m2 are small (i.e. the QALY difference
between TP and FN is only 0.0000079237), whereas costs of managing patients who test positive are
high. The low prevalence of patients who have a true eGFR < 30 ml/minute/1.73 m2 combined with
other factors means that specificity appears a more important cost-effectiveness driver than sensitivity,
as avoiding FPs translates into considerably higher net benefit gains than mismanaging FNs.
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The deterministic results for the scenario analyses are presented in Appendix 11 (see Tables 78 and 93).
Table 37 summarises the ranking of each strategy in terms of net benefit at £20,000 per additional
QALY for the base-case and scenario analyses. Figure 15 shows strategy ranks from the highest (top
line) to the lowest (bottom line) net benefit across scenario analyses. The strategies are labelled with
their corresponding number within the circles.
The results suggest that strategy 6, ‘RF+ i-STAT + Lab’, has the highest net benefit across the majority of
scenarios. However, this finding appears sensitive to alternative assumptions in terms of diagnostic accuracy
(scenarios 2 and 3), eGFR distribution (scenario 5), throughput estimates (scenario 6.3) and opportunity
costs of delayed/rescheduled scan (scenario 7.1). Despite some changes in rankings, differences in net
benefits between strategies, and particularly between i-STAT and StatSensor, appear extremely small. The
clinical and economic importance of the differences between individual devices and different types of
strategies may be limited.
When the diagnostic accuracy of POC devices is sourced solely from studies using the CKD-EPI
equation to calculate eGFRs (scenario 2), there is a switch in the net benefit rank between strategy 6
TABLE 37 Net benefit ranking of strategies for base-case and scenario analyses
Strategy
number
Base
case
Scenario
1 2 3 4 5 6.1 6.2 6.3 7.1 7.2 7.3 7.4 8 9 10.1 10.2
6 1 1 2 2 1 5 1 1 2 3 1 1 1 1 1 1 1
8 2 2 1 1 2 1 3 2 1 4 2 2 2 2 2 2 2
4 3 4 4 4 4 2 5 4 3 5 3 3 3 3 3 4 4
2 4 3 3 6 3 6 2 3 4 6 4 4 4 4 4 3 3
14 5 5 5 3 5 3 6 6 5 7 5 5 5 5 5 5 5
12 6 6 6 5 6 7 4 5 6 8 6 6 6 6 6 6 6
11 7 8 11 7 7 4 8 7 9 9 8 7 7 8 7 7 7
7 8 7 7 8 8 8 9 9 7 10 9 8 8 7 8 9 9
3 9 9 9 11 10 10 11 10 8 12 11 9 9 9 9 10 10
9 10 10 8 9 9 9 7 8 11 11 10 10 10 11 10 8 8
13 11 11 10 10 11 11 12 11 10 13 12 11 11 10 11 11 11
10 12 12 12 12 12 12 13 12 12 14 13 13 12 12 12 12 12
5 13 13 13 13 13 13 10 13 13 1 7 12 13 13 13 13 13
1 14 14 14 14 14 14 14 14 14 2 14 14 14 14 14 14 14
Scenarios:
l 1 – StatSensor-adjusted analysis.
l 2 – CKD-EPI equation studies.
l 3 – alternative risk factor questionnaire.
l 4 – eGFR distribution – Harris subgroup without prior eGFR.
l 5 – eGFR distribution – GSTT audit data population.
l 6.1 – throughput – 12.7% without a prior eGFR.
l 6.2 – throughput – 50% lower than base case.
l 6.3 – throughput – 50% higher than base case.
l 7.1 – proportion of cancelled CT scans (0%).
l 7.2 – proportion of cancelled CT scans (25%).
l 7.3 – proportion of cancelled CT scans (50%).
l 7.4 – proportion of cancelled CT scans (75%).
l 8 – anxiety from delay.
l 9 – effect of IVH (PC-AKI risk).
l 10.1 – management approach for test positives (50% IVH + contrast CT scan, 50% no contrast CT scan).
l 10.2 – management approach for test positives (one-third IVH + contrast CT scan, one-third no contrast CT scan
and one-third MRI).
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2 4 4 4 4 11 12 4 2 8 2 2 2 2 2 4 4
14 14 14 12 14 6 4 12 14 4 14 14 14 14 14 14 14
12 12 12 2 12 2 14 14 12 2 12 12 12 12 12 12 12
11 7 7 11 11 12 9 11 7 14 5 11 11 7 11 11 11
7 11 9 7 7 7 11 9 3 12 11 7 7 11 7 9 9
3 3 3 9 9 9 7 7 11 11 7 3 3 3 3 7 7
9 9 13 13 3 3 5 3 13 7 9 9 9 13 9 3 3
13 13 11 3 13 13 3 13 9 9 3 13 13 9 13 13 13
10 10 10 10 10 10 13 10 10 3 13 5 10 10 10 10 10
5 5 5 5 5 5 10 5 5 13 10 10 5 5 5 5 5
1 1 1 1 1 1 1 1 1 10 1 1 1 1 1 1 1
BC 1 2 3 4 5 6.1 6.2 6.3
Scenario 
7.1 7.2 7.3 7.4 8 9 10.1 10.2
FIGURE 15 Summary of net benefit ranking across scenario analysis. Scenario 1, StatSensor-adjusted analysis; scenario 2, CKD-EPI equation studies; scenario 3, alternative risk factor
questionnaire; scenario 4, eGFR distribution – Harris subgroup without prior eGFR; scenario 5, eGFR distribution – GSTT audit data population; scenario 6.1, throughput – 12.7%
without a prior eGFR; scenario 6.2, throughput – 50% lower than base case; scenario 6.3; throughput – 50% higher than base case; scenario 7.1, proportion of cancelled CT scans (0%);
scenario 7.2, proportion of cancelled CT scans (25%); scenario 7.3, proportion of cancelled CT scans (50%); scenario 7.4, proportion of cancelled CT scans (75%); scenario 8, anxiety from
delay; scenario 9, effect of IVH (PC-AKI risk); scenario 10.1, management approach for test positives (50% IVH + contrast CT scan and 50% no contrast CT scan); and scenario 10.2,
management approach for test positives (one-third IVH+ contrast CT scan, one-third no contrast CT scan and one-third MRI). BC, base case.
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(RF + i-STAT + Lab) and 8 (RF + StatSensor + Lab). When this source of data is used, the sensitivity
of all POC devices decreases compared with the base case, with StatSensor having the greatest
decrease in sensitivity compared with the base case (56.4% vs. 73.9%). This results in an increase in
the proportion of FNs for strategy 8, ‘RF + StatSensor + Lab’, with a consequent decrease in costs from
managing positive patients. The decrease in costs is sufficient to offset the higher costs of testing for
strategy 8, ‘RF + StatSensor + Lab’, compared with strategy 6, ‘RF + i-STAT + Lab’, and, under this
scenario, the strategy becomes the cost-effective alternative.
In scenario 3, it is assumed that risk factor screening is performed with a questionnaire with worse
diagnostic accuracy. Compared with the base-case analysis, the sensitivity of the questionnaire is
reduced from 100% to 88.2%, whereas specificity is reduced from 65.2% to 45.2%. The lower
specificity of the questionnaire results in an increase in throughput for POC testing for strategies
where POC testing is preceded by risk factor screening, with a consequent reduction in the costs
of POC testing. The cost per test of StatSensor (with risk factor screening) reduces proportionately
more than with i-STAT and, despite remaining the more costly of the two tests (£11.06 vs. £10.23,
respectively), this small difference in the cost of testing is now offset by the lower costs of managing
patients identified as positive by StatSensor. Therefore, strategy 8, ‘RF + StatSensor + Lab’, switches
with strategy 6, ‘RF + i-STAT + Lab’, as the cost-effective alternative for scenario 3. Strategy 14,
‘StatSensor + Lab’, also has a higher net benefit than both strategy 2, ‘RF + STAT’, and strategy 4,
‘RF + StatSensor’. This higher net benefit is due to an increase in the costs of testing in the strategies
including risk factor screening, given that the lower specificity of the questionnaire results in more
patients being tested with POC (even if the cost per POC test reduces).
Scenario 5 assumes that the underlying distribution of eGFR values in the relevant population matches
that of the GSTT audit population. This population is characterised by having a higher proportion
of patients with an eGFR < 30 ml/minute/1.73 m2 than the base case (15.9% vs. 0.6%). When the
proportion of patients with a true eGFR < 30 ml/minute/1.73 m2 is higher, there will be more patients
testing positive and thus receiving more intensive patient management. There will also be more
patients who can benefit from management to reduce PC-AKI (as risk will be overall higher), but
the benefit of being managed with IVH remains small. The proportion of patients who test positive
(and incur more costs for a small benefit) will be higher for strategies with lower specificity and higher
sensitivity. In this scenario, the strategy with the highest net benefit is strategy 8, ‘RF+ StatSensor+ Lab’,
followed by strategy 4, ‘RF + StatSensor’, and then strategy 14, ‘StatSensor+ Lab’. As StatSensor is the
POC device with lowest sensitivity, strategies including this device will result in proportionally fewer
positive POC tests with lower costs from delays and, where POC is not followed by laboratory testing,
lower costs from managing patients who test positive across the testing strategy. The increase in the
proportion of patients with a true eGFR < 30 ml/minute/1.73 m2 also results in a reduction in the cost
per test for all POC devices when combined with risk factor screening, but proportionally more for
StatSensor than for i-STAT. The cost-effectiveness of strategies including POC testing with StatSensor
is more favourable than that of strategies with other devices when the proportion of patients with a
true eGFR < 30ml/minute/1.73 m2 increases to 15.9% despite its lower sensitivity.
Higher levels of throughput (i.e. scenario 6.3) result in a switch in the net benefit rank between
strategies 6 and 8, with strategy 8, ‘RF + StatSensor + Lab’ generating higher net benefit. Higher
throughput reduces the cost per POC test for all devices. The cost per test of StatSensor is more
sensitive (as a result of the costs of quality control) to changes in throughput than i-STAT, and reduces
proportionately more compared with base case than the cost per i-STAT test. Therefore, strategy 8,
‘RF + StatSensor + Lab’, becomes less costly than strategy 6, ‘RF + i-STAT + Lab’, and becomes the
cost-effective strategy in scenario 6.3.
Scenarios 7.1–7.4 explore uncertainty in the proportion of patients who can have their laboratory test
and/or IVH performed urgently and, therefore, without incurring the opportunity costs of a delayed CT
scan. The results of the base-case analysis are robust to all alternative assumptions tested under this
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scenario except when it is assumed that all patients are urgent cases and none incurs the opportunity
costs of a delayed CT scan (i.e. scenario 7.1). If there were no delays to CT scanning from laboratory
testing and/or IVH, strategy 5, ‘RF + Lab’, would become the strategy with the highest net benefit,
followed by strategy 1, ‘Lab’. The two strategies are equivalent in terms of QALY gains (as risk factor
screening is assumed to be 100% sensitive), but risk factor screening allows the reduction in the
overall costs of testing as only patients who are risk factor positive receive the laboratory test. Under
scenario 7.1, these strategies become the least costly across all other strategies, because all other
costs of managing test-positive patients are incurred only by TPs (the strategies do not allow for
misclassification) and the costs of testing are lower than for the other strategies.
Scenarios 8–10.2 explored alternative assumptions concerning the impact of anxiety as a result of
delay (scenario 8), the effect of IVH (scenario 9) and the costs of alternative imaging decisions
(scenarios 10.1 and 10.2). Although there were some minor changes in rankings across these scenarios,
strategies 6 (RF + i-STAT + Lab) and 8 (RF+StatSensor + Lab) remained the highest ranked strategies
across all these scenarios.
As detailed in Strategies, a strategy of ‘no testing and manage all with contrast-enhanced CT’ was not
included in the base-case analysis, as this strategy was not deemed to be clinically appropriate given
the consistent recommendations reported across clinical guidelines recommending the use of some
form of screening or testing to identify individuals at risk of PC-AKI. However, for completeness, and
to aid the overall interpretation of the results, two additional scenarios were included (i.e. scenarios
11.1 and 11.2). Scenario 11.1 (see Table 94 in Appendix 11) replicated the base-case analysis, but
included an additional ‘no-testing’ strategy. Scenario 11.2 (see Table 95 in Appendix 11) included the
additional ‘no-testing’ strategy and also altered the assumptions concerning the effectiveness of IVH in
reducing the risk of PC-AKI.
In both scenarios, that is 11.1 and 11.2, the ‘no testing and manage all with contrast-enhanced CT’ was
associated with the highest net benefit.
Discussion of the independent economic assessment
The purpose of the decision model was to assess the cost-effectiveness of POC testing to assess kidney
function, for people who need contrast-enhanced CT imaging in a non-emergency situation and who do
not have a recent eGFR measurement. The decision model considered the potential benefits to, and
possible risks of, using a range of alternative POC testing approaches within the current CT pathway.
A potential limitation of the model is the assumption made in the base-case analysis that all individuals will
eventually proceed to a contrast-enhanced CT scan. This simplification was considered necessary given
the limited data available, the challenges of characterising the heterogeneity in the overall population and
the underlying reason for imaging and linking this to individualised clinical decision-making and associated
outcomes. In a real-world setting, the decision between alternative imaging modality will depend on
the balance between each patient’s risk of PC-AKI and the impact on diagnostic accuracy of choosing a
different imaging modality (which depends on the underlying condition). However, an extensive series
of scenario analyses were undertaken to explore the potential impact of alternative assumptions.
Uncertainties remain in terms of other clinical outcomes that could be affected by alternative imaging
decisions (e.g. potential health loss from using a suboptimal imaging modality to inform treatment) or by
delaying imaging (e.g. a change in underlying condition while waiting for a rescheduled scan).
The simplifying assumption on the opportunity cost of cancelling and rescheduling a CT scan may also
not hold across NHS trusts, as this depends on whether or not the loss of the CT scan slot can be
avoided. For example, some NHS trusts may be able to obtain laboratory tests and deliver any required
risk-mitigating actions within the same day or fill the cancelled slots with scans for non-elective patients.
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Although there is uncertainty on the proportion of CT scans that would be cancelled and rescheduled,
the results of the base-case analysis were robust to the range of alternative assumptions tested under
scenario analysis on this parameter, except when it is assumed that no patient incurs the opportunity
costs of a delayed CT scan.
The evidence on POC diagnostic accuracy is sparse; these estimates are informed by studies with small
cohorts of patients and with few patients with eGFRs < 30 ml/minute/1.73 m2. Although the small
number of patients below this diagnostic threshold is reflective of the expected distribution of eGFRs
in an outpatient population, it introduces uncertainty on the estimates of POC diagnostic accuracy and,
therefore, on the estimates of cost-effectiveness. Moreover, comparative evidence was available for
only three devices, which precluded the inclusion in the analysis of strategies of other commercially
available POC devices. The distribution of eGFR values in the model population was also informed
by audit data from a single NHS trust, which had only one individual with an eGFR < 30 ml/minute/
1.73 m2. Scenario analysis using audit data from another NHS trust with a higher prevalence of eGFR
< 30 ml/minute/1.73 m2 did not, however, change the type of optimal testing strategy.
Another potential limitation of the analysis is that it excludes the costs of implementing the use of POC
devices in the NHS, namely costs associated with staff training and laboratory governance. No evidence
was identified to inform these parameters, but training costs per patient are anticipated to be low
compared with the other elements of cost already included in the costs per POC test. The magnitude
of laboratory governance costs will vary across NHS trusts, as it will depend on whether or not POC
testing is already in use in radiology departments and if the trust has suitable IT connectivity. However,
the costs of implementation and laboratory governance would have to be substantial (i.e. in excess of
£80,000 per annum) to change the conclusions of the analysis. Furthermore, if POC devices were
available in radiology departments they might be used to measure eGFRs outside the bounds of this
particular decision problem, which could potentially reduce the costs per test by increasing throughput.
The evidence on the clinical outcomes of the relevant population is also affected by data sparsity.
The rates of PC-AKI conditional on eGFR values, risk of RRT and mortality subsequent to PC-AKI in
outpatients undergoing contrast-enhanced CT scan were informed by a single study. Furthermore, the
rates required additional assumptions on the links between PC-AKI and subsequent patient outcomes
(e.g. the assumption that the risk of RRT is independent of underlying eGFR value and depends on
only PC-AKI status). No evidence on the effect of contrast agents on risk of PC-AKI in an outpatient
population was identified (see Evidence of the risk of acute kidney injury from contrast agents), and pooled
evidence from three large propensity score-matched studies in inpatient populations suggested no
effect of contrast on PC-AKI risk (see Effect of contrast agents on post-contrast acute kidney injury). Given
that one of the studies included in the meta-analysis suggested a detrimental effect of contrast on
PC-AKI risk91 and the ongoing scientific debate on whether or not contrast agents modify the risk of
PC-AKI, this remains an area of uncertainty. However, findings were robust to scenario analysis assuming
an increased risk of PC-AKI from contrast agents.
The prophylactic effect of IVH on the risk of PC-AKI across different eGFR categories is also an area of
uncertainty that potentially limits the findings of this study. Although the majority of evidence identified
suggests that there is no effect of IVH on the risk of PC-AKI for patients with an eGFR ≥ 30 ml/minute/
1.73 m2, there is a lack of randomised evidence in patients with an eGFR < 30 ml/minute/1.73 m2 (see
Evidence on prophylactic interventions for post-contrast acute kidney injury). In the absence of relevant
evidence for patients with an eGFR < 30 ml/minute/1.73 m2, an assumption on the effect of IVH on the
risk of PC-AKI for these patients was required in the model (i.e. a small statistically non-significant effect
of 0.97 from IVH). Despite this limitation, the results were robust to scenario analysis increasing the
prophylactic effect of IVH for patients with an eGFR < 30 ml/minute/1.73 m2.
The finding that a scenario including a ‘no testing and manage all with contrast-enhanced CT’ strategy
had the highest net benefit of all the strategies suggests that additional testing costs required to
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obtain either a laboratory assessment or a POC test result may not provide sufficient improvement
in patient outcomes to warrant routine testing. Such a strategy is, however, unlikely to be considered
clinically acceptable. These findings also need to be considered alongside the limitations of the model
assumptions and the uncertainties that remain regarding the effect of contrast media on the risk of
PC-AKI, and the benefits of appropriate prophylactic management to reduce the risk of PC-AKI.
Conclusions of the cost-effectiveness section
The base-case cost-effectiveness results showed that the testing strategy with highest net benefit (i.e.
the strategy that appears to be cost-effective) was a three-step testing sequence that involves initially
screening all individuals for risk factors, testing with a POC device those individuals identified with at
least one risk factor and including a final confirmatory laboratory test for individuals who also test
positive with a POC device. Within this testing approach type, the specific POC device with the highest
net benefit was i-STAT; however, differences in the net benefit between the i-STAT and StatSensor
devices were very small. These findings appeared robust to a wide range of scenario analyses. Despite
some changes in rankings, differences in net benefits between many of the individual strategies
remained extremely small.
Differences in the cost and diagnostic specificity of the individual testing strategies appeared more
important drivers than diagnostic sensitivity. The reduction of PC-AKI risk and associated consequences
were not major drivers in the model as a result of the low risk of PC-AKI estimated for this population,
the lack of evidence suggesting an increased risk of PC-AKI associated with the use of contrast media
and the lack of evidence of impact of IVH in reducing the risk of PC-AKI.
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Chapter 6 Discussion
Statement of principal findings
Most of the 54 studies that were eligible for inclusion in the systematic review reported only
measurement bias or correlation outcomes and so were of limited relevance to the economic modelling
part of the assessment. Correlation results data are limited because results that might appear impressive
(i.e. correlation coefficients close to 1) can sometimes hide imperfect agreement between methods.
Of the studies reporting data on creatinine/eGFR measurement bias, results from the StatSensor
studies demonstrated wide variation in both the size and direction of bias. It is therefore important
that StatSensor users are aware of the availability of the offset facility to correct for any measurement
bias observed, as this did not appear to have been done in most StatSensor studies. It is also preferable
that any bias corrections should be informed by data from enzymatic laboratory reference methods, rather
than Jaffe methods, which are well known to be less accurate than enzymatic methods for measuring
levels of creatinine (unless they are IDMS aligned). Although potentially important measurement bias was
also identified in some studies of the i-STAT and ABL devices, in most of these studies the concordance
of results was generally better than was found in most of the StatSensor studies. No eligible studies
were available on the DRI-CHEM NX 500 device and few studies were available on the epoc and Piccolo
Xpress devices; the limited data and reporting in these studies, coupled with their small sample sizes,
made it difficult to draw conclusions about creatinine measurement biases.
All seven studies that reported diagnostic accuracy results based on creatinine thresholds were of the
StatSensor device. However, these studies were of limited value to this assessment because only two of
the seven studies explicitly reported results that incorporated an offset adjustment (both of which were
based on Jaffe laboratory methods) and diagnostic accuracy results based on creatinine thresholds are
not as clinically relevant as results based on eGFR thresholds.
Twelve studies reported eGFR diagnostic accuracy data, but these covered only three types of device:
StatSensor, i-STAT and ABL devices. Although half of these studies were assessed as having results
with a low risk of bias, there were some concerns about the applicability of results to the outpatient
CT setting in all but two studies. Results of the eGFR data synthesis show better sensitivity to detect
risk of PC-AKI for i-STAT and ABL devices than for StatSensor device. In addition, i-STAT and ABL
devices also have higher probabilities of correctly classifying individuals in the same eGFR categories
as the reference laboratory than StatSensor devices. This is particularly marked for the lower
categories that are of greatest clinical importance. Additional analyses carried out using adjusted
StatSensor data and including studies that used only the CKD-EPI equation confirmed these findings.
A three-step testing sequence that involves combining a risk factor questionnaire, POC testing and
confirmatory laboratory testing would potentially reduce unnecessary delays or rescheduling of
CT scans. In the light of existing evidence, this testing approach appears more cost-effective than
the current approach, which involves obtaining a recent laboratory-based measurement prior to
administering contrast media.
Strengths and limitations of the assessment
The systematic review was performed using transparent, reproducible and robust methods. Our
comprehensive literature searches sought to identify all relevant published and unpublished studies,
which minimised the possibility of publication or language biases affecting the review results. Similarly,
key review processes were performed in duplicate, which minimised the possibility of any reviewer
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errors and biases. This study also successfully obtained previously unpublished data from two important
studies of diagnostic accuracy based on eGFR thresholds. Study quality was evaluated in studies reporting
eGFR diagnostic accuracy data using a modified version of the QUADAS-2 tool. Appropriate synthesis
methods were used to evaluate the accuracy of the devices and provide the inputs needed to the economic
evaluation in the form of probabilities of correct classification by the POC device into the same eGFR
range as the reference laboratory. Uncertainty in the data was taken into account, although it was not
possible to fully account for between-study differences in results.
A further strength of this review was the broadness of its scope: in addition to studies reporting
diagnostic accuracy data, the review sought studies reporting measurement bias and clinical or
workflow outcomes.
The de novo decision model is the first formal evaluation of the potential clinical benefits, risks and costs
of incorporating POC testing to assess kidney function for people who need contrast-enhanced CT
imaging in a non-emergency outpatient setting and who present without a recent eGFR measurement.
The main strength of the decision model is the linkage between the diagnostic accuracy of a given
strategy, the impact on subsequent treatment decisions and the ultimate effect on health outcomes
and costs.
Some diagnostic accuracy studies were limited by small sample sizes, and most studies had few patients
with eGFR values of < 30 ml/minute/1.73 m2. Although this is reflective of outpatient populations, it
limits the data available for analyses based on the most important eGFR threshold of < 30 ml/minute/
1.73 m2 and it contributes to the uncertainty around diagnostic accuracy estimates. Few studies directly
compared different POC creatinine devices and eGFR diagnostic accuracy data were not available for
the ABL90 FLEX PLUS, DRI-CHEM NX 500, epoc and Piccolo Xpress POC devices. Available data on
the underlying distribution of eGFR values in the relevant population were also sparse and suggested
that few radiology outpatients have eGFR values of < 30 ml/minute/1.73 m2. This may, however, vary
across NHS trusts and is likely to depend on local-level organisation characteristics (e.g. whether the
hospital is a specialist centre and/or has renal services on site). Scenario analysis suggests, however,
that the findings on the optimal type of strategy are robust to alternative assumptions on the
distribution of eGFRs.
Another potential limitation of this assessment is the assumption made in the base-case analysis that all
individuals will eventually proceed to a contrast-enhanced CT scan. This simplification was considered
necessary given the limited data available, the challenges of characterising the heterogeneity in the overall
population and the underlying reason for imaging and linking this to individualised clinical decision-making
and associated outcomes. However, an extensive series of scenario analyses were undertaken to explore
the potential impact of alternative assumptions.
The assumption that all cancelled and rescheduled CT scans will result in the loss of the CT slot
(i.e. incur the cost of one CT scan) may also not reflect clinical practice across all NHS trusts. Although
this could limit the generalisability of the results, the cost-effectiveness results were mostly robust
to the range of alternative assumptions tested under scenario analysis on this parameter. The only
exception was the scenario assuming that no patient incurs the opportunity costs of a delayed CT scan.
The cost-effectiveness analysis did not include the costs of implementing the use of POC devices in the
NHS. Data were not available to fully quantify these costs, and the costs are likely to vary widely
across NHS trusts. Nevertheless, the addition of these costs is unlikely to change the findings of the
cost-effectiveness analysis.
The linkage of diagnostic accuracy data to clinical outcomes in the model relied on sparse data and
on a number of assumptions regarding the risk of PC-AKI conditional on eGFR values, and the link
between PC-AKI and subsequent patient outcomes. The effect of contrast media on the risk of PC-AKI
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and the effect of intravenous prophylaxis in reducing the risk of PC-AKI are areas of uncertainty.
However, findings were robust to scenario analysis assuming an increased risk of PC-AKI from contrast
agents, so resolving this uncertainty is unlikely to change the results of the cost-effectiveness analysis.
Uncertainties
There were few studies that reported data on the impact of POC devices in CT departments on the
use (or rates of non-use) of contrast agents for diagnostic procedures, nor were there few data on the
use of prophylactic treatments or workflow outcomes, such as cancelled appointments. No data were
available on studies of POC device on clinical outcomes, such as need for renal replacement therapy or
hospital admissions. The impact of POC devices on these important outcomes is therefore uncertain.
The model relied on a number of assumptions to establish a link between diagnostic accuracy data and
clinical outcomes given the data limitations. The following remain areas of uncertainty:
l diagnostic accuracy of POC devices in patients with an eGFR < 30 ml/minute/1.73 m2
l underlying distribution of eGFR
l proportion of CT scan slots lost as a result of cancelled and rescheduled CT scans
l impact on clinical outcomes from alternative imaging decisions and delays to imaging
l link between PC-AKI and subsequent patient outcomes
l effect of contrast media on risk of PC-AKI by category of eGFR
l effect of IVH on risk of PC-AKI by category of eGFR.
Among these areas of uncertainty, the proportion of CT scan slots lost is the most likely to affect the
results of the cost-effectiveness analysis, but only if all loss of CT scan slots can be avoided.
The finding that a scenario including a ‘no testing and manage all with contrast-enhanced CT’ strategy
had the highest net benefit of all the strategies suggests that additional testing costs required to obtain
either a laboratory assessment or a POC test result may not provide sufficient improvements in patient
outcomes to warrant routine testing. Such a strategy is, however, unlikely to be considered clinically
acceptable. Furthermore, the health benefits from providing prophylactic management to patients with
eGFRs are small given the proportion of patients with an eGFR < 30 ml/minute/1.73 m2, the assumption
that contrast media do not increase the risk of PC-AKI and the modest effect of prophylactic IVH in
reducing PC-AKI. Thus, these findings also need to be considered alongside the limitations of the model
assumptions and the uncertainties that remain regarding the effect of contrast media on the risk of
PC-AKI, and the benefits of appropriate prophylactic management to reduce the risk of PC-AKI.
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Chapter 7 Conclusions
Results from this systematic review of POC creatinine devices showed that i-STAT and ABL800/827devices are more accurate than StatSensor devices at correctly detecting individuals with an eGFR
< 30 ml/minute/1.73 m2 (better sensitivity). The synthesis also indicated that i-STAT and ABL devices
have higher probabilities than StatSensor devices of correctly classifying individuals in the same eGFR
categories as the reference laboratory. Additional analyses carried out using adjusted StatSensor data
and including only studies that used the CKD-EPI equation confirmed these findings.
A pragmatic review identified evidence from large studies of inpatients that suggests there is no
association between contrast agents and the risk of AKI in patients with an eGFR ≥ 45 ml/minute/
1.73 m2, although uncertainty exists about whether or not contrast agents are associated with a
small risk in patients with an eGFR < 45 ml/minute/1.73 m2. There was no evidence to suggest that
IVH is more effective than oral hydration for preventing PC-AKI or RRT or reducing mortality. In the
light of existing evidence, a three-step testing sequence, consisting of initially screening all individuals
for risk factors, testing with a POC device those individuals identified with at least one risk factor
and including a final confirmatory laboratory test for individuals who also test positive with a POC
device, appears to be cost-effective. Within this testing approach, the i-STAT device had the highest
net benefit; however, differences in the net benefit between the i-STAT and StatSensor devices were
very small.
Implications for health care
The findings suggest that the use of POC devices, compared with current practice, may reduce costs to the
health system arising from unnecessary delays in CT scanning appointments for the majority of individuals.
Any savings also need to be considered against the potential risks arising from misclassification. However,
although the use of POC devices results in a marginal reduction in outcomes compared with a strategy
of obtaining a laboratory measurement for all individuals, the loss in outcomes appears more than offset
by the estimated cost savings. These findings need to be considered alongside the uncertainties and
limitations of the analysis described in Chapter 6.
Suggested research priorities
Research is needed to provide more accurate and precise estimates of the distribution of eGFR results
in CT outpatient settings, particularly with respect to patients with an eGFR of < 30 ml/minute/1.73 m2.
Further studies are needed on the diagnostic accuracy and impact on workflow of different risk-
stratifying questionnaires for identifying CT outpatients attending without a recent eGFR who are at
high risk of PC-AKI. Uncertainty exists regarding questionnaire accuracy using the (currently) most
frequently used diagnostic threshold of eGFR < 30 ml/minute/1.73 m2 and also regarding which are the
optimal criteria to be included in the questionnaires.
Evidence on the diagnostic accuracy of the Piccolo, ABL90 FLEX PLUS, DRI-CHEM NX 500 and epoc
devices in outpatient CT settings is needed, as there are currently no available studies. Although it would
be useful to have further studies comparing the diagnostic accuracy of different POC devices in CT
outpatient settings at an eGFR threshold of < 30 ml/minute/1.73 m2, feasibility issues make it difficult to
recommend such studies, given the scarcity of CT outpatients without a recent laboratory eGFR result
who have an eGFR < 30ml/minute/1.73 m2. Broadening a study population to inpatients could solve the
issue of patient numbers, but nevertheless be problematic to undertake as such patients would already
have a recent laboratory eGFR result and so the use of POC devices would not be warranted. If such a
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study was undertaken, a key limitation would be the uncertainty about the applicability of its results to
CT outpatients. Nearly all i-STAT studies included in the review used whole-blood samples, whereas nearly
all studies of StatSensor used capillary samples. It is not clear whether or not the observed differences
in diagnostic accuracy between the two devices may be explained by the use of different blood samples.
Therefore, a study comparing the pros and cons (including accuracy, convenience and cost) of using
capillary samples versus whole-blood samples in POC devices may be relevant. Debate exists about how
best to resolve the issue of the risks of contrast media, with some suggesting a need for a randomised
study to fully determine the contribution of intravenous contrast media to the development AKI.97 Others
have documented that prospective studies in patients with an eGFR < 30 ml/minute/1.73 m2 have been
attempted but had to be terminated early; further clarification on the risk from contrast agents could be
gained from studies of specific patient subgroups that did not receive intravenous prophylaxis (e.g. CT
angiography), irrespective of renal function.96
CONCLUSIONS
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Appendix 1 Literature search strategies
Database search strategies
MEDLINE (Epub Ahead of Print, In-Process & Other Non-Indexed Citations,
Ovid MEDLINE® Daily and Ovid MEDLINE®)
URL: via Ovid – https://ovidsp.ovid.com/.
Date range searched: 1946 to 5 November 2018.
Date searched: 6 November 2018.
Records retrieved: 935.
Search strategy
1. Point-of-Care Systems/ (11,059)
2. Point-of-Care Testing/ (999)
3. point-of-care.ti,ab,kf. (15,874)
4. (POC or POCT).ti,ab,kf. (4593)
5. (rapid$ adj3 (test$ or determin$ or assess$ or analys$ or analyz$ or identif$ or measur$ or
screen$)).ti,ab. (72,301)
6. ((bedside$ or bed-side$) adj3 (test$ or determin$ or assess$ or analys$ or analyz$ or identif$ or
measur$ or screen$)).ti,ab. (3654)
7. ((on-site or onsite) adj3 (test$ or determin$ or assess$ or analys$ or analyz$ or identif$ or measur$
or screen$)).ti,ab. (2472)
8. (near adj4 patient$ adj4 test$).ti,ab. (429)
9. (near adj4 patient$ adj4 determin$).ti,ab. (18)
10. (near adj4 patient$ adj4 assess$).ti,ab. (40)
11. (near adj4 patient$ adj4 analys$).ti,ab. (52)
12. (near adj4 patient$ adj4 analyz$).ti,ab. (21)
13. (near adj4 patient$ adj4 identif$).ti,ab. (38)
14. (near adj4 patient$ adj4 measur$).ti,ab. (88)
15. (near adj4 patient$ adj4 screen$).ti,ab. (15)
16. or/1-15 (98,921)
17. Creatinine/ (53,591)
18. creatinin$ .ti,ab,kf. (103,420)
19. serumcreatinin$ .ti,ab,kf. (4)
20. SCr.ti,ab,kf. (6111)
21. or/17-20 (127,272)
22. 16 and 21 (584)
23. Kidney Function Tests/ (24,304)
24. Glomerular Filtration Rate/ (40,393)
25. ((kidney$ or renal) adj3 (function$ or dysfunction$)).ti,ab. (122,372)
26. glomerul$ filtration rate$ .ti,ab,kf. (39,656)
27. glomerulofiltration rate$ .ti,ab,kf. (6)
28. GFR.ti,ab,kf. (17,926)
29. eGFR.ti,ab,kf. (49,812)
30. or/23-29 (208,018)
31. 16 and 30 (531)
32. 22 or 31 (933)
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33. Computers, Handheld/ (3272)
34. ((handheld or hand held) adj2 (device$ or analyser$ or analyzer$)).ti,ab. (1598)
35. ((desktop or desk top) adj2 (device$ or analyser$ or analyzer$)).ti,ab. (74)
36. ((table top or tabletop or bench top or benchtop) adj2 (device$ or analyser$ or analyzer$)).ti,ab. (145)
37. ((portab$ or transportab$) adj2 (device$ or analyser$ or analyzer$)).ti,ab. (3217)
38. (near patient$ adj2 (device$ or analyser$ or analyzer$)).ti,ab. (28)
39. or/33-38 (8033)
40. 21 or 30 (290,065)
41. 39 and 40 (50)
42. 32 or 41 (966)
43. (i-STAT or iSTAT).ti,ab,kf. (486)
44. 40 and 43 (23)
45. (StatSensor or Stat Sensor).ti,ab,kf. (16)
46. ABL90 FLEX PLUS.ti,ab,kf. (0)
47. (ABL800 FLEX or ABL800FLEX or ABL 800 FLEX).ti,ab,kf. (25)
48. Dri-chem NX500.ti,ab,kf. (0)
49. epoc Blood Analysis.ti,ab,kf. (3)
50. Piccolo Xpress.ti,ab,kf. (7)
51. or/44-50 (69)
52. 42 or 51 (1003)
53. exp animals/not humans/ (4,511,292)
54. 54 52 not 53 (935).
Key
/ = indexing term [medical subject heading (MeSH) heading].
exp = exploded indexing term (MeSH heading).
$ = truncation.
ti,ab = terms in either title or abstract fields.
kf = author keywords field.
adj3 = terms within three words of each other (any order).
Cochrane Central Register of Controlled Trials (CENTRAL)
URL: via Wiley Online Library – https://onlinelibrary.wiley.com/.
Date range searched: issue 10 of 12, October 2018.
Date searched: November 2018.
Records retrieved: 107.
The strategy below was used to search both CENTRAL and CDSR.
Search strategy
#1 MeSH descriptor: [Point-of-Care Systems] this term only (387)
#2 MeSH descriptor: [Point-of-Care Testing] this term only (46)
#3 point-of-care:ti,ab,kw (1465)
#4 (POC or POCT):ti,ab,kw (1329)
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#5 (rapid* near/3 (test* or determin* or assess* or analys* or analyz* or identif* or measur* or
screen*)):ti,ab,kw (2811)
#6 ((bedside* or bed-side*) near/3 (test* or determin* or assess* or analys* or analyz* or identif* or
measur* or screen*)):ti,ab,kw (330)
#7 ((on-site or onsite) near/3 (test* or determin* or assess* or analys* or analyz* or identif* or
measur* or screen*)):ti,ab,kw (179)
#8 (“near” near/4 patient* near/4 test*):ti,ab,kw (46)
#9 (“near” near/4 patient* near/4 determin*):ti,ab,kw (3)
#10 (“near” near/4 patient* near/4 assess*):ti,ab,kw (9)
#11 (“near” near/4 patient* near/4 analys*):ti,ab,kw (1)
#12 (“near” near/4 patient* near/4 analyz*):ti,ab,kw (1)
#13 (“near” near/4 patient* near/4 identif*):ti,ab,kw (4)
#14 (“near” near/4 patient* near/4 measur*):ti,ab,kw (8)
#15 (“near” near/4 patient* near/4 screen*):ti,ab,kw (1)
#16 {OR #1-#15} (5677)
#17 MeSH descriptor: [Creatinine] this term only (3779)
#18 creatinin*:ti,ab,kw (17,537)
#19 serumcreatinin*:ti,ab,kw (34)
#20 SCr:ti,ab,kw (890)
#21 122-#20-#20-#20-#20 (17,896)
#22 #16 AND #21 (61)
#23 MeSH descriptor: [Kidney Function Tests] this term only (1162)
#24 MeSH descriptor: [Glomerular Filtration Rate] this term only (2488)
#25 ((kidney* or renal) near/3 (function* or dysfunction*)):ti,ab,kw (14,814)
#26 glomerul* next filtration next rate*:ti,ab,kw (7103)
#27 glomerulofiltration next rate*:ti,ab,kw (0)
#28 GFR:ti,ab,kw (4858)
#29 eGFR:ti,ab,kw (4823)
#30 {OR #23-#29} (21,219)
#31 #16 AND #30 (65)
#32 #22 OR #31 (103)
#33 MeSH descriptor: [Computers, Handheld] this term only (230)
#34 ((handheld or “hand held”) near/2 (device* or analyser* or analyzer*)):ti,ab,kw (227)
#35 ((desktop or “desk top”) near/2 (device* or analyser* or analyzer*)):ti,ab,kw (6)
#36 ((“table top” or tabletop or “bench top” or benchtop) near/2 (device* or analyser* or analyzer*)):
ti,ab,kw (5)
#37 ((portab* or transportab*) near/2 (device* or analyser* or analyzer*)):ti,ab,kw (330)
#38 ((“near patient” or “near patients”) near/2 (device* or analyser* or analyzer*)):ti,ab,kw (1)
#39 {OR #33-#38} (775)
#40 #21 OR #30 (32,349)
#41 #39 AND #40 (9)
#42 #32 OR #41 (112)
#43 (i-STAT or iSTAT):ti,ab,kw (20)
#44 (StatSensor or Stat-Sensor):ti,ab,kw (0)
#45 “ABL90 FLEX PLUS”:ti,ab,kw (0)
#46 (ABL800 FLEX or ABL800FLEX or ABL 800 FLEX):ti,ab,kw (4)
#47 Dri-chem NX500:ti,ab,kw (0)
#48 “epoc Blood Analysis”:ti,ab,kw (0)
#49 Piccolo Xpress:ti,ab,kw (0)
#50 123-#49-#49-#49-#49 (22)
#51 #42 OR #50 (133)
#52 #42 or #50 in Cochrane Reviews (26)
#53 #42 or #50 in Trials (107)
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Key
MeSH descriptor = indexing term (MeSH heading).
* = truncation.
ti,ab,kw = terms in either title or abstract or keyword fields.
near/3 = terms within three words of each other (any order).
next = terms are next to each other.
Cochrane Database of Systematic Reviews (CDSR)
URL: via Wiley Online Library – https://onlinelibrary.wiley.com/.
Date range searched: issue 11 of 12, November 2018.
Date searched: 6 November 2018.
Records retrieved: 26.
See Cochrane Central Register of Controlled Trials (CENTRAL) for search strategy used.
Cumulative Index to Nursing and Allied Health Literature (CINAHL Plus)
URL: via EBSCOhost – www.ebscohost.com/.
Date range searched: inception to 5 November 2018.
Date searched: 6 November 2018.
Records retrieved: 398.
Search strategy
S1 MH “Point-of-Care Testing” OR MH “Clinical Information Systems” (8790)
S2 TI point-of-care OR AB point-of-care (5832)
S3 TI (POC or POCT) OR AB (POC or POCT) (1220)
S4 TI ( rapid* N3 (test* or determin* or assess* or analys* or analyz* or identif* or measur* or
screen*) ) OR AB (rapid* N3 (test* or determin* or assess* or analys* or analyz* or identif* or measur*
or screen*) ) (8379)
S5 TI ( (bedside* or bed-side*) N3 (test* or determin* or assess* or analys* or analyz* or identif* or
measur* or screen*)) OR AB ( (bedside* or bed-side*) N3 (test* or determin* or assess* or analys* or
analyz* or identif* or measur* or screen*) ) (1641)
S6 TI ( (on-site or onsite) N3 (test* or determin* or assess* or analys* or analyz* or identif* or
measur* or screen*) ) OR AB ( (on-site or onsite) N3 (test* or determin* or assess* or analys* or
analyz* or identif* or measur* or screen*) ) (10,344)
S7 TI (near N4 patient* N4 test*) OR AB (near N4 patient* N4 test*) (152)
S8 TI (near N4 patient* N4 determin*) OR AB (near N4 patient* N4 determin*) (11)
S9 TI (near N4 patient* N4 assess*) OR AB (near N4 patient* N4 assess*) (23)
S10 TI (near N4 patient* N4 analys*) OR AB (near N4 patient* N4 analys*) (23)
S11 TI (near N4 patient* N4 analyz*) OR AB (near N4 patient* N4 analyz*) (5)
S12 TI (near N4 patient* N4 identif*) OR AB (near N4 patient* N4 identif*) (24)
S13 TI (near N4 patient* N4 measur*) OR AB (near N4 patient* N4 measur*) (36)
S14 TI (near N4 patient* N4 screen*) OR AB (near N4 patient* N4 screen*) 4)
S15 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
OR S14 (31,354)
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S16 MH “Creatinine” (8128)
S17 TI creatinin* OR AB creatinin* (13,520)
S18 TI serumcreatinin* OR AB serumcreatinin* (2)
S19 TI SCr OR AB SCr (737)
S20 S16 OR S17 OR S18 OR S19 (17,758)
S21 S15 AND S20 (186)
S22 MH “Kidney Function Tests” (2679)
S23 MH “Glomerular Filtration Rate” (8043)
S24 TI ( (kidney* or renal) N3 (function* or dysfunction*) ) OR AB ( (kidney* or renal) N3 (function*
or dysfunction*) ) (16,250)
S25 TI glomerul* N1 filtration N1 rate* OR AB glomerul* N1 filtration N1 rate* (6789)
S26 TI glomerulofiltration N1 rate* OR AB glomerulofiltration N1 rate* (2)
S27 TI GFR OR AB GFR (2398)
S28 TI eGFR OR AB eGFR (8593)
S29 S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 (30,731)
S30 S15 AND S29 (160)
S31 S21 OR S30 (289)
S32 MH “Computers, Hand-Held” (3826)
S33 MH “Portable Equipment” (1004)
S34 TI ( (handheld or “hand held”) N2 (device* or analyser* or analyzer*) ) OR AB ( (handheld or
“hand held”) N2 (device* or analyser* or analyzer*) ) (629)
S35 TI ( (desktop or “desk top”) N2 (device* or analyser* or analyzer*) ) OR AB ( (desktop or “desk
top”) N2 (device* or analyzer* or analyzer*) ) (36)
S36 TI ( (“table top” or tabletop or “bench top” or benchtop) N2 (device* or analyser* or analyzer*) )
OR AB ( (“table top” or tabletop or “bench top” or benchtop) N2 (device* or analyser* or analyzer*) ) (36)
S37 TI ( (portab* or transportab*) N2 (device* or analyser* or analyzer*) ) OR AB ( (portab* or
transportab*) N2 (device* or analyser* or analyzer*) ) (870)
S38 TI ( ((“near patient” or “near patients”) N2 (device* or analyser* or analyzer*)) ) OR AB ( ((“near
patient” or “near patients”) N2 (device* or analyser* or analyzer*)) ) (6)
S39 S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 (6102)
S40 S20 OR S29 (41,597)
S41 S39 AND S40 (11)
S42 S31 OR S41 (296)
S43 TI ( i-STAT or iSTAT ) OR AB ( i-STAT or iSTAT ) (92)
S44 TI ( StatSensor or Stat-Sensor ) OR AB ( StatSensor or Stat-Sensor ) (3)
S45 TI ABL90 FLEX PLUS OR AB ABL90 FLEX PLUS (0)
S46 TI ( (ABL800 FLEX or ABL800FLEX or ABL 800 FLEX) ) OR AB ( (ABL800 FLEX or
ABL800FLEX or ABL 800 FLEX) ) (7)
S47 TI Dri-chem NX500 OR AB Dri-chem NX500 (0)
S48 TI epoc Blood Analysis OR AB epoc Blood Analysis (6)
S49 TI Piccolo Xpress OR AB Piccolo Xpress (2)
S50 S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 (108)
S51 S42 OR S50 (398)
Key
MH = indexing term (CINAHL heading).
* = truncation.
TI = terms in the title.
AB = terms in the abstract.
N3 = terms within three words of each other (any order).
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Database of Abstracts of Reviews of Effects (DARE)
URL: via www.crd.york.ac.uk/CRDWeb/.
Date range searched: from inception to 31 March 2015.
Date searched: 6 November 2018.
Records retrieved: four.
Search strategy
The search strategy below was used to search all three of the Centre for Reviews and Dissemination
(CRD) databases: DARE, the HTA database and NHS Economic Evaluations Database (NHS EED).
As the term near is a stop word in the CRD databases it cannot be used as a search term. Therefore,
lines 8–15 and line 38 of the MEDLINE strategy were omitted from the search of the CRD databases.
1. MeSH DESCRIPTOR Point-of-Care Systems (157)
2. MeSH DESCRIPTOR Point-of-Care Testing (1)
3. (point-of-care) (224)
4. (POC or POCT) (23)
5. (rapid* NEAR3 (test* or determin* or assess* or analys* or analyz* or identif* or measur* or
screen*)) (370)
6. ((test* or determin* or assess* or analys* or analyz* or identif* or measur* or screen*) NEAR3
rapid*) (128)
7. ((bedside* or bed-side*) NEAR3 (test* or determin* or assess* or analys* or analyz* or identif* or
measur* or screen*)) (27)
8. ((test* or determin* or assess* or analys* or analyz* or identif* or measur* or screen*) NEAR3
(bedside* or bed-side*)) (14)
9. ((on-site or onsite) NEAR3 (test* or determin* or assess* or analys* or analyz* or identif* or
measur* or screen*)) (11)
10. ((test* or determin* or assess* or analys* or analyz* or identif* or measur* or screen*) NEAR3
(on-site or onsite)) (6)
11. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 (645)
12. MeSH DESCRIPTOR Creatinine (114)
13. (creatinin*) (499)
14. (serumcreatinin*) (0)
15. (SCr) (17)
16. #12 OR #13 OR #14 OR #15 503)
17. #11 AND #16 (7)
18. MeSH DESCRIPTOR Kidney Function Tests (53)
19. MeSH DESCRIPTOR Glomerular Filtration Rate (92)
20. ((kidney* or renal) NEAR3 (function* or dysfunction*)) OR ((function* or dysfunction*) NEAR3
(kidney* or renal) ) (541)
21. (glomerul* filtration rate*) (176)
22. (glomerulofiltration rate*) (0)
23. (GFR) OR (eGFR) (194)
24. #18 OR #19 OR #20 OR #21 OR #22 OR #23 (784)
25. #11 AND #24 (2)
26. #17 OR #25 (9)
27. MeSH DESCRIPTOR Computers, Handheld (13)
28. ((handheld or hand held) NEAR2 (device* or analyser* )or analyzer*)) OR ((device* or analyser* or
analyzer*) NEAR2 (handheld or hand held)) (19)
29. ((desktop or desk top) NEAR2 (device* or analyser* or analyzer*)) OR ((device* or analyser* or
analyzer*) NEAR2 (desktop or desk top)) (2)
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30. ((table top or tabletop or bench top or benchtop) NEAR2 (device* or analyser* or analyzer*)) OR
((device* or analyser* or analyzer*) NEAR2 (table top or tabletop or bench top or benchtop)) (0)
31. ((portab* or transportab*) NEAR2 (device* or analyser* or analyzer*)) OR ((device* or analyser* or
analyzer*) NEAR2 (portab* or transportab*)) (29)
32. #27 OR #28 OR #29 OR #30 OR #31 (59)
33. #16 OR #24 (1095)
34. #32 AND #33 (1)
35. #26 OR #34 (10)
36. (i-STAT) OR (iSTAT) (3)
37. (StatSensor) OR (Stat Sensor) (0)
38. (ABL90 FLEX PLUS) (0)
39. (ABL800 FLEX or ABL800FLEX or ABL 800 FLEX) (0)
40. (Dri-chem NX500) (0)
41. (epoc Blood Analysis) (0)
42. (Piccolo Xpress) (0)
43. #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 (13).
Key
MeSH DESCRIPTOR = indexing term (MeSH heading).
* = truncation.
NEAR3 = terms within three words of each other (order specified).
EconLit
URL: via Ovid – https://ovidsp.ovid.com/.
Date range searched: 1886 to 1 November 2018.
Date searched: 6 November 2018.
Records retrieved: 0.
Search strategy
1. point-of-care.mp. (9)
2. (POC or POCT).mp. (14)
3. (rapid$ adj3 (test$ or determin$ or assess$ or analys$ or analyz$ or identif$ or measur$ or
screen$)).mp. (319)
4. ((bedside$ or bed-side$) adj3 (test$ or determin$ or assess$ or analys$ or analyz$ or identif$ or
measur$ or screen$)).mp. (1)
5. ((on-site or onsite) adj3 (test$ or determin$ or assess$ or analys$ or analyz$ or identif$ or measur$
or screen$)).mp. (28)
6. (near adj4 patient$ adj4 test$).mp. (2)
7. (near adj4 patient$ adj4 determin$).mp. (0)
8. (near adj4 patient$ adj4 assess$).mp. (0)
9. (near adj4 patient$ adj4 analys$).mp. (0)
10. 10 (near adj4 patient$ adj4 analyz$).mp. (0)
11. 11 (near adj4 patient$ adj4 identif$).mp. (0)
12. 12 (near adj4 patient$ adj4 measur$).mp. (0)
13. 13 (near adj4 patient$ adj4 screen$).mp. (0)
14. 14 or/1-13 (369)
15. 15 creatinin$ .mp. (8)
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16. 16 serumcreatinin$ .mp. (0)
17. 17 SCr.mp. (53)
18. 18 or/15–17 (61)
19. 19 14 and 18 (0)
20. 20 ((kidney$ or renal) adj3 (function$ or dysfunction$)).mp. (7)
21. 21 glomerul$ filtration rate$ .mp. (1)
22. 22 glomerulofiltration rate$ .mp. (0)
23. 23 GFR.mp. (6)
24. 24 eGFR.mp. (1)
25. 25 or/20-24 (15)
26. 26 14 and 25 (0)
27. 27 19 or 26 (0)
28. 28 ((handheld or hand held) adj2 (device$ or analyser$ or analyzer$)).mp. (16)
29. 29 ((desktop or desk top) adj2 (device$ or analyser$ or analyzer$)).mp. (2)
30. 30 ((table top or tabletop or bench top or benchtop) adj2 (device$ or analyser$ or
analyzer$)).mp. (0)
31. 31 ((portab$ or transportab$) adj2 (device$ or analyser$ or analyzer$)).mp. (8)
32. 32 (near patient$ adj2 (device$ or analyser$ or analyzer$)).mp. (1)
33. 33 or/28-32 (25)
34. 34 18 or 25 (74)
35. 35 33 and 34 (0)
36. 36 27 or 35 (0)
37. 37 (i-STAT or iSTAT).mp. (180)
38. 38 34 and 37 (0)
39. 39 (StatSensor or Stat Sensor).mp. (0)
40. 40 ABL90 FLEX PLUS.mp. (0)
41. 41 (ABL800 FLEX or ABL800FLEX or ABL 800 FLEX).mp. (0)
42. 42 Dri-chem NX500.mp. (0)
43. 43 epoc Blood Analysis.mp. (0)
44. 44 Piccolo Xpress.mp. (0)
45. 45 38 or 39 or 40 or 41 or 42 or 43 or 44 (0)
46. 46 36 or 45 (0).
Key
$ = truncation.
mp = terms in either title, abstract, or heading word fields.
adj3 = terms within three words of each other (any order).
EMBASE
URL: via Ovid – https://ovidsp.ovid.com/.
Date range searched: 1974 to 5 November 2018.
Date searched: 6 November 2018.
Records retrieved: 1967.
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Search strategy
1. “point of care testing”/ (106,79)
2. rapid test/ (3395)
3. point-of-care.ti,ab,kw. (22,688)
4. (POC or POCT).ti,ab,kw. (7243)
5. (rapid$ adj3 (test$ or determin$ or assess$ or analys$ or analyz$ or identif$ or measur$ or
screen$)).ti,ab. (88,530)
6. ((bedside$ or bed-side$) adj3 (test$ or determin$ or assess$ or analys$ or analyz$ or identif$ or
measur$ or screen$)).ti,ab. (5676)
7. ((on-site or onsite) adj3 (test$ or determin$ or assess$ or analys$ or analyz$ or identif$ or measur$
or screen$)).ti,ab. (3323)
8. (near adj4 patient adj4 test$).ti,ab. (596)
9. (near adj4 patient$ adj4 determin$).ti,ab. (33)
10. (near adj4 patient$ adj4 assess$).ti,ab. (68)
11. (near adj4 patient$ adj4 analys$).ti,ab. (74)
12. (near adj4 patient$ adj4 analyz$).ti,ab. (27)
13. (near adj4 patient$ adj4 identif$).ti,ab. (70)
14. (near adj4 patient$ adj4 measur$).ti,ab. (125)
15. (near adj4 patient$ adj4 screen$).ti,ab. (22)
16. or/1-15 (124,452)
17. creatinine/ (156,366)
18. creatinine blood level/(97,275)
19. creatinin$ .ti,ab,kw. (164,758)
20. serumcreatinin$ .ti,ab,kw. (161)
21. SCr.ti,ab,kw. (10,539)
22. or/17-21 (240,268)
23. 16 and 22 (1184)
24. kidney function test/ (10,451)
25. exp glomerulus filtration rate/(84,857)
26. ((kidney$ or renal) adj3 (function$ or dysfunction$)).ti,ab. (179,335)
27. glomerul$ filtration rate$ .ti,ab,kw. (55,656)
28. glomerulofiltration rate$ .ti,ab,kw. (10)
29. GFR.ti,ab,kw. (33,036)
30. eGFR.ti,ab,kw. (93375)
31. or/24-30 (315,007)
32. 16 and 31 (988)
33. 23 or 32 (1837)
34. portable equipment/ (2209)
35. ((handheld or hand held) adj2 (device$ or analyser$ or analyzer$)).ti,ab. (2365)
36. ((desktop or desk top) adj2 (device$ or analyser$ or analyzer$)).ti,ab. (98)
37. ((table top or tabletop or bench top or benchtop) adj2 (device$ or analyser$ or analyzer$)).ti,
ab. (220)
38. ((portab$ or transportab$) adj2 (device$ or analyser$ or analyzer$)).ti,ab. (4155)
39. (near patient$ adj2 (device$ or analyser$ or analyzer$)).ti,ab. (45)
40. or/34-39 (8570)
41. 22 or 31 (476,117)
42. 40 and 41 (98)
43. or 42 (1905)
44. (i-STAT or iSTAT).ti,ab,kw,dv. (923)
45. 44 and 41 (79)
46. (StatSensor or Stat Sensor).ti,ab,kw,dv. (37)
47. ABL90 FLEX PLUS.ti,ab,kw,dv. (3)
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48. (ABL800 FLEX or ABL800FLEX or ABL 800 FLEX).ti,ab,kw,dv. (106)
49. Dri-chem NX500.ti,ab,kw,dv. (0)
50. epoc Blood Analysis.ti,ab,kw,dv. (8)
51. Piccolo Xpress.ti,ab,kw,dv. (34)
52. or/45-51 (256)
53. 43 or 52 (2077)
54. (animal/ or animal experiment/ or animal model/ or animal tissue/ or nonhuman/) not exp
human/ (5,588,968)
55. 53 not 54 (1967)
Key
/ = indexing term (Emtree heading).
exp = exploded indexing term (Emtree heading).
$ = truncation.
ti,ab = terms in either title or abstract fields.
kw = terms in the author keywords field.
dv = terms in the device trade name field.
adj3 = terms within three words of each other (any order).
Health Management Information Consortium (HMIC)
URL: via Ovid – https://ovidsp.ovid.com/.
Date range searched: 1979 to July 2018.
Date searched: 6 November 2018.
Records retrieved: five.
Search strategy
1. near patient tests/ (26)
2. point-of-care.mp. (225)
3. (POC or POCT).mp. (45)
4. (rapid$ adj3 (test$ or determin$ or assess$ or analys$ or analyz$ or identif$ or measur$ or
screen$)).mp. (280)
5. ((bedside$ or bed-side$) adj3 (test$ or determin$ or assess$ or analys$ or analyz$ or identif$ or
measur$ or screen$)).mp. (23)
6. ((on-site or onsite) adj3 (test$ or determin$ or assess$ or analys$ or analyz$ or identif$ or measur$
or screen$)).mp. (32)
7. (near adj4 patient$ adj4 test$).mp. (63)
8. (near adj4 patient$ adj4 determin$).mp. (0)
9. (near adj4 patient$ adj4 assess$).mp. (3)
10. (near adj4 patient$ adj4 analys$).mp. (3)
11. (near adj4 patient$ adj4 analyz$).mp. (0)
12. (near adj4 patient$ adj4 identif$).mp. (2)
13. (near adj4 patient$ adj4 measur$).mp. (0)
14. (near adj4 patient$ adj4 screen$).mp. (1)
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15. or/1-14 (605)
16. creatinine/ (3)
17. creatinin$ .mp. (116)
18. serumcreatinin$ .mp. (0)
19. SCr.mp. (22)
20. 16 or 17 or 18 or 19 (138)
21. 15 and 20 (3)
22. ((kidney$ or renal) adj3 (function$ or dysfunction$)).mp. (139)
23. glomerul$ filtration rate$ .mp. (60)
24. glomerulofiltration rate$ .mp. (0)
25. GFR.mp. (17)
26. eGFR.mp. (37)
27. 22 or 23 or 24 or 25 or 26 (187)
28. 15 and 27 (0)
29. portable equipment/ (74)
30. exp Portability/ (16)
31. ((handheld or hand held) adj2 (device$ or analyser$ or analyzer$)).mp. (16)
32. ((desktop or desk top) adj2 (device$ or analyser$ or analyzer$)).mp. (5)
33. ((table top or tabletop or bench top or benchtop) adj2 (device$ or analyser$ or analyzer$)).mp. (0)
34. ((portab$ or transportab$) adj2 (device$ or analyser$ or analyzer$)).mp. (19)
35. (near patient$ adj2 (device$ or analyser$ or analyzer$)).mp. (0)
36. 29 or 30 or 31 or 32 or 33 or 34 or 35 (123)
37. 20 or 27 (286)
38. 36 and 37 (0)
39. 21 or 28 or 38 (3)
40. (i-STAT or iSTAT).mp. (2)
41. (StatSensor or Stat Sensor).mp. (0)
42. ABL90 FLEX PLUS.mp. (0)
43. (ABL800 FLEX or ABL800FLEX or ABL 800 FLEX).mp. (0)
44. Dri-chem NX500.mp. (0)
45. epoc Blood Analysis.mp. (0)
46. Piccolo Xpress.mp. (0)
47. 40 or 41 or 42 or 43 or 44 or 45 or 46 (2)
48. 39 or 47 (5)
Key
/ = subject heading search.
$ = truncation.
mp = terms in either title, abstract, heading word or other title fields.
adj3 = terms within three words of each other (any order).
Health Technology Assessment (HTA) database
URL: via https://www.crd.york.ac.uk/CRDWeb/.
Date range searched: from inception to 31 March 2018.
Date searched: 6 November 2018.
Records retrieved: five.
See Database of Abstracts of Reviews of Effects (DARE) for search strategy used.
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NHS Economic Evaluations Database (NHS EED)
URL: via www.crd.york.ac.uk/CRDWeb/.
Date range searched: from inception to 31 March 2015.
Date searched: 6 November 2018.
Records retrieved: four.
See Database of Abstracts of Reviews of Effects (DARE) for search strategy used.
PubMed
URL: www.ncbi.nlm.nih.gov/pubmed/.
Date searched: 5 November 2018.
Records retrieved: 499.
Search strategy
Search ((((((((((((((“Creatinine”[Mesh:NoExp]) OR creatinin*[Title/Abstract]) OR serumcreatinin*[Title/
Abstract]) OR SCr[Title/Abstract])) OR (((((((“Kidney Function Tests”[Mesh:NoExp]) OR “Glomerular
Filtration Rate”[Mesh:NoExp]) OR (((kidney*[Title/Abstract] OR renal[Title/Abstract])) AND (function*
[Title/Abstract] OR dysfunction*[Title/Abstract]))) OR glomerul* filtration rate*[Title/Abstract]) OR
glomerulofiltration rate*[Title/Abstract]) OR GFR[Title/Abstract]) OR eGFR[Title/Abstract]))) AND
((((((((“Point-of-Care Systems”[Mesh]) OR “Point-of-Care Testing”[Mesh:NoExp]) OR point-of-care[Title/
Abstract]) OR ((POC[Title/Abstract] OR POCT[Title/Abstract]))) OR ((rapid*[Title/Abstract]) AND (test
[Title/Abstract] OR tests[Title/Abstract] OR testing[Title/Abstract] OR testings[Title/Abstract] OR
tested[Title/Abstract] OR determin*[Title/Abstract] OR assess*[Title/Abstract] OR analys*[Title/
Abstract] OR analyz*[Title/Abstract] OR identif*[Title/Abstract] OR measur*[Title/Abstract] OR screen*
[Title/Abstract]))) OR (((bedside*[Title/Abstract] OR bed-side*[Title/Abstract])) AND (test[Title/Abstract]
OR tests[Title/Abstract] OR testing[Title/Abstract] OR testings[Title/Abstract] OR tested[Title/
Abstract] OR determin*[Title/Abstract] OR assess*[Title/Abstract] OR analys*[Title/Abstract] OR
analyz*[Title/Abstract] OR identif*[Title/Abstract] OR measur*[Title/Abstract] OR screen*[Title/
Abstract]))) OR (((on-site[Title/Abstract] OR onsite[Title/Abstract])) AND (test[Title/Abstract] OR tests
[Title/Abstract] OR testing[Title/Abstract] OR testings[Title/Abstract] OR tested[Title/Abstract] OR
determin*[Title/Abstract] OR assess*[Title/Abstract] OR analys*[Title/Abstract] OR analyz*[Title/
Abstract] OR identif*[Title/Abstract] OR measur*[Title/Abstract] OR screen*[Title/Abstract]))) OR near
patient*[Title/Abstract]))) OR ((((((((“Creatinine”[Mesh:NoExp]) OR creatinin*[Title/Abstract]) OR
serumcreatinin*[Title/Abstract]) OR SCr[Title/Abstract])) OR (((((((“Kidney Function Tests”[Mesh:
NoExp]) OR “Glomerular Filtration Rate”[Mesh:NoExp]) OR (((kidney*[Title/Abstract] OR renal[Title/
Abstract])) AND (function*[Title/Abstract] OR dysfunction*[Title/Abstract]))) OR glomerul* filtration
rate*[Title/Abstract]) OR glomerulofiltration rate*[Title/Abstract]) OR GFR[Title/Abstract]) OR eGFR
[Title/Abstract]))) AND (((((“Computers, Handheld”[Mesh:NoExp]) OR (((handheld[Title/Abstract] OR
hand-held[Title/Abstract])) AND (device*[Title/Abstract] OR analyser*[Title/Abstract] OR analyzer*
[Title/Abstract]))) OR (((desktop[Title/Abstract] OR desk-top[Title/Abstract])) AND (device*[Title/
Abstract] OR analyser*[Title/Abstract] OR analyzer*[Title/Abstract]))) OR (((table-top[Title/Abstract]
OR tabletop[Title/Abstract] OR bench-top[Title/Abstract] OR benchtop[Title/Abstract])) AND (device*
[Title/Abstract] OR analyser*[Title/Abstract] OR analyzer*[Title/Abstract]))) OR (((portab*[Title/
Abstract] OR transportab*[Title/Abstract])) AND (device*[Title/Abstract] OR analyser*[Title/Abstract]
OR analyzer*[Title/Abstract]))))) OR (((((((((((i-STAT[Title/Abstract] OR iSTAT[Title/Abstract]))) AND
((((((“Creatinine”[Mesh:NoExp]) OR creatinin*[Title/Abstract]) OR serumcreatinin*[Title/Abstract]) OR
SCr[Title/Abstract])) OR (((((((“Kidney Function Tests”[Mesh:NoExp]) OR “Glomerular Filtration
Rate”[Mesh:NoExp]) OR (((kidney*[Title/Abstract] OR renal[Title/Abstract])) AND (function*[Title/
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Abstract] OR dysfunction*[Title/Abstract]))) OR glomerul* filtration rate*[Title/Abstract]) OR
glomerulofiltration rate*[Title/Abstract]) OR GFR[Title/Abstract]) OR eGFR[Title/Abstract])))) OR
((StatSensor[Title/Abstract] OR Stat-Sensor))) OR ABL90 FLEX PLUS[Title/Abstract]) OR ((ABL800
FLEX[Title/Abstract] OR ABL800FLEX[Title/Abstract] OR ABL 800 FLEX[Title/Abstract]))) OR Dri-chem
NX500[Title/Abstract]) OR epoc Blood Analysis[Title/Abstract]) OR Piccolo Xpress[Title/Abstract])))
NOT ((animals[mh] NOT humans[mh])))) AND ((pubstatusaheadofprint OR publisher[sb] OR
pubmednotmedline[sb])).
The above search strategy incorporates the following search line to limit to studies found in PubMed
but not available in Ovid MEDLINE:
(pubstatusaheadofprint OR publisher[sb] OR pubmednotmedline[sb])
See Duffy et al.125
Key
[Mesh] = exploded indexing term (MeSH heading).
[Mesh:noexp] = indexing term (MeSH heading) not exploded.
* = truncation.
[Title/Abstract]) = terms in either title or abstract fields.
Science Citation Index
URL: via Web of Science [Clarivate Analytics (formerly Thomson Reuters), Philadelphia, PA, USA] –
https://clarivate.com/.
Date range searched: 1900 to 5 November 2018.
Date searched: 6 November 2018.
Records retrieved: 1011.
Search strategy
# 34 #32 not #33 (1011)
Indexes=SCI-EXPANDED Timespan=1900-2018
# 33 TI=(animal or animals or rat or rats or mouse or mice or rodent or rodents or porcine or murine
or sheep or lamb or lambs or ewe or ewes or pig or pigs or piglet or piglets or sow or sows or minipig
or minipigs or rabbit or rabbits or cat or cats or kitten or kittens or dog or dogs or puppy or puppies or
monkey or monkeys or horse or horses or foal or foals or equine or calf or calves or cattle or heifer or
heifers or hamster or hamsters or chicken or chickens or livestock or alpaca* or llama*) (2,864,727)
# 32 #31 OR #30 OR #28 OR #20 OR # (161,053)
# 31 TS=(StatSensor or Stat-Sensor or ABL90 FLEX PLUS or ABL800 FLEX or ABL800FLEX or
ABL 800 FLEX or Dri-chem NX500 or epoc Blood Analysis or Piccolo Xpress) (75)
# 30 #29 AND #27 (26)
# 29 TS=(i-STAT or iSTAT) (455)
# 28 #27 AND #26 (56)
# 27 #19 OR #15 (255,088)
# 26 #25 OR #24 OR #23 OR #22 OR #21 (10,534)
# 25 TS=(near-patient* NEAR/2 (device* or analyser* or analyzer*)) (38)
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# 24 TS=((portab* or transportab*) NEAR/2 (device* or analyser* or analyzer*)) (7004)
# 23 TS=((table-top or tabletop or bench-top or benchtop) NEAR/2 (device* or analyser* or
analyzer*)) (281)
# 22 TS=((desktop or desk-top) NEAR/2 (device* or analyser* or analyzer*)) (201)
# 21 TS=((handheld or hand-held) NEAR/2 (device* or analyser* or analyzer*)) (3280)
# 20 #19 AND #14 (562)
# 19 #18 OR #17 (190,586)
# 18 TS=((glomerul* NEAR/1 filtration NEAR/1 rate*) OR (glomerulofiltration NEAR/1 rate*) OR
GFR OR eGFR) (93,612)
# 17 TS=((kidney* or renal) NEAR/3 (function* or dysfunction*)) (118,800)
# 16 #15 AND #14 (550)
# 15 TS=(creatinin* or serumcreatinin* or SCr) (99,211)
# 14 #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR
#1 (137,790)
# 13 TS=(“near” NEAR/4 patient* NEAR/4 screen*) (22)
# 12 TS=(“near” NEAR/4 patient* NEAR/4 measur*) (110)
# 11 TS=(“near” NEAR/4 patient* NEAR/4 identif*) (53)
# 10 TS=(“near” NEAR/4 patient* NEAR/4 analyz*) (20)
# 9 TS=(“near” NEAR/4 patient* NEAR/4 analys*) (65)
# 8 TS=(“near” NEAR/4 patient* NEAR/4 assess*) (67)
# 7 TS=(“near” NEAR/4 patient* NEAR/4 determin*) (32)
# 6 TS=(“near” NEAR/4 patient* NEAR/4 test*) (500)
# 5 TS=((“on-site” or “onsite”) NEAR/3 (test* or determin* or assess* or analys* or analyz* or
identif* or measur* or screen*)) (5961)
# 4 TS=((bedside* or bed-side*) NEAR/3 (test* or determin* or assess* or analys* or analyz* or
identif* or measur* or screen*)) (3668)
# 3 TS=(rapid* NEAR/3 (test* or determin* or assess* or analys* or analyz* or identif* or measur*
or screen*)) (109,855)
# 2 TS=(POC or POCT) (7275)
# 1 TS=(point-of-care) (16,121)
Key
TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields.
TI = search in title field.
* = truncation.
“ ” = phrase search.
NEAR/3 = terms within three words of each other (any order).
Ongoing, unpublished or grey literature search strategies
ClinicalTrials.gov
URL: https://clinicaltrials.gov/.
Date searched: 8 November 2018.
Records retrieved: 103.
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Search strategy
Twenty-six studies found for:
(creatinine OR serumcreatinine OR SCr) AND (point-of-care OR near patient)
Twenty-six studies found for:
(kidney function OR renal function OR kidney dysfunction OR renal dysfunction) AND (point-of-care
OR near patient)
Eight studies found for:
(glomerular filtration rate OR GFR OR eGFR) AND (point-of-care OR near patient)
Forty-three studies found for:
istat OR i-stat OR StatSensor OR Stat-Sensor OR ABL90 FLEX PLUS OR ABL800 FLEX OR
ABL800FLEX OR ABL 800 FLEX OR Dri-chem NX500 OR epoc Blood Analysis OR Piccolo Xpress
Conference Proceedings Citation Index: Science
URL: via Web of Science, Clarivate Analytics – https://clarivate.com/.
Date range searched: 1990 to 5 November 2018.
Date searched: 6 November 2018.
Records retrieved: 78.
Search strategy
# 34 #32 not #33 (78)
Indexes=CPCI-S Timespan=1900-2018
# 33 TI=(animal or animals or rat or rats or mouse or mice or rodent or rodents or porcine or murine
or sheep or lamb or lambs or ewe or ewes or pig or pigs or piglet or piglets or sow or sows or minipig
or minipigs or rabbit or rabbits or cat or cats or kitten or kittens or dog or dogs or puppy or puppies or
monkey or monkeys or horse or horses or foal or foals or equine or calf or calves or cattle or heifer
or heifers or hamster or hamsters or chicken or chickens or livestock or alpaca* or llama*) (258,819)
# 32 #31 OR #30 OR #28 OR #20 OR #16 (80)
# 31 TS = (StatSensor or Stat-Sensor or ABL90 FLEX PLUS or ABL800 FLEX or ABL800FLEX or
ABL 800 FLEX or Dri-chem NX500 or epoc Blood Analysis or Piccolo Xpress) (6)
# 30 #29 AND #27 (3)
# 29 TS=(i-STAT or iSTAT) (73)
# 28 #27 AND #26 (4)
# 27 #19 OR #15 (28,719)
# 26 #25 OR #24 OR #23 OR #22 OR #21 (8738)
# 25 TS=(near-patient* NEAR/2 (device* or analyser* or analyzer*)) (3)
# 24 TS=((portab* or transportab*) NEAR/2 (device* or analyser* or analyzer*)) (5017)
# 23 TS=((table-top or tabletop or bench-top or benchtop) NEAR/2 (device* or analyser* or
analyzer*)) (114)
# 22 TS=((desktop or desk-top) NEAR/2 (device* or analyser* or analyzer*)) (308)
# 21 TS=((handheld or hand-held) NEAR/2 (device* or analyser* or analyzer*)) (3501)
# 20 #19 AND #14 (32)
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# 19 #18 OR #17 (21,751)
# 18 TS=((glomerul* NEAR/1 filtration NEAR/1 rate*) OR (glomerulofiltration NEAR/1 rate*) OR
GFR OR eGFR) (9710)
# 17 TS=((kidney* or renal) NEAR/3 (function* or dysfunction*)) (13,364)
# 16 #15 AND #14 (53)
# 15 TS=(creatinin* or serumcreatinin* or SCr) (9631)
# 14 #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR
#1 (20,101)
# 13 TS=(“near” NEAR/4 patient* NEAR/4 screen*) (5)
# 12 TS=(“near” NEAR/4 patient* NEAR/4 measur*) (16)
# 11 TS=(“near” NEAR/4 patient* NEAR/4 identif*) (8)
# 10 TS=(“near” NEAR/4 patient* NEAR/4 analyz*) (5)
# 9 TS=(“near” NEAR/4 patient* NEAR/4 analys*) (6)
# 8 TS=(“near” NEAR/4 patient* NEAR/4 assess*) (8)
# 7 TS=(“near” NEAR/4 patient* NEAR/4 determin*) (3)
# 6 TS=(“near” NEAR/4 patient* NEAR/4 test*) (42)
# 5 TS=((“on-site” or “onsite”) NEAR/3 (test* or determin* or assess* or analys* or analyz* or identif*
or measur* or screen*)) (2391)
# 4 TS=((bedside* or bed-side*) NEAR/3 (test* or determin* or assess* or analys* or analyz* or
identif* or measur* or screen*)) (356)
# 3 TS=(rapid* NEAR/3 (test* or determin* or assess* or analys* or analyz* or identif* or measur*
or screen*)) (13,933)
# 2 TS=(POC or POCT) (1280)
# 1 TS=(point-of-care) (2689)
Key
TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields.
TI = search in title field.
* = truncation.
“ ” = phrase search.
NEAR/3 = terms within three words of each other (any order).
EU Clinical Trials Register
URL: www.clinicaltrialsregister.eu/ctr-search/search.
Date searched: 7 November 2018.
Records retrieved: 15.
Search strategy
1. Four results found for:
(creatinine OR serumcreatinine) AND (“point of care” OR point-of-care OR “near patient”)
2. Two results found for:
(“kidney function” OR “renal function” OR “kidney dysfunction” OR “renal dysfunction”) AND (“point of
care” OR point-of-care OR “near patient”)
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3. Three results found for:
(“glomerular filtration rate” OR “glomerulofiltration rate” OR GFR OR eGFR) AND (“point of care” OR
point-of-care OR “near patient”)
4. Six results found for:
istat OR i-stat OR “i stat” OR StatSensor OR Stat-Sensor OR “Stat Sensor” OR “ABL90 FLEX PLUS”
5. No results found for:
“ABL800 FLEX” OR ABL800FLEX OR “ABL 800 FLEX” OR “Dri-chem NX500”
6. No results found for:
“epoc Blood Analysis” OR “Piccolo Xpress”.
Open Access Theses and Dissertations
URL: https://oatd.org/.
Date searched: 8 November 2018.
Records retrieved: 36.
Search strategy
1. (creatinine OR serumcreatinine OR SCr) AND (“point of care”) (15)
2. (creatinine OR serumcreatinine OR SCr) AND (“near patient”) (0)
3. (“kidney function” OR “renal function” OR “kidney dysfunction” OR “renal dysfunction”) AND (“point
of care” OR “near patient”) (11)
4. (“glomerular filtration rate” OR GFR OR eGFR) AND (“point of care” OR “near patient”) (2)
5. (istat OR “i-stat”) AND (creatinine OR serumcreatinine OR SCr OR “glomerular filtration rate” OR
GFR OR eGFR) (2)
6. StatSensor OR “Stat-Sensor” OR “ABL90 Flex Plus” OR “ABL800 FLEX” OR “ABL800FLEX” OR “ABL
800 FLEX” OR “Dri-chem NX500” OR “epoc Blood analysis” OR “Piccolo Xpress”(6)
ProQuest Dissertations & Theses Global A&I
URL: via ProQuest – www.proquest.com/.
Date searched: 6 November 2018.
Records retrieved: 68.
Search strategy
1. (TI,AB,IF(point-of-care) OR TI,AB,IF(POC OR POCT)) AND (TI,AB,IF(creatinin* OR serumcreatinin*
OR SCr) OR TI,AB,IF((kidney* OR renal) NEAR/3 (function* OR dysfunction*)) OR TI,AB,IF(glomerul*
filtration rate*) OR TI,AB,IF(glomerulofiltration rate*) OR TI,AB,IF(GFR OR eGFR))
Fifteen results.
2. (TI,AB,IF(rapid* NEAR/3 (test* OR determin* OR assess* OR analys* OR analyz* OR identif* OR
measur* OR screen*)) OR TI,AB,IF((bedside* OR bed-side*) NEAR/3 (test* OR determin* OR assess* OR
analys* OR analyz* OR identif* OR measur* OR screen*))) AND (TI,AB,IF(creatinin* OR serumcreatinin*
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OR SCr) OR TI,AB,IF((kidney* OR renal) NEAR/3 (function* OR dysfunction*)) OR TI,AB,IF(glomerul*
filtration rate*) OR TI,AB,IF(glomerulofiltration rate*) OR TI,AB,IF(GFR OR eGFR))
Twenty-nine results.
3. TI,AB,IF((on-site OR onsite) NEAR/3 (test* OR determin* OR assess* OR analys* OR analyz* OR
identif* OR measur* OR screen*)) AND (TI,AB,IF(creatinin* OR serumcreatinin* OR SCr) OR TI,AB,IF
((kidney* OR renal) NEAR/3 (function* OR dysfunction*)) OR TI,AB,IF(glomerul* filtration rate*) OR TI,
AB,IF(glomerulofiltration rate*) OR TI,AB,IF(GFR OR eGFR))
Three results.
4. (TI,AB,IF(“near” NEAR/4 patient* NEAR/4 test*) OR TI,AB,IF(“near” NEAR/4 patient* NEAR/4
determin*) OR TI,AB,IF(“near” NEAR/4 patient* NEAR/4 assess*) OR TI,AB,IF(“near” NEAR/4 patient*
NEAR/4 analys*) OR TI,AB,IF(“near” NEAR/4 patient* NEAR/4 analyz*) OR TI,AB,IF(“near” NEAR/4
patient* NEAR/4 identif*) OR TI,AB,IF(“near” NEAR/4 patient* NEAR/4 measur*) OR TI,AB,IF(“near”
NEAR/4 patient* NEAR/4 screen*)) AND (TI,AB,IF(creatinin* OR serumcreatinin* OR SCr) OR TI,AB,IF
((kidney* OR renal) NEAR/3 (function* OR dysfunction*)) OR TI,AB,IF(glomerul* filtration rate*) OR TI,
AB,IF(glomerulofiltration rate*) OR TI,AB,IF(GFR OR eGFR))
Three results.
5. ((TI,AB,IF(creatinin* OR serumcreatinin* OR SCr) OR TI,AB,IF((kidney* OR renal) NEAR/3 (function*
OR dysfunction*)) OR TI,AB,IF(glomerul* filtration rate*) OR TI,AB,IF(glomerulofiltration rate*) OR TI,
AB,IF(GFR OR eGFR)) AND (TI,AB,IF((handheld OR hand-held) NEAR/2 (device* OR analyser* OR
analyzer*)) OR TI,AB,IF((desktop OR desk-top) NEAR/2 (device* OR analyser* OR analyzer*)) OR TI,AB,
IF((table-top OR tabletop OR bench-top OR benchtop) NEAR/2 (device* OR analyser* OR analyzer*))
OR TI,AB,IF((portab* OR transportab*) NEAR/2 (device* OR analyser* OR analyzer*)) OR TI,AB,IF((“near
patient” OR “near patients”) NEAR/2 (device* OR analyser* OR analyzer*)))) OR TI,AB,IF(i-STAT OR
iSTAT OR StatSensor OR Stat-Sensor OR ABL90 FLEX PLUS OR ABL800 FLEX OR ABL800FLEX OR
ABL 800 FLEX OR Dri-chem NX500 OR epoc Blood Analysis OR Piccolo Xpress)
Eighteen results.
PROSPERO
URL: www.crd.york.ac.uk/PROSPERO/.
Searched on: 6 November 2018.
Records retrieved: 13.
Search strategy
#1 MeSH DESCRIPTOR Point-of-Care Systems (41)
#2 MeSH DESCRIPTOR Point-of-Care Testing (14)
#3 point-of-care (171)
#4 POC or POCT (51)
#5 rapid* adj3 (test* or determin* or assess* or analys* or analyz* or identif* or measur* or screen*)
(210)
#6 (test* or determin* or assess* or analys* or analyz* or identif* or measur* or screen*) adj3 rapid* (88)
#7 ((bedside* or bed-side*) adj3 (test* or determin* or assess* or analys* or analyz* or identif*
or measur* or screen*)) (32)
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#8 (test* or determin* or assess* or analys* or analyz* or identif* or measur* or screen*) adj3
((bedside* or bed-side*)) (15)
#9 ((on-site or onsite) adj3 (test* or determin* or assess* or analys* or analyz* or identif* or
measur* or screen*)) (8)
#10 “near” adj4 patient* adj4 test* (5)
#11 “near” adj4 patient* adj4 determin* (0)
#12 “near” adj4 patient* adj4 assess* (0)
#13 “near” adj4 patient* adj4 analys* (0)
#14 “near” adj4 patient* adj4 analyz* (0)
#15 “near” adj4 patient* adj4 identif* (0)
#16 “near” adj4 patient* adj4 measur* (0)
#17 “near” adj4 patient* adj4 screen* (0)
#18 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
OR #14 OR #15 OR #16 OR #17 (432)
#19 MeSH DESCRIPTOR Creatinine (12)
#20 creatinin* (452)
#21 serumcreatinin* (0)
#22 SCr (54)
#23 #19 OR #20 OR #21 OR #22 (480)
#24 #18 AND #23 (5)
#25 MeSH DESCRIPTOR Kidney Function Tests (4)
#26 MeSH DESCRIPTOR Glomerular Filtration Rate (10)
#27 ((kidney* or renal) adj3 (function* or dysfunction*)) (536)
#28 glomerul* filtration rate* (192)
#29 glomerulofiltration rate* (0)
#30 GFR (167)
#31 eGFR (246)
#32 #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 (786)
#33 #32 AND #18 (7)
#34 #24 OR #33 (12)
#35 MeSH DESCRIPTOR Computers, Handheld (8)
#36 ((handheld or hand held) NEAR2 (device* or analyser* or analyzer*)) (40)
#37 ((device* or analyser* or analyzer*) NEAR2 (handheld or hand held)) (3)
#38 ((handheld or hand held) adj2 (device* or analyser* or analyzer*)) (40)
#39 ((device* or analyser* or analyzer*) adj2 (handheld or hand held)) (3)
#40 ((desktop or desk top) adj2 (device* or analyser* or analyzer*)) (0)
#41 ((device* or analyser* or analyzer*) adj2 (desktop or desk top)) (2)
#42 ((table top or tabletop or bench top or benchtop) adj2 (device* or analyser* or analyzer*)) (1)
#43 ((device* or analyser* or analyzer*) adj2 (table top or tabletop or bench top or benchtop)) (0)
#44 ((portab* or transportab*) adj2 (device* or analyser* or analyzer*)) (40)
#45 ((device* or analyser* or analyzer*) adj2 (portab* or transportab*)) (3)
#46 ((device* or analyser* or analyzer*) adj2 (“near” patient*)) (0)
#47 ((“near” patient*) adj2 (device* or analyser* or analyzer*)) (0)
#48 #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR
#46 OR #47 (82)
#49 ((function* or dysfunction*) adj3 (kidney* or renal)) (107)
#50 #32 OR #49 (808)
#51 #18 AND #50 (7)
#52 #50 OR #23 (1002)
#53 #52 AND #48 (1)
#54 #24 OR #51 OR #53 (13)
#55 i-STAT or iSTAT (1)
#56 StatSensor or Stat Sensor (0)
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#57 ABL90 FLEX PLUS (0)
#58 ABL800 FLEX or ABL800FLEX or ABL 800 FLEX (0)
#59 Dri-chem NX500 (0)
#60 epoc Blood Analysis (0)
#61 Piccolo Xpress (0)
#62 #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 (13)
Key
MeSH DESCRIPTOR = indexing term (MeSH heading).
* = truncation.
adj3 = terms within three words of each other (order specified).
World Health Organization’s International Clinical Trials Registry Platform
URL: www.who.int/ictrp/search/en/.
Date searched: 8 November 2018.
Records retrieved: 28.
Search strategy
1. Six records for six trials found for:
creatinine AND point of care
2. No results were found for:
creatinine AND near patient
3. No results were found for:
serumcreatinine AND point of care
4. No results were found for:
serumcreatinine AND near patient
5. No results were found for:
SCr AND point of care
6. No results were found for:
SCr AND near patient
7. Two records for two trials found for:
kidney function AND point of care
8. One trial found for:
kidney function AND near patient
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9. Two records for two trials found for:
renal function AND point of care
10. One trial found for:
renal function AND near patient
11. No results were found for:
kidney dysfunction AND point of care
12. No results were found for:
kidney dysfunction AND near patient
13. No results were found for:
glomerular filtration rate AND point of care
14. No results were found for:
glomerular filtration rate AND near patient
15. No results were found for:
glomerulofiltration rate AND point of care
16. No results were found for:
glomerulofiltration rate AND near patient
17. No results were found for:
GFR AND point of care
18. No results were found for:
GFR AND near patient
19. No results were found for:
eGFR AND point of care
20. No results were found for:
eGFR AND near patient
21. Seventeen records for 16 trials found for:
istat OR i-stat OR StatSensor OR Stat-Sensor OR ABL90 FLEX PLUS OR ABL800 FLEX OR
ABL800FLEX OR ABL 800 FLEX OR Dri-chem NX500 OR epoc Blood Analysis OR Piccolo Xpress
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Search for review evidence on the risk of acute kidney injury from contrast
agents following computed tomography scans
Ovid MEDLINE® ALL
URL: https://ovidsp.ovid.com.
Date range searched: 1946 to 27 November 2018.
Date searched: 28 November 2018.
Records retrieved: 291.
Search strategy
1. exp Acute Kidney Injury/ (42,013)
2. (acute adj2 (renal or kidney) adj2 (fail$ or injur$ or insufficien$)).ti,ab. (41,624)
3. ((acute or renal or kidney) adj2 tubular necrosis).ti,ab. (3611)
4. or/1-3 (60,170)
5. tomography, x-ray computed/ or colonography, computed tomographic/ or four-dimensional
computed tomography/ or positron emission tomography computed tomography/ or single photon
emission computed tomography computed tomography/or tomography, spiral computed/ or
multidetector computed tomography/ (374,663)
6. ((compute$ adj2 tomograph$) or tomodensitometry or cine-CT).ti,ab. (268,668)
7. ((CT or CAT) adj2 (scan$ or imag$)).ti,ab. (118,123)
8. ((CT or CAT) adj2 contrast).ti,ab. (8124)
9. (cross-sectional adj2 (scan$ or imag$)).ti,ab. (6368)
10. ((emission or positron or proton) adj2 tomograph$).ti,ab. (68,380)
11. (PET or PET-CT$ or PET?CT$ or CT-PET$ or CT?PET$).ti,ab. (85,352)
12. (SPECT or SPECT-CT$ or SPECT?CT$ or CT-SPECT$ or CT?SPECT$).ti,ab. (26,355)
13. (SPET or SPET-CT$ or SPET?CT$ or CT-SPET$ or CT?SPET$).ti,ab. (1327)
14. or/5-13 (624,723)
15. exp Administration, Intravenous/ (137,931)
16. (intravenous or IV).ti,ab. (609,985)
17. 15 or 16 (670,695)
18. 4 and 14 and 17 (223)
19. (contrast induced adj (AKI or acute kidney injury or nephropathy or tubular necrosis)).ti,ab. (2295)
20. (radiocontrast induced adj (AKI or acute kidney injury or nephropathy or tubular necrosis)).ti,
ab. (115)
21. ((postcontrast or post-contrast) adj (AKI or acute kidney injury or nephropathy or tubular
necrosis)).ti,ab. (22)
22. ((contrast or radiocontrast) adj nephropathy).ti,ab. (376)
23. (CI-AKI or CIAKI or PC-AKI).ti,ab. (403)
24. or/19–23 (2730)
25. 25 14 and 24 (326)
26. 18 or 25 (488)
27. exp animals/ not humans/ (4,519,266)
28. not 27 (480)
29. limit 28 to yr=“2012 -Current” (291)
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
158
Appendix 2 Data extraction
TABLE 38 Sample data extraction table for diagnostic accuracy data
Laboratory reference result – eGFR (ml/minute/1.73 m2)
POC device result – eGFR (ml/minute/1.73 m2)
0–29 30–44 45–59 ≥ 60
0–29
30–44
45–59
≥ 60
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TABLE 39 StatSensor devices: data used in main analysis of diagnostic accuracy (seven studies)
eGFR (ml/
minute/1.73m2)
Study (author
and year of
publication)
eGFR (ml/
minute/1.73m2)
Study
(author
and year of
publication)
eGFR (ml/
minute/1.73m2)
Study
(author
and year of
publication)
eGFR (ml/
minute/1.73m2)
Study (author
and year of
publication)
eGFR (ml/
minute/1.73m2)
Study (author and
year of publication)
Lab POC
Snaith
et al.,
201837
Krige,
201732 Lab POC
Houben
et al.,
201729 Lab POC
Inoue et al.,
201730 Lab POC
Shephard et al.,
201036 Lab POC
Korpi-
Steiner
et al.,
200931
Dorward
et al.,
201828
< 30 < 30 8 1 < 30 < 30 0 < 30 < 30 4 < 30 < 30 26 < 60 < 60 11 1
30–44 4 0 30–44 0 30–44 0 30–59 6 ≥ 60 57 0
45–59 0 0 45–59 0 ≥ 45 0 > 60 1
≥ 60 0 0 ≥ 60 0
Number
of tests
12 1 Number
of tests
0 Number
of tests
4 Number
of tests
33 Number
of tests
68 1
30–44 < 30 3 0 30–44 < 30 0 30–44 < 30 1 30–59 < 30 0 ≥ 60 < 60 0 NA
30–44 17 0 30–44 0 30–44 7 30–59 14 ≥ 60 198 NA
45–59 8 0 45–59 1 ≥ 45 0 > 60 6
≥ 60 0 0 ≥ 60 2
Number
of tests
28 0 Number
of tests
3 Number
of tests
8 Number
of tests
20 Number
of tests
198 186
45–59 < 30 0 0 ≥ 45 < 30 0 ≥ 45 < 30 1 ≥ 60 < 30 0
30–44 10 0 30–44 0 30–44 11 30–59 0
45–59 17 1 ≥ 45 348 ≥ 45 99 > 60 47
≥ 60 8 1
Number
of tests
35 2 Number
of tests
348 Number
of tests
111 Number
of tests
47
≥ 60 < 30 0 0
30–44 1 0
45–59 33 0
≥ 60 191 100
Number
of tests
225 100
Lab, laboratory; NA, not available.
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TABLE 40 i-STAT devices: data used in main analysis of diagnostic accuracy (five studies)
eGFR
(ml/minute/1.73 m2)
Study (author and year of
publication)
eGFR
(ml/minute/1.73 m2)
Study (author and year of
publication)
eGFR
(ml/minute/1.73 m2) Study (author and year of publication)
Lab POC
Snaith et al.,
201837
Snaith et al.,
201938 Lab POC aBotz et al., 201327 Lab POC
Korpi-Steiner et al.,
200931
Nichols et al.,
200733
< 30 < 30 12 0 < 30 < 30 12 < 60 < 60 66 9
30–44 0 0 ≥ 30 2 ≥ 60 2 0
45–59 0 0
≥ 60 0 0
Number of
tests
12 0 Number of
tests
14 Number of
tests
68 9
30–44 < 30 3 1 ≥ 30 < 30 NA ≥ 60 < 60 32 6
30–44 25 9 ≥ 30 NA ≥ 60 166 34
45–59 0 4
≥ 60 0 0
Number of
tests
28 14 Number of
tests
2028 Number of
tests
198 40
45–59 < 30 0 0
30–44 5 2
45–59 29 35
≥ 60 1 7
Number of
tests
35 44
≥ 60 < 30 0 0
30–44 1 1
45–59 14 7
≥ 60 210 234
Number of
tests
225 242
Lab, laboratory; NA, not available.
a Conference abstract.
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TABLE 41 ABL devices: data used in main analysis of diagnostic accuracy (three studies)
eGFR
(ml/minute/1.73 m2)
Study (author and year of
publication)
eGFR
(ml/minute/1.73 m2)
Study (author and year of
publication)
eGFR
(ml/minute/1.73 m2)
Study (author and year of
publication)
Lab POC Snaith et al., 201837 Lab POC Botz et al., 201327 Lab POC Korpi-Steiner et al., 200931
< 30 < 30 12 < 30 < 30 26 < 60 < 60 55
30–44 0 ≥ 30 3 ≥ 60 13
45–59 0
≥ 60 0
Number of
tests
12 Number of
tests
29 Number of
tests
68
30–44 < 30 0 30–59 < 30 NA ≥ 60 < 60 6
30–44 24 ≥ 30 NA ≥ 60 192
45–59 4
≥ 60 0
Number of
tests
28 Number of
tests
674 Number of
tests
198
45–59 < 30 0 ≥ 60 0–60 24
30–44 2 ≥ 60 2517
45–59 31
≥ 60 2
Number of
tests
35 Number of
tests
2541
≥ 60 < 30 0
30–44 0
45–59 1
≥ 60 224
Number of
tests
225
Lab, laboratory; NA, not available.
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TABLE 42 StatSensor: data used in adjusted analysis of diagnostic accuracy
eGFR (ml/minute/1.73 m2)
Study (author and year of
publication) eGFR (ml/minute/1.73 m2)
Study (author and year of
publication)
True POC
Shephard et al., 201036
(StatSensor – adjusted) True POC
Korpi-Steiner et al., 200931
(StatSensor – with offset)
< 30 < 30 32 < 60 < 60 40
30–59 1 ≥ 60 28
≥ 60 0
Number of tests 33 Number of tests 68
30–59 < 30 1 ≥ 60 < 60 24
30–59 17 ≥ 60 174
≥ 60 2
Number of tests 20 Number of tests 198
≥ 60 < 30 0
30–59 10
≥ 60 37
Number of tests 47
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TABLE 43 Characteristics and results of the Nijssen et al. cohort106
Study
(author and
year of
publication)
Characteristics
ResultsDesign Selection criteria
Population
characteristicsa
Contrast
volume Intervention
PC-AKI
definition
Nijssen et al.,
2018106
Retrospective cohort
Uncontrolled
comparison with
patients with an eGFR
30–59ml/minute/
1.73 m2 from the
AMACING trial
eGFR < 30 ml/minute/
1.73 m2 referred for an
elective procedure with
intravascular iodinated
contrast material
administration and
excluded from the
AMACING trial
Exclusion criteria:
l RRT
l Emergency procedures
l ICU
l Age: 74 years
(10 years)
l Male: 54%
l Inpatient: 40%;
l Baseline eGFR:
23.70 ml/minute/
1.73 m2 (4.26 ml/
minute/1.73 m2)
l Intra-arterial
contrast: 40%;
referral for
interventional
procedure: 25%;
CVD: 67%
81ml
(45 ml)
l Intravenous 0.9%
NaCl: 77%
l Intravenous 1.4%
NaHCO3: 8%
b
l No i.v. hydration:
16%c
Increase in SCr
levels by > 25%
or 44 µmol/l
within 2–6 days
post contrast
PC-AKI
l Standard i.v. hydration:
8/59 (13.6%)
l NaHCO3 i.v. hydration:
1/12 (8.3%)
l No treatment: 1/18
(5.6%)
l Standard i.v. hydration
(AMACING trial
arm): 2.7%
l (p = 0.0019)d
Dialysis (35 days)
l Standard i.v. hydration:
1/118 (0.85%)
l NaHCO3 i.v. hydration:
1/12 (8.3%)
l No treatment: 0/23
l Standard i.v. hydration
(AMACING trial arm): 0
l (p = 0.2646)e
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Study
(author and
year of
publication)
Characteristics
ResultsDesign Selection criteria
Population
characteristicsa
Contrast
volume Intervention
PC-AKI
definition
Mortality (35 days)
l Standard i.v. hydration:
11/119 (9.2%)
l NaHCO3 i.v. hydration:
0/12
l No treatment: 0/24
l Standard i.v. hydration
(AMACING trial
arm): 0
l (p < 0.0001)e
Complications of i.v.
hydration
l Standard i.v. hydration:
7/119 (5.9%)
l Standard i.v. hydration
(AMACING trial arm):
18/328 (5.5%)
l (p = 0.8529)
i.v., intravenous; NaCl, sodium chloride.
a Data are presented as n (%) or mean (SD).
b Standard prophylaxis: 3–4ml/kg per hour for 4 hours before and 4 hours after contrast administration.
c 3 ml/kg in 60 minutes before and 1 ml/kg per hour during 6 hours after contrast administration. Deviation from standard prophylaxis due to heart failure (42%), logistics (33%),
dyspnoea (17%) and diabetic renal failure (8%).
d Deviation from standard prophylaxis due to aortic valve stenosis (57%), fluid overload (17%), heart failure (9%), logistics (9%), renal function (4%), and in one case no reason was
recorded (4%).
e Standard hydration with an eGFR < 30 ml/minute/1.73 m2 (cohort arm) vs. an eGFR 30–59 ml/minute/1.73 m2 (AMACING trial arm).
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Appendix 3 Modelling collapsed
category data
Studies reporting on only collapsed categories were assumed to provide information on a function ofthe probabilities of interest. This function varied depending on which categories were collapsed,
with relationships determined using conditional partitioning of probabilities:
Pr(B jC) = Pr(A1 jC)Pr(B jA1,C) + Pr(A2 jC)Pr(B jA2,C), (6)
in which C is the true reported category, which is collapsed over (i.e. contains) categories A1 and A2
from Table 2, and B is the category estimated by the POC device. Note also that as A1 and A2 are
contained in C, Equation 6 can be simplified to:
Pr(B jC)Pr(A1 jC)Pr(B jA1) = Pr(A2 jC)Pr(B jA2). (7)
For each value of B, A1 and A2, Pr(B | A1) and Pr(B | A2) can be expressed in terms of the probabilities of
interest, Pjk.
In addition, it was also necessary to calculate Pr(A1 | C) and Pr(A2 | C), which are the conditional
probabilities of an individual belonging to true eGFR categories A1 and A2, given that they belong
to the joint category C. The probability that an individual included in a study in the synthesis has
true eGFR in category j, Tj, was estimated separately and used to calculate the conditional true
probabilities as:
Pr(A j jC) =
T j
T1 + T2
, j = 1, 2 (8)
The number of individuals classified by a POC device as belonging to the collapsed eGFR category,
given their true collapsed eGFR category (determined by the laboratory test), was also assumed to
follow a multinomial distribution, with dimensions depending on the number of categories reported
and the probabilities written in terms of Pjk, using Equation 7. For an example, see Appendix 3, Example
likelihood and probability calculations for collapsed data. Equations 7 and 8 can also be extended to
collapsing over more than two consecutive categories, when necessary.
Model for the probability that an individual has a true estimated
glomerular filtration rate in each category
All included studies were used to estimate the probability that an individual has true eGFR (as measured
by the laboratory) in each of the four categories of interest (see Table 2).
Let yij be the number of individuals in study i with true eGFR in category j, which is assumed to follow
a multinomial distribution:
(yi1, yi2, yi3, yi4)≈Multinomial

(T1, T2, T3, T4),Ni

, (9)
with Ni defining the total number of individuals in study i, and Tj the probabilities that an individual has
true eGFR in category j.
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The model was estimated in a Bayesian framework using Markov chain Monte Carlo in OpenBUGS
(version 3.2.3),21,22 in which the probabilities were given a non-informative Dirichlet prior distribution
with equal probabilities in each category:
(T1, T2, T3, T4)≈Dirichlet(1, 1, 1, 1). (10)
Studies reporting on collapsed categories contributed to the corresponding sum of probabilities Tj. The
number of individuals in the collapsed categories were assumed to follow a multinomial distribution
with an appropriate number of dimensions and probabilities written as functions of Tj.
Example likelihood and probability calculations for collapsed data
Shephard et al.36 reported the number of patients classified as having eGFRs of < 30, ≥ 30 and
30–59 ml/minute/1.73 m2 by the laboratory and StatSensor POC device (see Table 39).
The number of individuals classified by the POC device as belonging to each eGFR category, given true
eGFR category j = 1, 2, 3, rj1, r

j2, r

j3, were assumed to follow a multinomial distribution:
(rj1, r

j2, r

j3)∼Multinomial (p

j1, p

j2, p

j3), n j
 
, (11)
with nj defining the number of individuals with true eGFR in category j in this study. The probabilities
pjk were written as a function of the probabilities of interest pjk, according to Equation 7 by writing:
C = true eGFR 30–59 ml/minute/1:73 m2. (12)
A1 = true eGFR 30–44 ml/minute/1:73 m
2. (13)
A2 = true eGFR 45–49 ml/minute/1:73 m
2. (14)
Thus, letting B = POC eGFR < 30 ml/minute/1.73 m2, it can be written as:
p11 = Pr(POC eGFR < 30 j true eGFR < 30) = p11, (15)
p12 = Pr(POC eGFR 30–59 j true eGFR < 30) = p12 + p13, (16)
p13 = Pr(POC eGFR≥60 j true eGFR < 30) = p14, (17)
Letting B = POC eGFR < 30–59 ml/minute/1.73 m2 and noting that:
Pr(true eGFR 30–44 j true eGFR 30–59) =
Pr(true eGFR 30–44)
Pr(true eGFR 30–59)
=
T2
T2 + T3
, (18)
Pr(true eGFR 45–59 j true eGFR 30–59) =
Pr(true eGFR 30–44)
Pr(true eGFR 30–59)
=
T3
T2 + T3
, (19)
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It can be written:
p21 = Pr(POC eGFR < 30 j true eGFR 30–59) = p21
T2
T2 + T3
+ p31
T3
T2 + T3
, (20)
p22 = Pr(POC eGFR 30–59 j true eGFR 30–59) = (p22 + p23)
T2
T2 + T3
+ (p32 + p33)
T3
T2 + T3
, (21)
p23 = Pr(POC eGFR ≥60 j true eGFR 30–59) = p24
T2
T2 + T3
+ p34
T3
T2 + T3
, (22)
and letting B = POC eGFR ≥ 60 ml/minute/1.73 m2, it can be written as:
p31 = Pr(POC eGFR < 30 j true eGFR ≥60) = p41, (23)
p32 = Pr(POC eGFR 30–59 j true eGFR ≥60) = p42 + p43, (24)
p33 = Pr(POC eGFR ≥60 j true eGFR ≥60) = p44, (25)
thus linking all the probabilities with data available with the probabilities of interest.
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Appendix 4 OpenBUGS code for analyses
StatSensor main analysis (includes calculation of probability of true
estimated glomerular filtration rate in each category)
model{ 
# All categories 
for (i in 1:ny){                   # loop through studies with all categories 
  y[i,1:4] ~ dmulti(T[], N[i]) 
  # calculate residual deviance 
  for (m in 1:4){                  # loop through all reported thresholds 
    yhat[i,m] <-  T[m] * N[i]      # predicted number events 
    y1[i,m] <- max(y[i,m], 0.1)    # correction for zero cell 
    yhat1[i,m] <- max(yhat[i,m], 0.1) # correction for p=0 
    # Deviance contribution when non-zero cell (allows p=0) 
    ydv1[i,m] <- 2*y1[i,m]*(log(y1[i,m])-log(yhat1[i,m])) 
    # Calculate deviance contribution, when zero cell=zero 
    ydv[i,m] <- ydv1[i,m]*(1-equals(y[i,m],0)) 
   } 
  yresdev[i] <- sum(ydv[i,])       # summed residual deviance contribution for this 
study 
 } 
totresdevT <- sum(yresdev[])       # Total Residual Deviance 
T[1:4] ~ ddirch(omega[])           # prior distribution for T (WinBUGS compatible) 
for (j in 1:4){                    # loop through all categories 
  omega[j] <- 1                    # Dirichlet parameter (non-inf) 
 } 
# type A data: 0-30; 30-60; >60 
for (i in (ny+1):(ny+nyA)){        # loop through studies with type A data 
  y[i,1:3] ~ dmulti(TA[], N[i]) 
  # calculate residual deviance 
  for (m in 1:3){                  # loop through all reported thresholds 
    yhat[i,m] <-  TA[m] * N[i]     # predicted number events  
    y1[i,m] <- max(y[i,m], 0.1)    # correction for zero cell 
    yhat1[i,m] <- max(yhat[i,m], 0.1) # correction for p=0 
    # Deviance contribution when non-zero cell (allows p=0) 
    ydv1[i,m] <- 2*y1[i,m]*(log(y1[i,m])-log(yhat1[i,m])) 
    # Calculate deviance contribution, when zero cell=zero 
    ydv[i,m] <- ydv1[i,m]*(1-equals(y[i,m],0)) 
   } 
  yresdev[i] <- sum(ydv[i,1:3])    # summed residual deviance contribution for this 
study 
 } 
# link probabilities 
TA[1] <- T[1]                      # type A: true < 30 
TA[2] <- T[2] + T[3]               # type A: 30 < true < 60 
TA[3] <- T[4]                      # type A: true > 60 
# 
# type C data: 0-30; 30-45; >45 
for (i in (ny+nyA+1):(ny+nyA+nyC)){ # loop through studies with type C data 
  y[i,1:3] ~ dmulti(TC[], N[i]) 
  # calculate residual deviance 
  for (m in 1:3){                  # loop through all reported thresholds 
    yhat[i,m] <-  TC[m] * N[i]     # predicted number events  
    y1[i,m] <- max(y[i,m], 0.1)    # correction for zero cell 
    yhat1[i,m] <- max(yhat[i,m], 0.1) # correction for p=0 
    # Deviance contribution when non-zero cell (allows p=0) 
    ydv1[i,m] <- 2*y1[i,m]*(log(y1[i,m])-log(yhat1[i,m])) 
    # Calculate deviance contribution, when zero cell=zero 
    ydv[i,m] <- ydv1[i,m]*(1-equals(y[i,m],0)) 
   } 
  yresdev[i] <- sum(ydv[i,1:3])    # summed residual deviance contribution for this 
study 
 } 
# link probabilities 
TC[1] <- T[1]                      # type C: true < 30 
TC[2] <- T[2]                      # type C: 30 < true < 45 
TC[3] <- T[3] + T[4]               # type C: true > 45 
# 
# type E data: 0-60; >60 
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for (i in (ny+nyA+nyC+1):(ny+nyA+nyC+nyE)){  # loop through studies with type E 
data 
  y[i,1] ~ dbin(TE[1], N[i]) 
  # Deviance contribution 
  yhat[i,1] <- TE[1] * N[i]        # expected value of the numerators  
  y1[i,1] <- max(y[i,1], 0.1)      # correction for zero cell 
  yhat1[i,1] <- max(yhat[i,1], 0.1) # correction for p=0 
  # Deviance contribution when non-zero cell (allows p=0) 
  ydev1[i,1] <- 2 * (y1[i,1]*(log(y1[i,1])-log(yhat1[i,1])) 
             +(N[i]-y1[i,1])*(log(N[i]-y1[i,1])  
               - log(N[i]-yhat1[i,1]))) 
  # Deviance contribution when zero cell (allows p=0) 
  ydev0[i,1] <- 2*N[i]*log(N[i]/(N[i]-yhat[i,1])) 
  # Calculate deviance contribution 
  yresdev[i] <- ydev1[i,1]*(1-equals(y[i,1],0)) + ydev0[i,1]*equals(y[i,1],0) 
 } 
# link probabilities 
TE[1] <- T[1] + T[2] + T[3]        # type E: true < 60 
TE[2] <- T[4]                      # type E:  true > 60 
# 
# type F data: 0-30; >30 
for (i in (ny+nyA+nyC+nyE+1):(ny+nyA+nyC+nyE+nyF)){ # loop through studies with 
type F data 
  y[i,1] ~ dbin(TF[1], N[i]) 
  # Deviance contribution 
  yhat[i,1] <- TF[1] * N[i]        # expected value of the numerators  
  y1[i,1] <- max(y[i,1], 0.1)      # correction for zero cell 
  yhat1[i,1] <- max(yhat[i,1], 0.1) # correction for p=0 
  # Deviance contribution when non-zero cell (allows p=0) 
  ydev1[i,1] <- 2 * (y1[i,1]*(log(y1[i,1])-log(yhat1[i,1])) 
             +(N[i]-y1[i,1])*(log(N[i]-y1[i,1])  
               - log(N[i]-yhat1[i,1]))) 
  # Deviance contribution when zero cell (allows p=0) 
  ydev0[i,1] <- 2*N[i]*log(N[i]/(N[i]-yhat[i,1])) 
  # Calculate deviance contribution 
  yresdev[i] <- ydev1[i,1]*(1-equals(y[i,1],0)) + ydev0[i,1]*equals(y[i,1],0) 
 } 
# link probabilities 
TF[1] <- T[1]                      # type F: true < 30 
TF[2] <- T[2] + T[3] + T[4]        # type F:  true > 30 
# 
# p[j,m]: probability of being in true category j and POC category m 
# 
# All categories 
for (i in 1:ns){                   # loop through studies with all categories 
  for (j in 1:4){                 # loop through all categories 
    r[i,j,1:4] ~ dmulti(p[j,], n[i,j]) 
    # calculate residual deviance 
    for (m in 1:4){               # loop through all reported thresholds 
      # predicted number events  
      rhat[i,j,m] <-  p[j,m] * n[i,j] 
      r1[i,j,m] <- max(r[i,j,m], 0.1) # correction for zero cell 
      rhat1[i,j,m] <- max(rhat[i,j,m], 0.1) # correction for p=0 
      # Deviance contribution when non-zero cell (allows p=0) 
      dv1[i,j,m] <- 2*r1[i,j,m]*(log(r1[i,j,m])-log(rhat1[i,j,m])) 
      # Calculate deviance contribution, when zero cell=zero 
      dv[i,j,m] <- dv1[i,j,m]*(1-equals(r[i,j,m],0)) 
#      dv[i,j,m] <- 2*r[i,j,m]*(log(r[i,j,m])-log(rhat[i,j,m])) 
     } 
    dev[i,j] <- sum(dv[i,j,]) 
   } 
  # summed residual deviance contribution for this trial 
  resdev[i] <- sum(dev[i,1:4])        
 } 
totresdev <- sum(resdev[])         # Total Residual Deviance 
for (j in 1:4){                    # loop through all categories 
  p[j,1:4] ~ ddirch(alpha[])       # prior distribution for p (WinBUGS compatible) 
  alpha[j] <- 1                    # Dirichlet parameter (non-inf) 
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 } 
# 
# type A data: 0-30; 30-60; >60 
for (i in (ns+1):(ns+nsA)){        # loop through studies with type A data 
  for (j in 1:3){                  # loop through all categories 
    r[i,j,1:3] ~ dmulti(pA[j,], n[i,j]) 
    # calculate residual deviance 
    for (m in 1:3){               # loop through all reported thresholds 
      # predicted number events  
      rhat[i,j,m] <-  pA[j,m] * n[i,j] 
      r1[i,j,m] <- max(r[i,j,m], 0.1) # correction for zero cell 
      rhat1[i,j,m] <- max(rhat[i,j,m], 0.1) # correction for p=0 
      # Deviance contribution when non-zero cell (allows p=0) 
      dv1[i,j,m] <- 2*r1[i,j,m]*(log(r1[i,j,m])-log(rhat1[i,j,m])) 
      # Calculate deviance contribution, when zero cell=zero 
      dv[i,j,m] <- dv1[i,j,m]*(1-equals(r[i,j,m],0)) 
#      dv[i,j,m] <- 2*r[i,j,m]*(log(r[i,j,m])-log(rhat[i,j,m])) 
     } 
    dev[i,j] <- sum(dv[i,j,1:3]) 
   } 
  # summed residual deviance contribution for this trial 
  resdev[i] <- sum(dev[i,1:3])        
 } 
# link probabilities 
# type A: true < 30 
pA[1,1] <- p[1,1]                  # POC <30 
pA[1,2] <- p[1,2] + p[1,3]         # 30 < POC < 60 
pA[1,3] <- p[1,4]                  # POC >60 
# type A: 30 < true < 60 
sumA <- T[2]+T[3] 
pA[2,1] <- p[2,1]*T[2]/sumA + p[3,1]*T[3]/sumA  # POC <30 
pA[2,2] <- (p[2,2]+p[2,3])*T[2]/sumA + (p[3,2]+p[3,3])*T[3]/sumA # 30 < POC < 60 
pA[2,3] <- p[2,4]*T[2]/sumA + p[3,4]*T[3]/sumA  # POC >60 
# type A: true > 60 
pA[3,1] <- p[4,1]                  # POC <30 
pA[3,2] <- p[4,2] + p[4,3]         # 30 < POC < 60 
pA[3,3] <- p[4,4]                  # POC >60 
# 
# type C data: 0-30; 30-45; >45 
for (i in (ns+nsA+1):(ns+nsA+nsC)){ # loop through studies with type C data 
  for (j in 1:3){                  # loop through all categories 
    r[i,j,1:3] ~ dmulti(pC[j,], n[i,j]) 
    # calculate residual deviance 
    for (m in 1:3){                # loop through all reported thresholds 
      # predicted number events  
      rhat[i,j,m] <-  pC[j,m] * n[i,j] 
      r1[i,j,m] <- max(r[i,j,m], 0.1) # correction for zero cell 
      rhat1[i,j,m] <- max(rhat[i,j,m], 0.1) # correction for p=0 
      # Deviance contribution when non-zero cell (allows p=0) 
      dv1[i,j,m] <- 2*r1[i,j,m]*(log(r1[i,j,m])-log(rhat1[i,j,m])) 
      # Calculate deviance contribution, when zero cell=zero 
      dv[i,j,m] <- dv1[i,j,m]*(1-equals(r[i,j,m],0)) 
#      dv[i,j,m] <- 2*r[i,j,m]*(log(r[i,j,m])-log(rhat[i,j,m])) 
     } 
    dev[i,j] <- sum(dv[i,j,1:3]) 
   } 
  # summed residual deviance contribution for this trial 
  resdev[i] <- sum(dev[i,1:3])        
 } 
# link probabilities 
# type C: true < 30 
pC[1,1] <- p[1,1]                  # POC <30 
pC[1,2] <- p[1,2]                  # 30 < POC < 45 
pC[1,3] <- p[1,3] + p[1,4]         # POC >45 
# type C: 30 < true < 45 
pC[2,1] <- p[2,1]                  # POC <30 
pC[2,2] <- p[2,2]                  # 30 < POC < 45 
pC[2,3] <- p[2,3] + p[2,4]         # POC >45 
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# type C: true > 45 
sumC <- T[3]+T[4] 
pC[3,1] <- p[3,1]*T[3]/sumC + p[4,1]*T[4]/sumC  # POC <30 
pC[3,2] <- p[3,2]*T[3]/sumC + p[4,2]*T[4]/sumC  # 30 < POC < 45 
pC[3,3] <- (p[3,3]+p[3,4])*T[3]/sumC + (p[4,3]+p[4,4])*T[4]/sumC # POC >45 
# 
# type E data: 0-60; >60 
for (i in (ns+nsA+nsC+1):(ns+nsA+nsC+nsE)){ # loop through studies with type E data 
  for (j in 1:2){                  # loop through all categories 
    r[i,j,1] ~ dbin(pE[j,1], n[i,j]) 
    # Deviance contribution 
    rhat[i,j,1] <- pE[j,1] * n[i,j] # expected value of the numerators  
    r1[i,j,1] <- max(r[i,j,1], 0.1) # correction for zero cell 
    rhat1[i,j,1] <- max(rhat[i,j,1], 0.1) # correction for p=0 
    # Deviance contribution when non-zero cell (allows p=0) 
    dev1[i,j,1] <- 2 * (r1[i,j,1]*(log(r1[i,j,1])-log(rhat1[i,j,1])) 
             +(n[i,j]-r1[i,j,1])*(log(n[i,j]-r1[i,j,1])  
               - log(n[i,j]-rhat1[i,j,1]))) 
    # Deviance contribution when zero cell (allows p=0) 
    dev0[i,j,1] <- 2*n[i,j]*log(n[i,j]/(n[i,j]-rhat[i,j,1])) 
    # Calculate deviance contribution 
    dev[i,j] <- dev1[i,j,1]*(1-equals(r[i,j,1],0)) + dev0[i,j,1]*equals(r[i,j,1],0) 
   } 
  # summed residual deviance contribution for this study 
  resdev[i] <- sum(dev[i,1:2])        
 } 
for (j in 1:2){                    # loop through all categories 
  pE[j,2] <- 1-pE[j,1] 
 } 
# link probabilities 
# type E: true < 60 
sumE <- T[1]+T[2]+T[3] 
pE[1,1] <- (p[1,1]+p[1,2]+p[1,3])*T[1]/sumE + (p[2,1]+p[2,2]+p[2,3])*T[2]/sumE                   
+ (p[3,1]+p[3,2]+p[3,3])*T[3]/sumE # POC <60 
# type E: true > 60 
pE[2,1] <- p[4,1]+p[4,2]+p[4,3]    # POC <60 
# 
# 
# type C2 data: TRUE 0-30; 30-45; >45 (extra info of POC categories) 
for (i in (ns+nsA+nsC+nsE+1):(ns+nsA+nsC+nsE+nsC2)){# loop through studies w/ type 
C2 data 
  for (j in 1:2){                  # loop through true eGFR categories 1 and 2 
    r[i,j,1:4] ~ dmulti(p[j,], n[i,j]) # all POC categories reported 
    # calculate residual deviance 
    for (m in 1:4){                # loop through all reported thresholds 
      # predicted number events  
      rhat[i,j,m] <-  p[j,m] * n[i,j] 
      r1[i,j,m] <- max(r[i,j,m], 0.1) # correction for zero cell 
      rhat1[i,j,m] <- max(rhat[i,j,m], 0.1) # correction for p=0 
      # Deviance contribution when non-zero cell (allows p=0) 
      dv1[i,j,m] <- 2*r1[i,j,m]*(log(r1[i,j,m])-log(rhat1[i,j,m])) 
      # Calculate deviance contribution, when zero cell=zero 
      dv[i,j,m] <- dv1[i,j,m]*(1-equals(r[i,j,m],0)) 
#      dv[i,j,m] <- 2*r[i,j,m]*(log(r[i,j,m])-log(rhat[i,j,m])) 
     } 
    dev[i,j] <- sum(dv[i,j,1:4]) 
   } 
  # true eGFR category 3 
  r[i,3,1:3] ~ dmulti(pC2[3,], n[i,3]) # 3 POC categories reported 
  # calculate residual deviance 
  for (m in 1:3){                  # loop through all reported thresholds 
    # predicted number events  
    rhat[i,3,m] <-  pC2[3,m] * n[i,3] 
    r1[i,3,m] <- max(r[i,3,m], 0.1) # correction for zero cell 
    rhat1[i,3,m] <- max(rhat[i,3,m], 0.1) # correction for p=0 
    # Deviance contribution when non-zero cell (allows p=0) 
    dv1[i,3,m] <- 2*r1[i,3,m]*(log(r1[i,3,m])-log(rhat1[i,3,m])) 
    # Calculate deviance contribution, when zero cell=zero 
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    dv[i,3,m] <- dv1[i,3,m]*(1-equals(r[i,3,m],0)) 
#    dv[i,3,m] <- 2*r[i,3,m]*(log(r[i,3,m])-log(rhat[i,3,m])) 
   } 
  dev[i,3] <- sum(dv[i,3,1:3]) 
  # summed residual deviance contribution for this trial 
  resdev[i] <- sum(dev[i,1:3])        
 } 
# link probabilities 
# type C: true > 45 
pC2[3,1] <- pC[3,1]                # POC <30 
pC2[3,2] <- pC[3,2]                # 30 < POC < 45 
pC2[3,3] <- pC[3,3]                # POC >45 
} 
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OpenBUGS data
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i-STAT main analysis (includes calculation of probability of true estimated
glomerular filtration rate in each category)
model{ 
# All categories 
for (i in 1:ny){                   # loop through studies with all categories 
  y[i,1:4] ~ dmulti(T[], N[i]) 
  # calculate residual deviance 
  for (m in 1:4){                  # loop through all reported thresholds 
    yhat[i,m] <-  T[m] * N[i]      # predicted number events 
    y1[i,m] <- max(y[i,m], 0.1)    # correction for zero cell 
    yhat1[i,m] <- max(yhat[i,m], 0.1) # correction for p=0 
    # Deviance contribution when non-zero cell (allows p=0) 
    ydv1[i,m] <- 2*y1[i,m]*(log(y1[i,m])-log(yhat1[i,m])) 
    # Calculate deviance contribution, when zero cell=zero 
    ydv[i,m] <- ydv1[i,m]*(1-equals(y[i,m],0)) 
   } 
  yresdev[i] <- sum(ydv[i,])       # summed residual deviance contribution for this 
study 
 } 
totresdevT <- sum(yresdev[])       # Total Residual Deviance 
T[1:4] ~ ddirch(omega[])           # prior distribution for T (WinBUGS compatible) 
for (j in 1:4){                    # loop through all categories 
  omega[j] <- 1                    # Dirichlet parameter (non-inf) 
 } 
# type A data: 0-30; 30-60; >60 
for (i in (ny+1):(ny+nyA)){        # loop through studies with type A data 
  y[i,1:3] ~ dmulti(TA[], N[i]) 
  # calculate residual deviance 
  for (m in 1:3){                  # loop through all reported thresholds 
    yhat[i,m] <-  TA[m] * N[i]     # predicted number events  
    y1[i,m] <- max(y[i,m], 0.1)    # correction for zero cell 
    yhat1[i,m] <- max(yhat[i,m], 0.1) # correction for p=0 
    # Deviance contribution when non-zero cell (allows p=0) 
    ydv1[i,m] <- 2*y1[i,m]*(log(y1[i,m])-log(yhat1[i,m])) 
    # Calculate deviance contribution, when zero cell=zero 
    ydv[i,m] <- ydv1[i,m]*(1-equals(y[i,m],0)) 
   } 
  yresdev[i] <- sum(ydv[i,1:3])    # summed residual deviance contribution for this 
study 
 } 
# link probabilities 
TA[1] <- T[1]                      # type A: true < 30 
TA[2] <- T[2] + T[3]               # type A: 30 < true < 60 
TA[3] <- T[4]                      # type A: true > 60 
# 
# type C data: 0-30; 30-45; >45 
for (i in (ny+nyA+1):(ny+nyA+nyC)){ # loop through studies with type C data 
  y[i,1:3] ~ dmulti(TC[], N[i]) 
  # calculate residual deviance 
  for (m in 1:3){                  # loop through all reported thresholds 
    yhat[i,m] <-  TC[m] * N[i]     # predicted number events  
    y1[i,m] <- max(y[i,m], 0.1)    # correction for zero cell 
    yhat1[i,m] <- max(yhat[i,m], 0.1) # correction for p=0 
    # Deviance contribution when non-zero cell (allows p=0) 
    ydv1[i,m] <- 2*y1[i,m]*(log(y1[i,m])-log(yhat1[i,m])) 
    # Calculate deviance contribution, when zero cell=zero 
    ydv[i,m] <- ydv1[i,m]*(1-equals(y[i,m],0)) 
   } 
  yresdev[i] <- sum(ydv[i,1:3])    # summed residual deviance contribution for this 
study 
 } 
# link probabilities 
TC[1] <- T[1]                      # type C: true < 30 
TC[2] <- T[2]                      # type C: 30 < true < 45 
TC[3] <- T[3] + T[4]               # type C: true > 45 
# 
# type E data: 0-60; >60 
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for (i in (ny+nyA+nyC+1):(ny+nyA+nyC+nyE)){  # loop through studies with type E 
data 
  y[i,1] ~ dbin(TE[1], N[i]) 
  # Deviance contribution 
  yhat[i,1] <- TE[1] * N[i]        # expected value of the numerators  
  y1[i,1] <- max(y[i,1], 0.1)      # correction for zero cell 
  yhat1[i,1] <- max(yhat[i,1], 0.1) # correction for p=0 
  # Deviance contribution when non-zero cell (allows p=0) 
  ydev1[i,1] <- 2 * (y1[i,1]*(log(y1[i,1])-log(yhat1[i,1])) 
             +(N[i]-y1[i,1])*(log(N[i]-y1[i,1])  
               - log(N[i]-yhat1[i,1]))) 
  # Deviance contribution when zero cell (allows p=0) 
  ydev0[i,1] <- 2*N[i]*log(N[i]/(N[i]-yhat[i,1])) 
  # Calculate deviance contribution 
  yresdev[i] <- ydev1[i,1]*(1-equals(y[i,1],0)) + ydev0[i,1]*equals(y[i,1],0) 
 } 
# link probabilities 
TE[1] <- T[1] + T[2] + T[3]        # type E: true < 60 
TE[2] <- T[4]                      # type E:  true > 60 
# 
# type F data: 0-30; >30 
for (i in (ny+nyA+nyC+nyE+1):(ny+nyA+nyC+nyE+nyF)){ # loop through studies with 
type F data 
  y[i,1] ~ dbin(TF[1], N[i]) 
  # Deviance contribution 
  yhat[i,1] <- TF[1] * N[i]        # expected value of the numerators  
  y1[i,1] <- max(y[i,1], 0.1)      # correction for zero cell 
  yhat1[i,1] <- max(yhat[i,1], 0.1) # correction for p=0 
  # Deviance contribution when non-zero cell (allows p=0) 
  ydev1[i,1] <- 2 * (y1[i,1]*(log(y1[i,1])-log(yhat1[i,1])) 
             +(N[i]-y1[i,1])*(log(N[i]-y1[i,1])  
               - log(N[i]-yhat1[i,1]))) 
  # Deviance contribution when zero cell (allows p=0) 
  ydev0[i,1] <- 2*N[i]*log(N[i]/(N[i]-yhat[i,1])) 
  # Calculate deviance contribution 
  yresdev[i] <- ydev1[i,1]*(1-equals(y[i,1],0)) + ydev0[i,1]*equals(y[i,1],0) 
 } 
# link probabilities 
TF[1] <- T[1]                      # type F: true < 30 
TF[2] <- T[2] + T[3] + T[4]        # type F:  true > 30 
# 
# p[j,m]: probability of being in true category j and POC category m 
# 
# All categories 
for (i in 1:ns){                   # loop through studies with all categories 
  for (j in 1:4){                  # loop through all categories 
    r[i,j,1:4] ~ dmulti(p[j,], n[i,j]) 
    # calculate residual deviance 
    for (m in 1:4){                # loop through all reported thresholds 
      # predicted number events  
      rhat[i,j,m] <-  p[j,m] * n[i,j] 
      r1[i,j,m] <- max(r[i,j,m], 0.1) # correction for zero cell 
      rhat1[i,j,m] <- max(rhat[i,j,m], 0.1) # correction for p=0 
      # Deviance contribution when non-zero cell (allows p=0) 
      dv1[i,j,m] <- 2*r1[i,j,m]*(log(r1[i,j,m])-log(rhat1[i,j,m])) 
      # Calculate deviance contribution, when zero cell=zero 
      dv[i,j,m] <- dv1[i,j,m]*(1-equals(r[i,j,m],0)) 
#      dv[i,j,m] <- 2*r[i,j,m]*(log(r[i,j,m])-log(rhat[i,j,m])) 
     } 
    dev[i,j] <- sum(dv[i,j,]) 
   } 
  # summed residual deviance contribution for this trial 
  resdev[i] <- sum(dev[i,1:4])        
 } 
totresdev <- sum(resdev[])         # Total Residual Deviance 
for (j in 1:4){                    # loop through all categories 
  p[j,1:4] ~ ddirch(alpha[])       # prior distribution for p (WinBUGS compatible) 
  alpha[j] <- 1                    # Dirichlet parameter (non-inf) 
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 } 
# 
# type E data: 0-60; >60 
for (i in (ns+1):(ns+nsE)){        # loop through studies with type E data 
  for (j in 1:2){                  # loop through all categories 
    r[i,j,1] ~ dbin(pE[j,1], n[i,j]) 
    # Deviance contribution 
    rhat[i,j,1] <- pE[j,1] * n[i,j] # expected value of the numerators  
    r1[i,j,1] <- max(r[i,j,1], 0.1) # correction for zero cell 
    rhat1[i,j,1] <- max(rhat[i,j,1], 0.1) # correction for p=0 
    # Deviance contribution when non-zero cell (allows p=0) 
    dev1[i,j,1] <- 2 * (r1[i,j,1]*(log(r1[i,j,1])-log(rhat1[i,j,1])) 
             +(n[i,j]-r1[i,j,1])*(log(n[i,j]-r1[i,j,1])  
               - log(n[i,j]-rhat1[i,j,1]))) 
    # Deviance contribution when zero cell (allows p=0) 
    dev0[i,j,1] <- 2*n[i,j]*log(n[i,j]/(n[i,j]-rhat[i,j,1])) 
    # Calculate deviance contribution 
    dev[i,j] <- dev1[i,j,1]*(1-equals(r[i,j,1],0)) + dev0[i,j,1]*equals(r[i,j,1],0) 
#    dev[i,j] <- 2 * (r[i,j,1] * (log(r[i,j,1])-log(rhat[i,j,1]))   
#            +  (n[i,j]-r[i,j,1]) * (log(n[i,j]-r[i,j,1]) - log(n[i,j]-
rhat[i,j,1]))) 
   } 
  # summed residual deviance contribution for this study 
  resdev[i] <- sum(dev[i,1:2])        
 } 
for (j in 1:2){                    # loop through all categories 
  pE[j,2] <- 1-pE[j,1] 
 } 
# link probabilities 
# type E: true < 60 
sumE <- T[1]+T[2]+T[3] 
pE[1,1] <- (p[1,1]+p[1,2]+p[1,3])*T[1]/sumE + (p[2,1]+p[2,2]+p[2,3])*T[2]/sumE                   
+ (p[3,1]+p[3,2]+p[3,3])*T[3]/sumE # POC <60 
# type E: true > 60 
pE[2,1] <- p[4,1]+p[4,2]+p[4,3]    # POC <60 
# 
# type F data: 0-30; >30 
for (i in (ns+nsE+1):(ns+nsE+nsF)){ # loop through studies with all categories 
  for (j in 1:2){                  # loop through all categories 
    r[i,j,1] ~ dbin(pF[j,1], n[i,j]) 
    # Deviance contribution 
    rhat[i,j,1] <- pF[j,1] * n[i,j] # expected value of the numerators  
    r1[i,j,1] <- max(r[i,j,1], 0.1) # correction for zero cell 
    rhat1[i,j,1] <- max(rhat[i,j,1], 0.1) # correction for p=0 
    # Deviance contribution when non-zero cell (allows p=0) 
    dev1[i,j,1] <- 2 * (r1[i,j,1]*(log(r1[i,j,1])-log(rhat1[i,j,1])) 
             +(n[i,j]-r1[i,j,1])*(log(n[i,j]-r1[i,j,1])  
               - log(n[i,j]-rhat1[i,j,1]))) 
    # Deviance contribution when zero cell (allows p=0) 
    dev0[i,j,1] <- 2*n[i,j]*log(n[i,j]/(n[i,j]-rhat[i,j,1])) 
    # Calculate deviance contribution 
    dev[i,j] <- dev1[i,j,1]*(1-equals(r[i,j,1],0)) + dev0[i,j,1]*equals(r[i,j,1],0) 
#    dev[i,j] <- 2 * (r[i,j,1] * (log(r[i,j,1])-log(rhat[i,j,1]))   
#            +  (n[i,j]-r[i,j,1]) * (log(n[i,j]-r[i,j,1]) - log(n[i,j]-
rhat[i,j,1]))) 
   } 
  # summed residual deviance contribution for this trial 
  resdev[i] <- sum(dev[i,1:2])        
 } 
for (j in 1:2){                    # loop through all categories 
  pF[j,2] <- 1-pF[j,1] 
 } 
# link probabilities 
# type F: true < 30 
pF[1,1] <- p[1,1]                  # POC <30 
# type F: true > 30 
sumF <- T[2]+T[3]+T[4] 
pF[2,1] <- p[2,1]*T[2]/sumF + p[3,1]*T[3]/sumF + p[4,1]*T[4]/sumF # POC <30 
} 
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ABL main analysis (includes calculation of probability of true estimated
glomerular filtration rate in each category)
model{ 
# All categories 
for (i in 1:ny){                   # loop through studies with all categories 
  y[i,1:4] ~ dmulti(T[], N[i]) 
  # calculate residual deviance 
  for (m in 1:4){                  # loop through all reported thresholds 
    yhat[i,m] <-  T[m] * N[i]      # predicted number events 
    y1[i,m] <- max(y[i,m], 0.1)    # correction for zero cell 
    yhat1[i,m] <- max(yhat[i,m], 0.1) # correction for p=0 
    # Deviance contribution when non-zero cell (allows p=0) 
    ydv1[i,m] <- 2*y1[i,m]*(log(y1[i,m])-log(yhat1[i,m])) 
    # Calculate deviance contribution, when zero cell=zero 
    ydv[i,m] <- ydv1[i,m]*(1-equals(y[i,m],0)) 
   } 
  yresdev[i] <- sum(ydv[i,])       # summed residual deviance contribution for this 
study 
 } 
totresdevT <- sum(yresdev[])       # Total Residual Deviance 
T[1:4] ~ ddirch(omega[])           # prior distribution for T (WinBUGS compatible) 
for (j in 1:4){                    # loop through all categories 
  omega[j] <- 1                    # Dirichlet parameter (non-inf) 
 } 
# type A data: 0-30; 30-60; >60 
for (i in (ny+1):(ny+nyA)){        # loop through studies with type A data 
  y[i,1:3] ~ dmulti(TA[], N[i]) 
  # calculate residual deviance 
  for (m in 1:3){                  # loop through all reported thresholds 
    yhat[i,m] <-  TA[m] * N[i]     # predicted number events  
    y1[i,m] <- max(y[i,m], 0.1)    # correction for zero cell 
    yhat1[i,m] <- max(yhat[i,m], 0.1) # correction for p=0 
    # Deviance contribution when non-zero cell (allows p=0) 
    ydv1[i,m] <- 2*y1[i,m]*(log(y1[i,m])-log(yhat1[i,m])) 
    # Calculate deviance contribution, when zero cell=zero 
    ydv[i,m] <- ydv1[i,m]*(1-equals(y[i,m],0)) 
   } 
  yresdev[i] <- sum(ydv[i,1:3])    # summed residual deviance contribution for this 
study 
 } 
# link probabilities 
TA[1] <- T[1]                      # type A: true < 30 
TA[2] <- T[2] + T[3]               # type A: 30 < true < 60 
TA[3] <- T[4]                      # type A: true > 60 
# 
# type C data: 0-30; 30-45; >45 
for (i in (ny+nyA+1):(ny+nyA+nyC)){ # loop through studies with type C data 
  y[i,1:3] ~ dmulti(TC[], N[i]) 
  # calculate residual deviance 
  for (m in 1:3){                  # loop through all reported thresholds 
    yhat[i,m] <-  TC[m] * N[i]     # predicted number events  
    y1[i,m] <- max(y[i,m], 0.1)    # correction for zero cell 
    yhat1[i,m] <- max(yhat[i,m], 0.1) # correction for p=0 
    # Deviance contribution when non-zero cell (allows p=0) 
    ydv1[i,m] <- 2*y1[i,m]*(log(y1[i,m])-log(yhat1[i,m])) 
    # Calculate deviance contribution, when zero cell=zero 
    ydv[i,m] <- ydv1[i,m]*(1-equals(y[i,m],0)) 
   } 
  yresdev[i] <- sum(ydv[i,1:3])    # summed residual deviance contribution for this 
study 
 } 
# link probabilities 
TC[1] <- T[1]                      # type C: true < 30 
TC[2] <- T[2]                      # type C: 30 < true < 45 
TC[3] <- T[3] + T[4]               # type C: true > 45 
# 
# type E data: 0-60; >60 
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for (i in (ny+nyA+nyC+1):(ny+nyA+nyC+nyE)){  # loop through studies with type E 
data 
  y[i,1] ~ dbin(TE[1], N[i]) 
  # Deviance contribution 
  yhat[i,1] <- TE[1] * N[i]        # expected value of the numerators  
  y1[i,1] <- max(y[i,1], 0.1)      # correction for zero cell 
  yhat1[i,1] <- max(yhat[i,1], 0.1) # correction for p=0 
  # Deviance contribution when non-zero cell (allows p=0) 
  ydev1[i,1] <- 2 * (y1[i,1]*(log(y1[i,1])-log(yhat1[i,1])) 
             +(N[i]-y1[i,1])*(log(N[i]-y1[i,1])  
               - log(N[i]-yhat1[i,1]))) 
  # Deviance contribution when zero cell (allows p=0) 
  ydev0[i,1] <- 2*N[i]*log(N[i]/(N[i]-yhat[i,1])) 
  # Calculate deviance contribution 
  yresdev[i] <- ydev1[i,1]*(1-equals(y[i,1],0)) + ydev0[i,1]*equals(y[i,1],0) 
 } 
# link probabilities 
TE[1] <- T[1] + T[2] + T[3]        # type E: true < 60 
TE[2] <- T[4]                      # type E:  true > 60 
# 
# type F data: 0-30; >30 
for (i in (ny+nyA+nyC+nyE+1):(ny+nyA+nyC+nyE+nyF)){ # loop through studies with 
type F data 
  y[i,1] ~ dbin(TF[1], N[i]) 
  # Deviance contribution 
  yhat[i,1] <- TF[1] * N[i]        # expected value of the numerators  
  y1[i,1] <- max(y[i,1], 0.1)      # correction for zero cell 
  yhat1[i,1] <- max(yhat[i,1], 0.1) # correction for p=0 
  # Deviance contribution when non-zero cell (allows p=0) 
  ydev1[i,1] <- 2 * (y1[i,1]*(log(y1[i,1])-log(yhat1[i,1])) 
             +(N[i]-y1[i,1])*(log(N[i]-y1[i,1])  
               - log(N[i]-yhat1[i,1]))) 
  # Deviance contribution when zero cell (allows p=0) 
  ydev0[i,1] <- 2*N[i]*log(N[i]/(N[i]-yhat[i,1])) 
  # Calculate deviance contribution 
  yresdev[i] <- ydev1[i,1]*(1-equals(y[i,1],0)) + ydev0[i,1]*equals(y[i,1],0) 
 } 
# link probabilities 
TF[1] <- T[1]                      # type F: true < 30 
TF[2] <- T[2] + T[3] + T[4]        # type F:  true > 30 
# 
# p[j,m]: probability of being in true category j and POC category m 
# 
# All categories 
for (i in 1:ns){                   # loop through studies with all categories 
  for (j in 1:4){                 # loop through all categories 
    r[i,j,1:4] ~ dmulti(p[j,], n[i,j]) 
    # calculate residual deviance 
    for (m in 1:4){               # loop through all reported thresholds 
      # predicted number events  
      rhat[i,j,m] <-  p[j,m] * n[i,j] 
      r1[i,j,m] <- max(r[i,j,m], 0.1) # correction for zero cell 
      rhat1[i,j,m] <- max(rhat[i,j,m], 0.1) # correction for p=0 
      # Deviance contribution when non-zero cell (allows p=0) 
      dv1[i,j,m] <- 2*r1[i,j,m]*(log(r1[i,j,m])-log(rhat1[i,j,m])) 
      # Calculate deviance contribution, when zero cell=zero 
      dv[i,j,m] <- dv1[i,j,m]*(1-equals(r[i,j,m],0)) 
#      dv[i,j,m] <- 2*r[i,j,m]*(log(r[i,j,m])-log(rhat[i,j,m])) 
     } 
    dev[i,j] <- sum(dv[i,j,]) 
   } 
  # summed residual deviance contribution for this trial 
  resdev[i] <- sum(dev[i,1:4])        
 } 
totresdev <- sum(resdev[])         # Total Residual Deviance 
for (j in 1:4){                    # loop through all categories 
  p[j,1:4] ~ ddirch(alpha[])       # prior distribution for p (WinBUGS compatible) 
  alpha[j] <- 1                    # Dirichlet parameter (non-inf) 
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
182
 } 
# 
# type E data: 0-60; >60 
for (i in (ns+1):(ns+nsE)){        # loop through studies with type E data 
  for (j in 1:2){                  # loop through all categories 
    r[i,j,1] ~ dbin(pE[j,1], n[i,j]) 
    # Deviance contribution 
    rhat[i,j,1] <- pE[j,1] * n[i,j] # expected value of the numerators  
    r1[i,j,1] <- max(r[i,j,1], 0.1) # correction for zero cell 
    rhat1[i,j,1] <- max(rhat[i,j,1], 0.1) # correction for p=0 
    # Deviance contribution when non-zero cell (allows p=0) 
    dev1[i,j,1] <- 2 * (r1[i,j,1]*(log(r1[i,j,1])-log(rhat1[i,j,1])) 
             +(n[i,j]-r1[i,j,1])*(log(n[i,j]-r1[i,j,1])  
               - log(n[i,j]-rhat1[i,j,1]))) 
    # Deviance contribution when zero cell (allows p=0) 
    dev0[i,j,1] <- 2*n[i,j]*log(n[i,j]/(n[i,j]-rhat[i,j,1])) 
    # Calculate deviance contribution 
    dev[i,j] <- dev1[i,j,1]*(1-equals(r[i,j,1],0)) + dev0[i,j,1]*equals(r[i,j,1],0) 
   } 
  # summed residual deviance contribution for this study 
  resdev[i] <- sum(dev[i,1:2])        
 } 
for (j in 1:2){                    # loop through all categories 
  pE[j,2] <- 1-pE[j,1] 
 } 
# link probabilities 
# type E: true < 60 
sumE <- T[1]+T[2]+T[3] 
pE[1,1] <- (p[1,1]+p[1,2]+p[1,3])*T[1]/sumE + (p[2,1]+p[2,2]+p[2,3])*T[2]/sumE                   
+ (p[3,1]+p[3,2]+p[3,3])*T[3]/sumE # POC <60 
# type E: true > 60 
pE[2,1] <- p[4,1]+p[4,2]+p[4,3]    # POC <60 
# 
# type A2 data: 0-30; 30-60; >60 
for (i in (ns+nsE+1):(ns+nsE+nsA2)){ # loop through studies with type A2 data 
  for (j in 1:3){                  # loop through all categories 
    r[i,j,1] ~ dbin(pA2[j,1], n[i,j]) 
    # Deviance contribution 
    rhat[i,j,1] <- pA2[j,1] * n[i,j] # expected value of the numerators  
    r1[i,j,1] <- max(r[i,j,1], 0.1) # correction for zero cell 
    rhat1[i,j,1] <- max(rhat[i,j,1], 0.1) # correction for p=0 
    # Deviance contribution when non-zero cell (allows p=0) 
    dev1[i,j,1] <- 2 * (r1[i,j,1]*(log(r1[i,j,1])-log(rhat1[i,j,1])) 
             +(n[i,j]-r1[i,j,1])*(log(n[i,j]-r1[i,j,1])  
               - log(n[i,j]-rhat1[i,j,1]))) 
    # Deviance contribution when zero cell (allows p=0) 
    dev0[i,j,1] <- 2*n[i,j]*log(n[i,j]/(n[i,j]-rhat[i,j,1])) 
    # Calculate deviance contribution 
    dev[i,j] <- dev1[i,j,1]*(1-equals(r[i,j,1],0)) + dev0[i,j,1]*equals(r[i,j,1],0) 
   } 
  # summed residual deviance contribution for this study 
  resdev[i] <- sum(dev[i,1:3])        
 } 
for (j in 1:3){                    # loop through all categories 
  pA2[j,2] <- 1-pA2[j,1] 
 } 
# link probabilities 
# type A2: true < 30 
pA2[1,1] <- p[1,1]                 # POC <30 
# type A2: true 30-60 
pA2[2,1] <- pA[2,1]                # POC >30 
# probability for type A data 
sumA <- T[2]+T[3] 
pA[2,1] <- p[2,1]*T[2]/sumA + p[3,1]*T[3]/sumA  # POC <30 
# type A2: true > 60 
pA2[3,1] <- p[4,1] + p[4,2] + p[4,3] # POC >60 
} 
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Appendix 5 Quality assessment details
QUADAS-2: risk of bias – patient selection
Selection question 1: was a consecutive or random sample of patients enrolled?
Selection question 2: did the study avoid inappropriate exclusions?
Risk of bias: could the selection of patients have introduced bias?
Answers to the above questions for the patient selection domain are presented in Table 44.
TABLE 44 QUADAS-2 patient selection
Study
(author and
year of
publication) Description
Selection
question
Risk of
bias Notes1 2
aBotz et al.,
201327
2042 patients at risk of renal disease
prior to radiological examinations;
43% female; USA
We retrospectively obtained all
i-STAT1 and Radiometer Ltd 827
whole blood creatinine results
performed on the same day of
service as a serum creatinine for the
period January 1-December
31, 2011
UC UC UC Retrospective selection of patients
with both POC and refence standard
It is not clear how the patients were
classified as at risk of renal disease
Conference abstract
Dorward
et al., 201828
187 HIV-positive patients who
recently initiated first-line
ART, median age 31 years
(IQR 27–38 years); 62% female;
South Africa
Prospectively recruited trial arm
population
Yes No Low Excluded one patient with an eGFR
< 30 ml/minute/1.73 m2, who was
clinically unstable
Unlikely to introduce significant bias
Houben et al.,
201729
351 women due for contrast-
enhanced spectral mammography;
the Netherlands
Women eligible for contrast-
enhanced spectral mammography
between December 2014 and
June 2016
The women ‘were asked to
voluntarily participate in this
observational study’
UC Yes Low Not explicitly stated if consecutively
recruited, but appears likely
No inappropriate exclusions
Inoue et al.,
201730
233 consecutive outpatients scheduled
for contrast-enhanced CT studies
Of the 233 patients, 123 patient
samples were evaluated prior to
adjustment and the other 110
following adjustment
Yes Yes low Consecutive
No inappropriate exclusions
continued
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TABLE 44 QUADAS-2 patient selection (continued )
Study
(author and
year of
publication) Description
Selection
question
Risk of
bias Notes1 2
Korpi-Steiner
et al., 200931
Sample selection was not
consecutive because staff were
available only during selected hours
to perform creatinine testing.
Institutional protocol requires
creatinine/eGFR measurement for
patients older than 70 years,
patients with a history of diabetes
mellitus, and patients with a history
of renal disease or renal
transplantation
No UC Low Reasons provided for non-consecutive
recruitment are acceptable and
unlikely to introduce bias
There was no evidence of
inappropriate exclusion
Krige, 201732 103 mixed-ancestry healthy South
Africans; mean age 52 years;
69% female
Yes UC Low Random sampling
Nichols et al.,
200733
50 consecutive patients requiring
creatinine levels prior to
chemotherapy administration;
52% male; 6% black African
Yes Yes Low Consecutive
No inappropriate exclusions reported
aObrador
et al., 201234
257 diabetic patients; mean age
56.9 years (SD 12.5 years);
62% women
UC UC UC Insufficient information
Conference abstract
aShephard
et al., 200835
101 venous blood samples
No other information
UC UC UC Insufficient information
Conference abstract
Shephard
et al., 201036
100 patients (63 renal/dialysis
patients attending clinic, 37 healthy);
52% female
UC UC UC No information suggesting
recruitment was consecutive or
random
67% dialysis patients and 33%
healthy volunteers
Snaith et al.,
201837
Over a 6-week period in September
and October 2016, consecutive
adult outpatients (≥ 18 years)
attending a UK hospital phlebotomy
department for routine Urea and
Electrolytes (U&E) blood tests were
approached. No upper age limit was
adopted, but pregnant individuals
and those unable to consent
were excluded
300 attending for routine blood tests
(phlebotomy outpatients); mean age
60 years; 47% female; mean
creatinine concentration 92 µmol/l
Yes Yes Low Consecutive
No inappropriate exclusions
reported, although 61 consenting
patients were excluded because
target sample size of 300 had
been reached
Snaith et al.,
201938
CT outpatients without recent
(i.e. within 3 months) eGFR
Over an eight-week period between
February and April 2017 consecutive
adult outpatients (≥ 18 years)
attending for a contrast-enhanced
CT scan were approached
Yes Yes Low Consecutive
No inappropriate exclusions reported
ART, antiretroviral therapy; IQR, interquartile range; UC, unclear.
a Conference abstract.
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QUADAS-2: risk of bias – index test and reference standard
Selection question 1: is the reference standard likely to measure eGFR/creatinine accurately enough?
Selection question 2: was the same method used to calculate eGFR/creatinine for both index test and
reference standard?
Risk of bias: could the conduct or interpretation of the index test or reference standard have
introduced bias?
Answers to the above questions for the index test and reference standard domain are presented
in Table 45.
TABLE 45 QUADAS-2 index test and reference standard
Study
(author and
year of
publication) Description
Selection question
Risk of bias Notes1 2
aBotz et al.,
201327
i-STAT1 and Radiometer Ltd
827 whole-blood creatinine
Roche Cobas Enzymatic
C-501 analyzer
MDRD formula
Yes UC Low Conference abstract
No information suggesting
the method used to calculate
eGFR/creatinine for both
index test and reference
standard were different
Dorward
et al., 201828
Calibrated StatSensor
Xpress-I using finger-prick
capillary whole blood
Dimension EXL 200
Enzymatic
StatSensor Xpress-i, ‘factory
calibrated’ setting was used,
so (it appears that) the
authors did not add an offset
to the device, even though
the device has that
functionality
Only non–offset results are
reported
Yes UC Low No information suggesting
that the method used to
calculate eGFR/creatinine
for both index test and
reference standard were
different
Houben et al.,
201729
StatSensor used according to
manual instructions
Enzymatic reference
standard
StatSensor CREAT, no
mention of offset or
adjustments and only raw
results are reported
Yes UC UC Unclear if MDRD equation
used for POC and the
laboratory reference are the
same (factor 186 for POC vs.
175 for laboratory reference?)
continued
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TABLE 45 QUADAS-2 index test and reference standard (continued )
Study
(author and
year of
publication) Description
Selection question
Risk of bias Notes1 2
Inoue et al.,
201730
Adjusted and unadjusted
plots and table of results
show that the laboratory
eGFR measurements also
change, which is not
supposed to happen (it
should only adjust device
values). The reported
adjusted results from this
study may not represent
NHS practice. In addition,
therefore, only the
unadjusted results were
used for the synthesis
Uses StatSensor-i and
included an adjustment
(‘adjustment by applying
offset correction on the basis
of the slope and intercept of
internal sample’)
Yes Yes Low Low as assessment applies
only to unadjusted accuracy
estimates
Korpi-Steiner
et al., 200931
Different MDRD equations
used for laboratory
reference and i-STAT and
StatSensor
For laboratory reference and
ABL800: standard MDRD
calibrated to IDMS
traceability: eGFR (ml/
minute)= 175 × Cr−1.154 ×
Age−0.203 (× 0.742 if female)
(× 1.212 if African American)
For i-STAT and StatSensor:
MDRD equation originally
validated with conventional
creatinine calibrations: eGFR
(ml/minute) = 186 × Cr−1.154 ×
Age−0.203 (× 0.742 if female)
(× 1.212 if African American)
Results with offset (0.28mg/dl)
and no offset were reported
Yes No Low (ABL800)
High
(i-STAT and
StatSensor)
Different MDRD equations
used for laboratory
reference and i-STAT and
StatSensor
Krige, 201732 Capillary sample for POC
Siemens ADVIA 1800, which
used an IDMS-standardised
kinetic Jaffe assay method
StatSensor: no offset used
Yes No High Jaffe method for reference
laboratory (vs. enzymatic for
POC test)
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TABLE 45 QUADAS-2 index test and reference standard (continued )
Study
(author and
year of
publication) Description
Selection question
Risk of bias Notes1 2
Nichols et al.,
200733
Whole blood, green-top,
lithium heparin specimens
were collected by
venepuncture
MDRD formula
Jaffe and enzymatic used
Note that this assessment
focuses on only the MDRD
enzymatic laboratory
reference, which was used
for the pooled analyses
Yes Yes Low No significant concerns
MDRD used for both POC
and laboratory reference
aObrador
et al., 201234
Simple linear regression was
used to estimate a correction
factor to align i-STAT SCr to
IDMS-SCr
CKD staging was not
standard (0–4)
It is unclear what eGFR
values correspond to each
CKD stage
Diagnostic accuracy results
were reported only post
correction
Yes UC High Simple linear regression was
used to estimate a correction
factor to align i-STAT SCr to
IDMS-SCr
Diagnostic accuracy results
were reported only post
correction
aShephard
et al., 200835
The i-STAT had a positive
bias relative to the IDMS-
aligned laboratory method
(mean % bias of 5.6%
overall, 10.4% for samples
< 150 mmol/l and 4.5% for
samples > 150 mmol/l)
This bias was eliminated,
and an IDMS alignment
performed, by applying a
correction formula
Accuracy estimates were
reported only post
correction and alignment
Reference standard used
was enzymatic, with no
further details reported
UC UC High The i-STAT had a positive
bias relative to the
laboratory method
Mean % bias of 5.6%
overall, 10.4% for samples
< 150 mmol/l and 4.5% for
samples > 150 mmol/l
Correction and alignment
were performed
Accuracy estimates were
reported only post
correction and alignment
The reference laboratory
test used was enzymatic,
with no further details
reported
Shephard
et al., 201036
MDRD
An eGFR cut-off point of
60 ml/minute/1.73 m2
Two devices were tested:
Nova 1 and Nova 2
Yes No
(pre-adjustment)
High High risk after calibration
and adjustment as the offset
adjustment was performed
against the laboratory
reference using the same
samples
continued
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TABLE 45 QUADAS-2 index test and reference standard (continued )
Study
(author and
year of
publication) Description
Selection question
Risk of bias Notes1 2
2 × 2 table available only for
Nova 1
Tests were performed before
and after calibration
Two MDRD equations were
used: the factory factor was
186, and the factor used
post calibration was 175
(standard)
For POC, 186 and 175
factors were both used
to calculate sensitivity/
specificity estimates before
calibration; post calibration,
only 175 factors were used
Laboratory reference MDRD
equation used factor 175
before and after calibration
Plasma samples were used
only for the laboratory
reference
On calibration:
Using the Passing-Bablok
slope and intercept factors,
the significant overall
negative bias observed
across the full creatinine
concentration range with
the factory-calibrated Nova
1 device was corrected
using a reciprocal
recalibration equation:
Nova (recalibrated) = [Nova
(factory calibration) ×
1.3333] – 13.53 mmol/l
Results pre and post
correction are reported
For pre-calibration results
it appears that the eGFR
MDRD equation was used
with factor 186 (vs. factor
175 for the laboratory test)
Plasma was used for the
laboratory reference test
Snaith et al.,
201837
CKD-EPI was used for
POC tests and laboratory
reference for the main
analysis
No offset adjustments done
for any of the devices
Yes Yes Low CKD-EPI used for POC tests
and laboratory reference for
the main analysis
Enzymatic reference
standard
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QUADAS-2: risk of bias – flow and timing
Selection question 1: did all patients receive both the index test and reference standard?
Selection question 2: were all patients included in the analysis?
Selection question 3: did all patients receive the same reference standard?
Selection question 4: was there an acceptable time gap between taking the index test blood and the
reference standard blood samples?
Risk of bias: could the patient flow have introduced bias?
Answers to the above questions for the flow and timing domain are presented in Table 46.
TABLE 45 QUADAS-2 index test and reference standard (continued )
Study
(author and
year of
publication) Description
Selection question
Risk of bias Notes1 2
Laboratory reference
method: enzymatic (Cobas
8000, Roche)
. . . the between-run
imprecision was determined
using independent
commercially available QC
materials, the standard
practice in the laboratory
Clarification from
Dr Martine Harris
(personal communication):
Samples were taken
based on how they would
be clinical practice. Both
the ABL800 and i-STAT
were used with venous
samples only, the
StatSensor was the only
device where a capillary
sample was used
Snaith et al.,
201938
I-STAT and enzymatic (Cobas
8000, Roche)
CKD-EPI used for both
Yes Yes Low No significant concerns
QC, quality control; UC, unclear.
a Conference abstract.
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TABLE 46 QUADAS-2 flow and timing
Study
(author and
year of
publication) Description
Selection question
Risk of
bias Notes1 2 3 4
aBotz et al.,
201327
Retrospective
Analysed all i-STAT1
whole-blood creatinine
results performed on the
same day (not clear how
long in-between) of service
as a SCr within 1 year
Radiometer 827 results
did not appear to be all on
the same day
Yes Yes Yes UC Low See Description
Dorward et al.,
201828
Eight reference samples
were excluded as a result
of a laboratory strike or
because they were
processed 48 hours after
sampling
No No Yes Yes Low Exclusions are unlikely to
have significantly biased
the results
Houben et al.,
201729
14 excluded ‘due to the
inability to withdraw
venous blood through the
vacuum system used’
Blood drawn for
laboratory measurement
within 15 minutes of the
POC test
No No Yes Yes Low Exclusions are unlikely to
have introduced bias
Inoue et al.,
201730
Reported as consecutive
though retrospective
All blood samples taken in
the radiology suite prior
to CT
Time gap unknown, but
unlikely to be significant
Yes Yes Yes UC Low Unlikely
Korpi-Steiner
et al., 200931
Excess samples of lithium
heparin whole blood were
removed after sample
mixing to run on the
i-STAT, StatSensor, and
Radiometer methods
(in that order). This was
followed by centrifugation
of the sample for 2 minutes
at 4500 g for the analysis
of plasma creatinine on the
INTEGRA 400
Yes Yes Yes Yes Low Retrospective, but no
significant concerns about
flow
Krige, 201732 Both capillary and venous
blood samples were
collected at the same time
Time gap between
analysis of sample types
was not reported
Yes Yes Yes Yes Low Considered low, though
gap between analysis of
sample types was not
reported
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TABLE 46 QUADAS-2 flow and timing (continued )
Study
(author and
year of
publication) Description
Selection question
Risk of
bias Notes1 2 3 4
Nichols et al.,
200733
All blood analyses were
completed within 2 h
of specimen collection.
One specimen had too
little sample to allow
duplicate testing . . .
and was excluded
from the analysis
All samples were collected
over 3 days
Yes Yes Yes Yes Low See Description
aObrador
et al., 201234
No description
Conference abstract
Yes Yes Yes UC Low Insufficient information
Conference abstract
aShephard
et al., 200835
No description
Conference abstract
UC UC UC UC UC Insufficient information
Conference abstract
Shephard
et al., 201036
. . . blood specimens were
obtained from each
subject and immediately
analyzed in singlicate with
two StatSensor creatinine
devices using the same
reagent strip lot number.
A venous whole blood
specimen anticoagulated
with lithium heparin (. . .)
was obtained from each
subject at the same
time and sent to the
pathology laboratory
Predialysis results from
one patient were omitted
from graphs and statistical
calculations because of
very inconsistent results
Collection of POC and
laboratory reference
samples at the same time,
but time gap between
POC and laboratory
reference analysis is
unclear
Yes No Yes Yes Low See Description
Snaith et al.,
201837
Where there was
incomplete data, i.e.
results not available
across all methods, the
participants were
excluded from
the sample
After venous blood was
collected:
Capillary blood sampling
was performed from
the fingertip of each
Yes Yes Yes Yes Low See Description
continued
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TABLE 46 QUADAS-2 flow and timing (continued )
Study
(author and
year of
publication) Description
Selection question
Risk of
bias Notes1 2 3 4
participant by two
research radiographers
as would be the case
in routine practice. The
skin was pierced with a
spring-loaded lancet and
the sample collected
directly onto the analysis
strip avoiding squeezing
of the finger or milking
of blood
Contacted author – time
gap between samples was
within 10 minutes
Snaith et al.,
201938
One sample (SMonovette
Lithium Heparin 2.7 ml
tube, Ref 05.1553,
Sarstedt) was
transported to the
hospital laboratory for
routine analysis. The
other sample (1ml BD
Plastipak syringe,
Ref 303172, Becton
Dickinson, San Agustin
del Guadalix) was
immediately tested on
the PoC device within
the CT scan suite
If the POC test result
identified a decline in
kidney function from its
baseline result, this
prompted a requirement
to wait for laboratory
confirmation before CT
Contacted author – time
gap between samples was
within 10 minutes
Only four samples
excluded:
l One unable to
get blood
l One laboratory
sample haemolysed
l Two missing samples
Yes Yes Yes Yes Low See Description
UC, unclear.
a Conference abstract.
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QUADAS-2: applicability concerns
Applicability concerns 1: are there concerns that the included patients do not match the review
question?
Applicability concerns 2: are there concerns that the eGFR/creatinine thresholds used do not match the
review question?
Applicability concerns 3: are there concerns that the index test, its conduct or interpretation differ from
the review question?
Applicability concerns 4: are there concerns that the reference standard, its conduct or interpretation
differ from the review question?
Answers to the above questions for applicability concerns are presented in Table 47.
TABLE 47 QUADAS-2 applicability concerns
Study (author and
year of publication) Description
Applicability concerns
1 2 3 4
aBotz et al., 201327 Not clear how participants were classified as at risk of
renal disease
Not clear participants were outpatients
Conference abstract
eGFR thresholds: 30 and 60ml/minute/1.73 m2
Whole-blood samples used for POC
UC Low Low Low
Dorward et al.,
201828
HIV-positive population, younger and a higher proportion of
women than the average outpatient population
Only one patient had an eGFR < 60ml/minute/1.73 m2
eGFR threshold: 90
Finger-prick whole-blood sample used for POC
High High Low Low
Houben et al., 201729 Only women referred for contrast-enhanced spectral
mammography were recruited
Data on all relevant thresholds were extractable
High Low Low Low
Inoue et al., 201730 The pre-adjustment study included 123 consecutive outpatients
(74 males, 49 females, mean age 66.7 ± 12.5 years) who
underwent contrast-enhanced CT between September 2011
and February 2012
SCr levels of the patients had not been assessed in the month
preceding hospital admittance
In the post-adjustment study, 110 consecutive outpatients
(62 males, 48 females, mean age 70.1 ± 12.7 years) who
underwent contrast-enhanced CT at Kohka Public Hospital
between June and November 2012, were included
Low High High Low
continued
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TABLE 47 QUADAS-2 applicability concerns (continued )
Study (author and
year of publication) Description
Applicability concerns
1 2 3 4
< 30, 30–45 and > 45ml/minute/1.73 m2 thresholds extractable,
but equation used to calculate eGFR is not standard (Japanese
Society of Nephrology-Chronic Kidney Disease Initiatives)
Uses StatSensor-i and included an adjustment (‘adjustment by
applying offset correction on the basis of the slope and
intercept of internal sample’)
Adjusted and unadjusted plots and table of results show the
laboratory eGFR measurements also change, which is not
supposed to happen (it should adjust only the device values).
So the reported adjusted results from this study may not
represent NHS practice. Therefore, only unadjusted results
were assessed and used in the meta-analysis
Korpi-Steiner et al.,
200931
Patients referred for CT without a recent eGFR/SCr
measurement considered at risk
< 60 ml/minute/1.73 m2 threshold only
Excess lithium heparinised whole-blood samples used
Low High High Low
Krige, 201732 103 mixed-ancestry healthy outpatients attending nephrology
clinic; South Africans; mean age 52 years; 69% female
Jaffe method used
IPD reported allowed derivation of < 30ml/minute/1.73 m2
cut-off point data
High Low Low Low
Nichols et al., 200733 Only chemotherapy patients, but no significant reasons to
believe that they depart from the main population of interest
Only eGFR < 60 ml/minute/1.73 m2 cut-off point assessed
Low High Low Low
aObrador et al.,
201234
Only diabetics; 62% women
Simple linear regression was used to estimate a correction
factor to align i-STAT SCr to IDMS-SCr
Diagnostic accuracy results were reported only post correction
CKD staging was not standard (0–4)
It was unclear what eGFR values corresponded to each
CKD stage
High High High Low
aShephard et al.,
200835
Insufficient information (conference abstract)
Results reported only for eGFRs of 60 ml/minute/1.73 m2
Accuracy estimates were calculated only post correction
and alignment
UC High High Low
Shephard et al.,
201036
67% were dialysis patients; 33% were healthy volunteers
Only an eGFR < 60ml/minute/1.73 m2 cut-off point was
assessed
Low applicability concerns for post-calibration method
(uses standard MDRD factor, as per laboratory reference)
High High Low Low
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TABLE 47 QUADAS-2 applicability concerns (continued )
Study (author and
year of publication) Description
Applicability concerns
1 2 3 4
Study mentions StatSensor (not clear which model), but used an
adjustment to correct for bias
Results pre and post correction are reported
A similar adjustment could in theory be implemented in the
StatSensor Xpress-I, so potentially used on the NHS
Snaith et al., 201837 Phlebotomy outpatients
Characteristics may differ from outpatients scheduled for CT
without recent SCr measurement, but deemed unlikely to
significantly affect applicability
All relevant eGFR cut-off points reported
Study states device as only the StatSensor (unclear which
model) and did not use any offset
Only the raw results are available
Low Low Low Low
Snaith et al., 201938 CT outpatients without recent (within 3 months) eGFR
No significant concerns
Venous samples were used for POC testing
Low Low Low Low
IPD, individual participant data; UC, unclear.
a Conference abstract.
TABLE 48 Randomised controlled trials of PC-AKI prophylaxis: risk-of-bias assessment
Study
[author (trial
acronym) and
year of
publication]
Random
sequence
allocation
(selection
bias)
Allocation
concealment
(selection
bias)
Blinding of
participants and
personnel
(performance
bias)
Blinding of
outcome
assessment
(detection
bias)
Incomplete
outcome data
(attrition bias)
Selective
reporting
(reporting
bias)
Nijssen et al.,
(AMACING)
2017 and
2018104,105
+ + – + + +
Dussol et al.,
2006103
+ ? – + + ?
+, low risk of bias or level of applicability concerns; ?, unclear risk/concerns; –, high risk/concerns.
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Appendix 6 Systematic review of
cost-effectiveness studies
T able 49 lists the studies excluded from the review alongside reasons for exclusion.
TABLE 49 Summary of excluded studies
Study (author and year of publication) Reason for rejection
Adams et al., 1995126 Study does not include any comparators
No health outcomes were considered
Canadian Agency for Drugs and Technologies in Health, 2013127 Not a cost-effectiveness analysis
Lee-Lewandrowski et al., 201259 Cost analysis, no health outcomes were considered
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Appendix 7 Review of Shinkins et al.
(unpublished data)
TABLE 50 Confidential information has been removed
TABLE 51 Confidential information has been removed
TABLE 52 Confidential information has been removed
TABLE 53 Confidential information has been removed
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Appendix 8 Model inputs
TABLE 54 eGFR for all outpatients and those without a prior eGFR measurement (Harris data)
eGFR (ml/minute/1.73 m2) All outpatients, n (% of total)
Patients without a prior eGFR measurement,
n (% of total)
< 30 1 (0.12) 0 (0)
30–40 31 (3.8) 4 (3.85)
41–50 59 (7.23) 5 (4.81)
51–60 91 (11.15) 14 (13.46)
61–70 141 (17.28) 29 (27.88)
71–80 154 (18.87) 24 (23.08)
81–90 150 (18.38) 16 (15.38)
> 90 189 (23.16) 12 (11.54)
Total 816 104
TABLE 55 eGFR by reason for referral for all outpatients and those without a prior eGFR measurement (the Mid
Yorkshire Hospitals NHS Trust)
eGFR
( ml/minute/1.73 m2)
All outpatients, n (% of total)
Patients without a prior eGFR measurement,
n (% of total)
Reason for referral Reason for referral
Suspected cancer Urgent Routine Suspected cancer Urgent Routine
< 30 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0)
30–40 21 (5.4) 4 (2.6) 6 (2.2) 0 (0.0) 1 (6.7) 3 (3.9)
41–50 26 (6.7) 15 (9.6) 18 (6.7) 0 (0.0) 0 (0) 5 (6.5)
51–60 47 (12.0) 18 (11.5) 26 (9.6) 2 (16.7) 1 (6.7) 11 (14.3)
61–70 59 (15.1) 31 (19.9) 51 (18.9) 3 (25.0) 6 (40.0) 20 (26.0)
71–80 70 (17.9) 29 (18.6) 55 (20.4) 3 (25.0) 4 (26.7) 17 (22.1)
81–90 71 (18.2) 27 (17.3) 52 (19.3) 3 (25.0) 1 (6.7) 12 (15.6)
> 90 96 (24.6) 32 (20.5) 61 (22.6) 1 (8.3) 2 (13.3) 9 (11.7)
Total 390 (48) 156 (19) 270 (33) 12 (12) 15 (14) 77 (74)
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Risk factor screening questionnaires
TABLE 56 Risk factor screening questionnaires
Risk factors
Study (author and year of publication)
Azzouz et al.,
201414
Too et al., 201575 Snaith et al., 201938
Schreuder et al.,
2017116 Moos et al., 2014114
Original Modified Original/modified
RANZCR
RF
Model
A
Model
B
Model
1
Model
2
Model
3
Model
4
Renal disease ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Renal surgery ✗ ✗
Hypertension ✗ ✗ ✗ ✗ ✗ ✗ ✗
Gout ✗ ✗
Diabetes mellitus and/or
metformin
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Proteinuria ✗
Recent/current illness ✗
Cardiovascular disease ✗ ✗
Age (years)
> 75 ✗ ✗
> 60 ✗ ✗
Congestive heart failure ✗ ✗ ✗
Anaemia ✗
Use of diuretics ✗
Malignancy ✗
Multiple myeloma ✗
Waldenström’s
macroglobulinaemia
✗
RANZCR RF, The Royal Australian and New Zealand College of Radiologists guideline risk factors.
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TABLE 57 Diagnostic accuracy of risk factor screening: reference laboratory test
Questionnaire
Reference
test
eGFR
equation Population
eGFR (ml/minute/1.73 m2)
< 45 < 60
Sensitivity Specificity Sensitivity Specificity
Schreuder et al., 2017116
Model A Laboratory MDRD Non ICU and
non-emergency
patients scheduled
to i.v. contrast-
enhanced CT
100.0% 46.3% 88.0% 58.7%
Model B 100.0% 58.7% 76.1% 61.5%
Moos et al., 2014114
Model 1 Laboratory MDRD Non-ICU and
non-emergency
patients scheduled
to i.v. contrast-
enhanced CT
100.0% 18.8% 96.4% 20.1%
Model 2 100.0% 26.1% 96.4% 28.1%
Model 3 100.0% 38.8% 89.3% 41.1%
Model 4 100.0% 57.6% 76.8% 60.0%
Snaith et al., 201938
Originala Laboratory CKD-EPI Outpatients
attending for a
contrast-enhanced
CT
71.4% 48.6% 65.5% 50.8%
Modifieda 38.5% 67.6% 35.6% 68.0%
RANZCR RF 35.7% 83.9% 25.9% 85.1%
i.v., intravenous; RANZCR RF, The Royal Australian and New Zealand College of Radiologists guideline risk factors.
a The definition of acute illness differs across the original and the modified questionnaires, with the modified version
considering only patients as acutely ill if they were indicated for acute admission, diarrhoea and vomiting or had
recently commenced antibiotics, whereas the original questionnaire considered any acute illness.
TABLE 58 Post-contrast acute kidney injury events in patients undergoing contrast-enhanced CT angiography in an
outpatient setting
eGFR (ml/minute/1.73 m2)
Study (author and year of publication), % of total
Park et al.,
2016115
Nijssen et al.,
2017104
Nijssen et al.,
2018106
Kim et al.,
2010117
< 30 10.80% N/A 11.24% 12.07%
30–60 2.40% 2.65% N/A 1.30%
Number of patients (eGFR
< 30, 30–60 ml/minute/1.73 m2)
1666 (250, 1416) 603 (N/A, 603) 89 (89, N/A) 520 (58, 462)
N/A, not available.
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TABLE 59 Secondary outcomes results from Park et al.115
Secondary outcome
Propensity matching
Before After
HR (95% CI) p-value HR (95% CI) p-value
Death 1.05 (0.58 to 1.91) 0.86 0.90 (0.46 to 1.76) 0.75
Within 6 months 0.80 (0.31 to 2.07) 0.64 0.81 (0.29 to 2.31) 0.70
After 6 months 1.15 (0.53 to 2.49) 0.72 0.99 (0.41 to 2.40) 0.98
eGFR
≥ 30 ml/minute/1.73 m2 1.20 (0.53 to 2.72) 0.66 0.93 (0.35 to 2.51) 0.89
< 30 ml/minute/1.73 m2 0.87 (0.35 to 2.15) 0.76 0.79 (0.29 to 2.13) 0.64
Initiation of RRT 2.75 (1.52 to 4.98) 0.001 3.05 (1.43 to 6.47) 0.003
Within 6 months 4.54 (1.93 to 10.71) 0.001 8.61 (2.28 to 32.61) 0.002
After 6 months 1.73 (0.62 to 4.81) 0.30 1.15 (0.34 to 3.86) 0.83
eGFR
≥ 30 ml/minute/1.73 m2 4.47 (1.33 to 15.07) 0.02 5.23 (0.57 to 47.64) 0.14
< 30 ml/minute/1.73 m2 2.58 (1.34 to 4.97) 0.004 2.65 (1.15 to 6.15) 0.02
Note
The HRs comparing PC-AKI with no PC-AKI are adjusted for age, sex, total contrast volume used in the CT scan, serum
albumin, baseline eGFR and the history of diabetes mellitus.
TABLE 60 Consumable costs per test and time to test for each device
Device Testing material costed
Per test
Cost Time (minutes)
Devices included in the model
Abbott Point of Care
i-STAT Alinity
Creatinine cartridge £4.75 2
Nova Biomedical
StatSensor
Creatinine test strip £3.95 0.5
Radiometer Ltd
ABL800 FLEX
Per-test proportion of all testing materials £2.88 1
Other devices
Abaxis, Inc.
Piccolo Xpress
Kidney check rotor £12.00 12
Fujifilm Corporation
DRI-CHEM NX 500
DRI-CHEM creatinine slide; Fujifilm plasma filter £3.73 1
Radiometer Ltd
ABL90 FLEX PLUS
Per-test proportion of all testing materials £2.71 1
Siemens Healthineers AG epoc Test cartridge £5.75 1
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TABLE 61 Quality control costs for each device
Device
Cost per quality control check
Time to prepare QC
materials (minutes)
Frequency of
quality control
Excluding test-based
consumables
Including test-based
consumables
Devices included in model
Abbott Point of Care
i-STAT Alinity
£2.05 £6.80 45 minutes to bring to ambient
temperature, 1–2 minutes to
prepare materials
Every week/
every 25 tests
Nova Biomedical
StatSensor
£0.20 £4.15 Not known Every 24 hours
Radiometer Ltd
ABL800 FLEX
£5.01 £5.01 Automatic – no time to
prepare materials
Every 24 hours
Other devices
Abaxis, Inc.
Piccolo Xpress
£19.20 £31.20 30 minutes to bring to
ambient temperature
Every 30 days/
every 10 tests
Fujifilm Corporation
DRI-CHEM NX 500
£11.97 £15.70 30 minutes to bring to
ambient temperature,
30 minutes to mix
Every 30 days
Radiometer Ltd
ABL90 FLEX PLUS
£3.76 £3.76 Automatic – no time to
prepare materials
Every 24 hours
Siemens Healthineers
AG epoc
£28 £33.75 60 minutes to bring to
ambient temperature
Every 50 tests
QC, quality control.
TABLE 62 Annual maintenance costs
Device Annual maintenance cost Guarantee period
Devices included in model
Abbott Point of Care
i-STAT Alinity
£850 1 year
Nova Biomedical
StatSensor
£850 1 year
Radiometer Ltd
ABL800 FLEX
£4685 1 year
Other devices
Abaxis, Inc.
Piccolo Xpress
£1675 1 year
Fujifilm Corporation
DRI-CHEM NX 500
£750 1 year
Radiometer Ltd
ABL90 FLEX PLUS
£1315 1 year
Siemens Healthineers AG epoc £816 1 year
DOI: 10.3310/hta24390 Health Technology Assessment 2020 Vol. 24 No. 39
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
207
TABLE 63 Total device cost per POC test
Device
Capital
cost
Annual
servicing Consumables
Quality control
materials (including
test consumables)
Total device cost per
test (based on a
throughput of 92.6
patients per month)
Devices included in model
Abbott Point of Care
i-STAT Alinity
£0.92 £0.77 £4.75 £0.27 £6.71
Nova Biomedical
StatSensor
£0.71 £0.77 £3.95 £1.36 £6.79
Radiometer Ltd
ABL800 FLEX
£5.33 £4.22 £2.88 £1.65 £14.07
Other devices
Abaxis, Inc.
Piccolo Xpress
£1.56 £1.51 £12.00 £3.12 £18.19
Fujifilm Corporation
DRI-CHEM NX 500
£1.21 £0.68 £3.73 £0.17 £5.78
Radiometer Ltd
ABL90 FLEX PLUS
£2.13 £1.18 £2.71 £1.24 £7.27
Siemens Healthineers
AG epoc
£0.89 £0.73 £5.75 £1.58 £8.95
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TABLE 64 Staff time and costs for testing and quality control checks
Device
Pre-testing
staff time
(minutes)
Time to use
the device
to analyse
a sample
(minutes)
Staff cost
per test
conducted
Time for
quality control
(minutes)
Total quality
control staff
cost
Total staff
cost per test
conducted
(including
quality
control)a
Devices included in model
Abbott Point of Care
i-STAT Alinity
3 2 £2.08 3.5 £1.46 £2.14
Nova Biomedical
StatSensor
3 0.5 £1.46 2 £0.83 £1.73
Radiometer Ltd
ABL800 FLEX
3 1 £1.66 0 £0.00 £1.66
Other devices
Abaxis, Inc.
Piccolo Xpress
3 12 £6.25 13.5 £5.63 £6.81
Fujifilm Corporation
DRI-CHEM NX 500
3 1 £1.67 2.5 £1.04 £1.68
Radiometer Ltd
ABL90 FLEX PLUS
3 1 £1.49 0 £0.00 £1.49
Siemens Healthineers
AG epoc
3 1 £1.67 2.5 £1.04 £1.71
a Based on a throughput of 92.6 patients per month.
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TABLE 65 Unit costs related to RRT
Cost
category Resource use Units Source
Parameter,
unit cost Source/assumptions Cost
RRT Haemodialysis
sessions
Thrice-weekly
for 3 months
NICE
CG169108
£271.06 per
session
NHS Reference Costs 2017/18111
HRG currency code LE01 A,
haemodialysis for acute kidney
injury, ≥ 19 years111
£9758
CG, clinical guideline; HRG, Healthcare Resource Group.
TABLE 66 Model parameters (base-case analysis)
Parameter Value Source Probabilistic model setup
Population characteristics
Probability of eGFR (ml/
minute/1.73 m2)
< 30:a 0.006 Gamma distribution fitted to
the Mid Yorkshire Hospitals
NHS Trust data
NA
30–44:a 0.063
45–59:a 0.154
≥ 60:a 0.777
Age and male proportion 65 years, 51.7% Snaith et al., 201938 NA
% missing an eGFR 34% Cope et al., 201713 NA
Patients per site 272 monthly Harris all outpatient data NA
Diagnostic accuracy
Laboratory test Sensitivity: 100%
Specificity: 100%
Assumption NA
i-STAT Sensitivity: 84.1%
Specificity: 98.9%
Evidence synthesis of POC
diagnostic accuracy – main
analysis
Model draws from 1000
simulated values from the
meta-analysis posterior
distribution
ABL Sensitivity: 86.1%
Specificity: 99.2%
StatSensor Sensitivity: 73.9%
Specificity: 99.1%
Risk factor questionnaire Sensitivity: 100%
Specificity: 65.2%
Too et al., 201575 Independent beta
distributions fitted to the
diagnostic accuracy 2 × 2
tables
Sensitivity: α = 10.01;
β = 0.01 (continuity
correction of 0.01)
Specificity: α= 470; β = 881
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TABLE 66 Model parameters (base-case analysis) (continued )
Parameter Value Source Probabilistic model setup
Probability of AKI with contrast conditional on an
eGFR
< 30 ml/minute/1.73 m2 and
no i.v. hydration
11.1% Park et al., 2016115
Ahmed et al., 2018102
Log-normal distribution
fitted to an OR of PC-AKI
with i.v. hydration
[14]= 0.97; ln(SE) = 0.33
< 30 ml/minute/1.73 m2 and
i.v. hydration
10.8% Park et al., 2016115 Beta distribution: α= 27;
β= 223
≥ 30ml/minute/1.73 m2
with no i.v. hydration
2.4% Assumption Beta distribution: α= 34;
β= 1385
≥ 30 ml/minute/1.73 m2
with i.v. hydration
2.4% Park et al., 2016115 Beta distribution: α= 34;
β= 1385
Probability of RRT (no PC-AKI) 1.4% Park et al., 2016115 Beta distribution: α= 22;
β= 1583
Probability of RRT (PC-AKI) 11.1% Park et al., 2016115 Log-normal distribution
fitted to a HR of RRT given
PC-AKI = 8.61; ln(SE) = 0.679
Proportion of patients alive at
6 months post imaging
94.5% Park et al., 2016115 Independent beta
distributions fitted to
proportion of alive patients:
l No PC-AKI:
α= 1518; β = 87
l PC-AKI: α = 61; β = 56
HRQoL-adjusted life
expectancy
9.80 QALYs Calculated from ONS
mortality data,118 and Ara and
Brazier’s119 general population
utility equation
NA
QALY loss from RRT –0.0275 Wyld et al.120 and assuming
3 months of RRT
Gamma distribution fitted to
utility decrement from
RRT = 0.11; SE = 0.02
QALY loss from anxiety due to
delays
0 Assumption NA
Costs
Laboratory test £3.31 NHS Reference Costs 2017/18124 NA
Risk factor screening £1.11 Ledermann et al., 2010;77 and
NHS Reference Costs 2017/18124
NA
i-STAT without RF screening £8.85 See Point-of-care device costs NA
ABL800 FLEX without RF
screening
£15.73 See Point-of-care device costs NA
StatSensor without RF
screening
£8.52 See Point-of-care device costs NA
i-STAT with RF screening £11.96 See Point-of-care device costs NA
ABL800 FLEX with RF
screening
£36.36 See Point-of-care device costs NA
StatSensor with RF screening £14.25 See Point-of-care device costs NA
Contrast-enhanced CT scan £111.65 NHS Reference Costs 2017/18124 NA
continued
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TABLE 66 Model parameters (base-case analysis) (continued )
Parameter Value Source Probabilistic model setup
CT scan rebooking Confidential
information has
been removed
Shinkins et al. (in submission)b NA
CT scan cancellation £87.92 NHS Reference Costs 2017/18,124
assumed to be the cost of an
unenhanced CT scan
NA
i.v. hydration £340.89 NHS Reference Costs 2017/18124 NA
Adverse events from i.v.
hydration
£32.76 Nijssen et al., 2017;104 and NHS
Reference Costs 2017/18124
NA
Follow-up if test was positivea £186.49 NHS Reference Costs 2017/18124 NA
RRT £9758 NHS Reference Costs 2017/18124
and assuming thrice weekly
sessions for 3 months
NA
Mediating action if positivea
i.v. hydration and contrast-
enhanced CT scan
100% of patients Assumption NA
Unenhanced CT scan 0% of patients Assumption NA
MRI 0% of patients Assumption NA
Proportion of rebooked and
cancelled scans if test was
positivea
100% Assumption NA
i.v., intravenous; NA, not applicable (parameter set up deterministically); ONS, Office for National Statistics; RF, risk factor;
SE, standard error.
a According to the last test in the testing sequence.
b Shinkins et al. A streamlined pathway for iodinated intravenous contrast administration in computed tomography:
a comparative evaluation. 2020; in submission.
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Appendix 9 Supplementary cost-
effectiveness review
G iven that the initial scoping searches conducted while drafting the study protocol indicate that theexisting cost-effectiveness literature addressing the relevant decision problem is likely to be limited,
one targeted search was also conducted to identify further evidence. The aim of this search was to identify
cost-effectiveness studies evaluating the treatment and management of AKI. The additional review should
mitigate some of the potential limitations of the existing cost-effectiveness literature, as one of the key
conceptual issues concerns the nature of the linked evidence modelling required to estimate the
occurrence of PC-AKI and its associated consequences (e.g. CKD, end-stage renal disease and death).
Methods
Searches
Searches were undertaken to identify cost-effectiveness studies evaluating the treatment and management
of AKI. A search strategy was developed in MEDLINE (via Ovid) consisting of terms for AKI combined with
a search strategy developed by the Canadian Agency for Drugs and Technologies in Health (CADTH) to
limit retrieval to cost-effectiveness studies.128 The search was limited to studies published from 2012
onwards in any language. The MEDLINE strategy was adapted for use in all other databases searched.
The following databases were searched in January 2019: MEDLINE ALL (including Epub Ahead of
Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE), EconLit,
EMBASE, NHS EED, Research Papers in Economics (RePEc) and the Science Citation Index.
Database
Ovid MEDLINE(R) ALL.
Date range searched: 1946 to 11 January 2019.
Date searched: 14 January 2019.
Records retrieved: 2972 retrieved, of which 2157 remained after deduplication.
Search strategy
1. exp Acute Kidney Injury/ (42,239)
2. (acute adj2 (renal or kidney$ or nephr$) adj2 (fail$ or injur$ or insufficien$)).ti,ab. (42,016)
3. ((acute or renal or kidney$ or nephr$) adj2 tubular necrosis).ti,ab. (3660)
4. or/1-3 (60,629)
5. (contrast adj3 (kidney$ or renal or nephr$) adj3 (injur$ or fail$ or insufficien$ or tubular
necrosis)).ti,ab. (1049)
6. (contrast adj3 (AKI or nephropath$ or nephrotoxic$)).ti,ab. (2895)
7. ((radiocontrast or radio-contrast) adj3 (kidney$ or renal or nephr$) adj3 (injur$ or fail$ or
insufficien$ or tubular necrosis)).ti,ab. (69)
8. ((radiocontrast or radio-contrast) adj3 (AKI or nephropath$ or nephrotoxic$)).ti,ab. (299)
9. ((postcontrast or post-contrast) adj3 (kidney$ or renal or nephr$) adj3 (injur$ or fail$ or insufficien$
or tubular necrosis)).ti,ab. (19)
10. ((postcontrast or post-contrast) adj3 (AKI or nephropath$ or nephrotoxic$)).ti,ab. (13)
11. (CI-AKI or CIAKI or PC-AKI or PCAKI).ti,ab. (406)
12. or/5-11 (3991)
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13. 4 or 12 (62,842)
14. economics/ (26,988)
15. exp “costs and cost analysis”/ (221,067)
16. economics, dental/ (1901)
17. exp “economics, hospital”/ (23,279)
18. economics, medical/ (8991)
19. economics, nursing/ (3986)
20. economics, pharmaceutical/ (2833)
21. exp “Fees and Charges”/ (29,548)
22. exp Budgets/ (13,436)
23. budget*.ti,ab,kf. (26,878)
24. (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic*
or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or
finance or finances or financed).ti,kf. (207,844)
25. (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic*
or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or
finance or finances or financed).ab. /freq=2 (255,303)
26. (cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab,
kf. (142,936)
27. (value adj2 (money or monetary)).ti,ab,kf. (2107)
28. exp models, economic/ (13,754)
29. economic model*.ab,kf. (2928)
30. markov chains/ (13,149)
31. markov.ti,ab,kf. (19,884)
32. monte carlo method/ (26,253)
33. monte carlo.ti,ab,kf. (44,643)
34. exp Decision Theory/ (11,296)
35. (decision* adj2 (tree* or analy* or model*)).ti,ab,kf. (20,435)
36. or/14-35 (664,050)
37. 13 and 36 (769)
38. exp animals/ not humans/ (4,535,562)
39. 37 not 38 (763)
40. limit 39 to yr=“2012 -Current” (425).
Study selection
Studies using decision models to evaluate the cost-effectiveness of AKI management and published
from 2012 until 2019 were considered for inclusion. Only full economic evaluations that compared two
or more options and considered both costs and consequences (i.e. cost-minimisation, cost-effectiveness,
cost–utility and cost–benefit analyses) were considered.
Two researchers (AD and JA) independently screened the titles and abstracts of all reports identified
by the bibliographic searches, and full-text papers were subsequently obtained for assessment and
screened by at least two researchers. Disagreements were resolved by consensus.
Results
The initial search of economic databases identified a total of 2972 records, of which 2157 remained after
deduplication. Eight titles108,110,121,129–134 were identified as potentially relevant based on their titles and/or
abstracts. The full-text articles of these records were assessed for eligibility. Four studies108,110,121,129,130 were
found to meet the selection criteria and were included in the review. These studies were not subject to
a formal assessment, but were used to assist in the overall development of the new analytical model.
Table 67 shows the results of the searches, and Table 68 lists excluded studies alongside reasons for
exclusion. The studies identified in the review are summarised in Table 69.
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TABLE 67 Results of the AKI models search
Database
Number of records
Retrieved before
deduplication After deduplication
MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
425 420
EMBASE (via Ovid) 1649 1242
EconLit (via Ovid) 3 2
NHS EED (via CRD databases) 6 0
Science Citation Index (via Clarivate Analytics) 877 486
RePEc 12 7
Total in EndNote 2972 2157
TABLE 68 Summary of excluded studies
Study (author and year of publication) Reason for rejection
De Smedt et al., 2012131 Area under the curve model
Ethgen et al., 2015132 Does not compare patients with and patients without AKI
Kerr et al., 2014133 Not a comparison of alternative interventions
Petrovic et al., 2015134 Uses the RIFLE criteria to define AKI and had a paediatric population
RIFLE, risk, injury, failure, loss and end-stage renal disease.
TABLE 69 Studies identified in the review of AKI models
Study
(author, year
of publication
and country) Interventions
Patient
population
Time
horizon Model type Health states Key results
Chicaíza-
Becerra et al.,
2012,129
Colombia
Iso- and
low-osmolality
contrast media
Outpatients at
high risk of
CI-AKI
Lifetime Decision tree l Treatment + no
AKI+ death/
l No death;
treatment +
AKI+
l Dialysis/no
dialysis+
death/
l No death
Other alternatives
dominated by
iopamidol and
iodixanol
Iodixanol vs.
iopamidol=US$
14,660/LYG
CG169,108,110
UK
Prophylactic
hydration to
prevent CI-AKI
Patients at
high risk of
CI-AKI
Lifetime Markov model CKD stages 3–4,
CKD stage 5,
CI-AKI, death
NAC+ 0.9%
sodium chloride –
NMB= £47,957
Sodium
bicarbonate –
NMB = £47,585
At a threshold of
£20,000 per
additional QALY
continued
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Two studies quantify the impact of the interventions under comparison on costs and outcomes by
modelling CKD progression after AKI108,110,121 with a Markov model structure. One study130 also uses
a model Markov structure to compare cost-effectiveness between alternative contrast media, but
does not characterise CKD progression and considers only progression to myocardial infarction.
One study129 follows a more simplified structure, whereby a decision tree structure is used to
quantify the pay-offs in terms of costs and outcomes of dialysis and death.
The models from the National Clinical Guideline Centre108,110 and Chicaíza-Becerra et al.129 were considered
the most relevant examples of how costs and outcomes associated with AKI can be quantified, as they
represent the two extremes of model structure complexity in the context of CI-AKI. The studies were
examined with the aim of identifying important structural assumptions and parameter estimates, and
highlighting key areas of uncertainty. These studies are summarised and highlight the elements potentially
relevant to inform the conceptualisation and development of the new decision model.
TABLE 69 Studies identified in the review of AKI models (continued )
Study
(author, year
of publication
and country) Interventions
Patient
population
Time
horizon Model type Health states Key results
Hall et al.,
2018,121 UK
NEPHROCHECK®
(bioMérieux,
Marcy-l’Étoile,
France), cystatin C
in urine, plasma
and serum; and
NGAL in urine,
plasma and serum
ICU patients Lifetime Decision
tree+ two-
period decision
model
Decision tree:
l No AKI
l Test+ FP
l Test+FN
l Test+ TP
l Test+ TN
l Pre-admission
AKI
Hospitalisation
period: normal
kidney function in
ICU, four ICU AKI
stages:
1. Hospital ward
2. Hospital
ward + RRT
3. Discharge
4. Discharge +
RRT
Follow-up period:
outpatient
follow-up, CKD
stages 1–4, ESRD
no dialysis, ESRD+
dialysis, ESRD
transplant and
death
Cystatin C
(urine and plasma)
and NGAL
(urine and plasma)
dominated
by cystatin C
(serum)
ICERs for cystatin
C (serum), NGAL
(serum) and
NEPHROCHECK
were £11,476,
£25,492 and
£12,855,101 per
additional QALY,
respectively
Iannazzo
et al., 2014,130
Italy
Iodixanol vs. low-
osmolar contrast
media
Patients with
i.v. contrast
media CT
Lifetime Markov model AKI free, AKI,
myocardial
infarction and
death
Iodixanol
dominated low-
osmolar contrast
media
CG, clinical guideline; ESRD, end-stage renal disease; ICU, intensive care unit; i.v., intravenous; LYG, life-years gained;
NAC, N-acetylcysteine; NGAL, neutrophil gelatinase-associated lipocalin.
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
216
Review of Clinical Guideline number 169
The National Clinical Guideline Centre developed a Markov model to assess the cost-effectiveness
of prophylactic hydration strategies for the prevention of CI- AKI in patients at stage 3–4 CKD
(with and without diabetes) who need a CT scan.108,110 The analysis followed the perspective of the
NHS and PSS. Costs were expressed as Great British pounds (2011/12) and health outcomes as
QALYs. Costs and outcomes are discounted at an annual rate of 3.5%.
Model structure
The model considers a lifetime horizon and 3-month cycles. The structure of the model is depicted
elsewhere.110
The model is composed of four mutually exclusive health states: stage 3–4 CKD, stage 5 CKD, PC-AKI
(CI-AKI in the original text) and death. Patients enter the model through the stage 3–4 CKD state and
undergo a CT scan, and can then transition to PC-AKI, remain on the initial state or transition to stage 5
CKD. Patients who transition to PC-AKI will remain on that state for one cycle only (i.e. 3 months), and
either return to stage 3–4 CKD or progress to stage 5 CKD. After the first cycle, a continuous risk of
PC-AKI from repeated scans is assumed for patients in the stage 3–4 CKD state. Patients in stage 5 CKD
can only remain in the state or die. The model assumes no regression from stage 5 CKD to less severe
CKD states, and no further PC-AKI after transition to stage 5 CKD. Patients can transition to death from
any other state in the model.
Baseline transition probabilities and treatment effects
The population consists of patients with known stage 3–4 CKD (average age 70 years) presenting for a
CT scan in an unspecified setting. The data sources used to inform baseline transition probabilities to the
PC-AKI state, treatment effects from prophylactic hydration and PC-AKI mortality were drawn mostly
from studies in cardiovascular patients receiving contrast agents. The severity of AKI was assumed to
affect mortality rates only for the PC-AKI state. AKI stage-specific mortality rates were obtained from a
large observational study135 in coronary angiography patients. The rates were weighted by the relative
proportion of patients at each AKI severity stage following the cardiovascular intervention in the same
study to estimate the overall probability of death following PC-AKI. The baseline risk of PC-AKI was
informed by the incidence of AKI in the renal insufficiency subgroup prophylactically intravenously
hydrated with the 0.9% sodium chloride treatment from a trial comparing two hydration strategies
in patients undergoing coronary angiography.136 The probability of a repeat scan was derived from
0.9% SC
Oral fluids SB + 0.9% SC
0.45% SC SB
NAC +
0.45% SC
NAC + SB
NAC +
0.9% SC
2.67 0.20
0.782.78
1.72 1.03
0.8
FIGURE 16 Comparisons of relative treatment effects available from the meta-analysis of trials (CG169). CG, clinical
guideline; NAC, N-acetylcysteine; SB, sodium bicarbonate; SC, sodium chloride.
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the probability of repeat PCI in a trial of patients with coronary artery disease,137 and applied to the
baseline risk of PC-AKI to calculate the risk of PC-AKI from the second cycle in the model onwards.
The age-dependent probability of disease progression from stage 3–4 to stage 5 CKD was derived
from a retrospective longitudinal study of stage 3 CKD patients.138 The probability of death on stage
3–4 CKD was estimated by applying age- and sex-dependent standardised mortality rates (SMRs) to
UK general population life tables, and converting the annual rates to 3-month probabilities. The model
implicitly assumed the same rate of progression to stage 5 CKD and mortality for both stage 3 and
stage 4 CKD patients, despite the latter having more severe renal function impairment.
Mortality on stage 5 CKD was estimated by applying age- and sex-dependent SMRs from a prospective
cohort study in an end-stage renal disease population to UK general population life tables.
Baseline treatment properties in the model are summarised in Table 70, along with the sources of
evidence.
The treatment effect of each alternative prophylactic IVH strategy was estimated as a relative risk of
PC-AKI using a mix of direct and indirect comparisons, and applied to the baseline risk of PC-AKI for
the reference hydration strategy (i.e. 0.9% sodium chloride). Figure 16 illustrates the treatment effects
(i.e. RRs) estimated in comparison with 0.9% sodium chloride. Adverse events from prophylaxis were
not considered in the model.
Health-related quality of life
Health state utility was informed by a literature review conducted by the authors. Estimates from a
Japanese139 study reporting EQ-5D utility scores by CKD stage (i.e. 1–5) were applied to the UK
general population utility estimate for the 65–74 years age bracket140 to yield health state utility
estimates. The PC-AKI health state was estimated by multiplying the utility estimate for renal failure,
from a UK-based catalogue of EQ-5D index scores,141 by the same general UK population utility
estimate used to adjust the CKD states’ estimates.
TABLE 70 Baseline transition probabilities and treatment effects in the model
Transition Probability Source
Stage 3–4 to PC-AKI (first cycle) 0.0217 Mueller et al., 2002136
Stage 3–4 (second cycle and subsequent cycles) 0.0007 Mueller et al., 2002136
Serruys et al., 2009137
PC-AKI stage 1 to stage 5 CKD 0.015 James et al., 2011135
Applied to 83% of PC-AKI patients
PC-AKI stage 2–3 to stage 5 CKD 0.109 James et al., 2011135
Applied to 17% of PC-AKI patients
PC-AKI to stage 5 CKD 0.031 Calculated
CKD stage 3–4 to CKD stage 5 (mean age dependent) 0.001 Eriksen and Ingebretsen, 2006138
PC-AKI stage 1 to death 0.136 James et al., 2011135
Applied to 83% of PC-AKI patients
PC-AKI stage 2–3 to death 0.378 James et al., 2011135
Applied to 17% of PC-AKI patients
PC-AKI to death 0.182 Calculated
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Resource use and costs
The resource use and costs included in the model were the ones associated with the acquisition and
administration of the hydration strategies, and health state costs.
The acquisition unit costs for the hydration strategies were sourced from published national sources,
manufacturers’ price lists, and personal communications with the Commercial Medicines Unit of the
UK Department of Health and Social Care. The resource use associated with infusion (and dose) was
based on the hydration regimes that constituted each strategy, rather than the regimes on the trials
informing treatment effectiveness. It was assumed that only infusions lasting > 8 hours would require
hospitalisation. No administration costs were included for hydration strategies administered over a
shorter period. The unit cost for infusions requiring hospitalisation was that of a coronary angiography
excess bed-day from the National Schedule of Reference Costs 2011–2012.142
Health state unit costs were sourced from national published sources: National Schedule of Reference
Costs 2011–2012,142 Unit Costs of Health and Social Care 2012,143 the British National Formulary (BNF)
62144 and other NICE guidance. Resource use was based on assumptions informed by expert opinion.
Tables 71–74 summarise health states resource use and costs.
TABLE 71 Post-contrast acute kidney injury state costs and resource use
Category
Resource
use Source/details
Unit
cost Source
Cost per
cycle
PC-AKI 1 Event in the
model
£2013 Weighted average of AKI-related HRG codes
(LA07C-G) from the National Schedule of Reference
Costs 2011–2012142
£2013
TABLE 72 Stage 3–4 CKD state costs and resource use
Category Resource use Source/details
Unit
cost Source
Cost per
cycle
Nephrologist
appointment
1 Per cycle, assumption £157 National Schedule
of Reference Costs
2011–2012142
£157
eGFR measurement
Biochemistry 1 Per cycle, assumption £1.26 National Schedule
of Reference Costs
2011–2012142
£1.26
Phlebotomist 5 minutes Per cycle, assumption £3.42 Unit Costs of
Health and Social
Care 2012,
2012143
£3.42
Drugs
Diuretics 40 mg/day Assumed that 26% of patients
were in stage 4 and, of these
patients, around 60% would be
treated with furosemide
£0.26 BNF144 £4
Epoetin alpha 1788 units/week Applied to 9% of those patients
who are assumed to require
treatment for anaemia. The
dose and proportion of patients
were informed by previous
NICE guidance
£0.0051 BNF144 £11
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TABLE 73 Stage 5 CKD state costs and resource use for RRT patients
Cycle Category Resource use Source/details Unit cost Source
Cost per
cycle
First cycle
Nephrologist
appointment
2 Per cycle, assumption £157 National Schedule
of Reference Costs
2011–2012142
£374
eGFR
measurement
12 See Table 72 £4.67 See Table 72 £56
Epoetin alpha 1.788 units/week Applied to 33% of
patients who are
assumed to require
treatment for anaemia.
The dose and proportion
of patients informed by
previous NICE guidance
£0.01 BNF144 £39
Access procedure 1 Assumption £1323 Pooled average of
HRG codes for
RRT access
procedures from
the National
Schedule of
Reference Costs
2011–2012142
£1323
RRT 3 haemodialysis
sessions/week
7 peritoneal
dialysis sessions/
week
Assumption
Distribution of patients
on peritoneal dialysis
and haemodialysis (21%
and 79% of patients on
RRT, respectively) and
frequency of sessions
were informed by the
Renal Registry report
£157.76
haemodialysis
£54.70
peritoneal
dialysis
Activity-weighted
average of HRG
codes for RRT
procedures from
the National
Schedule of
Reference Costs
2011–2012142
£5460
After first cycle
Nephrologist
appointment
2 Per cycle, assumption £157 National Schedule
of Reference Costs
2011–2012142
£314
eGFR
measurement
12 See Table 72 £4.67 See Table 72 £56
Epoetin α 1.788 units/week Applied to 33% of
patients who are
assumed to require
treatment for anaemia.
The dose and proportion
of patients informed by
NICE CG114145
£0.01 BNF62144 £39
Access procedure 0.15 Assumption £1323 Pooled average of
HRG codes for
RRT access
procedures from
the National
Schedule of
Reference Costs
2011–2012142
£199
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The PC-AKI health state costs were estimated by pooling the average costs of all AKI-related HRG
codes in the NHS reference costs weighted by their respective activity. The cost per cycle was £2013.
Costs in stage 3–4 CKD include specialist appointments, eGFR measurements, anaemia management
with epoetin alpha and diuretics. The cost per cycle on this state was £176.
Patients in stage 5 CKD will incur costs associated with either RRT or conservative management
(management without RRT). It was assumed that 90% of patients received RRT and 10% received
conservative management. For patients on RRT the costs in stage 5 CKD differed for cycle 1 (£7252)
and for cycle 2 onwards (£6284 per cycle), with higher resource use intensity in cycle 1 as a result of
the need to perform access procedures for RRT before starting treatment. Access procedures are then
TABLE 73 Stage 5 CKD state costs and resource use for RRT patients (continued )
Cycle Category Resource use Source/details Unit cost Source
Cost per
cycle
RRT 3-weekly
haemodialysis
sessions or
7-weekly
peritoneal
dialysis sessions
Assumption
Distribution of patients
on peritoneal dialysis
and haemodialysis (21%
and 79% of patients on
RRT, respectively) and
frequency of sessions
were informed by the
Renal Registry report
£157.76 for
haemodialysis
£54.70 for
peritoneal
dialysis
Activity-weighted
average of HRG
codes for RRT
procedures from
the National
Schedule of
Reference Costs
2011–2012142
£5460
CG, clinical guideline.
TABLE 74 Stage 5 CKD state costs and resource use for conservative management patients
Category Resource use Source/details
Unit
cost Source
Cost per
cycle
Nephrologist
appointment
2 Per cycle, assumption £157 National
Schedule of
Reference Costs
2011–2012142
£374
Specialist nurse
Telephone
call
12 Per cycle, assumption £5.30 Unit Costs of
Health and Social
Care 2012143
£64
Home visit 3 Per cycle, assumption £22.08 Unit Costs of
Health and Social
Care 2012143
£66
eGFR
measurement
12 See Table 72 £4.67 See Table 72 £56
Drugs
Epoetin
alpha
1.788 units/week Applied to 33% of patients who are
assumed to require treatment for
anaemia. The dose and the proportion
of patients were informed by NICE
CG114145
£0.01 BNF144 £39
Diuretics 80 mg/day Assumed that 90% of patients would
be treated with furosemide
£0.26 BNF144 £43
CG, clinical guideline.
DOI: 10.3310/hta24390 Health Technology Assessment 2020 Vol. 24 No. 39
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
221
assumed to be required once every 1–5 years. Patients on conservative management for CKD stage 5
also incur the costs of diuretic drugs and additional check-ups. The cost per cycle of conservative
management was £642. Considering all patients (RRT and conservative management), the cost on
the first cycle was £6585 and £5512 per subsequent cycle.
Uncertainty
Joint parameter uncertainty was considered in the model by performing probabilistic sensitivity analysis.
Probabilistic distributions were attributed to most parameters in the model, and random draws of these
distributions were sampled over 1000 model simulations to yield probabilistic cost-effectiveness estimates.
The authors conducted an extensive number of scenario analyses testing assumptions around resource
use associated with IVH, costs of PC-AKI, age in the model, baseline risk of PC-AKI, probability of
repeat scans, treatment effect of hydration, health state utilities and discount rates.
Findings
Under base-case assumptions, the cost-effective strategy to prevent PC-AKI in patients with stage 3–4 CKD
undergoing CTwas considered to be IVH with 0.9% sodium chloride in addition to N-acetylcysteine (NAC),
with a NMB of £47,957 at a threshold of £20,000 per additional QALY. This strategy also had the highest
probability of cost-effectiveness (43%) at the same cost-effectiveness threshold. Sodium bicarbonate with
0.9% sodium chloride was the most effective strategy, generating 0.006 additional QALYs on average
compared with 0.9% sodium chloride in addition to NAC. However, the additional QALYs did not offset the
incremental costs when comparing these two strategies (£370).
The results were robust to the majority of the scenario analysis undertaken. The key drivers of the
model were identified as the cost of admission for the IVH regimens requiring it and the treatment
effectiveness estimates.
When it was assumed that all patients were inpatients and no additional costs of hospital admission
were considered for IVH strategies administered over periods longer than 8 hours, the cost-effective
strategy became sodium bicarbonate with 0.9% sodium chloride, with a NMB of £47,738 and 90%
probability of cost-effectiveness at £20,000 per QALY gained. When it was assumed that strategies
containing either 0.9% sodium chloride or sodium bicarbonate patients required a hospital admission,
sodium bicarbonate with 0.9% sodium chloride was also the cost-effective strategy with a NMB of
£47,304 and 70% probability of cost-effectiveness at £20,000 per QALY gained.
Applying the treatment effect for NAC plus sodium bicarbonate versus 0.9% sodium chloride estimated
from an alternative indirect link in the treatment effectiveness meta-analysis (RR = 0.63 instead of
1.03), the cost-effective strategy was NAC plus sodium bicarbonate with a NMB of £47,670 and 48%
probability of cost-effectiveness at £20,000 per QALY gained.
Limitations of the model in the context of our study
The model structure does not consider patients with normal kidney function and at earlier stages of
renal disease (i.e. CKD stages 1 and 2), as these were not part of the study population. Therefore, the
model would require substantial structural adaptations to include these patients.
The parameter estimates informed by evidence generated in the context of PCI and coronary
angiography are unlikely to be directly generalisable to the study population, as the underlying risk of
CI-AKI, severity of AKI and associated mortality are likely to be much higher for patients who:
l undergo intra-arterial contrast administration
l have more cardiovascular-related comorbidities that are also risk factors for AKI (e.g. diabetes
mellitus) than would be expected to be observed in an outpatient population referred for
intravenous contrast-enhanced CT.
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Review of the Chicaíza-Becerra et al.129 publication
The authors used a decision tree model to evaluate the cost-effectiveness of iso- and low-osmolality
contrast media for outpatients at high risk of PC-AKI from the perspective of the Colombian NHS.
Costs were expressed as US dollars, 2009 price year, and health outcomes as life-years gained. The
base-case results are presented for undiscounted costs and outcomes, as well as applying a 3% annual
rate on both.
Model structure
The decision tree considers a lifetime horizon and is illustrated in Chicaíza-Becerra et al.129
All patients undergo a procedure (not described) that requires administration of one of four possible
contrast media alternatives: iohexol, iodixanol, iopamidol or other low-osmolality contrast media. The
structure of the decision tree is the same for each of the four contrast agent options. The first chance
node divides patients according to their probability of having PC-AKI (CIN in the original paper) after
contrast administration. Patients who do not have PC-AKI can die or survive. Patients without PC-AKI
may have to undergo dialysis or not. All patients who suffer a PC-AKI event have a PC-AKI-specific
mortality risk at the last chance node. Surviving patients have the full life expectancy of the Colombian
general population (i.e. 74 years).
Probabilities and treatment effects
The study population is described as outpatients at high risk of PC-AKI; however, the authors do not
define what constitutes high risk in this context. The patients’ average age in the model is 63 years.
Table 75 summarises the probability estimates in the model and sources of evidence.
The authors do not state if dialysis is transient or permanent, or the period of time considered to
estimate the probability of dialysis. As the risk of death is not conditional on dialysis, dialysis is
likely to be transient. Furthermore, only 6 days of hospitalisation were considered for patients who
initiate dialysis (see Chicaíza-Becerra et al.129). The time period considered for the estimation of the
probabilities of death is not described.
Health-related quality of life
Health-related quality of life was not considered in the model because of the lack of health utility
estimates specific to Colombia at the time of the study. Effectiveness was measured in life-years
gained, and the average life expectancy of the Colombian population was assumed for patients who
survived in the model.
TABLE 75 Probabilities and treatment effects in the model
Probability Point estimate Source
Probability of PC-AKI
Iohexol 0.21 Solomon, 2005146
Nguyen et al., 2008147
Solomon and DuMouchel, 2006148
Iodixanol 0.09
Iodixanol 0.1
Other low-osmolality media 0.18
Mortality PC-AKI 0.16 From et al., 2008149
Mortality no AKI 0.05
Probability of dialysis (if PC-AKI) 0.36 Klarenbach et al., 2006150
Aguirre Caicedo, 2007151Probability of hospitalisation on a CCU 0.29
CCU, critical care unit.
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Resource use and costs
The study included the following elements of resource use and costs: direct costs related to contrast
media, and the treatment of associated renal complications. The cost of prophylactic IVH was not
included, as the same costs would apply to every strategy under comparison. The unit costs for
contrast media were market prices, and the unit cost of health-care use for handling complications was
taken from the Colombian national tariff set for medicines and health procedures. Table 76 summarises
the resource use in the model. Unit costs were not extracted as it was not clear whether or not the
costs reported in the study were unit costs.
Uncertainty
The model considered joint parameter uncertainty by performing probabilistic sensitivity analysis.
Probabilistic distributions were attributed to most parameters in the model, but no further details
are provided on the probabilistic sensitivity analysis. The authors conducted univariate deterministic
sensitivity analysis by varying most parameters within a range of values. The rationale for each range
of values was not presented.
Findings
The iohexol and other low-osmolality contrast media were dominated by iopamidol and iodixanol in the
base-case analysis. At a cost-effectiveness threshold of US$5356 per additional QALY (the Colombian
threshold value), iopamidol was identified as the cost-effective option for the analyses applying a 0%
and 3% annual discount rate on both costs and outcomes. Iopamidol was also the strategy most likely
to be cost-effective at a willingness to pay ranging between US$0 and US$11,740.
The results were sensitive to variation in the risk of PC-AKI for iopamidol (if it became higher than
0.11, iodixanol would dominate all strategies), and to the costs of the contrast media. Iopamidol
became less cost-effective when the price per 50-ml vial was higher than US$51 (base case US$26.6),
whereas iodixanol became cost-effective when the price for a 50-ml vial was lower than US$28 (base
case US$52.7).
TABLE 76 Summary of resource use in Chicaíza-Becerra et al.129
Category
Resource
use Source/details
Contrast media
Iopamidol 17.5 ml Assumes 5 ml of contrast agent for each kilogram of a
patient’s body weight divided by SCr level
The average weight in the model is assumed to be 70 kg and
the average SCr level 2 mg/dl
Iohexol
Other low osmolality
Iodixanol
Days of hospitalisation
Without nephropathy 2 Klarenbach et al., 2006150
Aguirre Caicedo, 2007151With nephropathy and no dialysis 4
With nephropathy and dialysis 6
Dialysis 1
Placement of temporary venous
catheter
1 Not clear to whom these costs apply in the model
Creatinine, BUN, electrolyte and blood
gas analyses
1
BUN, blood urea nitrogen.
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Limitations of the model in the context of the study
Although the model structure is flexible enough to consider the full population of non-emergency
outpatients presenting for a CT scan, the evidence sources informing the model are mostly informed by
studies in patients at a higher risk of PC-AKI (and subsequent events). Furthermore, the assumptions
on time frame for the occurrence of short-term events (i.e. death and dialysis) and for the duration of
adverse outcomes (dialysis) are not explicitly stated. Finally, the model does not consider HRQoL.
Conclusion
The structure of the model described in Chicaíza-Becerra et al.129 links PC-AKI to the relevant outcomes
in terms of costs and HRQoL, and can easily be adapted to address the decision problem in our study.
Although the model developed for CG169108,110 also allows us to establish this link, the additional
evidence that is required to parameterise this more complex model is not available for the population of
interest. The increased complexity of the CG169 model was necessary to capture the impact of PC-AKI
in a specific population with pre-existing grade 3–4 CKD disease, but is less relevant in the context of
this study. Furthermore, the model structure in CG169 does not consider patients with normal kidney
function and at earlier stages of renal disease (i.e. CKD stage 1 or 2), and would, therefore, require
substantial structural adaptation to reflect the population in our decision problem.
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Appendix 10 Base-case analysis results
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TABLE 77 Base-case cost-effectiveness deterministic results: full incremental analysis
Identification Management
Total Incremental
ICER (per QALY)Costs QALYs Costs QALYs
6 RF + i-STAT + Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH + contrast-enhanced CT scan
£275.84 9.99137100231 – – –
8 RF + StatSensor + Lab £276.15 9.99137099733 £0.31 –0.000000005 Dominated
4 RF + StatSensor £277.84 9.99137099733 £1.99 –0.000000005 Dominated
2 RF+ i-STAT £278.02 9.99137100231 £2.17 0.00000000000 Dominated
14 StatSensor + Lab £279.09 9.99137099733 £3.25 –0.000000005 Dominated
12 i-STAT + Lab £280.08 9.99137100231 £4.23 0.00000000000 Dominated
11 StatSensor £283.96 9.99137099733 £8.12 –0.00000000499 Dominated
7 RF +ABL800 FLEX+ Lab £284.39 9.99137100330 £8.55 0.00000000099 Extendedly dominated
3 RF +ABL800 FLEX £285.87 9.99137100330 £10.03 0.00000000099 Dominated
9 i-STAT £286.35 9.99137100231 £10.51 0.00000000000 Dominated
13 ABL800 FLEX+ Lab £286.70 9.99137100330 £10.86 0.00000000099 Dominated
10 ABL800 FLEX £290.99 9.99137100330 £15.14 0.00000000099 Dominated
5 RF + Lab £304.06 9.99137101011 £28.22 0.00000000779 £3,620,669,780
1 Lab £363.26 9.99137101011 £87.42 0.00000000779 Dominated
Lab, laboratory; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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Appendix 11 Scenario analyses results
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TABLE 78 Cost-effectiveness results: scenario 1: StatSensor-adjusted analysis
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH+ contrast-enhanced
CT scan
£363.26 9.991371010 9.97321 £199,464.16 0.00000 £0.00 14
2 RF + i-STAT £278.02 9.991371002 9.97747 £199,549.40 0.00426 £85.25 3
3 RF +ABL800 FLEX £285.87 9.991371003 9.97708 £199,541.55 0.00387 £77.39 9
4 RF + StatSensor £278.51 9.991371002 9.97745 £199,548.91 0.00424 £84.75 4
5 RF + Lab £304.06 9.991371010 9.97617 £199,523.36 0.00296 £59.20 13
6 RF + i-STAT + Lab £275.84 9.991371002 9.97758 £199,551.58 0.00437 £87.42 1
7 RF +ABL800
FLEX+ Lab
£284.39 9.991371003 9.97715 £199,543.03 0.00394 £78.87 7
8 RF + StatSensor + Lab £276.61 9.991371002 9.97754 £199,550.81 0.00433 £86.66 2
9 i-STAT £286.35 9.991371002 9.97705 £199,541.07 0.00385 £76.91 10
10 ABL800 FLEX £290.99 9.991371003 9.97682 £199,536.43 0.00361 £72.28 12
11 StatSensor £285.13 9.991371002 9.97711 £199,542.29 0.00391 £78.13 8
12 i-STAT+ Lab £280.08 9.991371002 9.97737 £199,547.34 0.00416 £83.18 6
13 ABL800 FLEX + Lab £286.70 9.991371003 9.97704 £199,540.72 0.00383 £76.56 11
14 StatSensor + Lab £279.62 9.991371002 9.97739 £199,547.80 0.00418 £83.65 5
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 79 Cost-effectiveness results: scenario 2: CKD-EPI equation studies
Identification Management
Total At £20,000 per QALY
NB
rankCosts NMB
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH+ contrast-enhanced
CT scan
£363.26 9.991371010 9.97321 £199,464.16 0.00000 £0.00 14
2 RF + i-STAT £277.73 9.991371001 9.97748 £199,549.69 0.00428 £85.54 3
3 RF +ABL800 FLEX £286.05 9.991371001 9.97707 £199,541.37 0.00386 £77.21 9
4 RF + StatSensor £278.67 9.991370989 9.97744 £199,548.75 0.00423 £84.60 4
5 RF + Lab £304.06 9.991371010 9.97617 £199,523.36 0.00296 £59.20 13
6 RF + i-STAT + Lab £275.72 9.991371001 9.97758 £199,551.70 0.00438 £87.54 2
7 RF +ABL800
FLEX+ Lab
£284.26 9.991371001 9.97716 £199,543.16 0.00395 £79.01 7
8 RF + StatSensor + Lab £275.68 9.991370989 9.97759 £199,551.74 0.00438 £87.59 1
9 i-STAT £285.70 9.991371001 9.97709 £199,541.72 0.00388 £77.57 8
10 ABL800 FLEX £291.85 9.991371001 9.97678 £199,535.57 0.00357 £71.41 12
11 StatSensor £287.65 9.991370989 9.97699 £199,539.77 0.00378 £75.61 11
12 i-STAT+ Lab £279.90 9.991371001 9.97738 £199,547.52 0.00417 £83.36 6
13 ABL800 FLEX + Lab £286.67 9.991371001 9.97704 £199,540.75 0.00383 £76.59 10
14 StatSensor + Lab £279.03 9.991370989 9.97742 £199,548.39 0.00421 £84.23 5
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 80 Cost-effectiveness results: scenario 3: alternative risk factor questionnaire
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH+ contrast-enhanced
CT scan
£363.26 9.991371010 9.97321 £199,464.16 0.00000 £0.00 14
2 RF+ i-STAT £280.52 9.991370997 9.97734 £199,546.90 0.00414 £82.74 6
3 RF +ABL800 FLEX £287.38 9.991370998 9.97700 £199,540.04 0.00379 £75.89 11
4 RF + StatSensor £279.71 9.991370993 9.97739 £199,547.71 0.00418 £83.55 4
5 RF + Lab £322.14 9.991371004 9.97526 £199,505.28 0.00206 £41.12 13
6 RF + i-STAT + Lab £277.09 9.991370997 9.97752 £199,550.33 0.00431 £86.18 2
7 RF +ABL800
FLEX+ Lab
£285.03 9.991370998 9.97712 £199,542.39 0.00391 £78.23 8
8 RF + StatSensor + Lab £277.05 9.991370993 9.97752 £199,550.37 0.00431 £86.22 1
9 i-STAT £286.35 9.991371002 9.97705 £199,541.07 0.00385 £76.91 9
10 ABL800 FLEX £290.99 9.991371003 9.97682 £199,536.43 0.00361 £72.28 12
11 StatSensor £283.96 9.991370997 9.97717 £199,543.46 0.00396 £79.30 7
12 i-STAT+ Lab £280.08 9.991371002 9.97737 £199,547.34 0.00416 £83.18 5
13 ABL800 FLEX + Lab £286.70 9.991371003 9.97704 £199,540.72 0.00383 £76.56 10
14 StatSensor + Lab £279.09 9.991370997 9.97742 £199,548.33 0.00421 £84.17 3
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 81 Cost-effectiveness results: scenario 4: eGFR distribution – Harris subgroup without a prior eGFR measurement
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH+ contrast-enhanced
CT scan
£361.06 9.991371782 9.97332 £199,466.38 0.00000 £0.00 14
2 RF+ i-STAT £275.59 9.991371778 9.97759 £199,551.85 0.00427 £85.47 3
3 RF +ABL800 FLEX £283.62 9.991371779 9.97719 £199,543.81 0.00387 £77.44 10
4 RF + StatSensor £275.65 9.991371776 9.97759 £199,551.78 0.00427 £85.41 4
5 RF + Lab £301.65 9.991371782 9.97629 £199,525.78 0.00297 £59.41 13
6 RF + i-STAT + Lab £273.62 9.991371778 9.97769 £199,553.82 0.00437 £87.44 1
7 RF +ABL800
FLEX+ Lab
£282.16 9.991371779 9.97726 £199,545.28 0.00395 £78.90 8
8 RF + StatSensor + Lab £274.16 9.991371776 9.97766 £199,553.27 0.00434 £86.90 2
9 i-STAT £283.47 9.991371778 9.97720 £199,543.96 0.00388 £77.59 9
10 ABL800 FLEX £288.69 9.991371779 9.97694 £199,538.74 0.00362 £72.37 12
11 StatSensor £281.34 9.991371776 9.97730 £199,546.10 0.00399 £79.72 7
12 i-STAT+ Lab £277.80 9.991371778 9.97748 £199,549.63 0.00416 £83.26 6
13 ABL800 FLEX + Lab £284.47 9.991371779 9.97715 £199,542.96 0.00383 £76.59 11
14 StatSensor + Lab £277.05 9.991371776 9.97752 £199,550.39 0.00420 £84.01 5
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 82 Cost-effectiveness results: scenario 5: eGFR distribution – GSTT audit data population
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH+ contrast-enhanced
CT scan
£460.78 9.991336844 9.96830 £199,365.95 0.00000 £0.00 14
2 RF+ i-STAT £374.98 9.991336644 9.97259 £199,451.76 0.00429 £85.80 6
3 RF +ABL800 FLEX £384.19 9.991336669 9.97213 £199,442.54 0.00383 £76.59 10
4 RF + StatSensor £364.55 9.991336515 9.97311 £199,462.18 0.00481 £96.23 2
5 RF + Lab £410.83 9.991336844 9.97080 £199,415.90 0.00250 £49.95 13
6 RF + i-STAT + Lab £372.81 9.991336644 9.97270 £199,453.93 0.00440 £87.97 5
7 RF +ABL800
FLEX+ Lab
£383.05 9.991336669 9.97218 £199,443.69 0.00389 £77.73 8
8 RF + StatSensor + Lab £362.79 9.991336515 9.97320 £199,463.94 0.00490 £97.98 1
9 i-STAT £383.53 9.991336644 9.97216 £199,443.20 0.00386 £77.25 9
10 ABL800 FLEX £389.08 9.991336669 9.97188 £199,437.66 0.00359 £71.70 12
11 StatSensor £371.11 9.991336515 9.97278 £199,455.62 0.00448 £89.67 4
12 i-STAT+ Lab £376.46 9.991336644 9.97251 £199,450.27 0.00422 £84.32 7
13 ABL800 FLEX + Lab £384.94 9.991336669 9.97209 £199,441.79 0.00379 £75.84 11
14 StatSensor + Lab £365.34 9.991336515 9.97307 £199,461.39 0.00477 £95.44 3
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 83 Cost-effectiveness results: scenario 6.1: throughput – 12.7% without a prior eGFR measurement
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH+ contrast-enhanced
CT scan
£361.06 9.991371782 9.97332 £199,466.38 0.00000 £0.00 14
2 RF+ i-STAT £278.41 9.991371778 9.97745 £199,549.02 0.00413 £82.65 2
3 RF +ABL800 FLEX £302.33 9.991371779 9.97626 £199,525.11 0.00294 £58.73 11
4 RF + StatSensor £280.85 9.991371776 9.97733 £199,546.58 0.00401 £80.21 5
5 RF + Lab £301.65 9.991371782 9.97629 £199,525.78 0.00297 £59.41 10
6 RF + i-STAT + Lab £276.44 9.991371778 9.97755 £199,550.99 0.00423 £84.62 1
7 RF +ABL800
FLEX+ Lab
£300.87 9.991371779 9.97633 £199,526.57 0.00301 £60.19 9
8 RF + StatSensor + Lab £279.36 9.991371776 9.97740 £199,548.07 0.00408 £81.70 3
9 i-STAT £286.30 9.991371778 9.97706 £199,541.14 0.00374 £74.76 7
10 ABL800 FLEX £307.40 9.991371779 9.97600 £199,520.04 0.00268 £53.66 13
11 StatSensor £286.54 9.991371776 9.97704 £199,540.90 0.00373 £74.52 8
12 i-STAT+ Lab £280.62 9.991371778 9.97734 £199,546.81 0.00402 £80.44 4
13 ABL800 FLEX + Lab £303.18 9.991371779 9.97621 £199,524.25 0.00289 £57.88 12
14 StatSensor + Lab £282.25 9.991371776 9.97726 £199,545.19 0.00394 £78.81 6
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 84 Cost-effectiveness results: scenario 6.2: throughput – 50% lower than the base case
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH+ contrast-enhanced
CT scan
£363.26 9.991371010 9.97321 £199,464.16 0.00000 £0.00 14
2 RF+ i-STAT £279.71 9.991371002 9.97739 £199,547.71 0.00418 £83.56 3
3 RF +ABL800 FLEX £297.07 9.991371003 9.97652 £199,530.35 0.00331 £66.20 10
4 RF + StatSensor £280.95 9.991370997 9.97732 £199,546.47 0.00412 £82.31 4
5 RF + Lab £304.06 9.991371010 9.97617 £199,523.36 0.00296 £59.20 13
6 RF + i-STAT + Lab £277.53 9.991371002 9.97749 £199,549.89 0.00429 £85.73 1
7 RF +ABL800
FLEX+ Lab
£295.59 9.991371003 9.97659 £199,531.83 0.00338 £67.67 9
8 RF + StatSensor + Lab £279.27 9.991370997 9.97741 £199,548.15 0.00420 £84.00 2
9 i-STAT £288.04 9.991371002 9.97697 £199,539.38 0.00376 £75.22 8
10 ABL800 FLEX £302.18 9.991371003 9.97626 £199,525.24 0.00305 £61.08 12
11 StatSensor £287.07 9.991370997 9.97702 £199,540.35 0.00381 £76.19 7
12 i-STAT+ Lab £281.77 9.991371002 9.97728 £199,545.65 0.00407 £81.49 5
13 ABL800 FLEX + Lab £297.90 9.991371003 9.97648 £199,529.52 0.00327 £65.36 11
14 StatSensor + Lab £282.21 9.991370997 9.97726 £199,545.21 0.00405 £81.06 6
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 85 Cost-effectiveness results: scenario 6.3: throughput – 50% higher than the base case
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH+ contrast-enhanced
CT scan
£363.26 9.991371010 9.97321 £199,464.16 0.00000 £0.00 14
2 RF+ i-STAT £277.45 9.991371002 9.97750 £199,549.97 0.00429 £85.81 4
3 RF +ABL800 FLEX £282.14 9.991371003 9.97726 £199,545.28 0.00406 £81.12 8
4 RF + StatSensor £276.80 9.991370997 9.97753 £199,550.62 0.00432 £86.46 3
5 RF + Lab £304.06 9.991371010 9.97617 £199,523.36 0.00296 £59.20 13
6 RF + i-STAT + Lab £275.28 9.991371002 9.97761 £199,552.14 0.00440 £87.98 2
7 RF +ABL800
FLEX+ Lab
£280.66 9.991371003 9.97734 £199,546.76 0.00413 £82.60 7
8 RF + StatSensor + Lab £275.12 9.991370997 9.97762 £199,552.30 0.00441 £88.14 1
9 i-STAT £285.79 9.991371002 9.97708 £199,541.63 0.00387 £77.47 11
10 ABL800 FLEX £287.25 9.991371003 9.97701 £199,540.17 0.00380 £76.01 12
11 StatSensor £282.93 9.991370997 9.97722 £199,544.49 0.00402 £80.34 9
12 i-STAT+ Lab £279.52 9.991371002 9.97740 £199,547.90 0.00419 £83.75 6
13 ABL800 FLEX + Lab £282.97 9.991371003 9.97722 £199,544.45 0.00401 £80.29 10
14 StatSensor + Lab £278.06 9.991370997 9.97747 £199,549.36 0.00426 £85.21 5
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 86 Cost-effectiveness results: scenario 7.1: proportion of cancelled CT scans (0%)
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH+ contrast-enhanced
CT scan
£273.51 9.991371010 9.97770 £199,553.91 0.00000 £0.00 2
2 RF+ i-STAT £277.20 9.991371002 9.97751 £199,550.22 –0.00018 –£3.69 6
3 RF +ABL800 FLEX £285.15 9.991371003 9.97711 £199,542.27 –0.00058 –£11.64 12
4 RF + StatSensor £277.16 9.991370997 9.97751 £199,550.26 –0.00018 –£3.64 5
5 RF + Lab £272.48 9.991371010 9.97775 £199,554.94 0.00005 £1.03 1
6 RF + i-STAT + Lab £275.03 9.991371002 9.97762 £199,552.39 –0.00008 –£1.51 3
7 RF +ABL800
FLEX+ Lab
£283.67 9.991371003 9.97719 £199,543.75 –0.00051 –£10.16 10
8 RF + StatSensor + Lab £275.47 9.991370997 9.97760 £199,551.95 –0.00010 –£1.96 4
9 i-STAT £284.87 9.991371002 9.97713 £199,542.55 –0.00057 –£11.36 11
10 ABL800 FLEX £289.82 9.991371003 9.97688 £199,537.60 –0.00082 –£16.30 14
11 StatSensor £282.77 9.991370997 9.97723 £199,544.65 –0.00046 –£9.25 9
12 i-STAT+ Lab £278.60 9.991371002 9.97744 £199,548.82 –0.00025 –£5.09 8
13 ABL800 FLEX + Lab £285.54 9.991371003 9.97709 £199,541.88 –0.00060 –£12.02 13
14 StatSensor + Lab £277.90 9.991370997 9.97748 £199,549.52 –0.00022 –£4.39 7
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 87 Cost-effectiveness results: scenario 7.1: proportion of cancelled CT scans (25%)
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH+ contrast-enhanced
CT scan
£295.95 9.991371010 9.97657 £199,531.47 0.00000 £0.00 14
2 RF+ i-STAT £277.40 9.991371002 9.97750 £199,550.02 0.00093 £18.55 4
3 RF +ABL800 FLEX £285.33 9.991371003 9.97710 £199,542.09 0.00053 £10.62 11
4 RF + StatSensor £277.33 9.991370997 9.97750 £199,550.09 0.00093 £18.62 3
5 RF + Lab £280.37 9.991371010 9.97735 £199,547.05 0.00078 £15.58 7
6 RF + i-STAT + Lab £275.23 9.991371002 9.97761 £199,552.19 0.00104 £20.72 1
7 RF +ABL800
FLEX+ Lab
£283.85 9.991371003 9.97718 £199,543.57 0.00060 £12.10 9
8 RF + StatSensor + Lab £275.64 9.991370997 9.97759 £199,551.78 0.00102 £20.31 2
9 i-STAT £285.24 9.991371002 9.97711 £199,542.18 0.00054 £10.71 10
10 ABL800 FLEX £290.11 9.991371003 9.97687 £199,537.31 0.00029 £5.84 13
11 StatSensor £283.07 9.991370997 9.97722 £199,544.35 0.00064 £12.88 8
12 i-STAT+ Lab £278.97 9.991371002 9.97742 £199,548.45 0.00085 £16.98 6
13 ABL800 FLEX + Lab £285.83 9.991371003 9.97708 £199,541.59 0.00051 £10.12 12
14 StatSensor + Lab £278.20 9.991370997 9.97746 £199,549.22 0.00089 £17.75 5
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 88 Cost-effectiveness results: scenario 7.3: proportion of cancelled CT scans (50%)
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH+ contrast-enhanced
CT scan
£318.39 9.991371010 9.97545 £199,509.03 0.00000 £0.00 14
2 RF+ i-STAT £277.61 9.991371002 9.97749 £199,549.81 0.00204 £40.78 4
3 RF +ABL800 FLEX £285.51 9.991371003 9.97710 £199,541.91 0.00164 £32.88 9
4 RF + StatSensor £277.50 9.991370997 9.97750 £199,549.92 0.00204 £40.89 3
5 RF + Lab £288.27 9.991371010 9.97696 £199,539.15 0.00151 £30.12 12
6 RF + i-STAT + Lab £275.44 9.991371002 9.97760 £199,551.98 0.00215 £42.95 1
7 RF +ABL800
FLEX+ Lab
£284.03 9.991371003 9.97717 £199,543.39 0.00172 £34.35 8
8 RF + StatSensor + Lab £275.81 9.991370997 9.97758 £199,551.61 0.00213 £42.57 2
9 i-STAT £285.61 9.991371002 9.97709 £199,541.81 0.00164 £32.77 10
10 ABL800 FLEX £290.40 9.991371003 9.97685 £199,537.02 0.00140 £27.99 13
11 StatSensor £283.36 9.991370997 9.97720 £199,544.06 0.00175 £35.02 7
12 i-STAT+ Lab £279.34 9.991371002 9.97740 £199,548.08 0.00195 £39.05 6
13 ABL800 FLEX + Lab £286.12 9.991371003 9.97706 £199,541.30 0.00161 £32.27 11
14 StatSensor + Lab £278.50 9.991370997 9.97745 £199,548.92 0.00199 £39.89 5
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 89 Cost-effectiveness results: scenario 7.4: proportion of cancelled CT scans (75%)
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH+ contrast-enhanced
CT scan
£340.83 9.991371010 9.97433 £199,486.60 0.00000 £0.00 14
2 RF+ i-STAT £277.81 9.991371002 9.97748 £199,549.61 0.00315 £63.01 4
3 RF +ABL800 FLEX £285.69 9.991371003 9.97709 £199,541.73 0.00276 £55.13 9
4 RF + StatSensor £277.67 9.991370997 9.97749 £199,549.75 0.00316 £63.16 3
5 RF + Lab £296.17 9.991371010 9.97656 £199,531.25 0.00223 £44.66 13
6 RF + i-STAT + Lab £275.64 9.991371002 9.97759 £199,551.78 0.00326 £65.18 1
7 RF +ABL800
FLEX+ Lab
£284.21 9.991371003 9.97716 £199,543.21 0.00283 £56.61 8
8 RF + StatSensor + Lab £275.98 9.991370997 9.97757 £199,551.44 0.00324 £64.84 2
9 i-STAT £285.98 9.991371002 9.97707 £199,541.44 0.00274 £54.84 10
10 ABL800 FLEX £290.69 9.991371003 9.97684 £199,536.73 0.00251 £50.13 12
11 StatSensor £283.66 9.991370997 9.97719 £199,543.76 0.00286 £57.16 7
12 i-STAT+ Lab £279.71 9.991371002 9.97739 £199,547.71 0.00306 £61.12 6
13 ABL800 FLEX + Lab £286.41 9.991371003 9.97705 £199,541.01 0.00272 £54.41 11
14 StatSensor + Lab £278.79 9.991370997 9.97743 £199,548.63 0.00310 £62.03 5
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 90 Cost-effectiveness results: scenario 8: anxiety from delay
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH + contrast-enhanced
CT scan
£363.26 9.982325151 9.96416 £199,283.24 0.00000 £0.00 14
2 RF+ i-STAT £278.02 9.991288549 9.97739 £199,547.75 0.01323 £264.51 4
3 RF +ABL800 FLEX £285.87 9.991298687 9.97701 £199,540.10 0.01284 £256.86 9
4 RF + StatSensor £277.84 9.991302192 9.97741 £199,548.20 0.01325 £264.96 3
5 RF + Lab £304.06 9.988187660 9.97298 £199,459.69 0.00882 £176.45 13
6 RF + i-STAT + Lab £275.84 9.991288549 9.97750 £199,549.93 0.01333 £266.69 1
7 RF +ABL800
FLEX+ Lab
£284.39 9.991298687 9.97708 £199,541.58 0.01292 £258.34 7
8 RF + StatSensor + Lab £276.15 9.991302192 9.97749 £199,549.89 0.01333 £266.65 2
9 i-STAT £286.35 9.991221895 9.97690 £199,538.08 0.01274 £254.84 11
10 ABL800 FLEX £290.99 9.991253148 9.97670 £199,534.08 0.01254 £250.84 12
11 StatSensor £283.96 9.991250450 9.97705 £199,541.05 0.01289 £257.81 8
12 i-STAT+ Lab £280.08 9.991221895 9.97722 £199,544.36 0.01306 £261.12 6
13 ABL800 FLEX + Lab £286.70 9.991253148 9.97692 £199,538.36 0.01276 £255.12 10
14 StatSensor + Lab £279.09 9.991250450 9.97730 £199,545.92 0.01313 £262.67 5
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 91 Cost-effectiveness results: scenario 9: effect of IVH (PC-AKI risk)
Strategy Identification
Management Total
At £20,000
per QALYCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced
CT scan
l Test positiveb – IVH + contrast-enhanced
CT scan
£363.26 9.991371010 9.97321 £199,464.16 0.00000 £0.00 14
2 RF+ i-STAT £278.09 9.991370798 9.97747 £199,549.33 0.00426 £85.17 4
3 RF +ABL800 FLEX £285.93 9.991370825 9.97707 £199,541.48 0.00387 £77.33 9
4 RF + StatSensor £277.96 9.991370662 9.97747 £199,549.46 0.00426 £85.30 3
5 RF + Lab £304.06 9.991371010 9.97617 £199,523.36 0.00296 £59.20 13
6 RF + i-STAT + Lab £275.92 9.991370798 9.97757 £199,551.50 0.00437 £87.34 1
7 RF +ABL800
FLEX+ Lab
£284.46 9.991370825 9.97715 £199,542.96 0.00394 £78.80 8
8 RF + StatSensor + Lab £276.27 9.991370662 9.97756 £199,551.14 0.00435 £86.98 2
9 i-STAT £286.43 9.991370798 9.97705 £199,540.99 0.00384 £76.83 10
10 ABL800 FLEX £291.05 9.991370825 9.97682 £199,536.37 0.00361 £72.21 12
11 StatSensor £284.08 9.991370662 9.97717 £199,543.33 0.00396 £79.17 7
12 i-STAT+ Lab £280.15 9.991370798 9.97736 £199,547.26 0.00416 £83.11 6
13 ABL800 FLEX + Lab £286.77 9.991370825 9.97703 £199,540.65 0.00382 £76.49 11
14 StatSensor + Lab £279.21 9.991370662 9.97741 £199,548.20 0.00420 £84.04 5
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 92 Cost-effectiveness results: scenario 10.1: management approach for test positives (50% IVH + contrast CT scan and 50% no contrast CT scan)
Identification Management
Total At £20,000 per QALY
NB rankCosts QALYs NHB (QALYs) NMB INHB (QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb –
¢ 50% IVH + contrast-enhanced CT scan
¢ 50% unenhanced contrast CT scan
£362.04 9.991370986 9.97327 £199,465.38 0.00000 £0.00 14
2 RF+ i-STAT £276.20 9.991370982 9.97756 £199,551.22 0.00429 £85.84 3
3 RF +ABL800 FLEX £284.28 9.991370982 9.97716 £199,543.14 0.00389 £77.76 10
4 RF + StatSensor £276.33 9.991370979 9.97755 £199,551.09 0.00429 £85.71 4
5 RF + Lab £302.84 9.991370986 9.97623 £199,524.58 0.00296 £59.20 13
6 RF + i-STAT+ Lab £274.82 9.991370982 9.97763 £199,552.60 0.00436 £87.22 1
7 RF +ABL800 FLEX + Lab £283.34 9.991370982 9.97720 £199,544.08 0.00394 £78.70 9
8 RF + StatSensor + Lab £275.25 9.991370979 9.97761 £199,552.17 0.00434 £86.79 2
9 i-STAT £283.07 9.991370982 9.97722 £199,544.35 0.00395 £78.97 8
10 ABL800 FLEX £288.39 9.991370982 9.97695 £199,539.03 0.00368 £73.65 12
11 StatSensor £281.31 9.991370979 9.97731 £199,546.11 0.00404 £80.73 7
12 i-STAT+ Lab £279.05 9.991370982 9.97742 £199,548.37 0.00415 £82.99 6
13 ABL800 FLEX + Lab £285.65 9.991370982 9.97709 £199,541.77 0.00382 £76.39 11
14 StatSensor + Lab £278.19 9.991370979 9.97746 £199,549.23 0.00419 £83.85 5
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 93 Cost-effectiveness results: scenario 10.2: management approach for test positives (one-third IVH+ contrast CT scan, one-third no contrast CT scan and one-third MRI)
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb –
¢ one-third IVH + contrast-enhanced
CT scan
¢ one-third unenhanced contrast CT scan
¢ one-third MRI
£361.77 9.991370978 9.97328 £199,465.65 0.00000 £0.00 14
2 RF+ i-STAT £275.80 9.991370975 9.97758 £199,551.62 0.00430 £85.97 3
3 RF +ABL800 FLEX £283.93 9.991370975 9.97717 £199,543.49 0.00389 £77.84 10
4 RF + StatSensor £275.99 9.991370973 9.97757 £199,551.43 0.00429 £85.78 4
5 RF + Lab £302.57 9.991370978 9.97624 £199,524.85 0.00296 £59.20 13
6 RF + i-STAT + Lab £274.59 9.991370975 9.97764 £199,552.83 0.00436 £87.18 1
7 RF +ABL800
FLEX+ Lab
£283.11 9.991370975 9.97722 £199,544.31 0.00393 £78.66 9
8 RF + StatSensor + Lab £275.05 9.991370973 9.97762 £199,552.37 0.00434 £86.72 2
9 i-STAT £282.34 9.991370975 9.97725 £199,545.08 0.00397 £79.43 8
10 ABL800 FLEX £287.81 9.991370975 9.97698 £199,539.60 0.00370 £73.95 12
11 StatSensor £280.72 9.991370973 9.97734 £199,546.70 0.00405 £81.05 7
12 i-STAT+ Lab £278.82 9.991370975 9.97743 £199,548.60 0.00415 £82.95 6
13 ABL800 FLEX + Lab £285.42 9.991370975 9.97710 £199,542.00 0.00382 £76.35 11
14 StatSensor + Lab £277.99 9.991370973 9.97747 £199,549.43 0.00419 £83.78 5
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
D
O
I:
1
0
.3
3
1
0
/h
ta2
4
3
9
0
H
e
a
lth
T
e
ch
n
o
lo
g
y
A
sse
ssm
e
n
t
2
0
2
0
V
o
l.2
4
N
o
.3
9
©
Q
u
een
’s
P
rin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
2
0
.T
h
is
w
o
rk
w
as
p
ro
d
u
ced
b
y
C
o
rb
ett
et
a
l.
u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
an
d
So
cial
C
are.T
h
is
issu
e
m
ay
b
e
freely
rep
ro
d
u
ced
fo
r
th
e
p
u
rp
o
ses
o
f
p
rivate
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,
th
e
fu
ll
rep
o
rt)
m
ay
b
e
in
clu
d
ed
in
p
ro
fessio
n
al
jo
u
rn
als
p
ro
vid
ed
th
at
su
itab
le
ackn
o
w
led
gem
en
t
is
m
ad
e
an
d
th
e
rep
ro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g.
A
p
p
licatio
n
s
fo
r
co
m
m
ercial
rep
ro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:
N
IH
R
Jo
u
rn
als
Lib
rary,
N
atio
n
al
In
stitu
te
fo
r
H
ealth
R
esearch
,
E
valu
atio
n
,
Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,
A
lp
h
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
p
to
n
Scien
ce
P
ark,So
u
th
am
p
to
n
SO
1
6
7
N
S,U
K
.
2
4
5
TABLE 94 Cost-effectiveness results: scenario 11.1: no testing – intravenous contrast media for all
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH+ contrast-enhanced
CT scan
£363.26 9.991371010 9.97321 £199,464.16 0.00000 £0.00 15
2 RF+ i-STAT £278.02 9.991371002 9.97747 £199,549.40 0.00426 £85.25 5
3 RF +ABL800 FLEX £285.87 9.991371003 9.97708 £199,541.55 0.00387 £77.39 10
4 RF + StatSensor £277.84 9.991370997 9.97748 £199,549.58 0.00427 £85.42 4
5 RF + Lab £304.06 9.991371010 9.97617 £199,523.36 0.00296 £59.20 14
6 RF + i-STAT + Lab £275.84 9.991371002 9.97758 £199,551.58 0.00437 £87.42 2
7 RF +ABL800
FLEX+ Lab
£284.39 9.991371003 9.97715 £199,543.03 0.00394 £78.87 9
8 RF + StatSensor + Lab £276.15 9.991370997 9.97756 £199,551.27 0.00436 £87.11 3
9 i-STAT £286.35 9.991371002 9.97705 £199,541.07 0.00385 £76.91 11
10 ABL800 FLEX £290.99 9.991371003 9.97682 £199,536.43 0.00361 £72.28 13
11 StatSensor £283.96 9.991370997 9.97717 £199,543.46 0.00396 £79.30 8
12 i-STAT+ Lab £280.08 9.991371002 9.97737 £199,547.34 0.00416 £83.18 7
13 ABL800 FLEX + Lab £286.70 9.991371003 9.97704 £199,540.72 0.00383 £76.56 12
14 StatSensor + Lab £279.09 9.991370997 9.97742 £199,548.33 0.00421 £84.17 6
15 No testing Contrast-enhanced CT £266.77 9.991370961 9.97803 £199,560.65 0.00482 £96.50 1
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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TABLE 95 Cost-effectiveness results: scenario 11.2: ‘no testing – intravenous contrast media for all’ combined with scenario 9 (effect of IVH)
Identification Management
Total At £20,000 per QALY
NB
rankCosts QALYs
NHB
(QALYs) NMB
INHB
(QALYs) INMB
1 Lab l Test negativea – contrast-enhanced CT scan
l Test positiveb – IVH+ contrast-enhanced
CT scan
£363.26 9.991371010 9.97321 £199,464.16 0.00000 £0.00 15
2 RF+ i-STAT £278.09 9.991370798 9.97747 £199,549.33 0.00426 £85.17 5
3 RF +ABL800 FLEX £285.93 9.991370825 9.97707 £199,541.48 0.00387 £77.33 10
4 RF + StatSensor £277.96 9.991370662 9.97747 £199,549.46 0.00426 £85.30 4
5 RF + Lab £304.06 9.991371010 9.97617 £199,523.36 0.00296 £59.20 14
6 RF + i-STAT + Lab £275.92 9.991370798 9.97757 £199,551.50 0.00437 £87.34 2
7 RF +ABL800
FLEX+ Lab
£284.46 9.991370825 9.97715 £199,542.96 0.00394 £78.80 9
8 RF + StatSensor + Lab £276.27 9.991370662 9.97756 £199,551.14 0.00435 £86.98 3
9 i-STAT £286.43 9.991370798 9.97705 £199,540.99 0.00384 £76.83 11
10 ABL800 FLEX £291.05 9.991370825 9.97682 £199,536.37 0.00361 £72.21 13
11 StatSensor £284.08 9.991370662 9.97717 £199,543.33 0.00396 £79.17 8
12 i-STAT+ Lab £280.15 9.991370798 9.97736 £199,547.26 0.00416 £83.11 7
13 ABL800 FLEX + Lab £286.77 9.991370825 9.97703 £199,540.65 0.00382 £76.49 12
14 StatSensor + Lab £279.21 9.991370662 9.97741 £199,548.20 0.00420 £84.04 6
15 No testing Contrast-enhanced CT £267.22 9.991369679 9.97801 £199,560.17 0.00480 £96.02 1
INHB, incremental net health benefit; INMB, incremental net monetary benefit; Lab, laboratory; NB, net benefit; RF, risk factor.
a According to any test in the testing sequence.
b According to the last test in the testing sequence.
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